# EDGAR Filing Document

**Accession Number:** 0001421744
**File Stem:** 0001104659-26-003453
**Filing Date:** 2026-1
**Character Count:** 705446
**Document Hash:** 124cfcc9d5e20f57c182e86b5c26f0ee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-003453.hdr.sgml**: 20260114

**ACCESSION NUMBER**: 0001104659-26-003453

**CONFORMED SUBMISSION TYPE**: 1-A

**PUBLIC DOCUMENT COUNT**: 67

**FILED AS OF DATE**: 20260114

**DATE AS OF CHANGE**: 20260113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cytonics Corp
- **CENTRAL INDEX KEY:** 0001421744
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 208883869
- **STATE OF INCORPORATION:** FL

**FILING VALUES:**
- **FORM TYPE:** 1-A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12702
- **FILM NUMBER:** 26531063

**BUSINESS ADDRESS:**
- **STREET 1:** 658 W INDIANTOWN RD
- **STREET 2:** SUITE 214
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33458-7535
- **BUSINESS PHONE:** (561) 575-4451

**MAIL ADDRESS:**
- **STREET 1:** 658 W. INDIANTOWN ROAD
- **STREET 2:** SUITE 214
- **CITY:** JUPTER
- **STATE:** FL
- **ZIP:** 33458

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTONICS CORP
- **DATE OF NAME CHANGE:** 20071219

## Part

**An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. Information contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the offering statement filed with the Commission is qualified. This Preliminary Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of any such state. We may elect to satisfy our obligation to deliver a Final Offering Circular by sending you a notice within two business days after the completion of our sale to you that contains the URL where the Final Offering Circular or the offering statement in which such Final Offering Circular was filed may be obtained.**

PRELIMINARY OFFERING CIRCULAR - SUBJECT TO COMPLETION

DATED: JANUARY 13, 2026

**CYTONICS CORPORATION**

![A close up of a logo AI-generated content may be incorrect.](tm2533753d1_1aimg001.jpg)

**658 West Indiantown Road, Suite 214, Jupiter, FL 33458**

**(443) 827-8135**

**<u>www.cytonics.com</u>**

**UP TO 9,600,000 SHARES OF COMMON STOCK**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**CONSISTING OF 8,000,000 SOLD SHARES AND 1**,**600,000 BONUS SHARES**

Cytonics Corporation (herein referred to as "Cytonics" "we," "us," "our," and the "Company") is offering up to 8,000,000 shares of our Common Stock (the "Shares") at $5.00 per share, for gross proceeds from the sale of Shares of up to $40,000,000 ("Maximum Offering Amount"). To offset some of the transactional expenses associated with this offering, we will charge each investor a fee equal to 3.5% of the dollar amount of Shares purchased by the investor ("Investor Processing Fee"). The minimum investment established for each investor is $1,000 in Shares plus the Investor Processing Fee ($1,035 total). For more information on the securities offered hereby, please see the item titled "<u>Securities Being Offered</u>" on page 66.

Investors who purchase $5,000 or more of Shares in this offering, and anyone who has already purchased Shares in the Company., will receive additional Shares ("Bonus Shares") as a bonus to their investments. The Company is offering up to 1,600,000 Bonus Shares. The maximum amount of Bonus Shares any investor may receive for any one investment is 20%. Bonus Shares are based on each investment and not aggregate investments. Bonus Shares will be issued as detailed in the "Plan of Distribution."

Shares are being offered on a "best efforts" basis. The sale of Shares will commence within two days from the date that the Offering Statement, of which this this Offering Circular is a part, as amended from time-to-time, is qualified by the Securities and Exchange Commission ("SEC"). This offering will terminate at the earlier to occur of: (i) all Shares offered hereby being sold, (ii) the date three years from the date this Offering Circular, as amended, is initially qualified by the SEC, or (iii) such earlier date as terminated by the Company.

---

| | | | |
|:---|:---|:---|:---|
| **Price of Common Stock** | **Price to Public [1]** | **Underwriting<br> Discount and<br> Commissions<br> [2]** | **Proceeds to<br> Issuer [3]** |
| Per Share | $5.00 | 0.23 | 4.78 |
| Investor Processing Fee Per Share(2)(4)(5) | $0.1875 | 0.007875 | 0.167125 |
| Investor Processing Fee Maximum(2)(4)(5) | $1400000 | 863000 | 1337000 |
| Maximum Offering Amount(2)(5) | $41400000 | 2233000 | 39167000 |
| Maximum Offering Amount with Bonus Shares(2)(5) | $49400000 | 2233000 | 39167000 |

---

(1) All
 amounts in this chart and circular are in U.S. dollars unless otherwise indicated. There is no minimum offering amount and no provision
 to escrow or return investor funds if any minimum number of Shares is not sold. All investor funds will be held in a processing account
 until an investor's subscription is accepted by the Company, at which time such funds will become available for the Company's
 use. We will conduct separate closings, which closings may be conducted on a rolling basis. Closings will be conducted promptly after
 receiving investor funds. We do not intend to hold a closing any less frequently than every 30 days.

(2) We
 have engaged DealMaker Securities LLC, referred to herein as the "Broker," for administrative and compliance related
 services in connection with this Offering. The Broker is not purchasing any securities from the Company with a view to sell those
 for the Company as part of the distribution of the security. The Broker will earn a commission of 4.5% of the amount of Shares sold
 in this offering and 4.5% of the Investor Processing Fees. The Broker will not earn a commission on the Bonus Shares issued by the
 Company. Affiliates of the Broker will earn certain fees related to this offering, which are included in the above table consisting
 of $30,000 for accountable expenses prior to the Offering commencing. Once the Offering commences, Affiliates will be
 compensated $90,000 in account management fees and up to $250,000 in supplemental marketing fees. The maximum compensation that the
 Broker may receive is $2,233,000, assuming we raise the Maximum Offering Amount. Please see " <u>Plan of Distribution</u> "
 for additional information.

(3) We
 expect to incur expenses relating to this offering in addition to the fees due to the Broker, including, but not limited to, legal,
 accounting, marketing, travel, and other miscellaneous expenses, which are not included in the foregoing table. See " <u>Use of Proceeds</u> " for more detail.

(4) The
 Investor Processing Fees will be applied towards the maximum amount the Company can raise under Regulation A and each unaccredited
 investor's investment limits, as discussed herein; however, no Shares will be issued in consideration for Investor Processing
 Fees.

(5) The
 Company may issue up to 1,600,000 Bonus Shares in this offering, if the maximum number of Bonus Shares is issued. The SEC applies
 a deemed value to Bonus Shares and counts such value against the maximum $75M that an issuer may raise each 12 months. The SEC applies
 a deemed value to Bonus Shares equal to the purchase price of the Shares being offered, or $5.00 per Bonus Share in our case. Thus,
 we will be deemed to have offered up to $8,000,000 in Bonus Shares, up to $40,000,000 in offered Shares, and up to $1,400,000 in
 Investor Processing Fees, for a total deemed potential maximum offering amount of $49,400,000.

*Generally, no sale may be made to you in this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth. Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to www.investor.gov.*

Our Shares are not now listed on any national securities exchange, quotation system or the Nasdaq stock market and there is no market for our securities. There is no guarantee, and it is unlikely, that an active trading market will develop in our securities. Investors should be prepared to hold our Shares indefinitely.

This offering is being made pursuant to Tier 2 of Regulation A, following the Form 1-A Offering Circular disclosure format.

**This offering is highly speculative and these securities involve a high degree of risk and should be considered only by persons who can afford the loss of their entire investment. See "<u>Risk Factors</u>" on Page 4. Investors in this offering will grant an irrevocable voting proxy to the company's President that will limit their ability to vote their Shares purchased in this offering until the occurrence of certain events specified in the proxy, none of which may ever occur.**

THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SOLICITATION MATERIALS. THESE SECURITIES ARE OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE SECURITIES OFFERED ARE EXEMPT FROM REGISTRATION.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [SUMMARY INFORMATION](#v1) | [2](#v1) |
| [RISK FACTORS](#v2) | [4](#v2) |
| [SPECIAL INFORMATION REGARDING FORWARD LOOKING STATEMENTS](#v3) | [23](#v3) |
| [DILUTION](#v4) | [23](#v4) |
| [PLAN OF DISTRIBUTION](#v5) | [23](#v5) |
| [USE OF PROCEEDS](#v6) | [29](#v6) |
| [DESCRIPTION OF BUSINESS](#v7) | [30](#v7) |
| [DESCRIPTION OF PROPERTY](#toc_008) | [58](#toc_008) |
| [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#toc_009) | [58](#toc_009) |
| [DIRECTORS, EXECUTIVE OFFICERS, AND SIGNIFICANT EMPLOYEES](#toc_010) | [61](#toc_010) |
| [COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS](#toc_011) | [64](#toc_011) |
| [SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS](#toc_012) | [65](#toc_012) |
| [INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS](#toc_013) | [66](#toc_013) |
| [SECURITIES BEING OFFERED](#toc_014) | [66](#toc_014) |
| [EXPERTS](#toc_015) | [75](#toc_015) |
| [WHERE YOU CAN FIND ADDITIONAL INFORMATION](#toc_016) | [75](#toc_016) |
| [FINANCIAL STATEMENTS](#toc_017) | [F-1](#toc_017) |

---

**SUMMARY INFORMATION**

This summary highlights some of the information in this Offering Circular. It is not complete and may not contain all of the information that you may want to consider. To understand this offering fully, you should carefully read the entire Offering Circular, including the section entitled "Risk Factors" and the exhibits, before making a decision to invest in our securities. Unless otherwise noted or unless the context otherwise requires, the terms "we," "us," "our," "Cytonics" and the "Company" refer to Cytonics Corporation together with its subsidiaries. In instances where we refer emphatically to "Cytonics Corporation" or where we refer to a specific subsidiary of ours by name, we are referring only to that specific legal entity. "Offering Statement" refers to the Company's Form 1-A, including Part I, Part II and Part III, filed with the SEC and amended from time to time. "Offering Circular" refers to this Offering Circular comprising Part II of the Offering Statement.

**The Company**

The Company is a research and development company, developing therapies and diagnostics for back and joint pain that it then licenses to unrelated third parties. The Company was incorporated in the State of Florida under the name Gamma Spine, Inc. on July 19, 2006 and was renamed Cytonics Corporation on April 17, 2007.

Cytonics is seeking to revolutionize osteoarthritis (OA) care. Initially, we aimed to captivate the regenerative medicine industry with the development of our breakthrough FACT™ diagnostic test for OA, which detects a biomarker that correlates with degree of cartilage damage from samples of patient joint fluid. This test allows for early detection and accurate diagnoses of OA. Licensed to Synthes (later acquired by Johnson & Johnson) in 2011, we believe this diagnostic paved the way for more personalized medicine and improved treatment plans.

The discovery of this biomarker led to the development of our flagship OA treatment: the Autologous Protease Inhibitor Concentrate (APIC™) therapy, which selectively concentrates a therapeutic protein called Alpha-2-Macroglobulin ("A2M") from patients' own blood for direct injection into their arthritic joints. APIC™ has treated over 10,000 patients to date, and its clinical and commercial successes are a testament to Cytonics' core A2M-based technology as a viable therapeutic modality for the treatment of osteoarthritis. APIC™ served as the basis for our current research and development which is centered on creating genetically-engineered "super A2M" variants.

Currently, we are focusing our attention on CYT-108, our genetically engineered A2M variant that demonstrated up to 200% more activity compared to the natural A2M protein. We believe that this recombinant protein therapy has the potential to be more effective than APIC™ in treating osteoarthritis patients. If approved by the FDA, CYT-108 may be one of the first "disease modifying" pharmaceuticals for OA, designed to address the disease on the molecular level by inhibiting the destructive enzymes that chew up cartilage tissue. If successful, CYT-108 may be able to halt the progression of OA and restore joint health and overall quality of life.

CYT-108 has recently completed a *first-in-human* Phase 1 clinical trial involving 19 patients suffering from osteoarthritis of the knee. The study was conducted in Australia without an active Investigational New Drug (IND) application with the FDA. The primary endpoint is safety, and secondary endpoints include patient reported outcomes of pain and mobility, and a biomarker measurement of cartilage damage. All patients have been dosed and the drug appears to be well-tolerated with no adverse events reported as of September 3, 2025. We expect the Phase 1 clinical study report to be finalized in Q4 2025. Following conclusion of the trial, we expect to submit an Investigational New Drug application to the FDA in late Q1 2026. The next stage of clinical trials will be conducted under an open IND with the FDA. There is no guarantee that we will be able to achieve these dates for conclusion of the Phase 1 clinical study and submission of the Investigational New Drug application.

Obtaining FDA approval for CYT-108 is a multi-phase process requiring extensive regulatory compliance, data collection, and clinical validation. By following these established procedures, we aim to ensure the product meets the highest safety and efficacy standards for commercialization.

**Dividends**

We have not paid any dividends to date and do not intend to declare dividends in the near future.

**Capitalization**

Pursuant to our amended and restated articles of incorporation, as amended, our authorized capital is 70,000,000 shares, of which (1) 50,000,000 shares are Common Stock, par value $0.001 per share (the "Common Stock"), and (2) 20,000,000 shares are Preferred Stock, par value $0.001 per share, which may, at the sole discretion of the Board of Directors be issued in one or more series (the "Preferred Stock"), of which the board designated: (a) 150,000 shares as Initial Preferred Stock; (b) 1,500,000 shares as Series A Preferred Stock; (c) 6,000,000 shares as Series B Preferred Stock; and (d) 10,000,000 shares as Series C Preferred Stock of which 510,000 shares are designated as Series C-1 Preferred Stock. As of December 30, 2025, the Company had approximately 13,858,460 Shares of Common Stock, 150,000 shares of Initial Preferred Stock, 576,190 shares of Series A Preferred Stock, 2,574,865 shares of Series B Preferred Stock, and 8,399,558 shares of Series C Preferred Stock issued and outstanding. Assuming a fully subscribed offering and the maximum number of Bonus Shares issued, following this offering, the Company would have approximately 23,458,460 Shares of Common Stock, 150,000 shares of Initial Preferred Stock, 576,190 shares of Series A Preferred Stock, 2,574,865 shares of Series B Preferred Stock, and 8,399,558 shares of Series C Preferred Stock issued and outstanding.

**Use of Proceeds**

In general, the Company will use net proceeds from the offering for clinical trials, drug production, operations, and offering expenses. See "Use of Proceeds" for more detail.

**Risks**

Investing in the Company involves substantial risk and you could lose your entire investment. You should carefully read the section titled "Risk Factors" and the other information included in this Offering Circular for a discussion of facts that you should consider before deciding to invest in our Shares.

**The Offering**

This Offering Circular relates to a best effort offering of up to 8,000,000 Shares of our Common Stock at a price of $5.00 per Share, for a potential Maximum Offering Amount of $40,000,000. The Company is also offering up to 1,600,000 Bonus Shares. See "Plan of Distribution" for more information on the Bonus Shares being offered. The Company will offer up to 20% of Bonus Shares based on investment amounts. Investors will also pay an Investor Processing Fee of 3.5% of their investment amounts. There is no minimum offering amount and no provision to escrow or return investor funds if any minimum number of Shares is not sold. The minimum investment amount established for each investor is $1,000 plus the Investor Processing Fee ($1,035 total). The Company may waive the minimum investment amount on a case-by-case basis for any reason or no reason at all.

Once this offering has been qualified by the SEC, we will conduct separate closings on a rolling basis promptly after receiving investor funds. We do not intend to hold closings less frequently than every 30 days. The offering will terminate on the earliest to occur of (i) the date subscriptions for the maximum offering amount have been accepted, (ii) the date which is three years from the date our Offering Statement, as amended, is initially qualified by the Commission, or (iii) any earlier date on which we elect to terminate the offering.

We have engaged DealMaker Securities LLC to act as the Broker of record in connection with this Offering, but not for underwriting or placement agent services. We have also engaged affiliates of Broker to provide other services relating to this offering. The maximum fees payable to Broker are $1,294,000.

In order to subscribe to purchase Shares, a prospective investor must visit our investor portal at www.invest.cytonics.com and complete a subscription agreement and send payment by wire transfer, ACH, credit card, or Stablecoin approved by our Broker, in accordance with the instructions provided within the portal.

Under Rule 251(d)(2)(i)(C) of the Securities Act, in Regulation A offerings such as this one, where the securities will not be listed on a registered national securities exchange upon qualification, the aggregate purchase price to be paid by an investor who is a natural person for the securities cannot exceed 10% of the greater of the investor's annual income or net worth, unless the purchaser is an accredited investor. In the case of an investor who is not a natural person, revenues or net assets for the investors' most recently completed fiscal year are used instead. We may accept or reject any subscription, in whole or in part, for any reason or no reason at all.

**ABOUT THIS CIRCULAR**

We have prepared this Offering Circular to be filed with the SEC for our offering of securities. The Offering Statement of which this Offering Circular is a part includes exhibits that provide more detailed descriptions of the matters discussed in this Offering Circular.

You should rely only on the information contained in this Offering Circular and exhibits. We have not authorized any person to provide you with any information different from that contained in this Offering Circular. The information contained in this Offering Circular is complete and accurate only as of the date of this Offering Circular, regardless of the time of delivery of this Offering Circular or sale of our Shares. This Offering Circular contains summaries of certain other documents, but reference is hereby made to the full text of the actual documents for complete information concerning the rights and obligations of the parties thereto. Numbers in this Offering Statement may be rounded to the nearest 100th decimal point.

**INDUSTRY AND MARKET DATA**

The industry and market data used throughout this Offering Circular have been obtained from our own research, surveys or studies conducted by third parties and industry or general publications. Industry publications and surveys generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. We believe that each of these studies and publications is reliable. We have not engaged any person or entity to provide us with industry or market data.

**TAX CONSIDERATIONS**

No information contained herein, nor in any prior, contemporaneous or subsequent communication should be construed by a prospective investor as legal or tax advice. We are not providing any tax advice as to the acquisition, holding or disposition of the securities offered herein. In making an investment decision, investors are strongly encouraged to consult their own tax advisor to determine the U.S. Federal, state and any applicable foreign tax consequences relating to their investment in our securities. This written communication is not intended to be "written advice," as defined in Circular 230 published by the U.S. Treasury Department

**RISK FACTORS**

*Any investment in our Common Stock involves a high degree of risk. Investors should carefully consider the risks described below and all of the information contained in this Offering Circular before deciding whether to purchase our Common Stock. Our business, financial condition or results of operations could be materially adversely affected by these risks if any of them actually occur. Some of these factors have affected our financial condition and operating results in the past or are currently affecting us. This Offering Circular also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described below and elsewhere in this Offering Circular. In addition to the other information provided in this Offering Circular, you should carefully consider the following risk factors in evaluating our business and before purchasing any of our Common Stock. Material risks identified by the Company are discussed in this section; however, discussion may not include all risks applicable to an investment in Shares to the extent such risks have not been contemplated by the Company.*

**Risks Related to this Offering and our Common Stock**

***There is no current market for any shares of the Company's securities.***

You should be prepared to hold this investment indefinitely. There is no established market for these securities and there may never be one. As a result, if you decide to sell these securities in the future, you may not be able to find a buyer. Investors should assume that they may not be able to liquidate their investment or be able to pledge their shares as collateral.

***Using a credit card to purchase shares may impact the return on your investment as well as subject you to other risks inherent in this form of payment.***

Investors in this offering may at some point have the option of paying for their investment with a credit card, which is not usual in the traditional investment markets. Transaction fees charged by your credit card company or cryptocurrency exchange service and interest charged on unpaid card balances (which can reach over 25% in some states) add to the effective purchase price of the shares you buy. The cost of using a credit card may also increase if you do not make the minimum monthly card payments and incur late fees. Using a credit card is a relatively new form of payment for securities and will subject you to other risks inherent in this form of payment, including that, if you fail to make credit card payments (e.g. minimum monthly payments), you risk damaging your credit score and payment by credit card may be more susceptible to abuse than other forms of payment. Moreover, where a third-party payment processor is used, your recovery options in the case of disputes may be limited. The increased costs due to transaction fees and interest may reduce the return on your investment.

The SEC's Office of Investor Education and Advocacy issued an Investor Alert dated February 14, 2018 entitled Credit Cards and Investments – A Risky Combination, which explains these and other risks you may want to consider before using a credit card to pay for your investment.

***We may need additional capital, which may be on terms more or less favorable than those offered in this offering.***

We may require additional capital and may require additional cash resources due to changed business conditions or other future developments. If our resources are insufficient to satisfy our cash requirements, we may seek to sell additional equity or debt securities or incur debt. The sale of additional equity securities could result in additional dilution to our stockholders. The incurrence of additional indebtedness would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations. We cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all, or that the terms provided won't be more or less favorable than those hereby offered.

***Because our management will have broad discretion and flexibility in how the net proceeds from this offering are used, we may use the net proceeds in ways in which you disagree.***

The intended use of proceeds from this offering is more particularly described in the Section titled "Use of Proceeds;" however, such description is not binding and the actual use of proceeds may differ from the description contained therein. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.

***The offering price of our Shares has been determined by management.***

Our management has determined the Shares offered by the Company. The price of the Shares we are offering was internally determined based upon the illiquidity and volatility of our Common Stock, our current financial condition and the prospects for our future cash flows and earnings, and market and economic conditions at the time of the offering. The offering price for the Common Stock sold in this offering may be more or less than the fair market value for our Common Stock.

***The best efforts structure of this offering may yield insufficient gross proceeds to fully execute our business plan.***

Shares are being offered on a best-efforts basis. We are not required to sell any specific number or dollar amount of Common Stock, but will use our best efforts to sell the Shares offered by us. As a "best effort" offering, there can be no assurance that the offering contemplated by this Offering Circular will result in any proceeds being made available to us.

***We may not register or qualify our securities with any state agency pursuant to blue sky regulations.***

The holders of our shares of Common Stock and persons who desire to purchase them in the future should be aware that there may be significant state law restrictions upon the ability of investors to resell our shares. We currently do not intend to and may not be able to qualify securities for resale in states which require shares to be qualified before they can be resold by our shareholders.

***We may experience investment delays.***

There may be a delay between the time an investor's subscription is accepted by the Company and the time the proceeds of this offering are deployed. During these periods, the Company may invest these proceeds in short-term certificates of deposit, money-market funds, or other liquid assets with FDIC-insured and/or NCUA-insured banking institutions, which will not yield a return as high as if deployed in our operations.

***Shares are being offered under an offering exemption, and if it were later determined that such exemption was not available, purchasers would be entitled to rescind their purchase agreements.***

Shares are being offered to prospective investors pursuant to Tier 2 of Regulation A under the Securities Act. Unless the sale of Shares should qualify for such exemption the investors might have the right to rescind their purchase of Shares. Since compliance with these exemptions is highly technical, it is possible that if an investor were to seek rescission, such investor would succeed. A similar situation prevails under state law in those states where Shares may be offered without registration. If a number of investors were to be successful in seeking rescission, the Company would face severe financial demands that could adversely affect the Company and, thus, the non-rescinding investors. Inasmuch as the basis for relying on exemptions is factual, depending on the Company's conduct and the conduct of persons contacting prospective investors and making the Offering, the Company will not receive a legal opinion to the effect that this Offering is exempt from registration under any federal or state law. Instead, the Company will rely on the operative facts as documented as the Company's basis for such exemptions.

***We do not anticipate paying any cash dividends.***

We presently do not anticipate that we will pay any dividends on any of our Common Stock in the foreseeable future. The payment of dividends, if any, would be contingent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment of any dividends will be within the discretion of our Board of Directors (the "Board"). We presently intend to retain all earnings to implement our business plan; accordingly, we do not anticipate the declaration of any dividends in the foreseeable future.

***We are relying on the exemption for insignificant participation by benefit plan investors under ERISA.***

The Plan Assets Regulation of the Employee Retirement Income Security Act of 1974 ("ERISA") provides that the assets of an entity will not be deemed to be the assets of a benefits plan if equity participation in the entity by benefit plan investors, including benefit plans, is not significant. The Plan Assets Regulation provides that equity participation in the entity by benefit plan investors is "significant" if, at any time, 25% or more of the value of any class of equity interest is held by benefit plan investors. Because we are relying on this exemption, we will not accept investments from benefit plan investments of 25% or more of the value of any class of equity interest. If repurchases of shares reach 25%, we may repurchase shares of benefit plan investors without their consent until we are under such 25% limit. See the section of this offering circular captioned "ERISA Considerations" for additional information regarding the Plan Assets Regulation.

***Investors in this offering will be required to arbitrate their claims relating to the purchase of Shares and will not be entitled to a jury trial or to bring class action with respect to claims arising under the Subscription Agreement, which could result in less favorable outcomes to the plaintiff(s) in any action under these Agreements.***

Investors in this offering will be bound by the Subscription Agreement, which includes a provision under which investors waive the right to a jury trial or class action for any eligible claim, which will be settled by binding arbitration as opposed to formal court process, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in such an action. By signing the Subscription Agreement, the investor warrants that the investor has reviewed this waiver with his or her legal counsel, and knowingly and voluntarily waives the investor's jury trial rights following consultation with the investor's legal counsel.

***The subscription agreement has a forum selection provision that requires disputes be resolved in state or federal courts in the state of Florida, regardless of convenience or cost to you, the investor.***

***We will be subject to ongoing public reporting requirements that are less rigorous than rules for more mature public companies, and our investors receive less information.***

We are required to report on an ongoing basis under the reporting rules set forth in Regulation A for Tier 2 issuers. The ongoing reporting requirements under Regulation A are more relaxed than for public companies reporting under the Exchange Act. The differences include, but are not limited to, being required to file only annual and semiannual reports, rather than annual and quarterly reports. Annual reports are due within 120 calendar days after the end of our fiscal year, and semiannual reports are due within 90 calendar days after the end of the first six months of our fiscal year.

We also may elect to become a public reporting company under the Exchange Act. If we elect or are required to do so, we will be required to publicly report on an ongoing basis as an emerging growth company, as defined in the JOBS Act, under the reporting rules set forth under the Exchange Act. For so long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not emerging growth companies, including, but not limited to:

● not being required
 to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;

● being permitted
 to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and

● being exempt
 from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute
 payments not previously approved.

In either case, we will be subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, and investors could receive less information than they might expect to receive from more mature public companies.

***If we are required to register any Shares under the Exchange Act, it would result in significant expense and reporting requirements that would place a burden on the Company.***

Subject to certain exceptions, Section 12(g) of the Exchange Act requires an issuer with more than $10 million in total assets to register a class of its equity securities with the Commission under the Exchange Act if the securities of such class are held of record at the end of its fiscal year by more than 2,000 persons or 500 persons who are not "accredited investors." To the extent the Section 12(g) assets and holders limits are exceeded, we intend to rely upon a conditional exemption from registration under Section 12(g) of the Exchange Act contained in Rule 12g5-1(a)(7) under the Exchange Act (the "Reg. A+ Exemption"), which exemption generally requires that the issuer (i) be current in its Form 1-K, 1-SA and 1-U filings as of its most recently completed fiscal year end; (ii) engage a transfer agent that is registered under Section 17A(c) of the Exchange Act to perform transfer agent functions; and (iii) have a public float of less than $75 million as of the last business day of its most recently completed semi-annual period or, in the event the result of such public float calculation is zero, have annual revenues of less than $50 million as of its most recently completed fiscal year. If the number of record holders of any Series of Interests exceeds either of the limits set forth in Section 12(g) of the Exchange Act and we fail to qualify for the Reg. A+ Exemption, we would be required to register such Series with the Commission under the Exchange Act. If we are required to register any Series of Interests under the Exchange Act, it would result in significant expense and reporting requirements that would place a financial burden on the Company and a time burden on our management.

***The Investor Processing Fee may not count toward your cost basis for tax purposes.***

The IRS and/or another relevant tax authority may consider the price of the Share before including the Investor Processing Fee as the cost basis for determining any gain or loss at a realization event. You should discuss with your tax advisor the appropriate way to determine the relevant tax obligation.

***Investors will hold minority interests in the Company.***

Following this offering, investors in their individual capacities will represent a minority of the Company's authorized stock. Further, investors will be required to sign a proxy granting the Company's President the authority to vote the investor's Shares as part of the subscription agreement. Accordingly, individual investors should anticipate little or no ability to direct the Company's operations.

***Investors in our securities could experience immediate and substantial dilution after this offering.***

The public offering price of our Shares is higher than the pro forma net tangible book value per share of the outstanding common shares immediately after this offering. As a result of this dilution, investors purchasing Shares in this offering could receive significantly less than the full purchase price that they paid for the Shares purchased in this offering in the event of a liquidation. Further, we have convertible securities with conversion prices less than the price per Share in this offering. Consequently, if these securities are exercised, there could be further dilution to the purchasers of our Shares.

Further, we are offering Bonus Shares to certain investors, thereby diluting any investor who is not issued Bonus Shares or any investor who is issued Bonus Shares at a lower percentage tier than other investors.

***Investors in the company's Common Stock have assigned their voting rights via an irrevocable proxy.***

In order to subscribe to this offering, each investor is required to grant an irrevocable proxy, giving the right to vote its shares of Common Stock to the Company's President, Joey Bose. This irrevocable proxy is indefinite, and will only terminate upon the occurrence of events specified in the proxy, which include the Company's IPO or acquisition by another entity, which may never occur. There are many risks associated with an indefinite proxy duration. This means that the proxy could remain in force indefinitely. This presents several risks to investors, including but not limited to:

· Loss
 of Voting Rights: Investors may have limited or no control over the voting of their shares, potentially restricting their ability
 to influence key corporate decisions such as mergers, acquisitions, governance changes, or strategic transactions.

· Potential Misalignment
 with Investor Interests: The President holding the proxy may act in a manner that does not align with the individual investor's
 interests, with no recourse for investors to override such actions.

· Reduced Liquidity and Marketability:
 Shares subject to an indefinite proxy may be less attractive to potential buyers, as the voting rights are effectively transferred,
 potentially affecting the resale value and liquidity of the shares.

· Corporate Governance Implications:
 The concentration of voting power in a designated proxy holder may result in decision-making that benefits the controlling party
 over minority investors, heightening the risk of conflicts of interest.

Investors in this offering should carefully evaluate the implications of the irrevocable proxy and consider the potential risks associated with the inability to exercise voting rights. Before investing, shareholders should review the terms of the proxy agreement and consult with their legal or financial advisors to understand the full scope of these limitations.

***If we do become publicly traded, the Company's stock price may be volatile.*** If the Company were to become publicly traded, the price of the Company's Common Stock is likely to be highly volatile and could fluctuate widely in price in response to various potential factors, many of which will be beyond the Company's control, including the following:

· goods or services
 by the Company or its competitors;

· additions or departures
 of key personnel;

· the Company's ability
 to execute its business plan;

· operating results that
 fall below expectations;

· loss of any strategic relationship;

· industry developments;

· economic and other external
 factors; and

· period-to-period fluctuations
 in the Company's financial results.

***This is a fixed price offering and the fixed offering price may not accurately represent the current value of us or our assets at any particular time. Therefore, the purchase price you pay for the Common Stock may not be supported by the value of our assets at the time of your purchase.***

This is a fixed price offering, which means that the offering price for our Common Stock is fixed and will not vary based on the underlying value of our assets at any time during the offering. Our Board of Directors has determined the offering price in its sole discretion. The fixed offering price for our Common Stock has been based on an assessment of the future potential economic value of Cytonics' drug development program, predicated on the commercialization of our lead drug asset, CYT-108. This estimation is based on assumptions that may not be accurate. Therefore, the fixed offering price established for our Common Stock may not be indicative of the true market value of the Company, which can only be determined by selling the shares in the public market or priced by an acquirer.

***The preparation of our financial statements involves the use of estimates, judgments and assumptions, and our financial statements may be materially affected if such estimates, judgments or assumptions prove to be inaccurate.***

Financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") typically require the use of estimates, judgments and assumptions that affect the reported amounts. Often, different estimates, judgments and assumptions could reasonably be used that would have a material effect on such financial statements, and changes in these estimates, judgments and assumptions may occur from period to period over time. Significant areas of accounting requiring the application of management's judgment include, but are not limited to, determining the fair value of assets and the timing and amount of cash flows from assets. These estimates, judgments and assumptions are inherently uncertain and, if our estimates were to prove to be wrong, we would face the risk that charges to income or other financial statement changes or adjustments would be required. Any such charges or changes could harm our business, including our financial condition and results of operations and the price of our securities.

***Future issuances of debt securities, which would rank senior to our Common Stock upon our bankruptcy or liquidation, and future issuances of Preferred Stock, which would rank senior to our Common Stock for the purposes of dividends and liquidating distributions, may adversely affect the level of return you may be able to achieve from an investment in our Common Stock.***

In the future, we may attempt to increase our capital resources by offering debt securities. Upon bankruptcy or liquidation, holders of our debt securities, and lenders with respect to other borrowings we may make, would receive distributions of our available assets prior to any distributions being made to holders of our Common Stock. Moreover, if we issue additional Preferred Stock, the holders of such Preferred Stock could be entitled to preferences over holders of Common Stock in respect of the payment of dividends and the payment of liquidating distributions. Because our decision to issue debt or preferred securities in any future offering, or borrow money from lenders, will depend in part on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any such future offerings or borrowings. Holders of our Common Stock must bear the risk that any future offerings we conduct or borrowings we make may adversely affect the level of return they may be able to achieve from an investment in our Common Stock.

***Fiduciaries investing the assets of a trust or pension or profit sharing plan must carefully assess an investment in our Company to ensure compliance with ERISA.***

In considering an investment in the Company of a portion of the assets of a trust or a pension or profit-sharing plan qualified under Section 401(a) of the Code and exempt from tax under Section 501(a), a fiduciary should consider (i) whether the investment satisfies the diversification requirements of Section 404 of ERISA; (ii) whether the investment is prudent, since the Common Stock are not freely transferable and there may not be a market created in which the Shares may be sold or otherwise disposed; and (iii) whether interests in the Company or the underlying assets owned by the Company constitute "Plan Assets" under ERISA.

***We may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a return.***

The principal purposes of this offering are to raise additional capital to use in accordance with our planned use of proceeds. Our management will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Investors in this offering will need to rely upon the judgment of our management with respect to the use of proceeds. If we do not use the net proceeds that we receive in this offering effectively, our business, financial condition, results of operations and prospects could be harmed. See "Use of Proceeds."

**Risks Related to our Business**

***We have not yet generated profits.***

We have not yet generated profits. The likelihood of our creation of a viable business must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the growth of a business, operation in a competitive industry, and the continued development of our technology and products. We anticipate that our operating expenses will increase for the near future, and there is no assurance that we will be profitable in the near future or ever. You should consider our business, operations and prospects in light of the risks, expenses and challenges faced as an emerging growth company.

***We depend heavily on our officers and key employees, and turnover of such personnel could harm our business.***

Our business and results of operations depend in significant part upon our executives. If we lose their services or if they fail to perform in their current positions, or if we are not able to attract and retain skilled personnel to replace employees as needed, our business could suffer.

***We may change our business strategy without stockholder consent, which may result in riskier operations than our current operations.***

We may change our business strategy and guidelines at any time without the consent of our stockholders, which could result in our making investments that are different from, and possibly riskier than, the investments described in this Offering Circular. A change in our business strategy could expose us to unknown risks.

***Current global financial conditions have been characterized by increased volatility which could negatively impact our business, prospects, liquidity and financial condition.***

Current global financial conditions and recent market events have been characterized by increased volatility and the resulting tightening of the credit and capital markets has reduced the amount of available liquidity and overall economic activity. We cannot guarantee that debt or equity financing, the ability to borrow funds or cash generated by loans will be available or sufficient to meet or satisfy our initiatives, objectives or requirements, nor can we guarantee that we will have access to efficient or effective financing structures.

***We intend to grow the size of our organization, and we may experience difficulties in managing any growth we may achieve.***

As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, financial, accounting, legal, and other resources. Future growth would impose significant added responsibilities on members of management. Our management may not be able to accommodate those added responsibilities, and our failure to do so could prevent us from effectively managing future growth, if any, and successfully growing our Company.

***We may not maintain sufficient insurance coverage for the risks associated with our business operations.***

Risks associated with our business and operations include, but are not limited to, claims for wrongful acts committed by our officers, directors, and other representatives, the loss of key personnel, risks posed by natural disasters, and risks of lawsuits from our employees. Any of these risks may result in significant losses. We cannot provide any assurance that our insurance coverage is sufficient to cover any losses that we may sustain, or that we will be able to successfully claim our losses under our insurance policies on a timely basis or at all. If we incur any loss not covered by our insurance policies, or the compensated amount is significantly less than our actual loss or is not timely paid, our business, financial condition and results of operations could be materially and adversely affected.

***Financial projections may be wrong.***

Certain financial projections concerning the future performance of the properties are based on assumptions of an arbitrary nature and may prove to be materially incorrect. No assurance is given that actual results will correspond with the results contemplated by these projections. It is possible that returns may be lower than projected, or that there may be no returns at all.

These and all other financial projections, and any other statements previously provided to the Purchaser relating to the Company or its prospective business operations that are not historical facts, are forward-looking statements that involve risks and uncertainties. Sentences or phrases that use such words as "believes," "anticipates," "plans," "may," "hopes," "can," "will," "expects," "is designed to," "with the intent," "potential" and others indicate forward-looking statements, but their absence does not mean that a statement is not forward- looking.

Such statements are based on our management's current estimates and expectations, along with currently available competitive, financial, and economic data. However, forward-looking statements are inherently uncertain. A variety of factors could cause business conditions and results to differ materially from what is contained in any such forward-looking statements.

It is possible that actual results from operation of the properties will be different than the returns anticipated by our management and/or that these returns may not be realized in the timeframe projected by our management, if at all.

***We might obtain lines of credit and other borrowings, which increases our risk of loss due to potential foreclosure.***

We may obtain lines of credit and long-term financing that may be secured by our assets. As with any liability, there is a risk that we may be unable to repay our obligations from the cash flow of our assets. Therefore, when borrowing and securing such borrowing with our assets, we risk losing such assets in the event we are unable to repay such obligations or meet such demands. Our ability to obtain and maintain access to these or similar kinds of credit facilities is significant for us to operate the business.

***Maintaining and enhancing our brand and reputation is critical to our growth and negative publicity could damage our brand and thereby harm our ability to compete effectively, which would materially adversely affect our business, results of operations and financial condition.***

Our brand and our reputation are important assets. Maintaining and enhancing our brand and reputation is critical to our ability to compete effectively. Our brand and reputation could be harmed if we fail to act responsibly or are perceived as not acting responsibly, or fail to comply with regulatory requirements as interpreted by certain governments or agencies thereof, in a number of other areas, such as safety and security, data security, privacy practices, sustainability, human rights (including in respect of our own operations and throughout our supply chain), matters associated with our broader supply chain (including owners and other third-party vendors and service providers), diversity, non-discrimination and support for employees and local communities. Media, legislative, or government scrutiny around our Company, including the perceived impact on neighborhood nuisance, privacy practices, provision of information as requested by certain governments or agencies thereof, business practices and strategic plans, our business partners, private companies where we have minority investments and our practices relating to our platform, offerings, employees, competition, litigation and response to regulatory activity, could adversely affect our brand and our reputation with our buyers, owners and communities. Social media compounds the potential scope of the negative publicity that could be generated and the speed with which such negative publicity may spread. Any resulting damage to our brand or reputation could materially adversely affect our business, results of operations and financial condition.

***Our results of operations and financial condition are subject to management's accounting judgments and estimates, as well as changes in accounting policies.***

The preparation of our financial statements requires us to make estimates and assumptions affecting the reported amounts of our assets, liabilities, revenues and expenses. If these estimates or assumptions are incorrect, it could have a material adverse effect on our results of operations or financial condition. Generally accepted accounting principles in the United States are subject to interpretation by the Financial Accounting Standards Board, the American Institute of Certified Public Accountants, the SEC and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results and could affect the reporting of transactions completed before the announcement of a change.

***Certain provisions of our Articles of Incorporation may make it more difficult for a third party to effect a change-of-control.***

Our amended and restated articles of incorporation authorizes the Board of Directors to issue up to 20,000,000 shares of Preferred Stock, of which approximately 2,350,000 shares remain undesignated. Such undesignated shares of Preferred Stock may be issued in one or more subseries, the terms of which may be determined at the time of issuance by the Board of Directors without further action by the stockholders. These terms may include preferences as to dividends and liquidation, conversion rights, redemption rights and sinking fund provisions. The issuance of any Preferred Stock could diminish the rights of holders of our Common Stock, and therefore could reduce the value of such Common Stock. In addition, specific rights granted to future holders of Preferred Stock could be used to restrict our ability to merge with, or sell assets to, a third party. The ability of the Board of Directors to issue Preferred Stock could make it more difficult, delay, discourage, prevent or make it more costly to acquire or effect a change-in-control, which in turn could prevent our stockholders from recognizing a gain in the event that a favorable offer is extended.

***Limitations on director and officer liability and indemnification of our Company's officers and directors by us may discourage stockholders from bringing suit against an officer or director.***

Our Company's amended and restated articles of incorporation and amended and restated bylaws provide, with certain exceptions as permitted by governing state law, that a director or officer shall not be personally liable to us or our stockholders for breach of fiduciary duty as a director, except for acts or omissions which involve intentional misconduct, fraud or knowing violation of law, or unlawful payments of dividends. These provisions may discourage stockholders from bringing suit against a director for breach of fiduciary duty and may reduce the likelihood of derivative litigation brought by stockholders on our behalf against a director.

***We are responsible for the indemnification of our officers and directors.***

Should our officers and/or directors require us to contribute to their defense, we may be required to spend significant amounts of our capital. Our articles of incorporation, as amended and bylaws, as amended also provide for the indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney's fees and other expenses incurred by them in any litigation to which they become a party arising from their association with or activities on behalf of our Company. This indemnification policy could result in substantial expenditures, which we may be unable to recoup. If these expenditures are significant, or involve issues which result in significant liability for our key personnel, we may be unable to continue operating as a going concern.

***Cytonics is obligated to pay certain fees and expenses.***

Cytonics will pay various fees and expenses related to its ongoing operations regardless of whether or not Cytonics' activities are profitable. These fees and expenses will require dependence on third-party relationships. Cytonics is generally dependent on relationships with its strategic partners and vendors, and Cytonics may enter into similar agreements with future potential strategic partners and alliances. Cytonics must be successful in securing and maintaining its third-party relationships to be successful. There can be no assurance that such third parties may regard their relationship with Cytonics as important to their own business and operations, that they will not reassess their commitment to the business at any time in the future, or that they will not develop their own competitive services or products, either during their relationship with Cytonics or after their relations with Cytonics expire. Accordingly, there can be no assurance that Cytonics' existing relationships or future relationships will result in sustained business partnerships, successful service offerings, or significant revenues for Cytonics.

***We have a history of operating losses and our auditors have indicated that there is a substantial doubt about our ability to continue as a going concern.***

To date, we have not been profitable and have incurred significant losses and cash flow deficits. For the fiscal years ended December 31, 2024 and 2023, we reported net losses of $4,526,921 and $1,946,860, respectively. For the fiscal periods ending June 30, 2025 and 2024, we reported net losses of $4,430,334 and $2,567,620, respectively. The Company also had an accumulated deficit of $33,646,205 as of June 30, 2025. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2 to the audited financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

***We expect to experience losses in the future and may not become profitable.***

Pursuant to our business strategy, we expect to continue to make expenditures on research, clinical trials, and regulatory approvals, which will adversely affect operating results until revenues from sales of our products reach a level at which these costs are supported. Our recent operations have been financed and are expected to continue to be financed primarily through sales by us of our equity and through debt. We anticipate, based on our current proposed plans and assumptions relating to operations, that the net proceeds from the sale of the Common Stock offered hereby, assuming a fully subscribed offering, will be sufficient to satisfy our contemplated cash requirements for approximately 24 months from the date of this Offering.

Since the formation of our Company, we have generated limited revenues, with the exception of the federal grant income, income from the sale of an exclusive license to our therapeutic products, and quarterly royalties. We may experience quarterly and annual losses, and expect to do so at least through the end of the 2025 calendar year. We are a research and development company that creates shareholder value by de-risking potential therapeutic drug assets through the FDA's regulatory framework. As such, our primary directive is *not* to achieve profitability. Instead, we strategically allocate investor capital to maximize shareholder value within the constraints of our drug development mission. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. We will need to generate significant revenues to achieve and maintain profitability.

***Our current and historical revenue is highly concentrated*.**

The Company's revenue is highly concentrated among a limited number of customers, which poses a significant customer concentration risk. The loss of any one of these key customers, or a significant reduction in their purchases or licensing fees, could materially impact the Company's revenue and financial stability. Cytonics' reliance on a concentrated customer base makes it vulnerable to changes in these customers' business needs, financial health, or strategic direction. This dependency may continue as the Company develops its portfolio and attempts to diversify its revenue sources, though there is no guarantee that future revenues will be less concentrated.

***If the Company cannot raise sufficient funds, it may not succeed.***

Cytonics is offering Common Stock in the amount of 8,000,000 shares and up to $40,000,000 in this Offering on a best-efforts basis and may not raise the complete amount. If we raise the full maximum amount in this Offering, even if the maximum amount is raised, the Company is likely to need additional funds in the future in order to grow, and if it cannot raise those funds for whatever reason, including reasons relating to the Company itself or to the broader economy, it may not survive. If the Company manages to raise a substantially lesser amount than the maximum amount, it will have to find other sources of funding for some of the plans outlined in "Use of Proceeds."

***Some of our products are ready for commercial sales, but there is no certainty that these products will be successfully marketed.***

Our ability to develop and commercialize products based on our proprietary technology will depend on our ability to develop products internally and may depend upon key outside partnerships that may not materialize on a timely basis or at all. There is no certainty that products employing our technology will be successfully marketed or licensed. Our products and technologies may prove to be unworkable or economically unfeasible. Many medical and pharmaceutical products require long development and testing periods and large capital investments with no certainty that the product will be successfully marketed.

***Some of our products are in the developmental stage and may require more testing.***

Our technologies are based on extensive testing, but there are still important questions and additional testing and development that will need to occur prior to making our products available for broad sale to the medical community. The Company may need to initiate expensive clinical studies to further support the use and market acceptance of our products. We have had limited technical input or evaluations with respect to our products from other physicians or medical professionals, and therefore have received limited validation of the potential efficacy of our products or their viability in the market from persons outside of our Company. Our limited resources in supporting our products could have a material adverse effect upon our business.

***We may have a limited number of products.***

We may not be able to afford to develop additional products. If the production or sales of any of our limited number of products do not meet our expectations, our dependence upon small numbers of products and our inability to quickly develop new products could have a material adverse effect upon our business, prospects, financial condition and results of operations.

***The failure of our products to gain market acceptance would have an adverse effect upon our ability to generate revenues and attain profitability***.

A significant challenge for us will be gaining market acceptance of our products. The participation and interest of practicing surgeons and other physicians will be critical. It may require significant time, effort and expense to attract sufficient numbers of physicians for our products to gain widespread acceptance. We cannot assure you that a sufficient number of physicians will invest the time required to gain familiarity with and be trained in the use of our products, or that, once trained, they will be committed to continued usage.

Similarly, other medical procedures and products can also treat certain of the medical indications that we believe can be treated by our products. The medical community widely accepts many alternative treatments, and certain of these other treatments have a long history of prior use. We cannot be certain that our products will gain acceptance over established treatments or that either physicians or the medical community in general will accept and use our products.

Market acceptance of our products depends on many factors, including our ability to convince prospective customers that our technology is an attractive alternative to other technologies, to manufacture products in sufficient quantities and at an acceptable cost, and to supply and service sufficient quantities of our products directly or through our strategic alliances. The industry is subject to rapid and continuous change arising from, among other things, consolidation and technological improvements.

One or more of these factors may vary unpredictably, which could have a material adverse effect upon our business, prospects, financial condition and results of operations.

***We will be dependent upon third party suppliers and manufacturers.***

Because of our limited resources, we will be dependent upon other companies to conduct research, supply key components and to manufacture our products. Our ability to develop and maintain relationships with these suppliers, as well as our ability to develop additional sources for key components and manufacturing capabilities, may be important for our long-term success. We cannot assure you that we will be able to establish or maintain relationships with third party suppliers and manufacturers that may be necessary for the execution of our business plan.

***Our potential inability to contract with qualified distributors to represent us and promote our products could have a negative effect on our business and financial performance.***

We will rely heavily on distributors to sell our products and to market our products to physicians. Our potential inability to establish distributor relationships could have a material adverse effect upon our business, prospects, financial condition and results of operations. If we are unable to establish relationships with qualified distributors, we will be unable to effectively compete for sales of our products in the medical industry.

***Reimbursement levels allowed by private and government insurance entities will affect the market acceptance of our products and our potential revenue.***

If we are unable to convince patients to pay cash or the health insurance entities to reimburse us for our products, it will very likely have a negative effect on our ability to generate significant revenues.

Physicians and hospitals are each responsible for the costs associated with surgical procedures. In order for both parties to receive payment for performing these surgical services they each must seek reimbursement from the patient and the patient's health care provider. The level of compensation is determined by reimbursement codes that are used to define each step of a surgical operation. Each code is defined by a detailed procedural description and associated level of monetary value. These industry standard codes are accepted throughout the healthcare industry and ultimately contribute to the success or failure of a new product introduction.

Physicians use codes, referred to as Current Procedural Terminology (CPT) codes, which are recognized by health care providers. Physicians define or code each step of an operative procedure by using a different code. These codes vary by procedure and often are subjective to the physician's specific definition of his procedure. These codes can be referenced from various sources such as the "Common Coding Scenarios for Comprehensive Spine Care," which is published annually by the American Medical Association. This code notation is submitted to the insurer and notifies the health care provider of what service or procedure was provided. A pre-established fee for that code number is then reimbursed to the operating physician. The code reimbursement value will vary based on the patient's insurance carrier as each carrier maintains different levels for reimbursement.

Not only does the surgeon submit for reimbursement for his surgery, but the hospital also provides a service requiring a separate code submission for reimbursement. Diagnosis-Related Group ("DRG") codes are codes responsible for hospital reimbursement under the Medicare Prospective Payment System. New DRG codes are continuously being created to more clearly address different procedures necessary in the medical industry.

Reimbursement for spine and orthopedic procedures will continue to change as the national healthcare system places pressure on the industry to lower costs. More specifically, manufacturers will continue to be under pressure to offer competitive pricing as health care providers look for alternatives to decrease costs.

***Our products are not currently covered by any specific Current Procedural Terminology ("CPT") code, and we do not expect that there will be any CPT code approved for reimbursement of our products any time in the near future.***

The CPT code set is maintained by the American Medical Association through the CPT Editorial Panel. CPT codes are used to describe medical, surgical, and diagnostic services and are designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers (including the Centers for Medicare and Medicaid Services and insurers) for administrative, financial (including reimbursement), and analytical purposes.

Our products are not currently covered by any specific CPT code, and we do not expect that there will be any CPT code approved for reimbursement of our products any time in the near future. Until such time that a CPT code is approved that covers one or more of our products, patients would be required to pay for our products out of pocket. The process of obtaining a new CPT code to cover a product can take years and is expensive and full of uncertainties. Our inability to obtain a CPT code for our products on a timely or acceptable basis could have a material adverse effect upon our business, prospects, financial condition and results of operations. Further, approval of a CPT code for our products may place substantial restrictions on the indications for which our products may be used or the persons with whom they may be used. To gain reimbursement for the use of a product for clinical indications other than those for which the product was initially approved or cleared or for significant changes to the product, further studies, including clinical trials and approvals, may be required.

***Our operations will be subject to extensive government regulation.***

Medical products, devices and therapies are subject to extensive government regulation and review. These regulations are constantly changing. While we believe that our proposed operations will be conducted in material compliance with applicable laws, we have not received or applied for a legal opinion from counsel or from any federal or state judicial or regulatory authority to this effect, and many aspects of our business operations have not been the subject of state or federal regulatory interpretation. Interpretation and enforcement of existing federal and state laws regulating health care, and future laws regulating health care, could have a material adverse effect upon our business, prospects, financial condition and results of operations.

Our founder and Chairman of our Board of Directors, Gaetano Scuderi, M.D., is a physician. He owns a significant percentage of our issued and outstanding shares. A number of our other investors are physicians. All of our investor physicians may have a conflict of interest in working in the best interests of patients while recommending our products to those patients, because they may receive a financial benefit from sales of our products as a result of their ownership interest in our Company.

*Physician Self-Referral Laws.* The federal self-referral law (known as the "Stark Law") imposes restrictions on physicians' referrals for certain designated health services reimbursable by Medicare or Medicaid to entities with which any such physician (or an immediate family member) has a financial relationship, whether through an ownership, debt or compensation arrangement, and it prohibits an entity from billing Medicare or Medicaid, or any other federally funded health benefit program, for services rendered pursuant to a prohibited referral. Violations can result in denial and recoupment of payments for services, imposition of substantial civil or monetary penalties and exclusion from Medicare and Medicaid. In addition, several states have adopted self-referral laws, some of which are not limited to Medicare or Medicaid reimbursed services or to certain designated health services. Violation of any such laws may result in the imposition of penalties on the physicians pursuant to applicable regulations, including fines and suspension or revocation of the physician's license. Investors should make their own determination as to the risk of violation of the Stark Law. Any sanctions imposed upon us could have a material adverse effect upon our business, prospects, financial condition and results of operations.

*Fraud and Abuse.* The anti-kickback provisions of the Social Security Act prohibit the solicitation, payment, receipt or offering of any direct or indirect remuneration in return for, or as an inducement for, referrals of patients for items or services reimbursable under Medicare, Medicaid or other federally funded health care benefit programs. Violation of these provisions, which are commonly known as the "Fraud and Abuse Law," can lead to the imposition of civil and criminal penalties upon all parties involved, including substantial civil monetary penalties and exclusion from Medicare, Medicaid and other federally funded health care benefit programs. The scope of prohibited conduct under the Fraud and Abuse Law is broad and it extends to economic arrangements involving hospitals, physicians and their business partners, including arrangements such as those contemplated by us. Applicable state regulations may also prohibit the payment of remuneration in return for referrals. Violation of these state regulations may result in the imposition of monetary penalties on physicians, and suspension or revocation of a physician's license. It is not certain that our operations will meet the requirements of a safe harbor under the Fraud and Abuse Law. We cannot assure you that our operations do not, or in the future will not, violate such law, and any sanctions imposed upon us could have a material adverse effect upon our business, prospects, financial condition and results of operations.

*Licensure and Corporate Practice of Medicine.* State laws and regulations combine to regulate the provision of health care services by prohibiting business entities, such as us, from practicing medicine or otherwise providing health care services without a license and from exercising control over the medical judgments or decisions of physicians and licensed entities. Violation of these requirements could result in civil and criminal sanctions against us. While we believe that our business as structured materially complies with these laws, we cannot assure you that the regulatory authorities or other parties will not assert that we are engaged in the corporate practice of medicine or the unlicensed provision of health care services, and if such an action were taken or such a determination were made, it could have a material adverse effect upon our business, prospects, financial condition and results of operations.

***We may not be able to obtain the regulatory approvals necessary to market our products. Further, if we fail to comply with the extensive governmental regulations that affect our business, we could be subject to penalties and could be precluded from marketing our products.***

Our research and development activities and the manufacturing, labeling, distribution and marketing of our products will be subject to regulation by numerous governmental agencies, including but not limited to the United States Food and Drug Administration ("FDA"), the State of Florida, HHS, CMS, and the Therapeutics and Goods Administration ("TGA") in Australia The FDA and TGA impose mandatory procedures and standards for the conduct of clinical trials and the production and marketing of products for diagnostic and human therapeutic use.

Our products are subject to approvals or clearances prior to marketing for commercial use. The process of obtaining necessary approvals or clearances can take years and is expensive and full of uncertainties. Our inability to obtain required regulatory approvals on a timely or acceptable basis could have a material adverse effect upon our business, prospects, financial condition and results of operations. Further, approvals or clearances may place substantial restrictions on the indications for which our products may be marketed or the persons to whom they may be marketed. To gain approval for the use of a product for clinical indications other than those for which the product was initially approved or cleared or for significant changes to the product, further studies, including clinical trials and approvals, may be required.

We believe that the most significant risk relates to the regulatory classification of certain of our products. In the filing of each application, we make a legal judgment about the appropriate form and content of the application. If the regulator disagrees with our judgment in any particular case and, for example, requires us to file a pre-market approval application rather than allowing us to market for approved uses while we seek broader approvals, or requires extensive additional clinical data, the time and expense required to obtain the required approval might be significantly increased or the approval might not be granted.

Approved products will be subject to continuing regulatory requirements relating to quality control and quality assurance, maintenance of records, reporting of adverse events, documentation, and labeling and promotion of medical devices.

The regulatory authorities require that our products be manufactured according to rigorous standards. These regulatory requirements may significantly increase our production or purchasing costs above currently expected levels and may even prevent us from making our products in quantities sufficient to meet market demand. If we change our approved manufacturing process, regulators may require a new approval before that process may be used. Failure to develop our manufacturing capability may mean that even if we develop promising new products, we may not be able to produce them profitably, as a result of delays and additional capital investment costs. Manufacturing facilities are also subject to inspections by or under the authority of the relevant regulator. In addition, failure to comply with applicable regulatory requirements could subject us to enforcement action, including product seizures, recalls, withdrawal of clearances or approvals, restrictions on or injunctions against marketing our product or products based on our technology, and civil and criminal penalties.

***The Affordable Care Act and other payment and policy changes may have a material adverse effect on us.***

The Patient Protection and Affordable Care Act enacted on March 23, 2010, as amended by the Health Care and Education Reconciliation Act of 2010 enacted on March 30, 2010, or, together, the Affordable Care Act, imposes a 2.3% excise tax on the sale of any taxable human medical device after December 31, 2012, subject to certain exclusions, by the manufacturer, producer or importer of such devices. The total cost to the industry was expected to be approximately $20 billion over ten years. This significant tax burden on our industry could have a material negative impact on the results of our operations and our cash flows. A significant portion of our sales will be considered medical device sales under this new legislation. Therefore, our products will be subject to this excise tax.

Further, the Affordable Care Act encourages hospitals and physicians to work collaboratively through shared savings programs, such as accountable care organizations, as well as other bundled payment initiatives, which may ultimately result in the reduction of medical device acquisitions and the consolidation of medical device suppliers used by hospitals. While passage of the Affordable Care Act may ultimately expand the pool of potential end-users of our products, the above-discussed changes could adversely affect the prices we are able to charge for our products or the amounts of reimbursement available for our products and could limit the acceptance and availability of our products. Each of these could have a material adverse effect on our financial position and the results of our operations.

Further, with the increase in demand for healthcare services, we expect both a strain on the capacity of the healthcare system and more proposals by legislators, regulators and third-party payers to keep healthcare costs down. Certain proposals, if passed, could impose limitations on the prices we will be able to charge for our products, or the amounts of reimbursement available from governmental agencies or third-party payers. These limitations could have a material adverse effect on our financial position and results of operations.

Federal healthcare reform continues to be a political issue, and it is unclear how federal elections may ultimately impact the effects of the Affordable Care Act. Various healthcare reform proposals have also emerged at the state level. We cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, or the effect any future legislation or regulation will have on us. However, an expansion in government's role in the United States healthcare industry may lower reimbursements for our products, reduce medical procedure volumes and adversely affect our business, possibly materially.

***Changes in the health care industry may require us to reduce the selling prices for our products or result in a reduction in the size of the market for our products, which could have a negative effect on our financial performance.***

Trends toward managed care, health care cost containment and other changes in government and private sector initiatives are placing increased emphasis on the delivery of more cost-effective medical therapies that could adversely affect the sale or the prices of our products. For example:

&nbsp;&nbsp;&nbsp;&nbsp;· Major third-party payers
 of hospital services, including Medicare and Medicaid and private health care insurers, have substantially revised their payment
 methodologies, which has resulted in stricter standards for reimbursement of hospital charges for certain medical procedures;

· Third-party payer cutbacks
 could create downward price pressure;

&nbsp;&nbsp;&nbsp;&nbsp;· Numerous legislative changes
 have been passed and others are being considered that would result in major reforms in the U.S. health care system that could have
 an adverse effect on our business;

· There has been a consolidation
 among health care facilities and purchasers of medical products in the United States and these entities, which prefer to limit the
 number of suppliers from which they purchase medical products, may decide not to purchase or to stop purchasing our products or demand
 discounts on our prices;

· There are proposed and
 existing laws and regulations in many markets regulating pricing and profitability of companies in the health care industry; and

· There have been initiatives
 by third-party payers to challenge the prices charged for medical products, which initiatives could affect our ability to sell products
 on a competitive basis.

Both the pressure to reduce prices for our products in response to these trends and the decrease in the size of the market as a result of these trends could adversely affect our future levels of revenues and profitability of sales.

In addition, there are laws and regulations that regulate the means by which companies in the health care industry may compete by discounting the prices of their products. Although we intend to exercise care in structuring our customer discount arrangements to comply with those laws and regulations, we cannot assure you that:

&nbsp;&nbsp;&nbsp;&nbsp;· Government officials charged
 with responsibility for enforcing those laws will not assert that our customer discount arrangements are in violation of those laws
 or regulations; or

· Government regulators or
 courts will interpret those laws or regulations in a manner consistent with our interpretation.

***We may be subject to material liability or litigation expenses for claims associated with our products or related instruments.***

Because of the nature of our business, we may become a defendant in medical malpractice, products liability or similar lawsuits, and may become subject to the attendant risk of substantial damage awards. Direct claims, suits or complaints could be asserted against us. While we expect to address these risks through comprehensive general liability insurance, we cannot assure you that such insurance will be available to us, affordable for us, or that any claim asserted against us will be covered by insurance, or will not exceed the coverage limits of applicable insurance. Further, we cannot assure you that we will be able to obtain any such insurance in the future, or that the insurance, if available, will not be too costly to obtain or maintain. A claim against us that is not defended by an insurance carrier, or a successful claim against or settlement by us in excess of our insurance coverage, or our inability to obtain or maintain insurance, could have a material adverse effect upon our business, prospects, financial condition and results of operations.

***Our current and planned business is inherently expensive, risky and may not be understood by or accepted in the marketplace, which could adversely affect our future value.***

The business currently conducted by the Company is financially speculative. To date, very few companies have been successful in their efforts to commercialize such a business. Furthermore, the number of people who may use our services is difficult to forecast with accuracy. Our future success is dependent on the establishment of the market for our services and our ability to capture a share of this market with the services and offerings we plan to develop. Due to the groundwork laid by the founders, our costs have been kept at a minimum. This allows us to become profitable quickly with a very minute amount of the potential market using our tools and resources.

***We may not effectively execute our strategy.***

Our business strategy requires that we successfully and simultaneously complete many tasks. To be successful, we will need to:

&nbsp;&nbsp;&nbsp;&nbsp;· Raise sufficient capital
 to fund our financial requirements;

· Develop products that gain
 market acceptance and can be sold at competitive prices;

· Negotiate effective business
 relationships and licensing agreements with others in the pharmaceutical and medical device industry;

· Attract and retain qualified,
 professional employees; and

· Evolve our business to
 gain advantages in an increasingly competitive environment.

We cannot assure you that we will be able to successfully execute any or all of the elements of our strategy. Our failure to successfully execute any one of the elements of our strategy may have a material adverse effect on our business and results of operations.

***We may fail to implement our business plan.***

Investors may lose their entire investment if we fail to implement our business plan. Our prospects must be considered in light of the risks, uncertainties, expenses, and difficulties frequently encountered by companies in their early stages of development. These risks include, without limitation, competition, the absence of ongoing revenue streams, inexperienced management and lack of brand recognition. We cannot guarantee that we will be successful in executing our business. If we fail to implement and create a base of operations for our proposed business, we may be forced to cease operations, in which case investors may lose their entire investment.

***Information technology system failures or breaches of our network security could interrupt our operations and adversely affect our business***.

We rely on our computer systems and network infrastructure across our operations. Our operations depend upon our ability to protect our computer equipment and systems against damage from physical theft, fire, power loss, telecommunications failure or other catastrophic events, as well as from internal and external security breaches, viruses and other disruptive problems. Any damage or failure of our computer systems or network infrastructure that causes an interruption in our operations could have a material adverse effect on our business and subject us to litigation or to actions by regulatory authorities.

We are continuing to develop our information technology capabilities, if we are unable to successfully upgrade or expand our technological capabilities, we may not have the ability to take advantage of market opportunities, manage our costs and transactional data effectively, satisfy customer requirements, execute our business plan or respond to competitive pressures.

***We are exposed to the risk of natural disasters, unusual weather conditions, pandemic outbreaks, political events, war and terrorism that could disrupt business and result in lower sales, increased operating costs and capital expenditures.***

Our headquarters and Company-operated locations, as well as certain of our vendors and customers, are located in areas which have been and could be subject to natural disasters such as floods, hurricanes, tornadoes, fires or earthquakes. Adverse weather conditions or other extreme changes in the weather, including resulting electrical and technological failures, may disrupt our business and may adversely affect our ability to continue our operations. These events also could have indirect consequences such as increases in the costs of insurance if they result in significant loss of property or other insurable damage. Any of these factors, or any combination thereof, could adversely affect our operations.

***Public health epidemics or outbreaks could adversely impact our business.***

In December 2019, a novel strain of coronavirus (COVID-19) emerged in China, setting in motion a global pandemic and unprecedented global disruptions. To the extent future unforeseen pandemics arise, they could adversely impact our operations, including, among others, our sales and marketing and ability to continue with clinical trials, and could generally have an adverse impact on our business and our financial results.

***Our business is located in Florida and may be subject to interruptions caused by hurricanes and other natural disasters.***

Our physical facilities and employees are all located in southeastern Florida and thus our business operations are more susceptible than businesses located in other parts of the country to interruptions caused by hurricanes and flooding. These natural disasters pose a risk of damage to our facilities and interruptions to our business, which could be prolonged, as a result of extended power outages, the unavailability of our employees during periods when they must attend to personal circumstances, and the inability of third parties to provide necessary services to us due to similar factors. Damage to our facilities and extended interruption of our business could result in lost revenues and other material adverse consequences for our business, which may not be adequately covered by insurance or for which insurance may not be available.

***Our Contract Drug Manufacturing Organization, Goodwin Biotechnology, is located in Florida and may be subject to interruptions caused by hurricanes and other natural disasters.***

Goodwin Biotechnology's ("GBI") physical facilities and employees are all located in southeastern Florida and thus their business operations are more susceptible than businesses located in other parts of the country to interruptions caused by hurricanes and flooding. These natural disasters pose a risk of damage to their facilities and interruptions to our business, which could be prolonged, as a result of extended power outages, the unavailability of our employees during periods when they must attend to personal circumstances, and the inability of third parties to provide necessary services to us due to similar factors. Damage to GBI's facilities and extended interruption of their business could result in delays in Cytonics' clinical trials and research, and other material adverse consequences for our business, which may not be adequately covered by insurance or for which insurance may not be available.

***Rapid growth may strain our resources.***

We expect to experience significant and rapid growth in the scope and complexity of our business, which may place a significant strain on our senior management team and our financial and other resources. Such growth, if experienced, may expose us to greater costs and other risks associated with growth and expansion. We may be required to hire a broad range of additional employees, including other support personnel, among others, in order to successfully advance our operations. We may be unsuccessful in these efforts or we may be unable to project accurately the rate or timing of these increases.

Our ability to manage our growth effectively will require us to continue to improve our operations, to improve our financial and management information systems, and to train, motivate, and manage our future employees. This growth may place a strain on our management and operational resources. The failure to develop and implement effective systems, or to hire and retain sufficient personnel for the performance of all of the functions necessary to effectively service and manage our business, or the failure to manage growth effectively, could have a materially adverse effect on our business, financial condition, and results of operations. In addition, difficulties in effectively managing the budgeting, forecasting, and other process control issues presented by such a rapid expansion could harm our business, financial condition, and results of operations.

***Our risk management efforts may not be effective which could result in unforeseen losses.***

We could incur substantial losses and our business operations could be disrupted if we are unable to effectively identify, manage, monitor, and mitigate financial risks, such as credit risk, interest rate risk, prepayment risk, liquidity risk, and other market-related risks, as well as operational risks related to our business, assets and liabilities. Our risk management policies, procedures, and techniques, including our scoring methodology, may not be sufficient to identify all of the risks we are exposed to, mitigate the risks we have identified or identify additional risks to which we may become subject in the future.

We plan to mitigate this risk by executing our business plan and creating cash flow in order to stem the need for debt acquisition to survive.

***Compliance with Regulation A and reporting to the SEC could be costly, and our management will be required to devote substantial time to the compliance requirements of Regulation A.***

Compliance with Regulation A could be costly and requires legal and accounting expertise. After qualifying this Form 1-A, we will be obligated to file an annual report on Form 1-K, a semiannual report on Form 1-SA, and current reports on Form 1-U.

Our legal and financial staff may need to be increased in order to comply with Regulation A. Compliance with Regulation A will also require greater expenditures on outside counsel, outside auditors, and financial printers in order to remain in compliance. Failure to remain in compliance with Regulation A may subject us to sanctions, penalties, and reputational damage and would adversely affect our results of operations.

***If we become a public reporting Company in the future, we will be required to publicly report on an ongoing basis as an "emerging growth Company" and will be subject to less rigorous public reporting requirements and cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors.***

If we become a public reporting Company in the future, we will be required to publicly report on an ongoing basis as an "emerging growth Company" (as defined in the Jumpstart Our Business Startups Act of 2012, which we refer to as the JOBS Act) under the reporting rules set forth under the Exchange Act. For so long as we remain an "emerging growth Company", we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not "emerging growth companies", including but not limited to:

***Members of our Board and our executive officers will have other business interests and obligations to other entities, and certain officers and directors may have conflicts of interest.***

None of our directors or our executive officers will be required to manage the Company as their sole and exclusive function and they may have other business interests and may engage in other activities in addition to those relating to the Company, provided that such activities do not compete with the business of the Company or otherwise breach their agreements with the Company. We are dependent on our directors and executive officers to successfully operate our Company. Their other business interests and activities could divert time and attention from operating our business.

Individuals serving on our Board of Directors or as our officers actively participate in other business ventures and investment opportunities, including those that may compete with us. A conflict of interest is likely to arise if a director or officer becomes affiliated with a business entity that is a competitor, customer, provider or supplier of, or otherwise does business with, our Company. Individuals with such conflicts are required to disclose any such conflicts to us pursuant to their fiduciary duty of loyalty to our Company as required by our corporate governance policies and Florida state law. However, we cannot be certain that our directors and officers will always make disclosures, and therefore we may not be able to determine if a conflict of interest exists.

**Intellectual Property Risks**

***Our success depends in part on our ability to obtain, maintain and protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.***

Our commercial success will depend in large part on obtaining and maintaining patent, trademark, trade secret and other intellectual property protection of our proprietary technologies and product candidate, which includes CYT-108, as well as successfully defending our patents and other intellectual property rights against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our product candidate is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected.

The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees to do so. Our pending and future patent applications may not result in issued patents. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether any of our platform advances and product candidates will be protectable or remain protected by valid and enforceable patents. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies.

***Our proprietary technology includes unpatented trade secrets, which we may not be able to protect.***

Our proprietary technology includes unpatented trade secrets, the competitive advantage of which is substantially dependent upon our ability to maintain their continued secrecy. Trade secrets are difficult to protect. We cannot assure you that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets, that those trade secrets will not be disclosed, or that we can effectively protect our unpatented trade secrets.

In an effort to protect our trade secrets, we have a policy of requiring our employees, consultants and advisors to execute proprietary information agreements upon commencement of employment or consulting relationships with us. We expect that these agreements will provide that all confidential information developed or made known to the individual during the course of his or her relationship with us must be kept confidential, except in specified circumstances. We cannot assure you, however, that these agreements will provide meaningful protection for our trade secrets or other proprietary information in the event of the unauthorized use or disclosure of confidential information.

***Third-party claims of intellectual property infringement may prevent, delay or otherwise interfere with our product discovery and development efforts.***

Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidate and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, *inter partes* review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidate. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidate may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our field, third parties may allege they have patent rights encompassing our product candidate, technologies or methods.

***Our intellectual property rights may not provide meaningful commercial protection for our products, which could enable third parties to use our technology or very similar technology and could reduce our ability to compete successfully.***

Our ability to compete effectively will depend, in part, on our ability to maintain the proprietary nature of our technologies, which includes our ability to obtain, protect and enforce patents on our technology and to protect our trade secrets. While our technology is subject to patent applications that cover significant aspects of our product line, our patent applications may not provide us with any significant competitive advantage. Others may challenge our patent applications and, as a result, our proprietary rights could be narrowed, invalidated or rendered unenforceable. Competitors may develop products similar to ours that our patent applications do not cover. Our current and future patent applications may not result in the issuance of patents. Further, there is a substantial backlog of patent applications in many patent offices and the approval or rejection of patent applications may take several years.

***We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful and could result in a finding that such patents are unenforceable or invalid.***

Competitors may infringe our patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.

In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. These types of mechanisms include re-examination, post-grant review, *inter partes* review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). These types of proceedings could result in revocation or amendment to our patents such that they no longer cover our product candidates. The outcome for any particular patent following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Defense of these types of claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.

Conversely, we may choose to challenge the patentability of claims in a third party's U.S. patent by requesting that the USPTO review the patent claims in re-examination, post-grant review, *inter partes* review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings), or we may choose to challenge a third party's patent in patent opposition proceedings in the European Patent Office, or EPO, or another foreign patent office. Even if successful, the costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our Common Stock. Any of the foregoing could have a material adverse effect on our business financial condition, results of operations and prospects.

***We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.***

We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our product candidates in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

***We are dependent upon a limited number of PhD's and MDs for the continued development of our proprietary technology, and if one or more of them were to become unavailable to us, our ability to continue the development of our technology could be adversely affected.***

Dr. Gaetano Scuderi, Dr. Lewis Hanna, Dr. Robert Bowser, Dr. Shawn Browning, and Dr. John David Laughlin are the named inventors of all or part of our patented technology, and we depend to a substantial degree upon some of them for continued development of our technology and applications of our technology to the spine and joint markets. We have the right of ownership in any future technologies or products that they may develop while working for the Company or as consultants. They have assigned their rights in our proprietary technology to the Company, and as employees and/or shareholders in our Company, continue to have an economic incentive to work with us on the development and commercialization of our technology. Nevertheless, we do not have any agreements with them that obligate them to continue providing services or other assistance to us, including in the continued development and commercialization of our products and our technology. If they were to cease providing assistance to us in these areas, our business could be adversely affected.

***Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.***

As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. Although no misappropriation or improper disclosure claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. We may then have to pursue litigation to defend against these claims. If we fail in defending any claims of this nature in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these types of claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our Common Stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities, and we may not have sufficient financial or other resources to adequately conduct this type of litigation or proceedings. For example, some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.

***We have disclosed detailed information regarding our intellectual property to certain of our competitors.***

We have disclosed some of our product designs and other proprietary information to certain potential partners who may also compete with us in the future. Although these parties have executed non-disclosure agreements with respect to the proprietary information, there can be no assurances that they will maintain the confidentiality of our intellectual property rights or refrain from infringing on our intellectual property rights.

***Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.***

Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Were a noncompliance event to occur, our competitors might be able to enter the market, which would have a material adverse effect on our business financial condition, results of operations and prospects.

***Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.***

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.

Past or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. For example, in March 2013, under the Leahy-Smith America Invents Act, or America Invents Act, the United States moved from a "first to invent" to a "first-to-file" patent system. Under a "first-to-file" system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO continues to promulgate new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the "first-to-file" provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on the specific patents discussed in this filing have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

Additionally, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case, *Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,* the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of our owned patents will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.

***Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.***

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

***If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.***

Depending upon the timing, duration and specifics of any FDA marketing approval of our product candidate, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, even if we were to seek a patent term extension, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.

**SPECIAL INFORMATION REGARDING FORWARD LOOKING STATEMENTS**

Some of the statements in this Offering Circular are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the factors set forth above under "Risk Factors." The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.

We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this document to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a non-reporting issuer. Further, Section 27A(b)(2)(D) of the Securities Act and Section 21E(b)(2)(D) of the Exchange Act expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with an initial public offering.

**DILUTION**

In the past 12 months, our CEO, Joey Bose, and the Company's Chairman, Gaetano J. Scuderi, purchased $5,000 and $100,000 of Shares, respectively, in our previous Regulation A offering, on the same terms as other investors at $3.00 per Share. Therefore, investors are not expected to experience immediate dilution due to these Shares being purchased by management. However, the public offering price of our Shares is higher than the pro forma net tangible book value per share of the outstanding Common Shares immediately after this offering. As a result of this dilution, investors purchasing Shares in this offering could receive significantly less than the full purchase price that they paid for the Shares purchased in this offering in the event of a liquidation. Further, we have outstanding convertible securities with strike prices less than the price per Share in this offering. Consequently, if these securities are exercised, there could be further dilution to the purchasers of our Shares. Further, we are offering Bonus Shares to certain investors investing $5,000 or more and existing investors, thereby diluting any investor who is not issued Bonus Shares or any investor who is issued Bonus Shares at a lower percentage than other investors.

**PLAN OF DISTRIBUTION**

We are offering up to 8,000,000 Shares of our Common Stock in the Company at a price per Share of $5.00, for a potential maximum Offering Amount of $40,000,000. The Company is also charging investors a 3.5% Investor Processing Fee, for additional proceeds to the Company of up to $1,400,000. No Shares will be issued in exchange for the Investor Processing Fee but the Broker will earn its commission on such fee. There is no minimum offering amount and no provision to return investor funds if a minimum number of Shares is not sold. All accepted subscription funds will be immediately available for the Company's use. No fractional Shares will be issued. The minimum investment established for each investor is $1,000, plus the Investor Processing Fee ($1,035 total), which minimum may be waived by the Company on a case by case basis for any reason or no reason at all.

To offset some of the transactional expenses associated with this offering, we will charge investors a fee equal to 3.5% of the dollar amount of Shares purchased. The Investor Processing Fee will be rounded to the nearest whole cent. No Shares will be issued in consideration for Investor Processing Fees

Investors will receive Bonus Shares as follows:

**Loyalty Bonus \| 5% Bonus Shares**

Prior investors in the Company are eligible for 5% Bonus Shares as a loyalty bonus regardless of the amount of shares of Common Stock they purchase in this Offering.

**Investment Incentives**

Invest $2,500 and receive 3% bonus shares

Bronze \| $5,000+

Invest $5,000+ and receive 5% bonus shares.

Silver \| $10,000+

Invest $10,000+ and receive 10% bonus shares + 1 hour call with Joey Bose (President and CEO).

Gold \| $20,000+

Invest $20,000+ and receive 15% bonus shares + all Silver Tier Company Perks, plus a conversation with Gaetano Scuderi, MD (Founder and board-certified orthopedic surgeon) regarding any musculoskeletal ailments you or a loved one are suffering from.

Diamond \| $50,000+

Invest $50,000+ and receive 20% bonus shares + all Silver and Gold Tier Company Perks.

Platinum \| $100,000+

Invest $100,000+ and receive 20% bonus shares + receive all Silver and Gold Tier Company Perks, plus free APIC<sup>TM</sup> treatment (our FDA-cleared therapy for osteoarthritis) (note: we will cover the cost of the APIC kit plus the physician's visit fee for administering the therapy, but not the initial consultation).

The maximum number of Bonus Shares that the Company will issue cannot be determined at this time; however, if the Company were to issue the maximum number of Bonus Shares possible, the Company would issue 1,600,000 Bonus Shares in this offering, for a total 9,600,000 offered Shares.

We intend to conduct multiple separate closings, which closings may be conducted on a rolling basis. Closings will occur promptly after receiving investor funds. We do not intend to conduct closings less frequently than every 30 days. This offering will terminate at the earlier to occur of: (i) all Shares offered hereby being sold, (ii) the date three years from the date this offering circular is initially qualified by the SEC, although the offering may be extended by an additional 180 days if the Company files a new offering statement covering these securities pursuant to SEC Rule 251 (d)(3)(i)(F) (notwithstanding the foregoing, the Company reasonably expects to sell all Bonds within two years from qualification), or (iii) such earlier date as terminated by the Company.

**Agreement with DealMaker Securities, LLC**

We have engaged DealMaker Securities, LLC as our Broker of record to assist in our self-driven capital raise on a best-efforts basis of our interests in those states where Broker is registered to undertake such activities. The Broker will not solicit potential investors and is under no obligation to purchase any securities or arrange for the sale of any specific number or dollar amount of securities.

The Company has also engaged affiliates of the Broker to provide certain ancillary services. The Broker and its affiliates provide separate services to the Company to help facilitate the offering, from establishment of the platform to be used for subscription processing, through back-office operations/compliance. Although orchestrated through the Broker, each affiliate has separate compensation, and agreements embedded into the Broker's services agreement.

Broker has not investigated the desirability or advisability of investment in the interests, nor approved, endorsed or passed upon the merits of purchasing the interests. Broker is not participating as an underwriter and under no circumstance will it recommend our Company's securities or provide investment advice to any prospective investor, or make any securities recommendations to investors. Broker is not distributing any offering circulars or making any oral representations concerning this offering circular or this offering. Based upon Broker's anticipated limited role in this offering, it has not and will not conduct extensive due diligence of this offering and no investor should rely on the involvement of Broker in this offering as any basis for a belief that it has done extensive due diligence. Broker does not expressly or impliedly affirm the completeness or accuracy of the offering statement and/or offering circular presented to investors by our Company. All inquiries regarding this offering should be made directly to our Company.

*Fees, Commissions and Discounts*

The following table shows the total maximum discounts and commissions payable to the Broker and its affiliates.

---

| | | |
|:---|:---|:---|
|  | Per Share | Total |
| Public offering price (including Investor Processing Fee) | $5.175 | $41400000 |
| Maximum broker and affiliate commissions and fees, | $0.2791 | $2233000 |
| Proceeds, before other expenses | $4.90 | $39167000 |

---

*Administrative and Compliance Related Functions*

With the services provided by the Broker and its affiliates there are different fee types associated with the specific services, which are routine for those service providers. None of the fees for the services are indeterminant in nature, and therefore have their own set maximum fees, and as described below none of these fees will exceed the "Maximum Dollar Compensation."

The compensation described below in a.), b.) and c.) payable to Broker and affiliates, will, in aggregate, not exceed $2,233,000 (if the offering is fully subscribed).

Broker has not investigated the desirability or advisability of investment in the interests, nor approved, endorsed or passed upon the merits of purchasing the interests. Broker is not participating as an underwriter and under no circumstance will it recommend our Company's securities or provide investment advice to any prospective investor, or make any securities recommendations to investors. Broker is not distributing any offering circulars or making any oral representations concerning this offering circular or this offering. Based upon Broker's anticipated limited role in this offering, it has not and will not conduct extensive due diligence of this offering and no investor should rely on the involvement of Broker in this offering as any basis for a belief that it has done extensive due diligence. Broker does not expressly or impliedly affirm the completeness or accuracy of the offering statement and/or offering circular presented to investors by our Company. All inquiries regarding this offering should be made directly to our Company.

a.) Administrative and Compliance Related Functions

Our Broker has agreed to provide the following services for commissions equal to 4.5% of the amount raised in this offering, including the Investor Processing Fees:

● Reviewing and performing due diligence on our Company and our management and principals and consulting with us regarding same;

● Consulting with our Company on best business practices regarding this raise in light of current market conditions and prior self-directed capital raises;

● White labelled platform customization to capture investor acquisition through the Broker's platform's analytic and communication tools;

● Consulting with our Company on question customization for investor questionnaire;

● Consulting with our Company on selection of webhosting services;

● Consulting with our Company on completing template for the Offering campaign page;

● Advising us on compliance of marketing materials and other communications with the public with applicable legal standards and requirements;

● Providing advice to our Company on preparation and completion of this offering circular;

● Advising our Company on how to configure our website for the offering working with prospective investors;

● Assisting our Company in the preparation of state, Commission and FINRA filings related to the Offering;

● Working with our personnel and counsel in providing information to the extent necessary;

● Reviewing investor information, including identity verification, performing Anti-Money Laundering ("AML") and other compliance background checks, and providing issuer with information on an investor in order for issuer to determine whether to accept such investor into the Offering;

● If necessary, discussions with us regarding additional information or clarification on a Company-invited investor;

● Coordinating with third-party agents and vendors in connection with performance of services;

● Reviewing each investor's subscription agreement to confirm such investor's participation in the Offering and provide a recommendation to us whether or not to accept the subscription agreement for the investor's participation;

● Contacting and/or notifying us, if needed, to gather additional information or clarification on an investor;

● Providing a dedicated account manager; and

● Providing ongoing advice to us on compliance of marketing material and other communications with the public, including with respect to applicable legal standards and requirements.

b.) Technology Services

The Company has also engaged Novation Solutions Inc. O/A DealMaker ("DealMaker"), an affiliate of Broker, to create and maintain the online subscription processing platform for the offering.

After the qualification by the Commission of the Offering Statement of which this Offering Circular is a part, this offering will be conducted using the online subscription processing platform of DealMaker through our website whereby investors will receive, review, execute and deliver subscription agreements electronically as well as make payment of the purchase price through a third-party processor by ACH debit transfer or wire transfer or credit card to an account we designate.

For these services, we have agreed to pay DealMaker $2,000 month for up to three months ($6,000) for accountable expenses, prior to the Offering commencing. Once the Offering commences, DealMaker will be paid $2,000 monthly for up to $18,000. The total expected compensation to be paid to DealMaker would not to exceed $24,000.

c.) Marketing Services

The Company has also engaged DealMaker Reach, LLC ("Reach"), an affiliate of Broker, for certain marketing advisory and consulting services. Reach may consult and advise on the design and messaging on creative assets, website design and implementation, paid media and email campaigns, advise on optimizing the Company's campaign page to track investor progress, and advise on strategic planning, implementation, and execution of Company's capital raise marketing budget. For marketing placement services relating to this offering, the Company will determine what services to use on a case-by-case basis and may pay fees for such services up to an additional $250,000. The Company has also agreed to pay Reach $8,000 a month for three months ($24,000) for accountable expenses, prior to the Offering commencing. Once the Offering commences, Reach will be paid a monthly fee of $8,000 for up to $72,000. The total expected compensation to be paid to Reach should not exceed $346,000.

**Investor Qualification Standards**

Our Shares are being offered and sold only to "qualified purchasers" (as defined in Regulation A under the Securities Act). "Qualified purchasers" include: (i) "accredited investors" under Rule 501(a) of Regulation D and (ii) all other investors so long as their investment in any of the interests of our Company does not represent more than 10% of the greater of their annual income or net worth (for natural persons), or 10% of the greater of annual revenue or net assets at fiscal year-end (for non-natural persons). We reserve the right to reject any investor's subscription in whole or in part for any reason, including if we determine in our sole and absolute discretion that such investor is not a "qualified purchaser" for purposes of Regulation A.

For an individual potential investor to be an "accredited investor" for purposes of satisfying one of the tests in the "qualified purchaser" definition, the investor must be a natural person who has:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. an individual net worth, or joint net worth with the person's spouse, that exceeds $1,000,000 at the time of the purchase, excluding the value of the primary residence of such person and the mortgage on that primary residence (to the extent not negative equity), but including the amount of debt that exceeds the value of that residence and including any increase in debt on that residence within the prior 60 days, other than as a result of the acquisition of that primary residence; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. earned income exceeding $200,000 in each of the two most recent years or joint income with a spouse exceeding $300,000 for those years and a reasonable expectation of the same income level in the current year.

If the investor is not a natural person, different standards apply. See Rule 501 of Regulation D for more details. For purposes of determining whether a potential investor is a "qualified purchaser," annual income and net worth should be calculated as provided in the "accredited investor" definition under Rule 501 of Regulation D.

If you live outside the United States, it is your responsibility to fully observe the laws of any relevant territory or jurisdiction outside the United States in connection with any purchase, including obtaining required governmental or other consent and observing any other required legal or other formalities.

Before making any representation that your investment does not exceed applicable federal thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to http://www.investor.gov. We may accept or reject any subscription, in whole or in part, for any reason or no reason at all.

An investment in our Shares may involve significant risks. Only investors who can bear the economic risk of the investment for an indefinite period of time and the loss of their entire investment should invest in our interests.

**How to Subscribe**

In order to invest, you will be required to subscribe to the offering via the Company's investor portal and agree to the terms of the offering, subscription agreement, and any other relevant exhibit attached thereto. Any potential investor will have time to review the subscription agreement, along with their counsel, prior to making any final investment decision.

After the Commission has qualified the offering statement, the offering will be conducted using the online subscription processing platform of Novation Solutions Inc. O/A DealMaker ("Technology Provider"), an affiliate of the Broker, through our website at <u>www.invest.cytonics.com</u> whereby investors in the offering will receive, review, execute, and deliver subscription agreements electronically. Payment of the purchase price for the interests will be made through a third-party processor.

As part of the subscription process, each prospective investor must represent in writing that they meet, among other things, all of the following requirements:

● the prospective investor has received, reviewed, and understands this offering circular and its exhibits;

● the prospective investor understands that an investment in Shares involve substantial risks;

● the prospective investor's overall commitment to non-liquid investments is, and after their investment in interests will be, reasonable in relation to their net worth and current needs;

● the prospective investor has adequate means of providing for their financial requirements, both current and anticipated, and has no need for liquidity in this investment;

● the prospective investor can bear the economic risk of losing their entire investment in interests;

● the prospective investor has such knowledge and experience in business and financial matters as to be capable of evaluating the merits and risks of an investment in interests; and

● the prospective investor agrees to the alternative dispute resolution, forum selection, and jury waiver terms in the Company.

Investors may subscribe by tendering funds via wire, credit or debit card, ACH, or accepted Stablecoin only; checks will not be accepted. Investors will subscribe via the Company's website and investor funds will be processed via DealMaker's integrated payment solutions. Funds will be held in the Company's payment processor account until the Broker has reviewed the proposed subscription, and the Company has accepted the subscription. Funds released to the Company's bank account will be net funds (investment less payment for processing fees and a holdback equivalent to 5% for 90 days).The Company will be responsible for payment processing fees, which are estimated at 2%. Upon each closing, funds tendered by investors will be made available to the Company for our use.

The Company maintains the right to accept or reject subscriptions in whole or in part, for any reason or for no reason, including, but not limited to: in the event that an investor fails to provide all necessary information, even after further requests from the Company, in the event an investor fails to provide requested follow up information to complete background checks or fails background checks, and in the event the Company receives oversubscriptions in excess of the maximum offering amount. Investors will be required to agree to indemnify our Company for misrepresentations of the investor within the subscription agreement or supplemental disclosures. Nonetheless, we may not require, and are not requiring, investors to waive any claims or remedies they may have against our Company under the Securities Act or Exchange Act.

All Shares will be issued in electronic form in book entry by our transfer agent. Once an investor's Shares have been issued, the investor will become a shareholder of our Company.

**Participation Right**

Pursuant to the terms of its Articles of Incorporation, as amended on February 16, 2011, the Company provided a notice to existing stockholders regarding their participation right in this offering under Regulation A. Under the participation right, existing stockholders have the right, but not the obligation, to purchase additional shares of the Company's Common Stock in this Regulation A offerings on a pro rata basis.

The notice for the participation right was provided in accordance with Rule 255(b) of Regulation A, and as such these indications of interest for the reserved shares are non-binding. Once this offering is qualified by the SEC, the Company will inform the stockholders that have indicated interest of their right to purchase their respective number of the reserved shares. Should the stockholder choose not to purchase their number of reserved Shares, the Company will make those shares available to any investor.

**Additional Information Regarding this Offering Circular**

We have not authorized anyone to provide you with information other than as set forth in this offering circular. Except as otherwise indicated, all information contained in this offering circular is given as of the date of this offering circular. Neither the delivery of this offering circular nor any sale made hereunder shall under any circumstances create any implication that there has been no change in our affairs since the date hereof.

From time to time, we may provide an "offering circular supplement" that may add, update or change information contained in this offering circular. We will also amend our offering statement annually while this offering is open to include updated financial statements. Any statement that we make in this offering circular will be modified or superseded by any inconsistent statement made by us in a subsequent offering circular supplement or amendment. The offering statement we filed with the SEC includes exhibits that provide more detailed descriptions of the matters discussed in this offering circular. You should read this offering circular and the related exhibits filed with the SEC and any offering circular supplement together with additional information contained in our annual reports, semiannual reports and other reports and information statements that we will file periodically with the SEC.

The offering statement and all amendments, supplements and reports that we have filed or will file in the future can be read on the SEC website at <u>www.sec.gov</u>.

**USE OF PROCEEDS**

The following table illustrates the amount of net proceeds to be received by the Company on the sale of the Shares offered hereby and the intended uses of such proceeds over an approximate 12 month period. It is possible that we may not raise the entire amount in Shares being offered through this Offering Circular. In such case, we will reallocate the use of proceeds as the Board of Directors deems to be in the best interests of the Company in order to effectuate its business plan. The intended use of proceeds are as follows:

***Capital Sources and Uses***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **100%** | **75%** | **50%** | **25%** |
| ***Proceeds from Sale of Shares*** | $40000000 | 30000000 | 20000000 | 10000000 |
| **Investor Processing Fees** | $1400000 | 1050000 | 700000 | 350000 |
| Offering Costs (1)(3) | $4140000 | 3105000 | 2070000 | 1035000 |
| **Use of Net Proceeds:** |  |  |  |  |
| Clinical Studies | $20000000 | 15000000 | 10000000 | 5000000 |
| Drug Production | $10000000 | 7500000 | 5000000 | 2500000 |
| Working Capital(2) | $7260000 | 5445000 | 3630000 | 1815000 |

---

<u>Notes:</u>

(1) DealMaker Securities
 LLC, referred to herein as the Broker, is engaged for administrative and compliance related services in connection with this Offering,
 but not for underwriting or placement agent services. Once the Commission has qualified the Offering Statement and this offering
 commences, the Broker will receive a cash commission equal to 4.5% of the amount raised in the offering. Additionally, the Broker
 and its affiliates will receive certain other fees (see "Plan of Distribution"). The Broker and its affiliates will receive a maximum cash compensation equal to $2,233,000
 in total. Our Company also expects to incur other expenses relating to this offering,
including, but not limited to, legal, accounting, compliance, travel, marketing, technology, printing and other miscellaneous fees. Any
monies budgeted for but not spent on offering expenses will be reallocated pro rata among the other categories in the above table.

(2) Working capital
 includes such things as investment in technology, marketing, payroll, ongoing legal and accounting, sales development, operations,
 repayment for Company financing arrangements as they come due, legal and accounting fees related to this offering, third-party payment
 processing, ongoing fees related to this offering, insurance costs, renovation and furnishing of properties to be sold to customers,
 and other typical operating costs. Proceeds from the sales of properties acquired through these raise proceeds may be put into operations
 or redeployed toward real estate.

(3) The Company has engaged
 DealMaker Reach, an affiliate of the Broker, for certain marketing advisory and consulting services. DealMaker Reach will consult
 and advise on paid media, partnership, email campaigns, and other marketing spend. The category of offering expenses related to marketing
 includes the expenses related to the paid media, partnerships, email campaigns, and other marketing spend associated with this Offering.

The allocation of the use of proceeds among the categories of anticipated expenditures represents management's best estimates based on the current status of the Company's proposed operations, plans, investment objectives, capital requirements, and financial conditions. Future events, including changes in economic or competitive conditions of our business plan or the completion of less than the total offering, may cause the Company to modify the above-described allocation of proceeds. The Company's use of proceeds may vary significantly in the event any of the Company's assumptions prove inaccurate. We reserve the right to change the allocation of net proceeds from the offering as unanticipated events or opportunities arise.

**DESCRIPTION OF BUSINESS**

**Overview**

We were originally organized on July 26, 2006 in Florida as Gamma Spine, Inc. On April 20, 2007, we changed our name from Gamma Spine, Inc. to Cytonics Corporation. We have one subsidiary, Cytonics Australia Pty Ltd. organized on August 25, 2023.

We were founded as a private research and development Company focusing on molecular diagnostic and therapeutic products for osteoarthritis ("OA"). Our first product was a biomarker assay ("Fibronectin Aggrecan Test," "FACT") to quantify the extent of cartilage damage that is the hallmark of osteoarthritis via quantification of the Fibronectin-Aggrecan Complex ("FAC"). The formation of this large protein complex is a direct result of protease-mediated catabolism of the cartilage tissue, the core mechanism that leads to cartilage degradation and painful bone-on-bone interaction in arthritic joints. We leveraged this nuanced understanding of cartilage damage to develop our first treatment for OA, the Autologous Protease Inhibitor Concentrate ("APIC") therapy, a device which enriches the therapeutic A2M protein from a patients' own blood to treat damaged joints. Having treated over 10,000 patients to-date, the clinical and commercial success of APIC™ is a testament to the power of A2M as a potent treatment for osteoarthritis, establishing the basis for our ongoing A2M-based biopharmaceutical research and development program.

Our core focus is on the development of CYT-108, a recombinant variant of the natural A2M protein that has up to 200% more protease-inhibition activity compared to the endogenous form. This genetically-engineered A2M variant has demonstrated structural improvements to joint anatomy and physiology in pre-clinical experiments. CYT-108 recently completed a first-in-human Phase 1 clinical trial and we expect the data to be published in 2025. . If approved by the FDA, CYT-108 is positioned to be a potential disease-modifying candidate for osteoarthritis, a fundamental leap forward in regenerative medicine.

Our intellectual property consists of 25 issued US and international patents covering all three of our technologies (FACT, APIC, and CYT-108), and 3 patents pending.

A few of our most notable milestones are listed below:

· During 2010
 and 2011 the Company was awarded $1,800,000 in NIH grants to pursue our innovative research into discovering treatments for osteoarthritis.

· Raised approximately
 $25,000,000 in funding from private equity, Equity Crowdfunding (Reg A+ and Reg CF), and licensing deals (Synthes Corp, CareStream
 America).

· Johnson &
 Johnson Development Corporation became a large shareholder acquiring 12% ownership on a fully diluted basis via their acquisition
 of Synthes Corp on May 29, 2011 and June 9, 2011.

**Industry Overview and Market**

OA is a degenerative disease that erodes the articular cartilage that protects your joints. Over 27,000,000 Americans currently suffer from OA. The aging population incidence of OA is projected to reach 25% of the adult population in the United States by 2030. While frequently thought of as a chronic disease of aging, OA is prevalent even amongst the young and healthy. As of 2024, post-traumatic osteoarthritis (PTOA) accounts for approximately 12% of all symptomatic osteoarthritis cases, This OA subtype occurs frequently in athletes that experience injury (e.g., ACL tear) on the field. Currently, limited treatment options for OA exist, and the current therapies are all palliative. They address the symptoms, but fail to address the root cause of the pain and inflammation, which is cartilage damage due to activity of proteases within the arthritic joint. Currently non-surgical OA recommended treatments include the following:

· Weight loss

· Exercise

· Hyaluronic
 Acid (HA) injections.

· Platelet-Rich-Plasma
 (PRP)

· Stem Cell Treatments

· Placental-Derived
 products

Notably, back pain is the second-most common reason patients visit their physicians and the most common reason for missed work. However, according to Orthopedics Today, spine surgery is rare with approximately 3.5% of the most severely affected patients receiving surgery. Back pain is the number one cause of healthcare expenditures, resulting in more than $100 billion in medical expenses annually. According to the National Ambulatory Care Survey, the two most common musculoskeletal reasons for patients visiting a physician were back pain, with 20 million visits, and knee pain, with 15 million visits annually. Of those visits, the second and third most common diagnoses were low back pain and osteoarthritis. One in five adults in the U.S. report being diagnosed by a physician with arthritis. By 2030, it is estimated by the NIH that approximately 70 million Americans will have doctor diagnosed arthritis compared to 42.7 million in 2002, a 58% increase for that period. The economic toll of arthritis in its various forms is estimated to result in excess of $86 billion in lost productivity and healthcare costs. This growth makes the spine and joint markets the fastest growing markets in orthopedics. These growing markets create a unique opportunity to commercialize innovative diagnostic and treatment technologies.

For patients with back or knee pain, making an accurate diagnosis is a substantial challenge for physicians. Both spine sciatic pain and knee or joint pain can have multiple etiologies. Various technologies exist to assist physicians to accurately diagnose these patients, but many are expensive and time consuming. MRI, CT scan, and Arthroscopy still require subjective judgment calls by the physician and radiologist. The costs of these diagnostic tests are staggering. The cost of an incorrect diagnosis is significant. Multiple trips to providers, duplicate tests, unnecessary physical therapy or treatments and days or weeks of lost work time are just a few of the compelling reasons providers and insurance carriers seek a less costly and more accurate diagnostic tool.

There are more than 4,500 domestic orthopedic surgeons and neurosurgeons in the U.S. that perform spine procedures for back pain. Many of these surgeons currently perform epidural injections as a first level of treatment for back pain. Additional levels of treatment include spine surgery fusion, discectomies, stenosis and laminectomies. It is estimated that the average U.S. spine surgeon performs 200 procedures a year with fusions accounting for 45% of all procedures, discectomies 44%, and stenosis and laminectomies 11%.

Additionally, according to the American Academy of Pain Management, there are over 6,000 pain management specialists throughout the U.S. that diagnose and treat back and joint pain. Many of these physicians perform 10 to 20 pain reduction procedures, including epidural injections, each day.

The Company is focused on serving the existing demand for spine and joint pain diagnosis and treatment and is developing new and innovative diagnostic and treatment technologies. We believe an effective treatment for OA would have a tremendous impact on both human well-being and the economic burden of the disease.

**Regulatory Regimes**

As a biotechnology company, we are subject to extensive legal and regulatory requirements. For example, we will need approval from regulatory agencies for our research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of our product candidates. Relevant regulatory authorities include, but are not limited to, the FDA, the European Medicines Agency, or EMA, an agency of the European Union in charge of the evaluation and supervision of medicinal products, the European Commission, which is the executive arm of the European Union, or EU, and other national regulatory authorities where we conduct clinical trials or seek marketing approval. The United States and certain jurisdictions outside the United States also regulate the pricing and reimbursement of such products. The processes for obtaining marketing approvals in the United States and in other countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.

*Licensure and Regulation of Biologics in the United States*

In the United States, our product candidates are regulated as biological products, or biologics, under the Public Health Service Act, or the PHSA, and the Federal Food, Drug, and Cosmetic Act, or the FDCA, and their implementing regulations promulgated by the FDA. The failure to comply with the applicable requirements at any time during the product development process, including nonclinical testing, clinical testing, the approval process, or post-approval process, may subject us to delays in the conduct of a clinical trial, regulatory review and approval, and/or subject us to administrative or judicial sanctions. Such sanctions may include, but are not limited to, the FDA's refusal to allow us to proceed with clinical testing of our product candidates, refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, receipt of untitled or warning letters, adverse publicity, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, and civil or criminal investigations and penalties brought by the FDA or the U.S. Department of Justice or other governmental entities.

As we seek approval to market and distribute a new biologic in the United States, we generally must satisfactorily complete each of the following steps:

● preclinical laboratory tests, animal studies, and formulation studies all performed in accordance with the FDA's current Good Laboratory Practice, or cGLP, regulations;

● manufacture of clinical investigational product according to current Good Manufacturing Practice, or cGMP;

● submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin;

● approval by an independent institutional review board, or IRB, representing each clinical trial site before each clinical trial may be initiated, or by a central IRB if appropriate;

● performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication, in accordance with the FDA's current Good Clinical Practice, or cGCP, regulations;

● preparation and submission to the FDA of a BLA for marketing approval of our product candidates for one or more proposed indications, including submission of detailed information on the manufacture and composition of our product candidates and proposed labeling;

● review of the BLA by FDA potentially with independent expert advice by an FDA advisory committee, where applicable;

● satisfactory completion of inspections of the manufacturing facility or facilities by FDA, including those of any third-party manufacturers, at which the product, or components thereof, are produced in order to assess compliance with cGMP requirements and to ensure that the facilities, methods, and controls are adequate to preserve the product's identity, strength, quality, and purity, and, if applicable, the FDA's current Good Tissue Practice, or cGTP, for the use of human cell and tissue products;

● satisfactory completion of any FDA audits of clinical trial sites to ensure compliance with cGCPs and the integrity of clinical data in support of the BLA;

● payment of user fees and securing FDA approval of the BLA; and

● compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, adverse event reporting, and compliance with any post-approval studies required or requested by the FDA.

*Preclinical Studies and Investigational New Drug Application*

Before testing any investigational biologic product candidate in humans, our product candidates must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation, and stability, as well as studies to evaluate the potential for safety, efficacy, and toxicity in animals. The conduct of the preclinical tests and the formulation of the compounds for use in the preclinical testing must comply with federal regulations and/or requirements. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. An IND is an exemption from the restrictions of the FDCA which permits an unapproved biologic product candidate to be shipped in interstate commerce for use in an investigational clinical trial. The FDA will notify us within 30 days after receipt of our IND application whether we are cleared to begin human clinical trials, unless before that time the FDA has concerns or questions about our product or conduct of the proposed clinical trial, including concerns that human research subjects would be exposed to unreasonable and significant health risks. In such a case, we and the FDA must resolve any outstanding concerns before the clinical trials can begin.

If the FDA raises concerns or questions during this 30-day period, including safety concerns or concerns due to regulatory non-compliance, the FDA may impose a partial or complete clinical hold with respect to our product. Such a clinical hold would delay either a proposed clinical trial, or cause suspension of an ongoing clinical trial, until all outstanding concerns have been adequately addressed, and the FDA has notified us that our clinical trials may proceed or recommence as authorized by the FDA.

*Human Clinical Trials in Support of a BLA*

Our clinical trials involve the administration of our product candidate to patients with the disease to be treated and are conducted under the supervision of a qualified principal investigator in accordance with cGCP requirements. Clinical trials are conducted under study protocols detailing, among other things, the objectives of the clinical trial, inclusion, and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and subsequent protocol amendments must be submitted to the FDA as part of the IND.

If we wish to conduct a clinical trial outside of the United States, we may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all of the FDA's IND requirements must be met unless waived. If a non-United States clinical trial is not conducted under an IND, we may submit data from a well-designed and well-conducted clinical trial to the FDA in support of our BLA, so long as the clinical trial is conducted in compliance with cGCP and the FDA is able to validate the data from the clinical trial and/or through an onsite inspection if the FDA deems it necessary.

For clinical trials conducted in the United States, each clinical trial must be reviewed and approved by an institutional review board, or IRB, either centrally or individually at each institution at which our clinical trials will be conducted. The IRB will consider, among other things, our clinical trial design, subject informed consent, ethical factors, and the safety of human subjects. The IRB must operate in compliance with FDA regulations governing IRBs. The FDA, the applicable IRB, or we may suspend or terminate a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the subjects or patients are being exposed to an unacceptable health risk. Some clinical trials receive additional oversight by an independent group of qualified experts organized by us, known as a data safety monitoring board or committee. This group receives and reviews data arising from the clinical trial on an ongoing basis and may recommend continuation of the clinical trial as planned, changes in clinical trial conduct, or cessation of the clinical trial at designated check points based on such data.

Clinical trials typically are conducted in three sequential phases; however, the phases may overlap or may be combined.

● Phase 1 clinical trials are initially conducted in a limited population of healthy humans or, for our products, in patients, in order to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics, and to identify a recommended Phase 2 dose.

● Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications, and to determine dose tolerance and optimal dosage. We may conduct multiple Phase 2 clinical trials to obtain information before beginning larger and costlier Phase 3 clinical trials. The Phase 2 clinical trial for our product candidates may serve as the pivotal trial, in which case a Phase 3 clinical trial will not be necessary.

● Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate the proposed effective dose and gather additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for labeling.

During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the status of clinical trials must be submitted to the FDA. Written IND safety reports must be submitted to the FDA and the investigators within 15 calendar days of receipt by us after determining that the information qualifies for such expedited reporting. IND safety reports are required for serious and unexpected suspected adverse events, findings from other studies or animal or *in vitro* testing that suggest a significant risk to humans in our clinical trials, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Additionally, we must notify FDA within seven calendar days after receiving information concerning any unexpected fatal or life-threatening suspected adverse reaction. Other external events may occur that can affect the conduct of our clinical trials, such as the COVID-19 pandemic or government shutdowns.

In some cases, the FDA may approve a BLA for our product candidate but require us to conduct additional clinical trials to further assess the product candidate's safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for our products. Additionally, a Phase 4 clinical trial could be implemented in an effort to evaluate other medical indications for a therapy.

There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries, such as *www.ClinicalTrials.gov*. We are required to register and disclose certain clinical trial information, including the product information, patient population, phase of investigation, clinical trial sites and investigators, and other aspects of the clinical trial on *www.ClinicalTrials.gov*. We are also obligated to disclose the results of our clinical trials after completion. Disclosure of the results of these clinical trials can be delayed until the new product or new indication being studied has been approved, up to a maximum of two years.

As a biotechnology company, we are subject to extensive legal and regulatory requirements. For example, we may need approval from regulatory agencies for our research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of our product candidates. Relevant regulatory authorities include, but are not limited to, the FDA, the European Medicines Agency, or EMA, an agency of the European Union in charge of the evaluation and supervision of medicinal products, the European Commission, which is the executive arm of the European Union, or EU, and other national regulatory authorities. The United States and certain jurisdictions outside the United States also regulate the pricing and reimbursement of such products. The processes for obtaining marketing approvals in the United States and in other countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.

**Our Products**

Our Company has developed protein-based diagnostics and therapeutics for chronic orthopedic diseases. Below is a brief description of products that we have developed and are currently active.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**PRODUCT** | &nbsp;&nbsp;**DESCRIPTION** | &nbsp;&nbsp;**VALUE** | &nbsp;&nbsp;**LAUNCH DATE** | &nbsp;&nbsp;**STATUS** | &nbsp;&nbsp;**LICENSING<br> AGREEMENT** | &nbsp;&nbsp;**MANUFACTURING<br> AGREEMENT** |
| &nbsp;&nbsp;**FACT™ (Fibronectin-Aggrecan Complex Test)** | &nbsp;&nbsp;Biomarker assay for the detection of cartilage damage.<br>Sold to physicians nationwide, often accompanying the sale of an APIC™ kit | &nbsp;&nbsp;Provides physicians with a quantitative method to determine the extent of cartilage damage and promotes APIC™ treatment | &nbsp;&nbsp;2010 | &nbsp;&nbsp;Lab Developed Test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration (FDA)<br>| &nbsp;&nbsp;Currently licensed to Christie Medical Holdings (Human application) | &nbsp;&nbsp;Currently manufactured by Christie Medical Holdings (Human application) |
| &nbsp;&nbsp;**Autologous Protease Inhibitor Concentrate ("APIC") therapy** | &nbsp;&nbsp;A device which enriches the therapeutic A2M protein from a patients' own blood to treat damaged joints. |  | &nbsp;&nbsp;January 2014 | &nbsp;&nbsp;510(k) clearance (FDA approval for medical devices)FDA Approved<br>| &nbsp;&nbsp;Currently licensed to: Christie Medical Holdings (Human application).<br>Expires 2029 | &nbsp;&nbsp;Currently manufactured by: Christie Medical Holdings (Human application).<br>Expires 2029 |
| &nbsp;&nbsp;**Autologous Protease Inhibitor Concentrate ("APIC") therapy for Veterinarian application** | &nbsp;&nbsp;A device which enriches the therapeutic A2M protein from a patients' own blood to treat damaged joints.<br>Same products directed animals. | &nbsp;&nbsp;Out-licensed to distributor in the equine veterinary industry, royalties on in-market sales starting in 2021 | &nbsp;&nbsp;January 2014 |  | &nbsp;&nbsp;Currently licensed to: Astaria Global, LLC (Veterinarian application)<br>Expires 2025 | &nbsp;&nbsp;Currently manufactured by: Astaria Global, LLC (Veterinarian application).<br>Expires 2025 |
| &nbsp;&nbsp;**Genetically engineered A2M variant, "CYT-108"** | &nbsp;&nbsp;Targets the root molecular cause of osteoarthritis in joints. | &nbsp;&nbsp;Lead drug candidate for osteoarthritis | &nbsp;&nbsp;TBD | &nbsp;&nbsp;Phase I clinical trial began Q1 2024 in Australia<br>Clinical Study Report expected in the Q4 2025<br>The IND application for CYT-108 as a treatment for osteoarthritis of the knee is under construction and will be submitted once the Phase 1 Clinical Study Report is published and reviewed by the FDA in a Type C meeting. |  | &nbsp;&nbsp;Currently manufactured by Goodwin Biotechnology, Inc |

---

***FACT™ (Fibronectin-Aggrecan Complex Test)***

In 2010, our Company launched our flagship product, a first-in-kind biomarker assay that detects byproducts of cartilage degradation in joint fluid, called "FACT™" (Fibronectin-Aggrecan Complex Test). The FACT™ diagnostic product is currently sold to physicians nationwide, and is used to assess the extent of cartilage damage in patients and determine the appropriate course of treatment. Samples of patient's joint (synovial) fluid are delivered to Cytonics' laboratory for testing, and the results are uploaded to a secure database accessible only to physicians. Over 900 kits were distributed to physicians in 2019, with roughly 934 kits distributed in 2020, 785 kits distributed in 2021, 127 kits distributed in 2022, and 126 kits distributed in 2023. The decline in sales is related to the shutdown of many medical offices during years affected by COVID-19, and the hurdle of re-establishing relationships with this customer base upon re-opening.

The FACT™ diagnostic product is currently sold to physicians nationwide and is used to assess the extent of cartilage damage in patients and determine the appropriate course of treatment. Samples of patient's joint (synovial) fluid are delivered to Cytonics' laboratory for testing, and the results are uploaded to a secure database accessible only to physicians.

***APIC™***

We have developed a range of therapeutic products for the treatment of painful osteoarthritis, back, and joint pain based upon our understanding of Fibronectin-Aggrecan Complex formation and the role that A2M plays in regulating cartilage degradation. The Company's first therapeutic product, APIC™ was cleared for sale via the 510(k) regulatory process in January 2014. This technology is predicated on Platelet Rich Plasma (PRP), a concentration of the plasma cells found in blood that is injected into joints that are painful and inflamed. The APIC™ system differs from PRP in that it selectively concentrates A2M while removing other blood proteins. The final preparation is a highly concentrated, A2M-rich solution that can be injected into damaged, painful, and inflamed joints.

The Company has entered into 2 third party licensing agreements with certain distributors of medical devices whereby the Company has granted sales, marketing manufacturing, and distribution licenses in the human and veterinary markets with exclusive rights to sell both domestically and internationally in the human and veterinary markets the APIC™ products and FACT™ products of the Company. Our APIC™ system has been used to successfully treat over 10,000 patients nationwide. It is also being used to treat racehorses with success.

***Alpha-2-Macroglobulin ("A2M") and Variant CYT - 108***

Alpha-2-Macroglobulin ("A2M") is a blood serum protein that plays a role in the clotting cascade. A2M is a well characterized, broad spectrum protease inhibitor that has demonstrated potent inhibitory activity against the proteases that are upregulation in OA. Unfortunately, naturally occurring levels of A2M are too low to lend any therapeutic benefit to damaged joints.

Our A2M technology has been proven to slow cartilage degradation, alleviate pain, eventually halt the progression of OA and allow the body's regenerative mechanisms to heal the damaged tissue. We believe our innovation is in combining our technologies. Specifically, we developed the Autologous Protease Inhibitor Concentrate ("APIC") system to concentrate the A2M found naturally in the bloodstream. This is achieved by drawing and centrifuging patient's blood, then filtering out all the proteins that could cause damage to the joint (such as proteases and inflammatory cytokines). This selectively concentrates the A2M protein found within the bloodstream 4-6x above naturally occurring levels.

The next generation of A2M variants is underway. We have leveraged our expertise in proteomics to create a library of over 100 genetically modified A2M variants. The A2M variants were genetically engineered with unique bait regions responsible for trapping and eliminating proteases. Our A2M variants have a stronger potency and greater specificity for the proteases that are responsible for OA, making these variants powerful protease inhibitors. We tested the ability of each variant to block cartilage degradation in animal models of OA and identified 2 exceptional variants for further testing, named "CYT-98" and "CYT-108.

***<u>Preclinical Development of CYT-108</u>***

***Drug Discovery & Lead Selection***

· Over 100 recombinant variants (rA2M)
 of the wild-type A2M (wt-A2M) protein were designed and tested for their inhibitory effects on 12 proteases involved in cartilage
 breakdown.

· Lead Selection:

o Four top-performing rA2M variants
 were identified and compared with wt-A2M in an ex vivo Bovine Cartilage Explant (BCE) model, where cartilage breakdown was induced
 using TNF-alpha and IL1-beta.

o Recombinant A2M (rA2M) variants
 demonstrated stronger inhibition of sulfated glycosaminoglycans (sGAGs) release than wt-A2M.

o The two most effective variants
 advanced to in vivo studies (Zhang et al., 2017).

***In Vivo Rat Model of Osteoarthritis***

· A rat anterior
 cruciate ligament transection (ACL-T) model was used to assess cartilage protection.

· The rA2M variants demonstrated
 superior protease inhibition and downregulation of protease gene expression.

· Fluorescence molecular
 tomography, immunohistochemical analysis, and RT-PCR confirmed cartilage protection.

· CYT-108 emerged as the most effective rA2M variant
 and was selected for further investigation.

***Manufacturing & Purification***

· Produced in
 Chinese hamster ovary (CHO) cells and purified through a multi-step process involving metal affinity, reverse-phase, and anion exchange
 chromatography.

· Virus inactivation and
 filtration steps ensure purity and safety.

· The final formulation is ultra-filtered for drug concentration
 and stability.

**Preclinical Pharmacokinetics & Safety Studies**

***Small Animal Studies***

· PK/PD studies
 in nude mice showed that fluorescently labeled A2M had a half-life of 4.0 – 4.7 days when administered intra-articularly or
 subcutaneously.

· Biodistribution: A2M was not detected in any organ
 or circulation, confirming localized drug activity.

***Large Animal Studies (Canine OA Model)***

· A non-GLP
 study in a canine post-traumatic OA model tested intra-articular and subcutaneous injections.

· Key Safety Findings:

o No adverse events or side effects
 observed with three 0.5 mg/kg intra-articular injections at one-week intervals.

o No systemic effects with three subcutaneous injections
 (5 mg/kg, 10× human dose equivalent).

o No changes in vital signs, blood analysis, or major
 organs (heart, kidney, liver, lung, brain, spleen).

***Efficacy Outcomes (Canine OA Model)***

· Cartilage & Bone Preservation\*

o 57% improvement in cartilage structure
 (Safranin-O staining).

o 46% increase in chondrocyte viability.

o 10% increase in proteoglycan content.

o 77% recovery of subchondral bone plate thickness. \*Note: these figures account for removal of outliers

· Synovial Membrane Recovery\*

o 57% reduction in synovial cellular
 thickening.

o 31% decrease in synovial hyperplasia. \*Note: these figures account for removal of outliers

***GLP IND-Enabling Study***

· Conducted to establish safety and
 pharmacokinetics for regulatory approval.

· Subcutaneous administration at 10× human dose
 simulated worst-case exposure scenarios.

· LC-MS/MS assay: CYT-108 detected in circulation within
 48 hours, triggering an immune response with anti-CYT-108 antibody formation.

· Data supported regulatory filings and approval for
 Phase 1 human trials in Australia.

***<u>Phase 1 Clinical Trial for CYT-108</u>***

The Phase 1 clinical trials for CYT-108 commenced in Q1 2024 in Australia. Our subsidiary, Cytonics Australia Pty Ltd., provides us with significant strategic advantages, including up to a 43.5% cash government subsidy on all R&D expenses and the ability to leverage a favorable exchange rate for conducting our Phase 1 clinical trial.

***Trial Design***

· Type: Multicenter, double-blind,
 randomized, placebo-controlled study.

· Objective: Evaluate the safety and
 tolerability of two doses of CYT-108 in patients with mild-to-moderate knee osteoarthritis.

· Treatment Schedule:

o Day 1: First intra-articular injection.

o Day 85: Second intra-articular injection.

o Follow-up visits: Days 8, 29, 57,
 85, 113, 183 (1, 4, 8, 12, 16, and 26 weeks post-first dose).

***Patient Selection***

· Total Enrollment: 22 participants.

· Randomization:

o Group 1 (12 patients): 5mL CYT-108
 (5mg/mL) via intra-articular injection (Day 1, Day 85).

o Group 2 (10 patients): 5mL placebo
 (PBS) via intra-articular injection (Day 1, Day 85).

· Sites: Two clinical sites, with
 no more than 13 participants per site to prevent site bias.

***Primary & Secondary Endpoints***

Primary Endpoint:

· Safety & Tolerability:
 Assessment of adverse events, vital signs, blood markers, and local reactions at injection sites.

Secondary Endpoints:

· Pharmacokinetics: Systemic absorption
 and clearance of CYT-108.

· Efficacy Signals:

o Improvement in pain scores (VAS,
 WOMAC).

o Synovial fluid analysis for biomarkers
 (ARGS fragment) of inflammation and cartilage degradation.

***Patient Withdrawal Criteria***

· Participants may withdraw voluntarily
 at any time.

· Clinical investigators can remove
 participants for safety concerns or other medical reasons.

***<u>Next Steps and Milestones</u>***

Outlined below is a detailed timeline of key milestones achieved during the Phase 1 trial, as well as the next steps planned for CYT-108's development:

· On
 April 2, 2024, we were granted regulatory approval to begin patient recruitment.

· As
 of June 2024 we have successfully recruited 22 patients.

· As
 of December 2024 all 22 patients have been dosed with either CYT-108 or placebo (saline).

· As
 of January 13, 2025, no drug-related adverse events have been reported.

· We anticipate that the
 final patient will receive their last dose in late Q4 2024.

o During
 Q1 and Q2 2025, we plan to conduct a 3-month follow-up period to assess safety and efficacy at the six-month mark.

o We
 will assess cartilage breakdown and patient reported outcomes (perceived pain and changes in mobility and daily function) in the
 CYT-108 treated and placebo groups.

o We
 will look for signs of "disease modification" by quantifying a cartilage degradation product found in blood and whether
 there are positive changes in patient reported outcomes of pain and mobility.

o A reduction in cartilage
 breakdown of the CYT-108 treated group relative to that of the placebo group would indicate that CYT-108 is targeting the molecular
 pathogenesis of osteoarthritis, and isn't merely an anti-inflammatory or pain reliever.

· The
 Phase 1 clinical study report is expected to be finalized in Q4 2025.

· The results of this study will serve as the
 foundation for our Investigational New Drug (IND) application, which we plan to submit in 2026.

It is important to note that clinical trial outcomes may not ultimately support the continued development of CYT-108. At the conclusion of the study, CYT-108 appears well-tolerated and no drug-related adverse events were reported.

Provided, CYT-108 demonstrates strong efficacy and safety results through Phase 1 and subsequent trials, our next steps toward commercialization include:

∙ Advancing to Phase 1/b/2a, Phase 2b, and Phase 3 Trials

o These will focus on confirming efficacy, dosing optimization, and further safety evaluation across larger, multi-national patient populations.

∙ FDA Approval and Licensing

o Following successful Phase 3 results, we will seek FDA approval, alongside approvals in additional global markets such as the European Union, Japan, and Australia.

∙ Target Market

o Our commercialization strategy prioritizes partnerships with healthcare providers, orthopedic clinics, and hospitals specializing in osteoarthritis treatment. Additionally, we will engage with payers to ensure broad insurance coverage and accessibility for patients.

∙ Distribution Channels

o We plan to leverage direct-to-physician sales teams, collaborate with major pharmaceutical distributors, and explore digital telehealth partnerships to maximize market reach.

∙ Market Education and Awareness

o We will conduct comprehensive educational campaigns targeting physicians, patients, and caregivers to highlight the "disease-modifying" benefits of CYT-108.

By focusing on these commercialization strategies, we aim to position CYT-108 as a groundbreaking treatment capable of reversing the root cause of osteoarthritis and significantly improving patients' quality of life.

**Concept Products**

The Company plans to develop additional products that include therapeutics that we plan to manufacture, outsource to contract manufacturing, or license to strategic partners. Products currently in development or envisioned include the following:

1. Recombinant Protein Therapeutic, CYT-108, a genetically engineered variant of the naturally occurring A2M protein for treating musculoskeletal and inflammatory disorders.

2. Recombinant Protein Therapeutic, CYT-108, a genetically
 engineered variant of the naturally occurring A2M protein for treating inflammatory lung diseases, such as Chronic Obstructive Pulmonary
 Disease ("COPD") and Acute Respiratory Distress Syndrome ("ARDS").

3. Recombinant Protein Therapeutic, CYT-108, a
 genetically engineered variant of the naturally occurring A2M protein for the treatment of metastatic melanoma.

No specific timeline has been defined by the Company for bringing the four listed products to market.

**Material Agreements**

We do not intend to manufacture the majority of our products, but instead we will use outside suppliers and contract manufacturers. See below for additional information regarding agreements we have reached with third parties to facilitate manufacturing, distribution, licensing etc.

***Christie Medical Holdings/CareStream Group***

On October 8, 2019 the Company entered into a letter of intent with Christie Medical Holdings, which are later acquired by CareStream Group. Effective January 1, 2020 the agreement granted Christie Medical Holdings an exclusive 10 year manufacturing, marketing and sales license with exclusive rights to sell both domestically and internationally in the human markets the Company's APIC™ and FACT products. On April 27, 2020 the terms and conditions of the letter of intent were superseded by that certain definitive Exclusive Sales, Marketing, Manufacturing and Distribution Agreement for Human Market, dated as of April 27, 2020, between the Company and Christie Medical Holdings.

As part of the agreement with CareStream Group, the Company was to receive a $450,000 nonrefundable license fee, payable to the Company as follows: (i) $50,000 upon execution of the contract in May 2020; and (ii) $80,000 on January 1 of each of the next five years through 2025. On January 1, 2024, the $80,000 installment payment was not made. Subsequently, on July 19, 2024, the contract was amended whereby CareStream agreed to immediately make the past due $80,000 installment payment, which it did pay to the Company, and the Company waived the final $80,000 installment due January 1, 2025. In addition, the monthly royalty was decreased from $21,667 per month to $15,000 per month for the remainder of the contract through 2029.

Unless extended, this agreement will terminate on December 31, 2029. The agreement may be terminated by the parties following bankruptcy of either party, breach of the agreement, or mutual agreement of the parties.

***Astaria Global, LLC***

On June 30, 2019, the Company entered into an Exclusive License Agreement for Manufacturing, Sales, Marketing and Distribution in the Veterinary Market with Astaria Global, LLC, a device distributor in the veterinary market, to sell the APIC™ products to equine physicians. This deal included a license purchase price of $400,000, payable at $100,000 due on September 30, 2019, and four annual payment of $75,000, with the final payment made on October 15, 2023. In addition, the Company receives a royalty on gross sales that began in calendar year 2021. The royalty is based on a defined percentage subject to certain quarterly minimums, which currently is set at 4% of product sales or $20,000 per quarter. Since entering into this agreement, in the aggregate, we have received approximately $640,000 from Astaria Global, LLC under the terms of this Exclusive License Agreement.

The agreement with Astaria is considered to be perpetual, unless terminated by the parties following bankruptcy of either party, breach of the agreement, or mutual agreement of the parties.

***Goodwin Biotechnology***

On September 9, 2024, the Company and Goodwin Biotechnology entered into a manufacturing agreement for the production of GMP-grade recombinant A2M variant, CYT-108. The agreement covers two GMP production runs through 2026, providing enough CYT-108 to conduct Phase 2 clinical trials. This agreement expires at the sole discretion of the Company. The manufacturing agreement is filed as Exhibit 6.8 to the Offering Statement of which this Offering Circular is a part.

***Suppliers***

We intend to select suppliers that have a substantial track record of working with FDA regulated medical products and maintaining good manufacturing practices that comply with FDA requirements. Each potential supplier will be audited by our staff to ensure they satisfy our requirements.

**Intellectual Property**

We seek to commercialize certain technology related to the medical treatment of conditions affecting the human spine and other major joint spaces in the body, including certain technology subject to patent applications (the "Intellectual Property"). The Intellectual Property currently includes 25 issued patents, and several US and international provisional patents and patents pending. We have invested over $2,500,000 in patent development.

The patent portfolio revolves around innovative systems, compositions, and methods for transplantation and treating various conditions with an emphasis on using Alpha-2-Macroglobulin (A2M) in enhanced therapeutic forms. The patents detail a range of liquid compositions that isolate A2M from biological samples such as blood or bone marrow, focusing on increasing the concentration of A2M while reducing other proteins to mitigate immunogenic responses. Notable patents include methods to treat joint inflammation, degeneration, and wounds by applying these compositions directly to affected areas, leveraging both natural and recombinant forms of A2M.

Several patents describe the engineering of A2M with non-natural bait regions to enhance its protease inhibition capabilities significantly, offering potential treatments for inflammatory diseases and conditions by modifying A2M to increase its therapeutic efficacy.

∙ Patent US10,265,388 and related patents EP2827882, DE2827882, FR2827882, GB2827882, and CA2865170 detail liquid compositions that isolate A2M from biological samples, such as blood or bone marrow, focusing on increasing the concentration of A2M while reducing other proteins to mitigate immunogenic responses.

∙ Patents US11,040,092 and US10,940,189 describe methods to treat joint inflammation, degeneration, and wounds by applying these compositions directly to affected areas, leveraging both natural and recombinant forms of A2M.

∙ Patents US10,400,028, US10,889,631, and US11,634,475, along with EP3221341, DE3221341, FR3221341, GB3221341, and AU2015349782 describe the engineering of A2M with non-natural bait regions to enhance its protease inhibition capabilities, offering potential treatments for inflammatory diseases and conditions by modifying A2M to increase its therapeutic efficacy.

∙ Patent US9,352,021 and US9,498,514 further explore topical applications for chronic wounds, demonstrating the versatile application of A2M-based therapies.

These patents, granted across multiple jurisdictions including the US, UK, EU, Canada, Australia, and Japan, underscore a strategic focus on leveraging the therapeutic potentials of A2M in various medical applications.

***The Company's Trademarks***

The following trademark(s) are registered with the United States Patent and Trademark Office.:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Trademark** | &nbsp;&nbsp;**Ser No.** | &nbsp;&nbsp;**Description** | &nbsp;&nbsp;**Duration** |
| &nbsp;&nbsp; **CYTONICS** | &nbsp;&nbsp;88-321585 | &nbsp;&nbsp;Consists of standard characters without claim to any particular font style, size or color | &nbsp;&nbsp;Expires September 17, 2029 |

---

***The Company's Patents***

We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business, including obtaining, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among, other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover, but is not limited to, our product candidates and components thereof, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, product candidates, and continuing innovation to develop, strengthen, and maintain our position in our product candidates. Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements; to preserve the confidentiality of our trade secrets; to maintain our licenses to use intellectual property owned or controlled by third parties; to defend and enforce our proprietary rights, including our patents; to defend against challenge and assertion by third parties of their purported intellectual property rights; and to operate without infringement of valid and enforceable patents and other proprietary rights of third parties.

The Company has the following patents issued and pending at this time:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Title** | **Registration Number** | **Description** | **File Date** | **Grant Date** | **Expiration Date** | **Country** |
| Systems, compositions, and methods for transplantation | 10265388 | 1. A liquid composition comprising:<br>(a) an alpha-2-macroglobulin polypeptide (A2M) from a biological sample that is blood or bone marrow aspirate from an individual mammal, wherein the concentration of the A2M is at least 1.1 times higher than in the biological sample;<br>(b) a non-A2M protein with a molecular weight of less than 500 kDa, wherein the concentration of the non-A2M protein with a molecular weight of less than 500 kDa is less than the concentration of the non-A2M protein with a molecular weight of less than 500 kDa in the biological sample, wherein the non-A2M protein with a molecular weight of less than 500 kDa is fibrinogen;<br>(c) a non-A2M protein with a molecular weight of less than 100 kDa, wherein the concentration of the non-A2M protein with a molecular weight of less than 100 kDa is less than the concentration of the non-A2M protein with a molecular weight of less than 100 kDa in the biological sample, wherein the non-A2M protein with a molecular weight of less than 100 kDa is C X C motif chemokine receptor 2 (CXCR2) or ATP Binding Cassette Subfamily F Member 1 (ABCF1);<br>(d) a fluid from the blood or bone marrow aspirate from the mammal; and<br>(e) an effective amount of an anti-coagulant selected from the group consisting of EDTA, tri-sodium citrate, acidcitrate-dextrose (ACD), citrate-phosphate-dextrose (CPD), citrate-phosphate-double dextrose (CP2D), and citrate-phosphate-dextrose-adenine (CPDA1), wherein the liquid composition is not coagulated, is substantially free of white blood cells, and comprises less amount of non-A2M proteins with a molecular weight of less than 500 kDa than in the biological sample; and wherein the liquid composition is prepared by a process comprising:<br>(i) passing a blood sample or bone marrow aspirate sample substantially free of white blood cells through a filter;<br>(ii) retaining the retentate from (i); and<br>(iii) adding the effective amount of the anti-coagulant to the retentate, wherein the filter has a molecular weight cut-off of about 500 kDa or less. | 2/21/2013 | 4/23/2019 | 2/21/2033 | US |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Systems, Compositions, and Methods for Transplantation | 11040092 | 1. A method of treating a disease or condition in a subject in need thereof, wherein the disease or condition (A) is associated with inflammation in a joint, spinal disc, bone, tendon, or ligament; (B) is associated with degeneration in a joint, spinal disc, bone, tendon, or ligament; (C) is associated with an injury of a joint, spinal disc, bone, tendon, or ligament; or (D) is associated with wound healing, the method comprising administering to the subject at an anatomic site in need of treatment a liquid composition comprising:<br>(a) an alpha-2-macroglobulin polypeptide (A2M) from a blood sample from the subject, wherein the A2M is present at a concentration at least 3.5 times higher than the concentration of the A2M in the blood sample from the subject; and<br>(b) platelet-rich plasma from the blood sample from the subject, wherein the liquid composition:<br>(i) comprises a non-A2M protein with a molecular weight of less than 500 kDa, wherein the non-A2M protein with a molecular weight of less than 500 kDa is present in the liquid composition at a concentration of at most 90% of the concentration of the non-A2M protein with a molecular weight less than 500 kDa in the blood sample from the subject, and wherein the non-A2M protein with a molecular weight of less than 500 kDa is fibrinogen;<br>(ii) is substantially non-immunogenic; and<br>(iii) is substantially free of white blood cells.<br>17. A method of treating a disease or condition in a subject in need thereof, wherein the disease or condition: (A) is associated with inflammation in a joint, spinal disc, bone, tendon, or ligament; (B) is associated with degeneration in a joint, spinal disc, bone, tendon, or ligament; (C) is associated with an injury of a joint, spinal disc, bone, tendon, or ligament; or (D) is associated with wound healing, the method comprising administering to the subject at an anatomic site in need of treatment a liquid composition comprising:<br>(a) an alpha-2-macroglobulin polypeptide (A2M) from a blood sample from the subject, wherein the A2M is present at a concentration at least 3.5 times higher than the concentration of the A2M in the blood sample from the subject; and<br>(b) platelet-rich plasma from the blood sample from the subject;<br>| 3/2/2018 | 6/22/2021 | 2/21/2033 | US |

---

wherein the liquid composition:<br>(i) comprises a non-A2M protein with a molecular weight of less than 500 kDa, wherein the non-A2M protein with a molecular weight of less than 500 kDa is present in the liquid composition at a concentration of at most 90% of the concentration of the non-A2M protein with a molecular weight less than 500 kDa in the blood sample from the subject;<br>(ii) comprises a non-A2M protein with a molecular weight of less than 100 kDa, wherein the non-A2M protein with a molecular weight of less than 100 kDa is present in the liquid composition at a concentration at most 90% of the concentration of the non-A2M protein with a molecular weight less than 100 kDa in the blood sample from the subject, and wherein the non-A2M protein with a molecular weight of less than 100 kDa is ATP Binding Cassette Subfamily F Member 1 (ABCF1);<br>(iii) is substantially non-immunogenic; and<br>(iv) is substantially free of white blood cells.<br>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Systems, Compositions, and Methods for Transplantation | 10940189 | &nbsp;&nbsp;&nbsp; 1. A composition comprising a recombinant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region, wherein:<br>(a) the non-natural bait region comprises:<br>&nbsp;&nbsp;&nbsp;&nbsp;(i) a sequence with 100% sequence identity to at least 24 contiguous amino acid residues of SEQ ID NO: 47; and<br>&nbsp;&nbsp;&nbsp;&nbsp;(ii) two or more protease recognition sequences;<br>(b) the non-natural bait region replaces the bait region of a wild-type A2M polypeptide with a sequence according to SEQ ID NO: 3; and the non-natural bait region has at least 70% identity to the entirety of SEQ ID NO: 47. | 3/2/2018 | 3/9/2021 | 2/21/2033 | US |
| Systems, Compositions, and Methods for Transplantation | 2827882 | 1. A liquid composition comprising:<br>(a) an alpha-2-macroglobulin polypeptide (A2M) isolated from a biological sample from a mammal, wherein a concentration of the A2M present in the liquid composition is at least 5 times higher than the concentration of A2M present in the biological sample, and<br>(b) plasma from the biological sample from the mammal;<br>wherein the liquid composition does not elicit an immune response in the mammal. | 2/21/2013 | 4/8/2020 | 2/21/2033 | EP |
| Systems, Compositions, and Methods for Transplantation | 2827882 | 1. A liquid composition comprising:<br>(a) an alpha-2-macroglobulin polypeptide (A2M) isolated from a biological sample from a mammal, wherein a concentration of the A2M present in the liquid composition is at least 5 times higher than the concentration of A2M present in the biological sample; and<br>(b) plasma from the biological sample from the mammal;<br>wherein the liquid composition does not elicit an immune response in the mammal. | 2/21/2013 | 4/8/2020 | 2/21/2033 | DE |
| Systems, Compositions, and Methods for Transplantation | 2827882 | 1. A liquid composition comprising:<br>(a) an alpha-2-macroglobulin polypeptide (A2M) isolated from a biological sample from a mammal, wherein a concentration of the A2M present in the liquid composition is at least 5 times higher than the concentration of A2M present in the biological sample; and<br>(b) plasma from the biological sample from the mammal;<br>wherein the liquid composition does not elicit an immune response in the mammal. | 2/21/2013 | 4/8/2020 | 2/21/2033 | FR |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Systems, Compositions, and Methods for Transplantation | 2827882 | 1. A liquid composition comprising:<br>(a) an alpha-2-macroglobulin polypeptide (A2M) isolated from a biological sample from a mammal, wherein a concentration of the A2M present in the liquid composition is at least 5 times higher than the concentration of A2M present in the biological sample; and<br>(b) plasma from the biological sample from the mammal;<br>wherein the liquid composition does not elicit an immune response in the mammal. | 2/21/2013 | 4/8/2020 | 2/21/2033GB |
| Systems, Compositions, and Methods for Transplantation | 2865170 | 1. A liquid composition comprising:<br>(a) an alpha-2-macroglobulin polypeptide (A2M) isolated from a plasma or bone marrow aspirate (BMA) sample from a mammal, wherein a concentration of the A2M present in the liquid composition is at least 5 times higher than the concentration of the A2M present in the plasma or BMA sample from the mammal from which the A2M was isolated; and<br>(b) plasma from the plasma sample from the mammal from which the A2M was isolated or BMA from the BMA sample from the mammal from which the A2M was isolated;<br>wherein the liquid composition does not elicit an immune response in the mammal. | 2/21/2013 | 12/22/2020 | 2/21/ 2033 CA |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Systems, Compositions, and Methods for Transplantation | 1. A substantially non-immunogenic liquid composition comprising:<br>(a) alpha-2-macroglobulin (A2M) isolated from a biological sample from a mammal, wherein the A2M is present at a concentration of at least 1.1 times higher than the concentration of A2M present in the biological sample from the mammal; and<br>(b) plasma, bone marrow aspirate (BMA), or another body fluid from the biological sample.<br>10. A method for enrichment of A2M from a biological sample obtained from a mammal comprising:<br>(a) flowing the sample through one or more filters, thereby separating the biological sample into a filtrate and a retentate; and<br>(b) collecting the retentate, wherein the retentate is enriched for A2M, wherein a concentration in said retentate of a non-A2M protein with a molecular weight of less than about 500 kDa is less than 90% of a concentration of the non-A2M protein in the biological sample, wherein the retentate further comprises plasma, bone marrow aspirate (BMA), or another body fluid from the biological sample and wherein the retentate is substantially non-immunogenic. | 2/21/2023 | 3/31/2018 | 2/21/2033 | AU |
| Alpha-2-macroglobulin compositions and therapeutic uses GB2501611B | 1. A liquid composition comprising:<br>(a) alpha-2-macroglobulin (A2M) isolated from a biological sample from an individual mammal, wherein the A2M is present at a concentration of at least 1.1 times higher than the concentration of A2M present in the biological sample from the individual mammal, and wherein the liquid composition is non-immunogenic to the individual mammal; and<br>(b) plasma, bone marrow aspirate (BMA), or another body fluid from the biological sample from the individual mammal. | 2/21/2013 | 3/14/2015 | 2/21/2033 | UK |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Systems, compositions and methods for transplantation | GB2503131B | 1. A composition comprising an isolated recombinant A2M polypeptide, wherein the recombinant A2M polypeptide comprises one or more non-natural bait regions, wherein the one or more non-natural bait regions replaces a wild-type A2M bait region and comprises one or more protease recognition sites not present in a wild-type A2M polypeptide, and wherein the recombinant A2M polypeptide is characterized by at least a 10% enhanced inhibition of two or more different proteases selected from serine proteases, threonine proteases, cysteine proteases, aspartate proteases, glutamic acid proteases, and metalloproteases, compared to wild-type A2M.<br>20. A composition comprising an isolated recombinant A2M polynucleotide, wherein the recombinant A2M polynucleotide encodes for one or more non-natural bait regions, wherein the one or more non-natural bait regions replaces a wild-type A2M bait region and comprises one or more protease recognition sites not present in a wild-type A2M polypeptide, and wherein the encoded recombinant A2M polypeptide is characterized by at least a 10% enhanced inhibition of two or more different proteases selected from serine proteases, threonine proteases, cysteine proteases, aspartate proteases, glutamic acid proteases, and metalloproteases, compared to wild-type A2M.<br>23. A method for determining the enhanced inhibition of a protease by a recombinant A2M polypeptide comprising:<br>(a) providing a recombinant A2M polypeptide comprising one or more non-natural bait regions, wherein the one or more non-natural bait regions replaces a wild-type A2M bait region and comprises one or more protease recognition sites not present in a wild-type A2M polypeptide, and wherein the recombinant A2M polypeptide is characterized by at least a 10% enhanced inhibition of two or more different proteases selected from serine proteases, threonine proteases, cysteine proteases, aspartate proteases, glutamic acid proteases, and metalloproteases, compared to wild-type A2M;<br>(b) contacting the recombinant A2M polypeptide with the protease and a substrate cleaved by the protease;<br>I contact a wild-type A2M polypeptide with the protease and the substrate cleaved by the protease; and<br>(d) comparing the amount of cleavage of the substrate from step (b) to the amount of cleavage of the substrate from step (c), thereby determining the enhanced inhibition of the protease by the recombinant A2M polypeptide. | 2/21/2013 | 11/18/2015 | 2/21/2033 | UK |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | 24. A method for making a recombinant A2M polynucleotide comprising:<br>(a) providing a vector containing a recombinant A2M polynucleotide comprising a sequence substantially similar to SEQ ID NO 2;<br>(b) digesting the vector containing a recombinant A2M polynucleotide with restriction endonucleases to form a linear vector without a wild-type A2M bait region; I ligating one end of one or more polynucleotides encoding one or more nonnatural bait regions, wherein the one or more non-natural bait regions encode for one or more protease recognition sites not present in a wild-type A2M polypeptide, to one end of the linear vector; and<br>(d) ligating the other end of the one or more polynucleotides encoding one or more of the non-natural bait regions to the other end of the linear vector, thereby forming a vector containing a recombinant A2M polynucleotide, and wherein a recombinant A2M polypeptide produced from the vector of (d) is characterized by at least a 10% enhanced inhibition of two or more different proteases selected from serine proteases, threonine proteases, cysteine proteases, aspartate proteases, glutamic acid proteases and metalloproteases, compared to wild-type A2M. | | | | |
| Apparatus for enriching a bio-fluid with respect to the concentration of alpha-2-macroglobulin GB2522561B | 1. An apparatus comprising: a flow filtration module comprising an inlet, an outlet, and one or more filters fluidly connected between the inlet and outlet; and a centrifuge, wherein a flow of a supernatant of a biological sample from a mammal obtained by centrifuging the biological sample with the centrifuge passes through the one or more filters to produce a composition comprising an alpha-2-macroglobulin (A2M) polypeptide at a concentration that is at least 1.1 times higher than the concentration of A2M polypeptide present in the biological sample; wherein the composition further comprises plasma, bone marrow aspirate (BMA), or another body fluid from the biological sample; and wherein the one or more filters has a pore size with a molecular weight cut-off of at most 500 kDa.<br>| 2/21/2013 | 9/21/2016 | 2/21/2033 | UK |

---

<br> 2. An apparatus comprising: a flow filtration module comprising an inlet, an outlet, and one or more filters fluidly connected between the inlet and outlet; and a pump in fluid connection with the filtration module, wherein the pump is coupled to the filtration module upstream of the inlet or downstream of the outlet, wherein activation of the pump produces a flow of the biological sample from the inlet to the outlet and through the one or more filters to produce a composition comprising an alpha-2-macroglobulin (A2M) polypeptide at a concentration that is at least 1.1 times higher than the concentration of A2M polypeptide present in the biological sample; wherein the composition further comprises plasma, bone marrow aspirate (BMA), or another body fluid from the biological sample; and wherein the one or more filters has a pore size with a molecular weight cut-off of at most 500 kDa.<br>9. A apparatus comprising: a flow filtration module comprising an inlet, an outlet, and two or more filters; wherein the two or more filters are fluidly connected in series between the inlet and outlet; wherein a flow of a biological sample from a mammal passes through the at least two filters to produce a composition comprising an A2M polypeptide at a concentration that is at least 1.1 times higher than the concentration of A2M present in the biological sample; wherein a first filter of the two or more filters has a pore size of at most 1 micron; and wherein a second filter of the two or more filters has a pore size with a molecular weight cut-off of at most 500 kDa, wherein the composition further comprises plasma, bone marrow aspirate (BMA), or another body fluid from the biological sample.<br>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Systems, compositions, and methods for transplantation and treating conditions | 9352021 | 1. A method for the treatment or prophylaxis of a chronic wound in a mammalian subject, comprising topically applying to the chronic wound an effective amount of a composition comprising an alpha-2-macroglobulin polypeptide (A2M) isolated from a biological sample from said mammalian subject wherein the composition does not elicit an immune response by the mammalian subject when topically applied to the chronic wound<br>15. A method for the treatment or prophylaxis of a chronic wound in a mammalian subject, comprising topically applying to the chronic wound an effective amount of a composition comprising an alpha-2-macroglobulin polypeptide (A2M) isolated from a biological sample from said mammalian subject, wherein the composition comprises:<br>(a) the A2M at a concentration of at least 1.1 times higher than a concentration of A2M present in the biological sample; and<br>| 8/28/2014 | 5/31/2016 | 8/28/2034 | US |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | | (b) a body fluid from the biological sample;<br>wherein the composition does not elicit an immune response by the mammalian subject when topically applied to the chronic wound.<br>20. A method for the treatment or prophylaxis of a chronic wound in a mammalian subject, comprising topically applying to the chronic wound an effective amount of a composition comprising an alpha-2-macroglobulin polypeptide (A2M) isolated from a biological sample from said mammalian subject, wherein the composition comprises a first and second plurality of non-A2M proteins, wherein the first plurality of non-A2M proteins have a molecular weight of more than 10 kDa and are present at a concentration at least 1.1 times higher than a concentration of those proteins in the biological sample; and the second plurality of non-A2M proteins have a molecular weight less than 500 kDa and are present at an amount of less than 90% of an amount of those proteins in the biological sample;<br>wherein the composition does not elicit an immune response by the mammalian subject when topically applied to the chronic wound. | | | | |
| Systems, compositions, and methods for transplantation and treating conditions | 9498514 | 1. A method for the treatment or prophylaxis of a chronic wound in a mammalian subject, comprising topically applying to the chronic wound an effective amount of a composition comprising a recombinant alpha-2-macroglobulin polypeptide (A2M) comprising a non-natural bait region that replaces a wild-type A2M bait region.<br>19. A wound dressing comprising an effective amount of a composition for the treatment or prophylaxis of a chronic wound in a mammalian subject, wherein the composition comprises a recombinant alpha-2-macroglobulin polypeptide (A2M) comprising a non-natural bait region that replaces a wild-type A2M bait region. | 3/25/2016 | 11/22/2016 | 8/28/2034 | US |
| Therapeutic variant alpha-2-macroglobulin compositions | 10400028 | 1. A composition comprising a recombinant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region, wherein the non-natural bait region comprises a sequence with at least 80% identity to SEQ ID NO: 20. | 11/20/2015 | 9/3/2019 | 11/20/2035 | US |
| Therapeutic variant alpha-2-macroglobulin compositions | 10889631 | 1. A method of treating a mammalian subject with an inflammatory disease or condition, comprising administering to the subject a pharmaceutical composition comprising:<br>(a) a pharmaceutically effective amount of a recombinant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region, wherein the non-natural bait region comprises a sequence with at least 80% identity to SEQ ID NO: 20; and<br>(b) a pharmaceutically acceptable carrier. | 7/7/2019 | 1/12/2021 | 11/20/2025 | US |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Therapeutic variant alpha-2-macroglobulin compositions | 11634475 | 1. A pharmaceutical composition comprising:<br>(a) a therapeutically effective amount of a recombinant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region, wherein the non-natural bait region comprises a sequence comprising SEQ ID NO: 82:<br>X1X2X3X4X5X6X7X8<br>wherein:<br>X1 is an amino acid selected from the group consisting of glycine (G), proline (P) and glutamic acid (E);<br>X2 is any natural amino acid;<br>X3 is any natural amino acid;<br>X4 is glycine (G) or glutamic acid (E);<br>X5 is an amino acid selected from the group consisting of glycine (G), valine (V), leucine (L), serine (S), alanine (A), phenylalanine (F) and threonine (T);<br>X6 is any natural amino acid;<br>X7 is any natural amino acid; and<br>X8 is glycine (G); and<br>(b) a pharmaceutically acceptable carrier;<br>wherein the non-natural bait region further comprises a sequence comprising EXEΘ4XG (SEQ ID NO: 83), wherein each X is any natural amino acid and Θ4 is an amino acid selected from the group consisting of glycine (G), valine (V), glutamic acid (E), alanine (A), threonine (T), serine (S), glutamine (Q), proline (P), asparagine (N) and aspartic acid (D);<br>wherein the non-natural bait region comprises a sequence with at least 70% sequence identity to SEQ ID NO: 20; and<br>wherein the non-natural bait region does not comprise SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122 or SEQ ID NO: 123.<br>| 12/3/2020 | 4/25/2023 | 12/22/2035 | US |

---

<br> 16. A method of formulating a pharmaceutical composition comprising:<br>(a) a therapeutically effective amount of a recombinant alpha-2-macroglobulin (A2M) polypeptide and a pharmaceutically acceptable carrier, wherein the recombinant A2M polypeptide comprises a non-natural bait region, wherein the non-natural bait region comprises a sequence comprising SEQ ID NO: 82:<br>X1X2X3X4X5X6X7X8<br>wherein:<br>X1 is an amino acid selected from the group consisting of glycine (G), proline (P) and glutamic acid (E);<br>X2 is any natural amino acid;<br>X3 is any natural amino acid;<br>X4 is glycine (G) or glutamic acid (E);<br>X5 is an amino acid selected from the group consisting of glycine (G), valine (V), leucine (L), serine (S), alanine (A), phenylalanine (F) and threonine (T);<br>X6 is any natural amino acid;<br>X7 is any natural amino acid; and<br>X8 is glycine (G); and<br>(b) a pharmaceutically acceptable carrier;<br>wherein the non-natural bait region further comprises a sequence comprising EXEΘ4XG (SEQ ID NO: 83), wherein each X is any natural amino acid and Θ4 is an amino acid selected from the group consisting of glycine (G), valine (V), glutamic acid (E), alanine (A), threonine (T), serine (S), glutamine (Q), proline (P), asparagine (N) and aspartic acid (D);<br>wherein the non-natural bait region comprises a sequence with at least 70% sequence identity to SEQ ID NO: 20; and<br>wherein the non-natural bait region does not comprise SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122 or SEQ ID NO: 123.<br>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Therapeutic variant alpha-2-macroglobulin compositions | 3221341 | 1. A composition comprising a recombinant variant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region comprising a plurality of protease recognition sequences, wherein:<br>(i) the non-natural bait region comprises a sequence with at least 92% identity to a sequence selected from the group consisting of SEQ ID NOs 6-30;<br>(ii) the recombinant variant A2M polypeptide comprises at least 80% sequence identity to SEQ ID NO 3;<br>(iii) the recombinant variant A2M polypeptide comprises at least 500 amino acids;<br>(iv) the recombinant variant A2M polypeptide is characterized by an enhanced inhibition of a protease selected from the group consisting of a serine protease, a threonine protease, a cysteine protease, an aspartate protease, a metalloprotease, a glutamic acid protease, and combinations thereof, compared to an inhibition of the protease by a wild-type A2M protein; and<br>(v) the non-natural bait region has a sequence that does not comprise a sequence selected from the group consisting of SEQ ID NOs 84-143. | 11/20/2015 | 7/29/2020 | 11/20/2035 |
| Therapeutic variant alpha-2-macroglobulin compositions | 3221341 | 1. A composition comprising a recombinant variant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region comprising a plurality of protease recognition sequences, wherein:<br>(i) the non-natural bait region comprises a sequence with at least 92% identity to a sequence selected from the group consisting of SEQ ID NOs 6-30;<br>(ii) the recombinant variant A2M polypeptide comprises at least 80% sequence identity to SEQ ID NO 3;<br>(iii) the recombinant variant A2M polypeptide comprises at least 500 amino acids;<br>(iv) the recombinant variant A2M polypeptide is characterized by an enhanced inhibition of a protease selected from the group consisting of a serine protease, a threonine protease, a cysteine protease, an aspartate protease, a metalloprotease, a glutamic acid protease, and combinations thereof, compared to an inhibition of the protease by a wild-type A2M protein; and<br>(v) the non-natural bait region has a sequence that does not comprise a sequence selected from the group consisting of SEQ ID NOs 84-143. | 11/20/2015 | 7/29/2020 | 11/20/2035 DE |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Therapeutic variant alpha-2-macroglobulin compositions | 3221341 | 1. A composition comprising a recombinant variant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region comprising a plurality of protease recognition sequences, wherein:<br>(i) the non-natural bait region comprises a sequence with at least 92% identity to a sequence selected from the group consisting of SEQ ID NOs 6-30;<br>(ii) the recombinant variant A2M polypeptide comprises at least 80% sequence identity to SEQ ID NO 3;<br>(iii) the recombinant variant A2M polypeptide comprises at least 500 amino acids;<br>(iv) the recombinant variant A2M polypeptide is characterized by an enhanced inhibition of a protease selected from the group consisting of a serine protease, a threonine protease, a cysteine protease, an aspartate protease, a metalloprotease, a glutamic acid protease, and combinations thereof, compared to an inhibition of the protease by a wild-type A2M protein; and<br>(v) the non-natural bait region has a sequence that does not comprise a sequence selected from the group consisting of SEQ ID NOs 84-143. | 11/20/2015 | 7/29/2020 | 11/20/2035 | FR |
| Therapeutic variant alpha-2-macroglobulin compositions | 3221341 | 1. A composition comprising a recombinant variant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region comprising a plurality of protease recognition sequences, wherein:<br>(i) the non-natural bait region comprises a sequence with at least 92% identity to a sequence selected from the group consisting of SEQ ID NOs 6-30;<br>(ii) the recombinant variant A2M polypeptide comprises at least 80% sequence identity to SEQ ID NO 3;<br>(iii) the recombinant variant A2M polypeptide comprises at least 500 amino acids;<br>(iv) the recombinant variant A2M polypeptide is characterized by an enhanced inhibition of a protease selected from the group consisting of a serine protease, a threonine protease, a cysteine protease, an aspartate protease, a metalloprotease, a glutamic acid protease, and combinations thereof, compared to an inhibition of the protease by a wild-type A2M protein; and<br>(v) the non-natural bait region has a sequence that does not comprise a sequence selected from the group consisting of SEQ ID NOs 84-143. | 11/20/2015 | 7/29/2020 | 11/20/2035 | GB |
| Therapeutic variant alpha-2-macroglobulin compositions | 2015349782 | 1. A composition comprising a recombinant variant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region comprising a plurality of protease recognition sequences, wherein the non-natural bait region comprises a sequence with at least 92% overall identity to a sequence selected from the group consisting of SEQ ID NOs: 6-30. | 11/20/2015 | 11/26/2020 | 11/20/2025 | AU |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Therapeutic variant alpha 2-macroglobulin composition | 6861152 | 1. A composition comprising a recombinant variant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region comprising a plurality of protease recognition sequences, wherein the non-natural bait region comprises a sequence selected from the group consisting of SEQ ID NOs 6-30, wherein the recombinant variant A2M polypeptide comprises at least 90% sequence identity to SEQ ID NO 3, wherein the recombinant variant A2M polypeptide is characterized by an enhanced inhibition of a protease selected from the group consisting of a serine protease, a threonine protease, a cysteine protease, an aspartate protease, a metalloprotease, a glutamic acid protease, and combinations thereof, compared to an inhibition of the protease by a wild-type A2M protein, and wherein the non-natural bait region has a sequence that does not comprise a sequence selected from the group consisting of SEQ ID NOs 84-143. | 11/20/2015 | 3/31/2021 | 11/20/2035 | JP |
| Therapeutic variant alpha2-macroglobulin compositions | 7166022 | 1. A pharmaceutical composition for use in a method of treating a mammalian subject with an inflammatory disease or condition, wherein the method comprises administering the pharmaceutical composition to the subject, and wherein the pharmaceutical composition comprises:<br>(a) a recombinant alpha-2-macroglobulin (A2M) polypeptide comprising a non-natural bait region, wherein the non-natural bait region comprises a sequence with at least 90% identity to SEQ ID NO: 20, wherein the non-natural bait region comprises each of the sequences of SEQ ID NOs: 34, 36, and 80, wherein the recombinant A2M polypeptide comprises at least 90% sequence identity to SEQ ID NO 3, and wherein the non-natural bait region has a sequence that does not comprise a sequence selected from the group consisting of SEQ ID NOs 84-143; and<br>(b) a pharmaceutically acceptable carrier. | 2/26/2021 | 10/27/2022 | 11/20/2035 | JP |
| Systems, Compositions, and Methods for Transplantation | 17/211,261 | Pending | 3/24/2021 | 3/23/2041\* |  | US |
| Systems, Compositions, and Methods for Transplantation | 3095010 | Pending | 2/21/2013 | 2/20/2033\* |  | CA |
| Therapeutic Variant Alpha-2-Macroglobulin Compositions | 18/178,917 | Pending | 3/6/2023 | 3/5/2043\* |  | US |
| Therapeutic Variant Alpha-2-Macroglobulin Compositions | 2967973 | Pending | 11/20/2015 | 11/19/2035\* |  | CA |

---

\*E*xcluding any potential Patent Term Adjustment ("PTA") or Patent Term Extension ("PTE")*.

**Research**

We currently have a staff of 1 full time employee and 7 technical consultants, including 2 PhD's, 5 MD's, and 2 MBA's. These advisors serve as scientific, financial and regulatory consultants.

In 2013, our research team developed a series of recombinant variants of A2M which has the potential to be a treatment for osteoarthritis, back and joint pain. *In vitro* and *in vivo* testing on small animal models of trauma-induced arthritis have demonstrated a high degree of safety and efficacy of our recombinant A2M product. Since 2015,we have outsourced drug development to Goodwin Biotechnology, a contract services provider with expertise in cell line development, scale up, and GMP manufacturing. See Exhibit 6.8 to the Offering Statement of which this Offering Circular is a part.

We contracted with Goodwin Laboratory (Plantation, Florida) for GLP/GMP production of our A2M variants and pre-clinical trials. We believe we currently have produced enough GMP-grade drug product to complete our Phase 1 clinical trial.

In 2023, we contracted with Southern Star Research, and Australian CRO, to coordinate our first-in-human Phase 1 clinical trial. See Exhibit 6.9 to the Offering Statement of which this Offering Circular is a part. We have contracted three independent clinical study sites along the eastern coast of Australia. We have begun our Phase 1 clinical trial and dosed all patients in the 22 participant study. As of September 3, 2025, no adverse events have been reported and CYT-108 appears to be well-tolerated. We expect the Phase 1 Clinical Study Report to be finalized in Q4 2025, at which point we will analyze the efficacy data to determine if CYT-108 has a positive effect on patient perceived pain, changes in mobility, and cartilage degradation.

**Competition**

The spine and orthopedic markets are known for their intense competition; however, in the field of orthopedic diagnostics and biologic therapeutics there are very few competitors. Our primary competition will be companies that provide the existing standard of care including steroids, NSAIDs, visco supplementation, and closed irrigation treatments. We believe that by proving a clinical and economic advantage over existing treatments, we will be able to compete effectively. We will, however, be competing for market share against other drug and device companies that may possess greater resources and experience than us.

Given the large market potential for therapies, it is likely that other pharmaceutical companies and orthopedic companies have internal development programs for therapeutic products that will compete with our products.

**Pricing Strategy**

Our pricing strategy is to position our products as premium priced products, however, to be less expensive than the current treatment algorithms for spine and joint pain. We will work closely with patients, insurance carriers and workman's compensation providers to determine a fair price for our assay and therapeutic products.

**Organizational Structure**

The Company has one subsidiary, Cytonics Australia Pty Ltd. Cytonics Australia Pty Ltd. is a fully owned subsidiary established specifically to manage the expenses associated with clinical trials. This strategic structuring facilitates the Company's eligibility to claim up to a 43.5% Research and Development Tax Incentive ("RDTI") offered by the Australian government. The constitution of Cytonics Australia Pty Ltd. outlines the governance framework that directs Company management, ensuring compliance with the provisions of the Corporations Act.

The Australian Taxation Office may reject or materially alter the RDTI annual claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company's net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt. Under the RDTI Program, up to 43.5% of R&D expenditures may be reimbursed in the form of cash. In order to qualify for the maximum reimbursement, the Company plans to remain in compliance with applicable Australian tax laws and has contracted with an Australian tax and accounting specialist, Prime Financial, who manages the accounting and tax filings for our Australian subsidiary.

**Employees**

We currently have a staff of 1 full time employee, no part time employees and 7 technical consultants, including 2 PhD's, 3 MDs, and 2 MBA's. These advisors serve as scientific, financial and regulatory consultants.

**Litigation**

From time to time, the Company may be involved in a variety of legal matters that arise in the normal course of business.

On January 8, 2018, we received a letter from the trustee for IRC Clinics, Inc. ("IRC") in their ongoing bankruptcy case advising us that their filing had been converted from Chapter 11 to Chapter 7 on January 9, 2017 and that the trustee's duty is to liquidate IRC and collect all monies contractually due to it, which it said also includes funds owed by the Company to IRC pursuant to a Master Services Agreement dated February 15, 2015. The Company had a discussion with the attorney for the trustee for IRC, and he advised that they were not aware of this dispute and the Company has not had any communications with the attorney for the trustee for IRC since June 21, 2018. There was no specific dollar amount demanded.

The Company is not currently involved in any litigation, and its management is not aware of any pending or threatened legal actions relating to its intellectual property, conduct of its business activities, or otherwise.

**Reports to Security Holders**

We are required to keep appropriate books of the business at our principal offices. The books will be maintained for both tax and financial reporting purposes on a basis that permits the preparation of financial statements in accordance with U.S. GAAP. For financial reporting purposes and tax purposes, the fiscal year and the tax year align with the calendar year end, unless otherwise determined by our Board of Directors in accordance with the Internal Revenue Code. We will file with the SEC periodic reports as required by applicable securities laws.

Under the Securities Act, we must update this Offering Circular upon the occurrence of certain material events. We will file updated Offering Circulars and Offering Circular supplements with the SEC. We are also subject to the informational reporting requirements of the Exchange Act that are applicable to Tier 2 companies whose securities are offered pursuant to Regulation A, and accordingly, we will file annual reports, semiannual reports and other information with the SEC. We will provide such documents and periodic updates electronically through the SEC's EDGAR system at www.sec.gov. We will provide holders with copies via email or paper copies at any time upon request.

**Transfer Agent**

We have engaged DealMaker Engage LLC as our transfer agent.

**Bankruptcy, Receivership, Etc.**

Not applicable.

**Reclassification, Merger, Consolidation, Etc.**

Not applicable.

**DESCRIPTION OF PROPERTY**

We do not lease or own any real property.

**MANAGEMENT'S DISCUSSION AND ANALYSIS<br> OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*You should read the following discussion and analysis of our financial condition and results of operations together with the "Components of Results of Operations", "Results of Operations", consolidated financial statements and related notes included elsewhere in this Offering Circular. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section titled "Risk Factors" or in other parts of this Offering Circular. Our historical results are not necessarily indicative of the results that may be expected for any period in the future.*

**Results of Operations**

***Year ended December 31, 2024 compared to year ended December 31, 2023***

Circumstances which led to the performance of financial statements:

During the year ended December 31, 2024, the Company sustained a net loss of $4,526,921 and had net cash used in operating activities of $3,042,437. As of December 31, 2024, the Company had an accumulated deficit of $29,225,962. These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the consolidated financial statements.

The majority of our operating expenses are related to the research and development of the Company's experimental drug candidate, CYT-108, as a treatment for osteoarthritis. R&D expense 2024: $2,659,416 R&D expense 2023: $1,497,236 R&D expenses increased due to the Phase 1 clinical study. The Company recognizes revenues from licensing and royalty fees received from the granting of exclusive sales, marketing, manufacturing, and distribution rights associated with the Company's functional intellectual property. The Company typically requires a non-refundable license fee, paid over several years, and quarterly royalty payments based on a percentage of sales, subject to minimum guaranteed quarterly royalty amounts. Revenue 2024: $306,669 Revenue 2023: $417,500 Revenues did not change significantly from the prior year. To date, the Company has funded its research and development and operating activities through sales of debt and equity securities, grant funding, and revenues generated from the licensing of its products. During the year ended December 31, 2024, the Company received proceeds of $3,377,794, net of direct offering costs, from the sale of Series C Preferred Shares, $1,500,000 from the issuance of common shares and options, and $100,000 from the issuance of contingently convertible notes payable.

**Semi-annual period ended June 30, 2025 compared to June 30, 2024.**

For the semi-annual periods ended June 30, 2025 and 2024, we generated revenues of $130,000 and $170,002, respectively, and reported net losses of $4,420,243 and $2,564,000, respectively, and negative cash flow from operating activities of $1,651,711 and $1,101,405, respectively. As of June 30, 2025, we had stockholders' equity of approximately $1,851,442.

*<u>Revenues</u>*

Our revenues totaled $130,000 and $170,002 for the semi-annual period ended June 30, 2025 and 2024, respectively. The decrease is due to a contractual amendment reducing by $6,667 per month the monthly royalty from our largest customer.

*<u>Selling, General, and Administrative Expenses</u>*

Selling, general, and administrative expenses totaled $2,234,201 and $1,265,107 for the semi-annual period ended June 30, 2025 and 2024, respectively. The reason for the increase in these expenses was primarily due to a $857,852 increase in stock-based compensation, a $68,251 increase in marketing and trade shows, a $62,324 increase in dues and subscriptions and a $21,275 increase in regulatory fees, partially offset by a $78,049 decrease in bad debt expense.

*<u>Professional Fees</u>*

Professional fees totaled $421,705 and $343,732 for the semi-annual period ended June 30, 2025 and 2024, respectively. These expenses included legal, accounting and auditing expenses. The increase was primarily attributable to a $96,795 increase in consulting fees.

*<u>Research and Development Expenses</u>*

Research and development expenses totaled $1,755,584 and $819,724 for the semi-annual period ended June 30, 2025 and 2024, respectively. The increase in the research and development expenses was attributable to the Phase 2 clinical trial.

*<u>Interest Expense</u>*

Interest expense totaled $0 and $205,840 for the semi-annual period ended June 30, 2025 and 2024, respectively. The decrease in interest expense resulted from the elimination of all notes payable in 2024 (through a combination of cash payments and conversions to common shares).

*<u>Net Loss</u>*

Net loss totaled $4,420,243 and $2,564,000 for the semi-annual period ended June 30, 2025 and 2024, respectively. The primary reasons for the increase in loss were the increase in selling, general and administrative expenses and research and development expenses, as discussed above.

**Liquidity and Capital Resources**

We have primarily financed our operations through the sale of unregistered equity, promissory notes and warrants. As of June 30, 2025, our Company had cash totaling $2,562,193.

Our capital requirements going forward will consist of financing our operations until we are able to reach a level of revenues and gross margins adequate to equal or exceed our ongoing operating expenses. Although we believe that we have access to capital resources, there are no commitments in place for new financing and there can be no assurance that we will be able to obtain funds on commercially acceptable terms, if at all. We expect to have ongoing needs for working capital in order to: (a) fund operations; and (b) to continue research and development. To that end, we may be required to raise additional funds through equity or debt financing. However, there can be no assurance that we will be successful in securing additional capital. If we are unsuccessful, we may need to: (a) initiate cost reductions; (b) forego business development opportunities; (c) seek extensions of time to pay liabilities; or (d) seek protection from creditors.

In addition, if we are unable to generate adequate cash from operations, and if we are unable to find sources of funding, it may be necessary for us to sell all or a portion of our assets, enter into a business combination, or reduce or eliminate operations. These possibilities, to the extent available, may be on terms that result in significant dilution to our shareholders or that result in our shareholders losing all of their investment in our Company.

Cash provided by financing activities for the semi-annual period ended June 30, 2025 totaled $1,791,040. Such amount was from our Regulation A+ equity crowdfunding.

**Off-Balance Sheet Arrangements**

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders' equity or that are not reflected in our financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

**Trends**

For the six months ended June 30, 2025, compared with the same period in 2024, the Company's most significant developments were financial and clinical in nature. The Company successfully completed its Phase 1 clinical trial of CYT-108 in April 2025, providing important safety and tolerability data that has de-risked the development program and supports progression into a planned Phase 1b/2a study. In parallel, the Company conducted a larger Regulation A+ financing in 2025, which resulted in greater investment proceeds and a stronger cash position to fund operations.

Because the Company remains in clinical development, it does not generate revenues from product sales, and traditional production, sales, and inventory metrics are not applicable. Instead, management evaluates progress through research and development milestones, regulatory interactions, and access to capital.

Research and development expenses increased in the first half of 2025 compared to the same period in 2024, reflecting continued clinical operations, regulatory consulting, and manufacturing activities related to CYT-108. General and administrative expenses remained relatively stable, although investor relations and marketing costs increased in connection with the larger Regulation A+ offering.

Looking forward, management expects research and development costs to rise further as the Company advances CYT-108 into the next stage of clinical testing. The Company anticipates additional financing will be required to support the Phase 1b/2a study and subsequent development activities. Key uncertainties that may materially affect future operating results include the timing and outcome of FDA regulatory review, the Company's ability to raise additional capital on favorable terms, and broader conditions in the biotechnology and capital markets.

**DIRECTORS, EXECUTIVE OFFICERS, AND SIGNIFICANT EMPLOYEES**

Our Board of Directors is elected annually by our shareholders. The Board of Directors appoints our executive officers annually.

Our directors and executive officers as of the date of this Offering Circular are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Position** | **Age** | **Term of Office** | **Expected Hours** |
| Anjun (Joey) Bose | Chief Executive Officer, President, Director | 34 | 03/18 – Present(1) | Full time |
| Lewis Hanna, PhD | Chief Scientific Officer | 75 | 02/08 – 09/25 | Full time |
| Gaetano J. Scuderi, MD | Chief Medical Officer, Chairman | 67 | 07/06 - Present | 5 hours per week |
| Gordon V. Ramseier | Director | 78 | 01/08 - Present | N/A |
| Tracy Goeken, MD | Director | 49 | 11/19– Present | N/A |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Mr. Bose was elected to the Board in November 2020.

***Anjun K. (Joey) Bose – CEO, President, and Director***

Mr. Bose is the President of the Company and has served in such capacity starting in May of 2018. Mr. Bose has over 10 years experience in biotechnology research development and investment banking. His principal activities include coordinating capital raising efforts, initiating clinical trials for two lead drug candidates, filing and maintaining patent protection of intellectual property, and identifying strategic buyers and out-licensing opportunities for the Company. From August 2017 to May 2018, Mr. Bose served as the VP of Investment Banking from Affinia Capital, LLC. From August 2015 to August 2017, Mr. Bose served as an Associate of Investment Banking at CG Capital Markets, LLC. From August 2012 to August 2015, Mr. Bose was a graduate student engaged in academic research at Johns Hopkins University. Mr. Bose began his R&D career at the University of Virginia where he developed a novel assay to measure phosphatase activity in the context of cancer biology. He continued his graduate studies in protein engineering at Johns Hopkins University, where he elucidated cell signaling pathways dysregulated in blood cancers. He went on to pursue a career in biotechnology investment banking at a number of boutique banks in Palm Beach County, Florida. He holds a B.S. in Biomedical Engineering from the University of Virginia and a M.S. in Biomedical Engineering from Johns Hopkins University.

***Gaetano J. Scuderi, MD – Chief Medical Officer and Chairman of the Board of Directors***

Dr. Scuderi is the Founder and Chairman of the Board of Cytonics Corporation and has served as a director of Cytonics Corporation since July 2006. Dr. Scuderi previously served as the CEO of the Company from 2015 to 2018. Dr. Scuderi is a fellowship-trained spine surgeon and has practiced medicine since 1993 to the present. Dr. Scuderi currently practices orthopedic surgery in Jupiter, FL which he has been engaged in since 2013. He was previously Clinical Assistant Professor in the Department of Orthopedic Surgery of Stanford University from 2009 to 2012. Dr. Scuderi has published over 50 scientific articles and is a member of American Academy of Orthopedic Surgeons (AAOS). His paper entitled, "Improving Response to Treatment for Patients with DDD by the use of Molecular Markers" was awarded Best Paper at 2015's annual meeting of the International Spine Intervention Society (ISIS). He graduated medical school from State University of New York at Buffalo, N.Y. in 1987 and completed his Residency and Internship at University of Miami School of Medicine, Jackson Memorial Medical Center. He then went on to a fellowship in spine surgery at UCSD.

***Gordon V. Ramseier – Director***

Mr. Ramseier has served as a director of the Board of Directors of Cytonics Corporation, since January 2018. Since February 2018 to the present, he co-founded and currently serves as the President of BCI LifeSciences LLC, an advisory firm, comprised of distinguished senior level executives from the life sciences industry. From January 1995 to September of 2019, he founded and served as the Executive Director of the Sage Group, Inc. Earlier in his career, he served as Director of Marketing and Gynecological Products at G.D. Searle and Product Manager of Pfizer Laboratories. Mr. Ramseier has served as a non-executive chairman of Metacrine Sciences Inc. from 1997 to 1999. He serves as Director of Business Development and Member of Advisory Board at Vessel Metrics, LLC. He was a Partner at Booz, Allen and Hamilton Management Consultants from 1979 to 1986. From 1992 to 1995, Mr. Ramseier was President and Chief Executive Officer of OncoTherapeutics, an early stage, private biopharmaceutical company focusing on innovative, immunotherapeutic approaches to cancer, located in Cranbury, NJ. From 1986 to 1990, he was President and CEO of Immunetech Pharmaceuticals, Inc., of San Diego. From 1986 to 1990, he served as President and Chief Executive Officer at Dura. He has operated a private consulting company since 1994 and also performed consulting work from 1990 to 1992. He served as a Partner in the Healthcare Industries Practice providing strategic planning services to such diverse clients as Johnson & Johnson, Bayer, The National Wholesale Druggists Association and Blue Cross. His work with the National Wholesale Druggists Association produced a landmark study of the U.S. drug wholesaling industry. Prior to entering the emerging company arena, Mr. Ramseier was 9 years with Booz, Allen and Hamilton, a recognized international management consulting firm. He served as Founding Vice Chairman of the BCNJ. He has been Executive Director of The Sage Group, Inc. since 1995. He serves as a Member of the Board of Directors/Trustee of Biotechnology Council of New Jersey. He served as a Director of Dura Pharmaceuticals Inc. since 1986. He served as a Director of BioNJ Inc. He served on the boards of seven emerging LifeScience companies. Mr. Ramseier received M.B.A. (With Distinction) from the Amos Tuck School of Business Administration, Dartmouth College and B.S. in Chemistry from Washington & Lee University.

***Tracy Goeken, MD – Director***

Cytonics welcomed Tracy Goeken, MD to the Company's Board of Directors in 2019. As a member of the Board, Dr. Goeken will help drive the Company's direction and manage clinical trials. Dr. Goeken brings over 15 years of expertise in the biopharmaceutical industry and currently serves as the Chief Medical Officer for Linical Americas, a contract research organization that provides the full spectrum of drug development services. Prior to Linical, Dr. Goeken held positions at The Methodist Hospital Research Institute in Houston, Texas, Pharm-Olam International, Nuron Biotech, and Somahlution. During his tenure as Vice President of Clinical and Medical Affairs at Nuron Biotech Inc., the company secured $80mm in financing for the commercialization and expansion of its vaccine Meningitec. Mr. Goeken received his Doctor of Medicine (MD) from St. Christopher's College of Medicine, Luton, England Doctor of Medicine and Bachelor of Science (B.Sc.) in Biology-Chemistry from Southern Nazarene University, Bethany, Oklahoma Bachelor of Science.

***Ketan Desai, MD PhD – Medical Advisor***

Ketan Desai currently serves as the Chief Medical Officer, Levolta Pharmaceuticals. Desai has filed 15 INDs and 5 NDAs/BLAs, showcasing his expertise in advancing drugs through various stages of development, particularly in fields such as rheumatology, oncology, and immunology. As the founder, co-founder, and leader of multiple biotech companies, Dr. Desai has significantly impacted the pharmaceutical industry. He holds five patents, with products developed under his leadership successfully entering the market, such as enhanced bioavailability formulations for curcumin.

With decades of experience spanning global pharmaceutical giants and niche biotech ventures, Dr. Desai has excelled in clinical, regulatory strategy, and preclinical development. His work includes overseeing trials from Phase I to IV, contributing to his reputation as a seasoned CMO and entrepreneur.

***Iain Lachlan (Lachy) McLean, MD, PhD – Medical Advisor***

Iain Lachlan (Lachy) McLean currently serves as the Chief Medical Officer of Genascence Corporation. Lachy McLean has over 20 years of experience as a physician-scientist and biopharma executive. His career includes pivotal roles in global organizations, where he led early and late-stage drug development programs, regulatory filings, and precision medicine strategies, culminating in FDA approval for sparsentan (FILSPARI™) for IgA Nephropathy. Dr. McLean has an expansive therapeutic focus on immunology, inflammation, and rare diseases. His work spans small molecules, protein therapeutics, gene therapy, and digital health. He has pioneered initiatives involving wearable devices and biomarker-driven clinical trial designs to enhance patient stratification and therapeutic outcomes. Beyond leadership roles, Dr. McLean has authored numerous publications in rheumatology and immunology and mentored students and fellows in academia. He continues to influence biopharma through consulting, strategic partnerships, and industry-academic collaborations.

***Mark Schweitzer, MD – Medical Advisor***

Currently Mark Schweitzer serves as the Vice President for Health Affairs at Wayne State University. Dr. Mark Schweitzer has over 20 years of corporate governance experience, including serving as Dean of the largest medical school in the U.S. and Vice President for Health Affairs at Wayne State University. He has overseen budgets exceeding $2 billion and led organizational restructurings that resulted in significant financial efficiencies and increased revenues. With eight international patents and roles on advisory boards for medical device and biotech startups, Dr. Schweitzer has advised on pivotal clinical trial designs, FDA submissions, and the commercialization of disruptive technologies. His work spans orthopedic devices, AI in healthcare, and magnetic resonance imaging. Dr. Schweitzer serves as Editor-in-Chief and Associate Editor for leading medical journals and has contributed to international standards for AI in science. His contributions extend to overseeing diversity and equity initiatives and advancing the development of international healthcare systems and scientific ethics.

***Geoffry Abrams, MD – Medical Advisor***

Geoffrey D. Abrams currently serves as the Associate Professor of Orthopaedic Surgery at Stanford University. Dr. Abrams is an Associate Professor in the Department of Orthopedic Surgery at Stanford University, specializing in Sports Medicine and arthroscopic procedures for the shoulder, knee, and elbow. His practice includes tendon and ligament reconstruction, upper extremity joint replacement, and treatment of complex orthopedic conditions. He is Board Certified in Orthopedic Surgery with a subspecialty certificate in Sports Medicine. Dr. Abrams is actively involved in cutting-edge research on tendon disease, particularly the role of microRNA and tendon-derived stem cells in disease pathogenesis. With over 120 peer-reviewed scientific articles and 30 book chapters to his name, he has made significant contributions to orthopedic literature. He is a sought-after speaker at national and international meetings and serves as a mentor within the academic community. As Director of Sports Medicine for Stanford Varsity Athletics, Dr. Abrams plays a pivotal role in athlete care and performance. He serves as Head Team Physician for Stanford varsity sports and Assistant Team Physician for the NFL's San Francisco 49ers. He has also previously held a similar role with the NBA's Golden State Warriors, further showcasing his expertise in sports medicine at the highest levels of competition

***Mukesh Ahuja, MD – Medical Advisor***

Mukesh Ahuja, MD currently serves as the Global Clinical Head of Osteoarthritis, Paradigm Biopharmaceuticals. Dr. Mukesh Ahuja serves as the Global Clinical Head of Osteoarthritis at Paradigm Biopharmaceuticals, where he directs the clinical and medical strategy for novel treatments of inflammatory conditions. He has successfully led multiple large-scale clinical trials, advancing innovations in orthopedic medicine. With over 20 years of experience, Dr. Ahuja has overseen research programs involving hundreds of subjects, with budgets ranging from $1.5M to $2.5M annually. His leadership in multi-center trials for joint reconstruction and spine devices has contributed to improved patient outcomes and operational efficiency. Dr. Ahuja has spearheaded regenerative solutions at Rush University Medical Center, significantly improving the financial performance of research programs. His work has bridged clinical trial goals with market messaging while ensuring regulatory compliance and fostering advancements in orthopedic surgical techniques.

**Committees**

We have not established any Board committees.

**Family Relationships**

There are no familial relationships between any of our officers and directors.

**Director or Officer Involvement in Certain Legal Proceedings**

Our current directors and executive officers have not at any time in the past five (5) years been convicted in a criminal proceeding (excluding traffic violations and other minor offenses) and no petition under the federal bankruptcy laws or any state insolvency law was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of any such officers or directors, or any partnership in which they were a general partner at or within two years before the time of such filing, or any corporation or business association of which he or she was an executive officer at or within two years before the time of such filing.

**Code of Ethics**

We have not adopted a Code of Ethics.

**COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS**

For the fiscal year ended December 31, 2024, we compensated our four highest-paid directors and executive officers as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name and Position** | **Capacities in<br> which<br> compensation<br> was received** | **Cash<br> compensation ($)** |  | **Other<br> compensation ($)** | **Total<br> compensation ($)** |  |
| Anjun (Joey) Bose, CEO, President, Director | Employee | 190833 | (1) | 246226 | 437059 |  |
| Lewis Hanna, PhD, Chief Scientific Officer | Independent Contractor | 29000 | (2) |  | 29000 |  |
| Tracy Goeken, MD | Director |  |  |  |  | (3) |
| Gordon Ramseier | Director |  |  |  |  | (3) |

---

(1) In 2024, Mr. Bose's salary was increased
 to an annual salary of $275,000 with up to $100,000 performance bonus tied to the completion of certain objectives. As part of his compensation
 package, his previously vested common stock options were forfeited and he received options to acquire 1,760,615 shares of common stock
 at an exercise price of $1.50 with a 10 year term.

(2) Lewis Hanna, PhD earned a consulting fee of $29,000 in 2024 in consideration for his services as a consultant to the Company, pursuant to the Separation Agreement which took precedent to the Employment Agreement between Mr. Hanna and the Company *.* See Exhibit 6.4 to the Offering Statement of which this Offering Circular is a part.

(3) For the fiscal year ended December 31, 2024, we paid our independent directors for their services as directors. Tracy Goeken, MD, and Gordon Ramseier each received 50,000 common stock options with an exercise price of $2.00 per share and 5 year expiration from the grant date of January 1, 2024.

Other than cash and stock-based compensation set out above, no other compensation was provided to the executive officers or directors in their capacities as officers and directors of the Company.

***Employment Agreements***

In 2024, the Company entered into a letter of agreement with Joey Bose to retain his services as President & CEO of the Company with an annual base salary of $275,000 with the option for $100,000 in milestone bonuses, and 1,760,615 common stock options at an exercise price of $1.50 per share, vested immediately. This agreement replaced a previous agreement with Mr. Bose when he was initially engaged as President of the Company.

***Stock Options***

In April 2007, the Company's shareholders adopted the 2007 Stock Incentive Plan (the "2007 Plan"), providing for the grant of stock options and restricted stock awards to employees, non-employee service providers and Board members. Stock options granted under the 2007 Plan may include non-statutory stock options as well as incentive stock options intended to qualify under Section 422 of the Internal Revenue Code. Awards under the 2007 Plan may be granted only during the ten years immediately following the effective date of the plan.

During 2018, the Company's Board adopted the 2018 Stock Incentive Plan (the "2018 Plan"), as amended on May 25, 2021, effectively replacing the 2007 Plan, to provide for the issuance of up to 10,000,000 shares of stock through the grant of stock options, restricted stock, or restricted stock units.

In January 2023, the Company granted options to three board directors to purchase an aggregate of 150,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.501 per stock option, which vested 12,500 per quarter (fully vested as of December 31, 2023) and are exercisable over five years.

In June 2023, the Company granted options to its Chief Executive Officer to purchase an aggregate of 434,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.515 per stock option, which vested immediately and are exercisable over five years.

In October 2023 through December 2023, debt holders were given options to purchase an aggregate of 245,000 shares of Common Stock at an exercise price of $2.30 per share that were fully vested on issuance and are exercisable over five years (see Note 6). Stock compensation expenses for non-debt related grants during the year ended December 31, 2023 was $321,427.

In January 2024, the Company granted options to two board directors to purchase an aggregate of 100,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.150 per stock option, which vest 12,500 per quarter and are exercisable over five years. In January 2024, the Company granted options to an advisor to purchase an aggregate of 50,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.681 per stock option, which vest 4,167 per quarter and are exercisable over five years.

In June 2024, the Company canceled all outstanding and vested options (883,800 options exercisable at $2.00 per share, expiring at various dates from October 2025 through June 2028, having an aggregate fair value of $203,558 at the date of cancelation) of its Chief Executive Officer in exchange for newly granted options to purchase an aggregate of 1,760,615 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.752 per stock option, which vested immediately and are exercisable over ten years. The issuance of the new options to the Chief Executive Officer are deemed a repricing of the canceled options and, accordingly, the associated expense recognized is the excess, if any, of the fair value of the newly issued options over the fair value of the options that were canceled.

In October 2024, the Company granted options to five medical advisory board members to purchase an aggregate of 1,207,510 shares of Common Stock at an exercise price of $1.21 per share, having a grant date fair value of $0.686 per stock option, or $828,010, which vest 75,469 per quarter and are exercisable over five years.

On December 31, 2024, the Company had options outstanding to purchase 7,762,401 shares of Common Stock under the 2007 and 2018 Plans, at exercise prices ranging from $0.05 to $2.30 per share.

On June 30, 2025, the Company had options outstanding to purchase 10,510,494 shares of Common Stock under the 2007 and 2018 Plans, at exercise prices ranging from $0.05 to $3.00 per share.

**SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS**

The following table sets forth the ownership, as of September 30, 2025, the voting securities of the Company that are owned by executive officers and directors, and other persons holding more than 10% of any class of the Company's voting securities, or having the right to acquire those securities. The table assumes that all options and warrants have vested. The Company's voting securities include all shares of the Company's Common Stock.

To the best of our knowledge, the persons named have sole voting and investment power with respect to such shares, except as otherwise noted. There are not any pending or anticipated arrangements that may cause a change in control.

As of September 30, 2025, there are a total of 13,858,460 votes eligible to be cast in any Company vote. Of such votes, Joey Bose, as president of the Company holds proxies to vote 2,305,444 Shares on behalf of investors. Investors in this offering will be required to grant our President a proxy to vote their Shares, as contained in our subscription agreement.

Except as otherwise indicated and under applicable community property laws, we believe that the beneficial owners of our Common Stock listed below have sole voting and investment power with respect to the shares shown.

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name and Address<br> of Beneficial<br> Owner** | &nbsp;&nbsp;**Title of class** | &nbsp;&nbsp;**Amount and<br> nature of<br> beneficial<br> ownership** | &nbsp;&nbsp;**Amount and<br> nature of<br> beneficial<br> ownership<br> acquirable** | &nbsp;&nbsp;**Percent of<br> class** |
| &nbsp;&nbsp;**Common Stock** | &nbsp;&nbsp;**Common Stock** | &nbsp;&nbsp;**Common Stock** | &nbsp;&nbsp;**Common Stock** | &nbsp;&nbsp;**Common Stock** |
| &nbsp;&nbsp;Geatano Scuderi, MD 151 Fishermans Way, Jupiter, FL 33477 | &nbsp;&nbsp;Common Stock | &nbsp;&nbsp;6,422,120 shares of Common Stock | &nbsp;&nbsp;22,500 Stock options | &nbsp;&nbsp;32.9% |
| &nbsp;&nbsp;**Initial Preferred Stock** | &nbsp;&nbsp;**Initial Preferred Stock** | &nbsp;&nbsp;**Initial Preferred Stock** | &nbsp;&nbsp;**Initial Preferred Stock** | &nbsp;&nbsp;**Initial Preferred Stock** |
| &nbsp;&nbsp;N/A |  |  |  |  |
| &nbsp;&nbsp;**Series A Preferred Stock** | &nbsp;&nbsp;**Series A Preferred Stock** | &nbsp;&nbsp;**Series A Preferred Stock** | &nbsp;&nbsp;**Series A Preferred Stock** | &nbsp;&nbsp;**Series A Preferred Stock** |
| &nbsp;&nbsp;N/A |  |  |  |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Series B Preferred Stock** | &nbsp;&nbsp;**Series B Preferred Stock** | &nbsp;&nbsp;**Series B Preferred Stock** | &nbsp;&nbsp;**Series B Preferred Stock** | &nbsp;&nbsp;**Series B Preferred Stock** |
| &nbsp;&nbsp;Johnson and Johnson Development Corporation | &nbsp;&nbsp;Preferred Stock (Series B) | &nbsp;&nbsp;3,375,000 shares of Preferred Stock | &nbsp;&nbsp;0 Stock options | &nbsp;&nbsp;22% |
| &nbsp;&nbsp;**Series C Preferred Stock** | &nbsp;&nbsp;**Series C Preferred Stock** | &nbsp;&nbsp;**Series C Preferred Stock** | &nbsp;&nbsp;**Series C Preferred Stock** | &nbsp;&nbsp;**Series C Preferred Stock** |
| &nbsp;&nbsp;N/A |  |  |  |  |
| &nbsp;&nbsp;**Directors and Officers as a Group** | &nbsp;&nbsp;**Directors and Officers as a Group** | &nbsp;&nbsp;**Directors and Officers as a Group** | &nbsp;&nbsp;**Directors and Officers as a Group** | &nbsp;&nbsp;**Directors and Officers as a Group** |
|  | &nbsp;&nbsp;Common Stock | &nbsp;&nbsp;6,562,386 shares of Common Stock | &nbsp;&nbsp;3,013,115 Stock options | &nbsp;&nbsp;48.7% |

---

**INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS**

Except as described herein (or within the section entitled Executive Compensation of this Offering Circular), none of the following parties (each a "Related Party") has, in our fiscal years ended 2023 and 2024, had any material interest, direct or indirect, in any transaction with us or in any presently proposed transaction that has or will materially affect us:

· any of our directors or officers;

· any nominee for election as a director;

· any person who beneficially owns, directly or indirectly, shares carrying more than 10% of the voting rights attached to our outstanding shares of Common Stock; or

· any member of the immediate family (including spouse, parents, children, siblings and in- laws) of any of the above persons.

Lewis Hanna, PhD earned a consulting fee of $29,000 in 2023 in consideration for his services as a consultant to the Company, pursuant to the Separation Agreement which took precedent to the Employment Agreement between Mr. Hanna and the Company*.*

As of December 31, 2024, the Company had $62,312 accounts payable and expenses due to related parties.

**SECURITIES BEING OFFERED**

The following description is a summary of the material rights of shareholders; however; only Common Stock is being offered pursuant to this Offering Circular. Shareholder rights are dictated via the Company's Articles of Incorporation and Bylaws, each as amended from time to time. The foregoing documents have been filed as exhibits to this Offering Circular.

None of our securities are currently listed or quoted for trading on any national securities exchange or national quotation system.

Pursuant to our amended and restated articles of incorporation, as amended, our authorized capital is 70,000,000 shares, of which (1) 50,000,000 shares are Common Stock, par value $0.001 per share, and (2) 20,000,000 shares are Preferred Stock, par value $0.001 per share, which may, at the sole discretion of the Board of Directors be issued in one or more series, of which the board designated: (a) 150,000 shares as Initial Preferred Stock; (b) 1,500,000 shares as Series A Preferred Stock; (c) 6,000,000 shares as Series B Preferred Stock; and (d) 10,000,000 shares as Series C Preferred Stock of which 510,000 shares are designated as Series C-1 Preferred Stock. As of December 30, 2025, the Company had approximately 13,858,460 Shares of Common Stock, 150,000 shares of Initial Preferred Stock, 1,152,380 shares of Series A Preferred Stock, 5,149,730 shares of Series B Preferred Stock, and 8,399,628 shares of Series C Preferred Stock issued and outstanding.

<u>Common Stock</u>

Each Share of Common Stock entitles the holder to one vote, either in person or by proxy, at meetings of shareholders. Shareholders may take action by written consent. Cumulative voting is not allowed.

Holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available. We have not paid any dividends to Common Stockholders since our inception, and we presently anticipate that all earnings, if any, will be retained for the development of our business. Any future disposition of dividends will be at the discretion of our Board of Directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements, and other factors.

Holders of our Common Stock have no pre-emptive rights or other subscription rights, redemption or sinking fund provisions. Upon our liquidation, dissolution or winding up, the holders of our Common Stock will be entitled to share ratably in the net assets legally available for distribution to shareholders after the payment of all our debts and other liabilities.

**Irrevocable Proxy**

By subscribing to this offering, investors grant an irrevocable proxy to the Company's President to (i) vote all securities held of record by the investor (including any shares of the Company's capital stock that the investor may acquire in the future), (ii) give and receive notices and communications, (iii) execute any written consent, instrument or document that the President determines is necessary or appropriate at the President's complete discretion, and (iv) take all actions necessary or appropriate in the judgment of the President for the accomplishment of the foregoing. As a result of this proxy, it is possible that investors will be precluded from voting on mergers, acquisitions, or dispositions involving the Company for the duration of the proxy. Further, it could allow the Company to take actions that investor believe would be disadvantageous to their ownership in the Company. The proxy will survive the death, incompetency and disability of an individual investor and, if an investor is an entity, will survive the merger or reorganization of the investor or any other entity holding the shares of our Common Stock. The proxy will also be binding upon the heirs, estate, executors, personal representatives, successors and assigns of an investor (including any transferee of the investor). Any transferee of the investors party to the subscription agreement must agree to be bound by the terms of the proxy. The proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offer and sale of our Common Stock or the effectiveness of a registration statement under the Exchange Act covering our Common Stock. The Company acknowledges that these termination events may never occur; therefore, the proxy shall remain in effect indefinitely. Investors in this offering should carefully evaluate the implications of the irrevocable proxy and consider the potential risks associated with the inability to exercise voting rights. Before investing, shareholders should review the terms of the proxy agreement and consult with their legal or financial advisors to understand the full scope of these limitations.

**Preferred Stock**

The Board of Directors of the Company may be resolution authorize the issuance of shares of Preferred Stock from time to time in one or more series. The Company may reissue shares of Preferred Stock that are redeemed, purchased, or otherwise acquired by the Company unless otherwise provided by law. The Board of Directors is authorized to fix or alter the designations, powers and preferences, and relative, participating, optional or otherwise rights if any, and qualifications, limitations or restrictions thereof, including, without limitation, dividend rights (and whether dividends are cumulative), conversion rights, if any, voting rights (including the number of votes if any, per share, as well as the number of members, if any, of the Board of Directors or the percentage of members, if any, of the Board of Directors each class or series of Preferred Stock may be entitled to elect), rights and terms of redemption (including, sinking fund provisions, if any), redemption price and liquidation preferences of any wholly unissued series of Preferred Stock, and the number of shares constituting any such series and the designation thereof, and to increase or decrease the number of shares of any such series subsequent to the issuance of shares of such series, but not below the number of shares of such series then issued.

***Participation Right***

Each of the classes of Preferred Stock described below includes a participation right to purchase their pro rata share of any proposed new issuance of securities.

*Initial Preferred Stock*

The rights, preferences, restrictions and other matters relating to the Initial Preferred Stock are as follows:

∙ There is authorized to be issued out of the authorized and unissued shares of Preferred Stock of the Company a series of Preferred Stock designated as the "Initial Preferred Stock" ("Initial Preferred Stock") and the number of shares constituting such class shall be 150,000. Each share of Series A Preferred Stock will have a par value $0.001 and a stated value equal to $2.00 ("Initial Purchase Price").

∙ Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders shall be entitled to receive out of the assets, after provision for payment of the Company's debts and other liabilities and in parity with the holders of Series A Preferred Stock and in preference to, whether capital or surplus, of the Company an amount equal to the stated value for each share of Series A Preferred Stock before any distribution or payment shall be made to the holders of junior securities, and if the assets of the Company shall be insufficient to pay in full such amounts to the holders of the Initial Preferred Stock and Series A Preferred Stock, the entire assets to be distributed to the holders of the Initial Preferred Stock and Series A Preferred Stock shall be reasonably distributed among the holders of the Initial Preferred Stock and Series A Preferred Stock in accordance with the respective stated value amounts that would be payable on such shares if all amounts payable thereon were paid in full in proportion to their relative Initial Purchase Price of the Initial Preferred Stock and the Series A Purchase Price of the Series A Preferred Stock and the holders of the Common Stock, Series B Preferred Stock and of any other junior securities shall not be entitled to participate in the distribution of the assets of the Company in respect of their ownership. Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, after the holders of Initial Preferred Stock and the holders of the Series A Preferred Stock shall have been paid in full the preferential amounts to which they shall be entitled to receive on account of their Initial Preferred Stock and Series A Preferred Stock, then the holders of Series B Preferred Stock shall be paid in full the preferential amount to which they shall be entitled to receive on account of their Series B Preferred Stock and finally any remaining net assets of the Company shall be distributed ratably amount the holders of Initial Preferred Stock, Series A Preferred Stock Series B Preferred Stock and Common Stock (where each share of Initial Preferred Stock, Series A Preferred Stock and Series B Preferred Stock being deemed for such purposes to equal the number of shares of Common Stock into which they are convertible)

∙ If the Company declares or makes any dividend or other distribution of its assets to holders of shares of Common Stock, the holders of Initial Preferred Stock will be entitled to participate in such distribution to the same extent that the holder would have participated if the holder had held the number of shares of Common Stock acquirable upon complete conversion of the Initial Preferred Stock.

∙ Holders of the Initial Preferred Stock shall be entitled to cast 1.2 votes for each share held of the Initial Preferred Stock (number of shares of Common Stock which each share of Initial Preferred Stock is convertible into) on all matters presented to the stockholders of the Company for stockholder vote which shall vote along with holders of the Company's Common Stock on such matters.

∙ Pursuant to a voluntary conversion, each share of Initial Preferred Stock is convertible at any time into 1.2 shares of Common Stock, subject to adjustment in a forward or reverse stock split. Pursuant to an automatic conversion, each share of Initial Preferred Stock shall automatically be converted, without the payment of any additional consideration, into the number of shares of Common Stock immediately upon consummation of the Company's first underwritten public offering resulting in at least 20 million of proceeds to the Corporation net of underwriting discounts and commissions and offering expenses

∙ Except as otherwise stated herein, there are no
 other rights, privileges, or preferences attendant or relating to in any way the Initial Preferred Stock, including by way of illustration
 but not limitation, those concerning dividend, ranking, other redemption, participation, or anti-dilution rights or preferences.

∙ The Company may not do any of the following without the written consent or affirmative vote of at least a majority of the outstanding shares of the Initial Preferred Stock (in addition to any other vote required by law or the Company's Articles of Incorporation, as amended) separately as a single class with each share of Initial Preferred Stock having one vote on such matter: (i) increase or decrease the authorized number of shares of any class or series of capital stock, (ii) redeem or repurchase any shares of Common Stock or Preferred Stock (other than pursuant to employee or consultant agreements giving the Company the right to repurchase shares upon the termination of services pursuant to the terms of the applicable agreement), (iii) declare or pay any dividend or otherwise make a distribution to holders of Preferred Stock or Common Stock or (iv)liquidate, dissolve, or wind-up the business and affairs of the Company, effect any Liquidation Event, or consent, agree or commit to do any of the foregoing without conditioning such consent, agreement or commitment upon obtaining the approval of a majority of the majority of the outstanding shares of Initial Preferred Stock.

*Series A Preferred Stock*

The rights, preferences, restrictions and other matters relating to the Series A Preferred Stock are as follows:

∙ There is authorized to be issued out of the authorized and unissued shares of Preferred Stock of the Company a series of Preferred Stock designated as the "Series A Preferred Stock" ("Series A Preferred Stock") and the number of shares constituting such class shall be 1,500,000. Each share of Series A Preferred Stock will have a par value $0.001 and a stated value equal to $4.00 ("Series A Purchase Price").

∙ Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders shall be entitled to receive out of the assets, after provision for payment of the Company's debts and other liabilities and in parity with the holders of Initial Preferred Stock and in preference to, whether capital or surplus, of the Company an amount equal to the stated value for each share of Initial Preferred Stock before any distribution or payment shall be made to the holders of junior securities, and if the assets of the Company shall be insufficient to pay in full such amounts to the holders of the Series A Preferred Stock and Initial Preferred Stock, the entire assets to be distributed to the holders of the Series A Preferred Stock and Initial Preferred Stock in accordance with the respective stated value amounts that would be payable on such shares if all amounts payable thereon were paid in full in proportion to their relative Series A Purchase Price of the Series A Preferred Stock and the Initial Purchase Price of the Initial Preferred Stock and the holders of the Common Stock, Series B Preferred Stock and of any other junior securities shall not be entitled to participate in the distribution of the assets of the Company in respect of their ownership. Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, after the holders of Series A Preferred Stock and the holders of the Initial Preferred Stock shall have been paid in full the preferential amounts to which they shall be entitled to receive on account of their Series A Preferred Stock and Initial Preferred Stock, then the holders of Series B Preferred Stock shall be paid in full the preferential amount to which they shall be entitled to receive on account of their Series B Preferred Stock and finally any remaining net assets of the Company shall be distributed ratably amount the holders of Series A Preferred Stock, Initial Preferred Stock Series B Preferred Stock and Common Stock (where each share of Series A Preferred Stock, Initial Preferred Stock and Series B Preferred Stock being deemed for such purposes to equal the number of shares of Common Stock into which they are convertible)

∙ If the Company declares or makes any dividend or other distribution of its assets to holders of shares of Common Stock, the holders of Series A Preferred Stock will be entitled to participate in such distribution to the same extent that the holder would have participated if the holder had held the number of shares of Common Stock acquirable upon complete conversion of the Series A Preferred Stock.

∙ Holders of the Series A Preferred Stock shall be entitled to cast a number of votes for each share held of the Series A Preferred Stock equal to the largest number of shares of Common Stock which each share of Series A Preferred Stock is convertible into on all matters presented to the stockholders of the Company for stockholder vote which shall vote along with holders of the Company's Common Stock on such matters.

∙ Pursuant to a voluntary conversion, each share of Series A Preferred Stock is convertible at any time into one share of Common Stock, subject to adjustment in a forward or reverse stock split. Pursuant to an automatic conversion, each share of Series A Preferred Stock shall automatically be converted, without the payment of any additional consideration, into the number of shares of Common Stock immediately upon consummation of the Company's first underwritten public offering resulting in at least 20 million of proceeds to the Company net of underwriting discounts and commissions and offering expenses

∙ If the Company proposes to issue any Common Stock or any securities of the Company which entitle the holder thereof to acquire Common Stock (collectively, "New Issue Securities"), the Company shall first offer the New Issue Securities to the holders of Series A Preferred Stock for a period of five (5) business days after receipt of the of the participation notice to the holders of Series A Preferred Stock, each holder of Series A Preferred Stock shall have the option, exercisable by written notice to the Company, to accept the Company's offer as to all or any part of such holder's proportionate number of the New Issue Securities. The participation rights do not apply to the issuance and sale by the Company, from time to time hereafter, of (i) shares of the Common Stock or any securities of the Company which entitle the holder thereof to acquire Common Stock to employees, officers, or directors of, or consultants to, the Company, as compensation for their services to the Company pursuant to arrangements approved by the Board of Directors, (ii) shares of Common Stock issued and sold in a firm commitment underwritten public offering (which shall not include an equity line of credit or similar financing arrangement) resulting in net proceeds to the Company of in excess of $15,000,000 or (iii) shares of Common Stock issued as consideration for the acquisition of another Company or business in which the shareholders of the Company do not have a majority ownership interest, which acquisition has been approved by the Board of Directors or (iv) shares of Common Stock issuable upon the exercise of outstanding securities of the Company which entitle the holder thereof to acquire Common Stock (but not amendments thereto).

∙ If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from holders of at least 50% of the Series A Preferred Stock then outstanding ("Initiating Series A Holders") that the Company file a Form S-3 registration statement with respect to the shares of Common Stock issuable upon conversion of such holder's Series A Preferred Stock having an anticipated aggregate offering price, of at least $5 million, then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the "Series A Demand Notice") to all holders of Series A Preferred Stock other than the Initiating Series A Holders; and (ii) as soon as practicable, and in any event within one hundred twenty days (120) after the date such request is given by the Initiating Series A Holders, file a Form S-3 registration statement under the Securities Act covering all shares of Common Stock issuable upon conversion of Series A Preferred Stock requested to be included in such registration by any other holders, as specified by notice given by each such holder to the Company within twenty (20) days of the date the Series A Demand Notice is given, and in each case, subject to the limitations of Section 10(b). If the Company proposes to register any of its Common Stock under the Securities Act, in connection with the public offering of such securities solely for cash, other than (i) a registration relating .to the sale of securities to employees of the Company pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to transaction pursuant to Rule 145 promulgated by the Securities and Exchange Commission under the Securities Act; or (iii) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered, the Company shall, at such time, promptly give each holder of Series A Preferred Stock notice of such registration. Upon the request of each such holder given within twenty (20) days after such notice is given by the Company, the Company shall cause to be registered all of the shares of Common Stock issuable upon conversion of such holder's Series A Preferred Stock that each such holder has requested to be included in such registration.

∙ Except as otherwise stated herein, there are no other rights, privileges, or preferences attendant or relating to in any way the Series A Preferred Stock, including by way of illustration but not limitation, those concerning dividend, ranking, other redemption, participation, or anti-dilution rights or preferences.

∙ The Company may not do any of the following without the written consent or affirmative vote of at least a majority of the outstanding shares of the Series A Preferred Stock (in addition to any other vote required by law or the Company's Articles of Incorporation, as amended) separately as a single class with each share of Series A Preferred Stock having one vote on such matter: (i) increase or decrease the authorized number of shares of any class or series of capital stock, (ii)redeem or repurchase any shares of Common Stock or Preferred Stock (other than pursuant to employee or consultant agreements giving the Company the right to repurchase shares upon the termination of services pursuant to the terms of the applicable agreement), (iii)declare or pay any dividend or otherwise make a distribution to holders of Preferred Stock or Common Stock or (iv)liquidate, dissolve, or wind-up the business and affairs of the Company, effect any Liquidation Event, or consent, agree or commit to do any of the foregoing without conditioning such consent, agreement or commitment upon obtaining the approval of a majority of the majority of the outstanding shares of Series A Preferred Stock .

*Series B Preferred Stock*

The rights, preferences, restrictions and other matters relating to the Series B Preferred Stock are as follows:

∙ There is authorized to be issued out of the authorized and unissued shares of Preferred Stock of the Company a series of Preferred Stock designated as the "Series B Preferred Stock" ("Series B Preferred Stock") and the number of shares constituting such class shall be 6,000,000. Each share of Series B Preferred Stock will have a par value $0.001 and a stated value equal to its purchase price ("Series B Purchase Price").

∙ Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, after provision for payment of the Company's debts and other liabilities, and after the holders of Initial Preferred Stock and Series A Preferred Stock shall have been paid in full the preferential amounts to which they shall be entitled to receive on account of their Initial Preferred Stock and Series A Preferred Stock, then the holders of Series B Preferred Stock shall be paid in full the preferential amount to which they shall be entitled to receive on account of their Series B Preferred Stock and finally any remaining net assets of the Company shall be distributed ratably amount the holders of Initial Preferred Stock, Series A Preferred Stock Series B Preferred Stock and Common Stock (where each share of Initial Preferred Stock, Series A Preferred Stock and Series B Preferred Stock being deemed for such purposes to equal the number of shares of Common Stock into which they are convertible)

∙ If the Company declares or makes any dividend or other distribution of its assets to holders of shares of Common Stock, the holders of Series B Preferred Stock will be entitled to participate in such distribution to the same extent that the holder would have participated if the holder had held the number of shares of Common Stock acquirable upon complete conversion of the Series A Preferred Stock.

∙ Holders of the Series B Preferred Stock shall be entitled to cast a number of votes for each share held of the Series B Preferred Stock equal to the largest number of shares of Common Stock which each share of Series B Preferred Stock is convertible into on all matters presented to the stockholders of the Company for stockholder vote which shall vote along with holders of the Company's Common Stock on such matters.

∙ Pursuant to a voluntary conversion, each share of Series B Preferred Stock is convertible at any time into one share of Common Stock, subject to adjustment in a forward or reverse stock split. Pursuant to an automatic conversion, each share of Series B Preferred Stock shall automatically be converted, without the payment of any additional consideration, into the number of shares of Common Stock immediately upon consummation of the Company's first underwritten public offering resulting in at least 20 million of proceeds to the Corporation net of underwriting discounts and commissions and offering expenses

∙ Except as otherwise stated herein, there are no other rights, privileges, or preferences attendant or relating to in any way the Series B Preferred Stock, including by way of illustration but not limitation, those concerning dividend, ranking, other redemption, participation, or anti-dilution rights or preferences.

∙ If the Company proposes to issue any Common Stock or any securities of the Company which entitle the holder thereof to acquire Common Stock (collectively, "New Issue Securities"), the Company shall first offer the New Issue Securities to the holders of Series B Preferred Stock for a period of five (5) business days after receipt of the of the participation notice to the holders of Series B Preferred Stock, each holder of Series B Preferred Stock shall have the option, exercisable by written notice to the Company, to accept the Company's offer as to all or any part of such holder's proportionate number of the New Issue Securities. The participation rights do not apply to the issuance and sale by the Company, from time to time hereafter, of (i) shares of the Common Stock or any securities of the Company which entitle the holder thereof to acquire Common Stock to employees, officers, or directors of, or consultants to, the Company, as compensation for their services to the Company pursuant to arrangements approved by the Board of Directors, (ii) shares of Common Stock issued and sold in a firm commitment underwritten public offering (which shall not include an equity line of credit or similar financing arrangement) resulting in net proceeds to the Company of in excess of $15,000,000 or (iii) shares of Common Stock issued as consideration for the acquisition of another Company or business in which the shareholders of the Company do not have a majority ownership interest, which acquisition has been approved by the Board of Directors or (iv) shares of Common Stock issuable upon the exercise of outstanding securities of the Company which entitle the holder thereof to acquire Common Stock (but not amendments thereto).

∙ If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from holders of at least 50% of the Series B Preferred Stock then outstanding ("Initiating Series B Holders") that the Company file a Form S-3 registration statement with respect to the shares of Common Stock issuable upon conversion of such holder's Series B Preferred Stock having an anticipated aggregate offering price, of at least $5 million, then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the "Series B Demand Notice") to all holders of Series B Preferred Stock other than the Initiating Series B Holders; and (ii) as soon as practicable, and in any event within one hundred twenty days (120) after the date such request is given by the Initiating Series B Holders, file a Form S-3 registration statement under the Securities Act covering all shares of Common Stock issuable upon conversion of Series B Preferred Stock requested to be included in such registration by any other holders, as specified by notice given by each such holder to the Company within twenty (20) days of the date the Series B Demand Notice is given, and in each case, subject to the limitations of Section 10(b). If the Company proposes to register any of its Common Stock under the Securities Act, in connection with the public offering of such securities solely for cash, other than (i) a registration relating .to the sale of securities to employees of the Company pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to transaction pursuant to Rule 145 promulgated by the Securities and Exchange Commission under the Securities Act; or (iii) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered, the Company shall, at such time, promptly give each holder of Series B Preferred Stock notice of such registration. Upon the request of each such holder given within twenty (20) days after such notice is given by the Company, the Company shall cause to be registered all of the shares of Common Stock issuable upon conversion of such holder's Series B Preferred Stock that each such holder has requested to be included in such registration.

∙ The Company may not do any of the following without the written consent or affirmative vote of at least a majority of the outstanding shares of the Series B Preferred Stock (in addition to any other vote required by law or the Company's Articles of Incorporation, as amended) separately as a single class with each share of Series B Preferred Stock having one vote on such matter: (i) increase or decrease the authorized number of shares of any class or series of capital stock, (ii)redeem or repurchase any shares of Common Stock or Preferred Stock (other than pursuant to employee or consultant agreements giving the Company the right to repurchase shares upon the termination of services pursuant to the terms of the applicable agreement), (iii)declare or pay any dividend or otherwise make a distribution to holders of Preferred Stock or Common Stock or (iv)liquidate, dissolve, or wind-up the business and affairs of the Company, effect any Liquidation Event, or consent, agree or commit to do any of the foregoing without conditioning such consent, agreement or commitment upon obtaining the approval of a majority of the majority of the outstanding shares of Series B Preferred Stock.

*Series C Preferred Stock*

The rights, preferences, restrictions and other matters relating to the Series C Preferred Stock are as follows:

∙ There is authorized to be issued out of the authorized and unissued shares of Preferred Stock of the Company a series of Preferred Stock designated as the "Series C Preferred Stock" ("Series C Preferred Stock") and the number of shares constituting such class shall be 10,000,000 of which 500,000 shares shall be designated as "Series C-1 Preferred Stock." Unless otherwise specified, the Series C Preferred Stock and the Series C-1 Preferred Stock may be referred to herein together as the Series C Preferred Stock and shall have the same rights, preferences, privileges, and restrictions. Each share of Series C Preferred Stock, that is not a Series C-1 Preferred Stock will have a par value $0.0001 and a stated value equal to $2.00 ("Series C Purchase Price"). For each share of Series C-1 Stock, the purchase price shall be the lesser of (1) $1.60 and (B) the quotient resulting from dividing (1) $32,400,000 by (2) the number of shares of Common Stock issued and outstanding on a fully diluted basis per share value of a share of Common Stock, on a fully diluted basis (i.e., assuming full conversion and exercise of Preferred Stock, notes, and options into shares of Common Stock) immediately prior to the closing of the Qualified Equity Financing. "Qualified Equity Financing" means the first sale (or series of related sales) by the Company of its Preferred Stock following the date of issuance from which the Company receives gross proceeds of not less than $1,000,000 (excluding the aggregate amount of securities converted into Preferred Stock in connection with such sale (or series of related sales)), or the first sale by the Company of Common Stock in an initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, whichever is sooner.

∙ Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders shall be entitled to receive out of the assets, after provision for payment of the Company's debts and other liabilities and in parity with the holders of Initial Preferred Stock and Series A Preferred Stock, and in preference to, and, before any amount or property shall be paid or distributed on account of any junior securities, to be paid in full in cash with respect to each share of Series C Preferred Stock out of the assets of the Company available for distribution to shareholders, an amount equal to the Series C Purchase Price. If upon any liquidation, dissolution or winding-up of the Company, the amount available for distribution among the holders of all outstanding Initial Preferred Stock, Series A Preferred Stock, and Series C Preferred Stock is insufficient to permit the payment of the Initial Purchase Price to the holders of Initial Preferred Stock, the Series A Purchase Price to the holders of Series A Preferred Stock, the Series C Purchase Price to the holders of Series C Preferred Stock, in full, then the amount available for distribution shall be distributed among the holders of the Initial Preferred Stock, the holders of Series A Preferred Stock, and the holders of the Series C Preferred Stock, ratably in proportion to the relative purchase price held by such holders, and the holders of Common Stock, the Series B Preferred Stock, and any other junior securities shall in no event be entitled to participate in the distribution of any assets of the Company in respect of their ownership thereof. Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, after the holders of Initial Preferred Stock and the holders of Series A Preferred Stock and the holders of the Series C Preferred Stock shall have been paid in full the preferential amounts to which they shall be entitled to receive on account of their Preferred Stock, respectively, then the holders of Series B Preferred Stock shall be paid in full the preferential amount to which they shall be entitled to receive on account of their Series B Preferred Stock, and finally any remaining net assets of the Company shall be distributed ratably among the holders of Initial Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Common Stock (with each share of Initial Preferred Stock, each share of Series A Preferred Stock, each share of Series B Preferred Stock and each share of Series C Preferred Stock, being deemed for such purpose to equal the number of shares of Common Stock, including fractions thereof, into which such share of Initial Preferred Stock, such share of Series A Preferred Stock and such share of Series B Preferred Stock and such Shares of Series C Preferred Stock is convertible in accordance with the provisions of thereof). Upon any (i) sale of the Company or (ii) reorganization of the Company required by any court or administrative body in order to comply with any provision of law, after the holders of Initial Preferred Stock and the holders of Series A Preferred Stock and the Series C Preferred Stock shall have been paid in full the preferential amounts to which they shall be entitled to receive on account of their Preferred Stock, respectively, any remaining net assets of the Company shall be distributed ratably among the holders of Initial Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, the Series C Preferred Stock and Common Stock (with each share of Initial Preferred Stock, each share of Series A Preferred Stock, and each share of Series B Preferred Stock and Series C Preferred Stock being deemed for such purpose to equal the number of shares of Common Stock, including fractions thereof,
into which such share of Preferred Stock is convertible in accordance with terms thereof).

∙ If the Company declares or makes any dividend or other distribution of its assets to holders of shares of Common Stock, the holders of Series C Preferred Stock will be entitled to participate in such distribution to the same extent that the holder would have participated if the holder had held the number of shares of Common Stock acquirable upon complete conversion of the Series C Preferred Stock.

∙ Holders of the Series C Preferred Stock shall be entitled to cast a number of votes for each share held of the Series C Preferred Stock equal to the largest number of shares of Common Stock which each share of Series C Preferred Stock is convertible into on all matters presented to the stockholders of the Company for stockholder vote which shall vote along with holders of the Company's Common Stock on such matters and shall vote as a separate single class with each share of Series C Preferred Stock having one vote, on any proposed amendment to these Amended and Restated Articles of Incorporation which will adversely affect the rights, privileges, and preferences of Series C Preferred Stock or otherwise designate a class of Preferred Stock that will have rights, privileges and preferences pari passu or senior to those of Series C Preferred Stock.

∙ Pursuant to a voluntary conversion, each share of Series C Preferred Stock is convertible at any time into one share of Common Stock, subject to adjustment in a forward or reverse stock split. Pursuant to an automatic conversion, each share of Series C Preferred Stock shall automatically be converted, without the payment of any additional consideration, into the number of shares of Common Stock immediately upon consummation of the Company's first underwritten public offering resulting in at least 20 million of proceeds to the Corporation net of underwriting discounts and commissions and offering expenses

∙ Except as otherwise stated herein, there are no other rights, privileges, or preferences attendant or relating to in any way the Series C Preferred Stock, including by way of illustration but not limitation, those concerning dividend, ranking, other redemption, participation, or anti-dilution rights or preferences.

∙ The Company may not do any of the following without the written consent or affirmative vote of at least a majority of the outstanding shares of the Series C Preferred Stock (in addition to any other vote required by law or the Company's Articles of Incorporation, as amended) separately as a single class with each share of Series C Preferred Stock having one vote on such matter: (i) increase or decrease the authorized number of shares of any class or series of capital stock, (ii) redeem or repurchase any shares of Common Stock or Preferred Stock (other than pursuant to employee or consultant agreements giving the Company the right to repurchase shares upon the termination of services pursuant to the terms of the applicable agreement), (iii) declare or pay any dividend or otherwise make a distribution to holders of Preferred Stock or Common Stock or (iv) liquidate, dissolve, or wind-up the business and affairs of the Company, effect any Liquidation Event, or consent, agree or commit to do any of the foregoing without conditioning such consent, agreement or commitment upon obtaining the approval of a majority of the majority of the outstanding shares of Series C Preferred Stock .

∙ If the Company proposes to issue any Common Stock or any securities of the Company which entitle the holder thereof to acquire Common Stock (collectively, "New Issue Securities"), the Company shall first offer the New Issue Securities to the holders of Series C Preferred Stock for a period of five (5) business days after receipt of the of the participation notice to the holders of Series C Preferred Stock, each holder of Series C Preferred Stock shall have the option, exercisable by written notice to the Company, to accept the Company's offer as to all or any part of such holder's proportionate number of the New Issue Securities. The participation rights do not apply to the issuance and sale by the Company, from time to time hereafter, of(i) shares of the Common Stock or any securities of the Company which entitle the holder thereof to acquire Common Stock to employees, officers, or directors of, or consultants to, the Company, as compensation for their services to the Company pursuant to arrangements approved by the Board of Directors, (ii) shares of Common Stock issued and sold in a firm commitment underwritten public offering (which shall not include an equity line of credit or similar financing arrangement) resulting in net proceeds to the Company of in excess of $15,000,000 or (iii) shares of Common Stock issued as consideration for the acquisition of another Company or business in which the shareholders of the Company do not have a majority ownership interest, which acquisition has been approved by the Board of Directors or (iv) shares of Common Stock issuable upon the exercise of outstanding securities of the Company which entitle the holder thereof to acquire Common Stock (but not amendments thereto).

∙ If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from holders of at least 50% of the Series C Preferred Stock then outstanding ("Initiating Series C Holders") that the Company file a Form S-3 registration statement with respect to the shares of Common Stock issuable upon conversion of such holder's Series C Preferred Stock having an anticipated aggregate offering price, of at least $5 million, then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the "Series C Demand Notice") to all holders of Series C Preferred Stock other than the Initiating Series C Holders; and (ii) as soon as practicable, and in any event within one hundred twenty days (120) after the date such request is given by the Initiating Series C Holders, file a Form S-3 registration statement under the Securities Act covering all shares of Common Stock issuable upon conversion of Series C Preferred Stock requested to be included in such registration by any other holders, as specified by notice given by each such holder to the Company within twenty (20) days of the date the Series C Demand Notice is given, and in each case, subject to the limitations of Section 10(b). If the Company proposes to register any of its Common Stock under the Securities Act, in connection with the public offering of such securities solely for cash, other than (i) a registration relating .to the sale of securities to employees of the Company pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to transaction pursuant to Rule 145 promulgated by the Securities and Exchange Commission under the Securities Act; or (iii) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered, the Company shall, at such time, promptly give each holder of Series C Preferred Stock notice of such registration. Upon the request of each such holder given within twenty (20) days after such notice is given by the Company, the Company shall cause to be registered all of the shares of Common Stock issuable upon conversion of such holder's Series C Preferred Stock that each such holder has requested to be included in such registration.

**Provisions of Note in Our Amended and Restated Certificate of Incorporation**

*Anti-Takeover Effects of Certain Provisions of Our Articles of Incorporation and Bylaw*s

Provisions of our amended and restated articles and our amended and restated bylaws could make it more difficult to acquire us by means of a merger, tender offer, proxy contest, open market purchases, removal of incumbent directors and otherwise. These provisions, which are summarized below, are expected to discourage types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because negotiation of these proposals could result in an improvement of their terms.

*Vacancies.* Newly created directorships resulting from any increase in the number of directors and any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other cause may be filled by a majority of the remaining directors on the Board.

*Bylaws.* Our articles of incorporation and bylaws authorizes the board of directors to adopt, repeal, rescind, alter or amend our bylaws without shareholder approval.

*Removal*. Except as otherwise provided, a director may be removed from office only by the affirmative vote of the holders of not less than a majority of the voting power of the issued and outstanding stock entitled to vote.

*Calling of Special Meetings of Stockholders.* Our bylaws provide that special meetings of stockholders for any purpose or purposes may be called at any time only by the Board.

*Effects of authorized but unissued Common Stock and blank check Preferred Stock.* One of the effects of the existence of authorized but unissued Common Stock and undesignated Preferred Stock may be to enable our board of directors to make more difficult or to discourage an attempt to obtain control of our Company by means of a merger, tender offer, proxy contest or otherwise, and thereby to protect the continuity of management. If, in the due exercise of its fiduciary obligations, the board of directors were to determine that a takeover proposal was not in our best interest, such shares could be issued by the board of directors without stockholder approval in one or more transactions that might prevent or render more difficult or costly the completion of the takeover transaction by diluting the voting or other rights of the proposed acquirer or insurgent stockholder group, by putting a substantial voting block in institutional or other hands that might undertake to support the position of the incumbent board of directors, by effecting an acquisition that might complicate or preclude the takeover, or otherwise.

In addition, our amended and restated articles of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of Preferred Stock. The issuance of shares of Preferred Stock could decrease the amount of earnings and assets available for distribution to holders of shares of Common Stock. The issuance also may adversely affect the rights and powers, including voting rights, of those holders and may have the effect of delaying, deterring or preventing a change in control of our Company.

**Disclosure of commission position on indemnification for securities liabilities**

The Company's Bylaws and Certificate of Incorporation, subject to the provisions of Florida Law, contain provisions which allow the corporation to indemnify its officers and directors against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service to the Company if it is determined that person acted in good faith and in a manner which he reasonably believed was in the best interest of the Company. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, may be unenforceable.

**EXPERTS**

The financial statements of Cytonics Corporation as of December 31, 2024 and 2023, and for each of the two years in the period ended December 31, 2024, included in this Offering Statement have been audited by Salberg & Company, PA, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing.

**WHERE YOU CAN FIND ADDITIONAL INFORMATION**

We have filed with the SEC an offering statement on Form 1-A under the Securities Act with respect to the interests offered by this Offering Circular. This Offering Circular does not contain all of the information included in the Offering Statement, portions of which are omitted as permitted by the rules and regulations of the SEC. For further information pertaining to us and the interests to be sold in this offering, you should refer to the offering statement and its exhibits. Whenever we make reference in this offering circular to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the offering statement for copies of the actual contract, agreement or other document filed as an exhibit to the offering statement or such other document, each such statement being qualified in all respects by such reference. Upon the qualification of this offering, we will be subject to the informational requirements of Tier 2 of Regulation A and will be required to file annual reports, semi-annual reports, current reports and other information with the SEC. We anticipate making these documents publicly available, free of charge, on our website as soon as reasonably practicable after filing such documents with the SEC.

You can read the Offering Statement and our future filings with the SEC over the Internet at the SEC's website at www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facility at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities.

We will answer inquiries from potential investors concerning the Shares, the Company and other matters relating to the offer and sale of the Shares under this Offering Circular.

Requests and inquiries regarding this offering circular should be directed to:

**Cytonics Corporation**

658 West Indiantown Road, Suite 214, Jupiter, FL 33458

(443) 827-8135

Email: joey.bose@cytonics .com

We will provide requested information to the extent that we possess such information or can acquire it without unreasonable effort or expense.

**FINANCIAL STATEMENTS**

**CYTONICS CORPORATION AND SUBSIDIARY<br> CONSOLIDATED FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
|  | **Page** |
| [Report of Independent Registered Public Accounting Firm (PCAOB #106)](#fin_1) | [F-2](#fin_1) |
| [Consolidated Balance Sheets as of December 31, 2024 and 2023](#fin_2) | [F-4](#fin_2) |
| [Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023](#fin_3) | [F-5](#fin_3) |
| [Consolidated Statements of Changes in Stockholders' Equity for the Years Ended December 31, 2024 and 2023](#fin_4) | [F-6](#fin_4) |
| [Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023](#fin_5) | [F-7](#fin_5) |
| [Notes to Consolidated Financial Statements](#fin_6) | [F-8](#fin_6) |

---

![](tm2533753d1_fin1img01.jpg)

**Report of Independent Registered Public Accounting Firm**

To the Stockholders and the Board of Directors of:

Cytonics Corporation:

<u>Opinion on the Financial Statements</u>

We have audited the accompanying consolidated balance sheets of Cytonics Corporation and subsidiary (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in stockholders' equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2024 and 2023, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

<u>Going Concern</u>

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has a net loss of $4,526,921 and net cash used in operations of $3,042,437 for the year ended December 31, 2024. The Company also had an accumulated deficit as of December 31, 2024 of $29,245,962. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's Plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

<u>Basis for Opinion</u>

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

2295 NW Corporate Blvd., Suite 240 • Boca Raton, FL 33431-7326

Phone: (561) 995-8270 • Toll Free: (866) CPA-8500 • Fax: (561) 995-1920

www.salbergco.com • info@salbergco.com

*Member National Association of Certified Valuation Analysts • Registered with the PCAOB*

*Member CPAConnect with Affiliated Offices Worldwide • Member AICPA Center for Audit Quality*

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

<u>Critical Audit Matters</u>

The critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Valuation of Stock Options

As described in Footnote 3 "Stock-based Compensation Expense", Footnote 5 "2024 Note" and Footnote 7 "Stockholders" Equity, to the consolidated financial statements, the Company recorded $1,202,051 stock-based compensation expense for compensatory stock option grants in year 2024 and grants in previous years and $28,876 of a debt discount for stock options issued with debt, to certain employees and debt holders, respectively and recorded , $19,464 for common shares granted to a consultant for services. The Company had to obtain a valuation of the business which was then allocated to the various classes of capital stock outstanding in order to determine the value of the common stock on the grant dates. This common stock value was then used to value the common shares issued for services and used in a modified Black-Scholes option pricing model to determine the value of the options on the grant or issuance dates.

We identified the valuation of the stock options as a critical audit matter. Auditing management's valuation of stock options involved a high degree of subjectivity.

The primary procedures we performed to address these critical audit matters included (a) reviewed management's process for valuing the business and the stock options, (b) determined whether the valuation method management selected was reasonable by comparing it to generally accepted methodologies for valuing a business and stock options, (c) tested management's valuation of the business and stock options by testing assumptions and data used in the valuation models, and (d) recomputed the stock options valuations. We agreed with management's final conclusions with regard to the stock options valuation.

![](tm2533753d1_fin1img02.jpg)

SALBERG & COMPANY, P.A.

We have served as the Company's auditor since 2023*.*

Boca Raton, Florida

April 30, 2025

**CYTONICS CORPORATION AND SUBSIDIARY**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| &nbsp;&nbsp;&nbsp;**Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $2432955 | $602933 |
| &nbsp;&nbsp;&nbsp;Accounts receivable (net of allowance for credit losses of $0) | 50000 | 120000 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 61222 | 26532 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 2544177 | 749465 |
| Accounts receivable, non-current, net |  | 76191 |
| Deferred offering costs | 29002 |  |
| Deposit | 204754 | 204531 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $2777933 | $1030187 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $198825 | $295503 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses - related parties | 62312 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 261137 | 295503 |
| Notes payable, net of debt discount of $0 and $68,681, respectively | - | 176319 |
| &nbsp;&nbsp;&nbsp;Total liabilities | 261137 | 471822 |
| Commitments and contingencies - See Note 6 |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred Stock, $0.001 par value; 20,000,000 shares authorized |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible Initial Preferred Stock, $0.001 par value; 150,000 shares designated, issued and outstanding | 150 | 150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible Series A Preferred Stock, $0.001 par value; 1,500,000 shares designated; 576,190 and 563,690 shares issued and outstanding, respectively | 576 | 564 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible Series B Preferred Stock, $0.001 par value; 6,000,000 shares designated; 2,574,865 shares issued and outstanding | 2575 | 2575 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible Series C and C-1 Preferred Stock, $0.001 par value; 10,000,000 shares designated; 8,399,558 and 5,439,376 shares issued and outstanding, respectively | 8400 | 5440 |
| &nbsp;&nbsp;&nbsp;Common stock, par value $0.001 per share; 50,000,000 shares authorized; 11,589,652 and 10,241,391 shares issued and outstanding, respectively | 11589 | 10241 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 31726570 | 25219205 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | (7102) | 19231 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (29225962) | (24699041) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 2516796 | 558365 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $2777933 | $1030187 |

---

The accompanying notes are an integral part of the consolidated financial statements.

**CYTONICS CORPORATION AND SUBSIDIARY**

**CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended** | **For the Years Ended** |
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| Revenues: |  |  |
| &nbsp;&nbsp;&nbsp;License and royalty revenues | $306669 | $417500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 306669 | 417500 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Research and development expense | 2659416 | 1497236 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Research and development credit | (293488) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net research and development expense | 2365928 | 1497236 |
| &nbsp;&nbsp;&nbsp;Payroll expense | 402916 | 213603 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 191040 | 79783 |
| &nbsp;&nbsp;&nbsp;Professional fees | 1709038 | 579738 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 4668922 | 2370360 |
| Loss from operations | (4362253) | (1952860) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 32154 | 17630 |
| &nbsp;&nbsp;&nbsp;Interest (expense) | (196822) | (11630) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other (expense), net | (164668) | 6000 |
| Net loss before income taxes | (4526921) | (1946860) |
| Tax benefit | - | - |
| Net loss | $(4526921) | $(1946860) |
| Other comprehensive income: |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | (26333) | 19231 |
| Comprehensive loss | $(4553254) | $(1927629) |
| Net loss per share: |  |  |
| &nbsp;&nbsp;&nbsp;Basic and diluted | $(0.41) | $(0.19) |
| Weighted average number of common shares outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;Basic and diluted | 11050362 | 10246794 |

---

The accompanying notes are an integral part of the consolidated financial statements.

**CYTONICS CORPORATION AND SUBSIDIARY**

**CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**

**FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023**

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Initial<br> Convertible** | **Initial<br> Convertible** | **Series-A<br> Convertible** | **Series-A<br> Convertible** | **Series-B<br> Convertible** | **Series-B<br> Convertible** | **Series-C and C-1 <br> Convertible** | **Series-C and C-1 <br> Convertible** | | | | | | |
|  | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | Shares | Amount | Shares | Amount | **Shares** | **Amount** | **Additional**<br>**Paid-In**<br>**Capital** | **Accumulated<br> Other**<br>**Comprehensive**<br>**Income (Loss)** |<br>**Accumulated**<br>**Deficit** |<br>**Total** |
| **Balance - December 31, 2022** | 150000 | $150 | 576190 | $576 | 2574865 | $2575 | 4702042 | $4703 | 10257042 | $10257 | $23867651 | $- | $(22752181) | $1133731 |
| &nbsp;&nbsp;&nbsp;Common shares issued for services rendered |  |  |  |  |  |  |  |  | 9349 | 9 | 10155 |  |  | 10164 |
| &nbsp;&nbsp;&nbsp;Issuance of preferred shares for cash, net of |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;issuance costs |  |  |  |  |  |  | 737334 | 737 |  |  | 947718 |  |  | 948455 |
| &nbsp;&nbsp;&nbsp;Shares given back to Company |  |  | (12500) | (12) |  |  |  |  | (25000) | (25) | 37 |  |  |  |
| &nbsp;&nbsp;&nbsp;Stock options issued with debt |  |  |  |  |  |  |  |  |  |  | 72217 |  |  | 72217 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  |  |  |  |  |  |  |  |  | 321427 |  |  | 321427 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation gain |  |  |  |  |  |  |  |  |  |  |  | 19231 |  | 19231 |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | - | - | - | - | - | - | (1946860) | (1946860) |
| **Balance - December 31, 2023** | 150000 | 150 | 563690 | 564 | 2574865 | 2575 | 5439376 | 5440 | 10241391 | 10241 | 25219205 | 19231 | (24699041) | 558365 |
| &nbsp;&nbsp;&nbsp;Reissuance of shares previously canceled in 2023 |  |  | 12500 | 12 |  |  |  |  | 25000 | 25 | (37) |  |  |  |
| &nbsp;&nbsp;&nbsp;Common shares issued for services rendered |  |  |  |  |  |  |  |  | 18913 | 19 | 19445 |  |  | 19464 |
| &nbsp;&nbsp;&nbsp;Issuance of preferred shares for cash, net of |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;issuance costs |  |  |  |  |  |  | 2751760 | 2752 |  |  | 3375042 |  |  | 3377794 |
| &nbsp;&nbsp;&nbsp;Debt discount for common stock options |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;issued with convertible notes |  |  |  |  |  |  |  |  |  |  | 28876 |  |  | 28876 |
| &nbsp;&nbsp;&nbsp;Common shares and options issued for cash |  |  |  |  |  |  |  |  | 1304348 | 1304 | 1498696 |  |  | 1500000 |
| &nbsp;&nbsp;&nbsp;Issuance of preferred shares upon |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;conversion of convertible notes and accrued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;interest |  |  |  |  |  |  | 208422 | 208 |  |  | 383292 |  |  | 383500 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  |  |  |  |  |  |  |  |  | 1202051 |  |  | 1202051 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation loss |  |  |  |  |  |  |  |  |  |  |  | (26333) |  | (26333) |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | - | - | - | - | - | - | (4526921) | (4526921) |
| **Balance - December 31, 2024** | 150000 | $150 | 576190 | $576 | 2574865 | $2575 | 8399558 | $8400 | 11589652 | $11589 | $31726570 | $(7102) | $(29225962) | $2516796 |

---

The accompanying notes are an integral part of the consolidated financial statements.

**CYTONICS CORPORATION AND SUBSIDIARY**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended** | **For the Years Ended** |
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| **Cash Flows From Operating Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(4526921) | $(1946860) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for credit losses | 78049 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount | 97557 | 7107 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 1221515 | 331591 |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 68142 | 52562 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (34690) | (3699) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deposit | (223) | (204531) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 54134 | 47687 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in operating activities** | (3042437) | (1716143) |
| **Cash Flows From Investing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of intangible assets | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in investing activities** | - | - |
| **Cash Flows From Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Repayments of notes payable |  | (60000) |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of convertible notes | 100000 | 245000 |
| &nbsp;&nbsp;&nbsp;Repayments of convertible notes | (50000) |  |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of common shares and options | 1500000 |  |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of preferred shares, net of offering costs | 3377794 | 948455 |
| &nbsp;&nbsp;&nbsp;Deferred offering costs | (29002) |  |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by financing activities** | 4898792 | 1133455 |
| **Effect of exchange rate changes on cash** | (26333) | 19231 |
| **Net increase (decrease) in cash** | 1830022 | (563457) |
| **Cash at beginning of year** | 602933 | 1166390 |
| **Cash at end of year** | $2432955 | $602933 |
| **Supplemental Disclosure of Cash Flow Information:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $15000 | $288 |
| &nbsp;&nbsp;&nbsp;Cash paid for taxes | $- | $- |
| **Supplemental Disclosure of Non-Cash Investing and Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Issuance of preferred shares upon conversion of convertible notes and accrued interest | $383500 | $- |
| &nbsp;&nbsp;&nbsp;Issuance of stock options with debt | $28876 | $72217 |

---

The accompanying notes are an integral part of the consolidated financial statements.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 1 NATURE OF BUSINESS**

**Overview**

Cytonics Corporation (the "Company") is a research and development company that develops therapies and diagnostics for back and joint pain, which it then licenses to unrelated third parties. The Company was incorporated in the State of Florida under the name Gamma Spine, Inc. on July 19, 2006 and was renamed Cytonics Corporation on April 17, 2007.

**NOTE 2 GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS**

During the year ended December 31, 2024, the Company sustained a net loss of $4,526,921 and had net cash used in operating activities of $3,042,437. As of December 31, 2024, the Company had an accumulated deficit of $29,225,962. These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the consolidated financial statements.

To date, the Company has funded its research and development and operating activities through sales of debt and equity securities, grant funding, and revenues generated from the licensing of its products. During the year ended December 31, 2024, the Company received proceeds of $3,377,794, net of direct offering costs, from the sale of Series-C Preferred Shares, $1,500,000 from the issuance of common shares and options, and $100,000 from the issuance of contingently convertible notes payable.

Management's plans regarding these matters include the raising of additional funding through investments by strategic partners and from private and public sales of securities to fund its operations and its research and development activities. The Company expects to incur net losses until such time it develops biopharmaceuticals and medical devices with the intent of licensing or selling the related intellectual property, or alternatively, until it successfully merges with another operating entity. The Company's ability to continue its operations is dependent upon its ability to obtain additional capital through public or private equity offerings, debt financings or other sources; however, financing may not be available to the Company on acceptable terms, or at all. The Company's failure to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategy, and the Company may be forced to curtail or cease operations.

The outcome of management's plans cannot be determined with any degree of certainty. Accordingly, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business for one year from the date the consolidated financial statements are issued. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

**NOTE 3 — ACCOUNTING POLICIES**

**Basis of Presentation**

The accompanying consolidated financial statements have been prepared in conformity with accounting principles accepted in the United States of America (U.S. GAAP) for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC).

**Foreign Currency**

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

Foreign currency transaction gains and losses are a result of the effect of exchange rate changes on transactions denominated in currencies other than the AUD, the functional currency of our subsidiary. Transaction gains and losses are recognized in Other income (expense), net, in the consolidated statements of operations. For the years ended December 31, 2024 and 2023, the Company recorded a net foreign currency transaction gain(loss) of $(9) and $119, respectively, which are included in selling, general and administrative expenses in the accompanying consolidated statements of operations.

**Use of Estimates**

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying Notes. Actual results could differ materially from those estimates. The Company's most significant estimates include the allowance for credit losses, fair value of stock-based compensation, and the fair value of stock options issued with convertible notes and notes payable.

**Principles of Consolidation**

The accompanying consolidated financial statements include the accounts of Cytonics Corporation and its wholly-owned subsidiary Cytonics Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.

**Fair Value of Financial Instruments**

The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Subtopic 825-10, "Financial Instruments" ("ASC 825-10") requires disclosure of the fair value of certain financial instruments. The estimated fair value of certain financial instruments, including accounts receivable and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the consolidated financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk.

**Cash and Cash Equivalents**

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents at December 31, 2024 and 2023.

**Fair Value Measurements**

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:

● Level 1 – Quoted prices in active markets for identical assets or liabilities.

● Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

● Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**Accounts Receivable and Allowance for Credit Losses**

The Company adopted ASC 326 "Financial Instruments – Credit Losses" on January 1, 2023. The Company recognizes an allowance for credit losses on accounts receivable and other receivables in an amount equal to the estimated probable losses net of recoveries under the current expected credit loss method. Accounts receivables are stated at the amount management expects to collect from outstanding balances. The Company estimates the collectability of its receivables and establishes allowances for the amount of accounts receivable that the Company estimates to be uncollectible. The Company bases these allowances on its historical collection experience, the length of time accounts receivables are outstanding, the financial condition of individual customers, and current economic conditions that may affect a customer's ability to pay. An individual balance is charged to the allowance when all collection efforts have been exhausted and it is deemed likely to be uncollectible, taking into consideration the financial condition of the customer and other factors. At December 31, 2024 and 2023 no allowance for credit losses relating to the Company's accounts receivable was deemed necessary. Accounts receivables that are expected to be received within the period of one year are classified as current. Non-current account receivables are receivables outstanding and expected to be received after the period of one year and are reflected at their present value using a discount rate of 5%.

**Australian Goods and Services Tax ("GST")**

Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office.

Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

As of December 31, 2024 and 2023, the Company was owed $53,127 and $17,514, respectively, from the Australian Taxation Office, which is included in Prepaid expenses and other current assets.

**Intangible Assets**

The Company's intangible assets include seven U.S. patents (US 10,265,388, US 11,040,092, US 10,940,189, US 9,352,021, US 9,498,514, US 10,400,028, US 10,889,631), three U.K. patents (GB2501611, GB2503131, and GB2522561), two European patents (EP 2827882 and EP 3221341; each of which is validated in FR, DE, and GB), one Canadian patent (CA 2865170), two Australian patents (AU 2013222414, AU 2015349782), and one Japanese patent (JP 6861152). The Company also has five additional related pending patent applications. The cost of issued patents is capitalized and amortized over the life of the patents, which is 20 years from the earliest filing date of the non-provisional or PCT application to which priority is claimed. The costs of patent in development are expensed as they are incurred. The unamortized costs associated with previously capitalized patents that have expired or been abandoned are written off.

The Company assesses potential impairments of its intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Any required impairment loss is measured as the amount by which the asset's carrying value exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to operating results. The Company had no impairment of intangible assets for the year ended December 31, 2024 and 2023.

**Revenue Recognition**

The Company follows Accounting Standards Codification 606 ("ASC 606"). ASC 606 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASC also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer purchase orders, including significant judgments.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

The Company recognizes revenue when obligations under the terms of a contract with a customer are satisfied. This occurs with the transfer of control or access to the Company's licenses or the performance of services. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.

Contracts with customers consist of licensing arrangements and, optionally, research and development-related services. Revenues from licensing and royalty fees are received from the granting of exclusive sales, marketing, manufacturing, and distribution rights associated with the Company's functional intellectual property (IP). The Company's performance obligation is satisfied at a point in time (upon delivery to the customer) where the Company has no remaining obligation to support or maintain the intellectual property licensed to the customer. The Company typically requires a non-refundable license fee, paid over several years, and quarterly royalty payments based on a percentage of sales, subject to minimum guaranteed quarterly royalty amounts. For contracts whereby customer payments shall be received over time, at the time of contract execution, the Company applies an implied discount to the license fees in order to calculate the net present value of the contractual payments.

Revenue from license fees is recognized at a point in time when the Company transfers the functional IP to the customer, as long as management believes the total consideration owed by the customer for the license fee is probable to be received. Due to the financing component embedded in the license fee, the Company records the revenue and accounts receivable at their net present value using an estimated discount rate at the point in time when the performance obligation associated with the license fee has been completed. Management applies a discount rate that reflects the customers' creditworthiness and the amount that would have been received from the customer if the license fee was paid upon execution of the contract. The effect of the financing component is subsequently recognized as interest income over the payment term.

Minimum guaranteed royalty (MGR) payments are not binding and are considered to be contingent on the customers' ability to generate sales. The Company's contracts include termination clauses for nonpayment by customers or mutual agreement. The termination clauses are likely to be triggered if the customer is unable to make the MGRs. The Company has historically made price concessions when needed by customers. Given the contractual nature of the MGRs and customary business practices, the Company recognizes revenue from MGRs pursuant to ASC 606-10-55-65 guidance for a sales-based or usage-based royalty, which requires recognition for a sales-based royalty promised in exchange for a license of intellectual property only when (or as) the later of the following events occurs:

a. The subsequent sale or usage
 occurs.

b. The performance obligation
 to which some or all of the sales-based or usage-based royalty has been satisfied (or partially satisfied).

The Company recognizes revenue from MGRs when they become due under the terms of the contract and the consideration has been received or is expected to be received.

Licenses and royalties due under the contract not yet received have been reflected as accounts receivable on the balance sheets, net of any implied discounts to net present value.

Except for the estimate of the discount rate applied to license fees to be received over a period of years, the Company's contracts do not include multiple performance obligations or variable consideration. Since the Company's revenue is generated from a small number of customer contracts, it does not have material contract assets or liabilities.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

During 2020, the Company received consideration from a customer in connection with the granting of exclusive sales, marketing, manufacturing, and distribution rights associated with the Company's functional intellectual property. The executed contract required a $450,000 nonrefundable license fee from the customer, payable to the Company as follows: (i) $50,000 upon execution of the contract in May 2020; and (ii) $80,000 on January 1 of each of the next five years through 2025. In the event the contract is terminated prior to its ten-year term, the customer is required to pay a portion of the license fee based on a sliding scale and the year of termination. On January 1, 2024, the customer failed to make the $80,000 installment payment due. Subsequently, on July 19, 2024, the contract was amended whereby the customer agreed to immediately make the past due $80,000 installment payment, which it did pay to the Company, and the Company waived the final $80,000 installment due January 1, 2025, which was recorded as a provision for credit losses and included in selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. In addition, the monthly royalty was decreased from $21,667 per month to $15,000 per month for the remainder of the contract through 2029.

As of December 31, 2024, the remaining nonrefundable fee due from the customer was $0. As of December 31, 2023, the remaining nonrefundable fee due from the customer was $156,161, of which $80,000 was included in accounts receivable and $76,161, net of a $3,809 discount, was included in accounts receivable, non-current.

During the years ended December 31, 2024 and 2023, the Company recognized revenue from license fees and MGRs of $306,669 and $417,500, respectively, which is presented on the statement of operations as license and royalty revenues.

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended** | **For the Years Ended** |
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| APIC<sup>1</sup> and VET<sup>2</sup> Royalties | $306669 | $320000 |
| Licensing Revenue | - | 97500 |
| Total Revenue | $306669 | $417500 |

---

<sup>1</sup> APIC stands for Autologous Protease Inhibitor Concentrate

<sup>2</sup> Royalty income from Veterinary Market

**Stock-Based Compensation Expense**

Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For stock-based awards to employees, non-employees and directors, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model, which includes variables such as the expected volatility of the Company's share price, the exercise behavior of its grantees, interest rates, and dividend yields. These variables are projected based on the Company's historical data, experience, and other factors. In the case of awards with multiple vesting periods, the Company has elected to use the graded vesting attribution method, which recognizes compensation cost on a straight-line basis over each separately vesting portion of the award as if the award was, in substance, multiple awards.

**Research and Development**

The Company enters into consulting, research, and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services. The Company's research and development expenses involves costs associated with (i) entering R&D collaboration agreements with third party contractors to manufacture and develop Cyt-108 through upcoming clinical trials; and (ii) other costs incurred in the development of intellectual property. The third party contractors include, but are not limited to, contract research organizations, contract drug manufacturing organizations, investigational sites and consultants. Costs incurred in connection with research and development activities are expensed as incurred.

In accordance with ASC 730-10, *"Research and Development-Overall,"* research and development costs are expensed when incurred. Total research and development costs for the year ended December 31, 2024 and 2023 were $2,365,928 (net of a tax credit of $293,488 – see below) and $1,497,236, of which $1,231,357 and $157,859, respectively, was incurred by the Australian subsidiary.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

The Company may apply for research and development tax concessions with the Australian Taxation Office, under the Research and Development Tax Incentive ("RDTI") Program, on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company's net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt. Under the RDTI Program, up to 43.5% of R&D expenditures may be reimbursed in the form of cash.

During the year ended December 31, 2024, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $293,488, which is reflected as a reduction in research and development expense in the accompanying consolidated statements of operations and comprehensive income (loss).

**Earnings (Loss) Per Share**

Basic earnings (loss) per common share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Shares issued during the year are weighted for the portion of the year that they were outstanding. Except when the effect would be anti-dilutive, diluted earnings per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive common shares that were outstanding during the period.

The computation of basic and diluted income (loss) per share excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended** | **For the Years Ended** |
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| Options | 7762401 | 4407076 |
| Convertible preferred shares | 15061668 | 12101486 |
| Total potentially dilutive shares | 22824069 | 16508562 |

---

**Income Taxes**

The Company accounts for its income taxes in accordance with accounting principles generally accepted in the United States of America, which requires, among other things, recognition of future tax benefits and liabilities measured at enacted rates attributable to temporary differences between financial statement and income tax bases of assets and liabilities and to net tax operating loss carryforwards to the extent that realization of these benefits is more likely than not. The Company periodically evaluates the realizability of its net deferred tax assets. The Company's policy is to account for interest and penalties relating to income taxes, if any, in "income tax expense" in its consolidated statements of operations and include accrued interest and penalties within "accrued liabilities" in its consolidated balance sheets, if applicable. For the years ended December 31, 2024 and 2023, no income tax related interest or penalties were assessed or recorded.

**Comprehensive Income (Loss)**

Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) consists of foreign currency translation adjustments that have been excluded from the determination of net income (loss).

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**Segment reporting**

The Company operates as a single operating segment as a research and development company that is developing therapies and diagnostics for back and joint pain. In accordance with ASC 280 – "Segment Reporting", the Company's chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report annually selected segment information and entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under "Segment Reporting" due to their similarities in economic characteristics such as nature of services; and procurement processes. All revenues and expenses as reflected in the accompanying consolidated statements of operations and comprehensive loss, and all assets and liabilities as reflected in the accompanying consolidated balance sheets are allocated to the one segment.

**Recent Accounting Pronouncements**

In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on accounting for convertible debt instruments by removing the separation models for: (1) convertible debt with a cash conversion feature; and (2) convertible instruments with a beneficial conversion feature. As a result, the Company will not separately present in equity an embedded conversion feature in such debt. Instead, we will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. We expect the elimination of these models will reduce reported interest expense and increase reported net income for the Company's convertible instruments falling under the scope of those models before the adoption of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. ASU 2020-06 became effective for the Company on January 1, 2024. The adoption of this update did not have a material impact on the Company's consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which significantly changes how entities will measure credit losses for most financial assets, including accounts receivable. ASU No. 2016-13 will replace today's "incurred loss" approach with an "expected loss" model, under which companies will recognize allowances based on expected rather than incurred losses. On November 15, 2019, the FASB delayed the effective date of Topic 326 for certain small public companies and other private companies until fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC's definition, as well as private companies and not-for-profit entities. ASU 2016-13 became effective for the Company on January 1, 2023. The adoption of this update did not have a material impact on the Company's consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires entities to provide more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function. The new disclosures will require entities to separately present expenses for significant line items, including but not limited to, depreciation, amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and, in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company does not expect the adoption of this new guidance to have a material impact on the consolidated financial statements.

There are other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company's financial position, results of operations or cash flows.

**NOTE 4 — DEPOSIT**

In December 2023, the Company contracted with Southern Star Research ("Southern Star"), an Australian Contract Research Organization ("CRO"), for research and development services related to the Phase 1 clinical trial. Southern Star required a deposit equal to 20% of the statement of work (totaling approximately 1, 5000,000 AUD). The research and development services are expected to be completed in 2025, at which time the deposit shall be utilized to pay any remaining amounts due under the statement of work, with and any remaining deposit returned to the Company. Accordingly, the Company provided Southern Star with a deposit of $204,754 and $204,531, which is reflected as a non-current asset on the accompanying consolidated balance sheet as of December 31, 2024 and 2024, respectively.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

**NOTE 5 — NOTES PAYABLE**

**2022 Notes**

During 2022, the Company issued promissory notes in the principal amount of $360,000 (collectively referred to as the "2022 Notes") with applicable interest per annum ranging from 15% to 20%.

The 2022 Notes are due at the earlier of the close of a qualified equity financing or one year from the date of the note ("Maturity Date"). Qualified equity financing is defined as when the Company issues and sells shares of its equity securities to investors prior to the Maturity Date in an equity financing of not less than $1.5 or $2.0 million. Upon Qualified equity financing, the outstanding principal amount plus interest, as if the loan were being repaid on the Maturity Date. (e.g., if the principal amount of the Note is $100,000, then upon a qualified financing the holder shall be repaid $115,000, which is inclusive of all accrued interest of 15%), would be due and payable.

During the year ended December 31, 2023, the remaining principal amount of $60,000 and accrued interest of $9,000 was repaid in cash and the remaining unamortized debt discount of $3,571 was expensed to interest expense.

As of December 31, 2024, and 2023, the outstanding principal on the 2022 Notes was $0. As of December 31, 2024 and 2023, outstanding interest on the 2022 Notes was $0.

**2023 Notes**

During October 31, 2023 through December 21, 2023, the Company issued convertible promissory notes having an aggregate face value of $245,000 along with 5-year stock options to purchase an aggregate of 245,000 common shares at $2.30 per share in exchange for proceeds of $245,000. As a result of the issuance of the common stock options, an aggregate amount of $72,217 of debt discount was recorded with a corresponding increase in additional paid-in capital based on the relative fair value method.

**2024 Note**

On January 11, 2024, the Company issued a convertible promissory note having a face value of $100,000 (the "2024 Note") along with 5-year stock options to purchase an aggregate of 100,000 common shares at $2.30 per share in exchange for proceeds of $100,000. As a result of the issuance of the common stock options, $28,876 of debt discount was recorded with a corresponding increase in additional paid-in capital based on the relative fair value method.

The 2023 and 2024 convertible notes bear interest at 15% per annum. All unpaid outstanding principal and interest are due in two years from the respective date of each note.

If the Company issues and sells Equity Securities in which the Company receives gross proceeds of $2,000,000 or more (a "Qualified Financing"), then the 2023 Notes and Full Interest (i.e., 24 months of interest as if the loan was repaid on the maturity date) will automatically convert into Equity Securities upon consummation of the Qualified Financing at a 20% discount to the Equity Securities share price.

If the Company issues and sells Equity Securities in which the Company receives gross proceeds of $2,000,000 or more (a "Qualified Financing"), then 50% of the 2024 Note and 50% of the Full Interest (i.e., 24 months of interest as if the loan was repaid on the maturity date) will automatically convert into Equity Securities upon consummation of the Qualified Financing at a 20% discount to the Equity Securities share price.

At any time after 12 months from the issue date, the Company has the right to prepay the note whereby the Holder will be entitled to receive their principal plus Full Interest. Prior to repayment, the investors shall be given a 10-day notice and the option to convert the outstanding principal amount of the 2023 Notes plus the Full Interest at a 20% discount to the current share price of $2.30 per share of Preferred Series C Stock.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

A Qualified Financing occurred on May 28, 2024. As a result, in June 2024, the Company repaid $50,000 of principal and $15,000 of interest (Full Interest on the $50,000) in cash. In addition, $295,000 of principal and $88,500 of accrued interest (Full Interest on the $295,000) was converted into an aggregate of 208,422 shares of Preferred Series C Stock.

During the year ended December 31, 2024 and 2023, the Company amortized $97,557 and $3,536 of debt discount to interest expense, and recognized $99,265 and $4,235 of interest expense, respectively, in the statements of operations. As of December 31, 2024 and 2023, the carrying value of the convertible notes was $0 and $176,319, net of unamortized debt discount of $0 and $68,681, respectively.

**NOTE 6 — COMMITMENTS AND CONTINGENCIES**

**Legal Matters**

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. At December 31, 2024, there were no other pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's consolidated operations and there are no proceedings in which any of the Company's directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company's interest.

**NOTE 7 — STOCKHOLDERS' EQUITY**

**Common Stock**

The Company is authorized to issue 50,000,000 shares of Common Stock with a par value of $0.001 per share.

In January 2023, 9,349 shares of Common Stock, having a fair value of $10,164, were issued to a consultant for services rendered.

In January 2024, the Company reissued 25,000 shares of Common Stock that had been previously canceled in 2023.

On May 28, 2024, the Company entered into a letter of intent to sell 1,304,348 shares of Common Stock and 1,500,000 five-year stock options to purchase shares of Common Stock at $1.15 per share in exchange for a subscription receivable of $1,500,000, which was received on July 19, 2024.

In June 2024, 18,913 shares of Common Stock, having a fair value of $19,464, were issued to a consultant for services rendered.

On December 31, 2024, and 2023, the Company had 11,589,652 and 10,241,391 shares of Common Stock issued and outstanding, respectively. The holders of Common Stock are entitled to one vote for each share held of record on such matters and in such manner as may be provided by law. Subject to preferences applicable to any shares of the Company's outstanding Preferred Stock, the holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available. In the event of a liquidation, dissolution, or winding up of the Company, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of liabilities and liquidation preferences of any shares of the Company's outstanding Preferred Stock. Holders of Common Stock have no pre-emptive rights or rights to convert their Common Stock into any other securities. There are no redemption or sinking fund provisions applicable to the Common Stock. All outstanding shares of Common Stock are fully paid and non-assessable.

**Preferred Stock**

*Authorized Shares, Liquidation Preferences, Voting Rights, and Automatic Conversion Feature*

The Company is authorized to issue 20,000,000 shares of Preferred Stock with a par value of $0.001 per share. The Board of Directors has designated: (a) 150,000 shares as Initial Preferred Stock; (b) 1,500,000 shares as Series A Preferred Stock; (c) 6,000,000 shares as Series B Preferred Stock; and (d) 10,000,000 shares as Series C Preferred Stock of which 510,000 shares are designated as Series C-1 Preferred Stock.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

In the event of any liquidation event, all shares of Initial, Series A and Series C Preferred Stock are pari passu with each other, and Series B is last in preference, but all have a liquidation preference over shares of Common Stock.

All holders of shares of Preferred Stock will vote with holders of Common Stock as a single class and will participate in all dividends that are declared and paid on Common Stock on the same basis as if each share of Preferred Stock were converted into Common Stock.

All shares of Preferred Stock will automatically convert upon a Public Offering into shares of Common Stock.

*Convertible Initial Preferred Stock*

As of December 31, 2024, and 2023, the Company had 150,000 shares of Initial Preferred Stock (Initial Preferred) issued and outstanding. The Initial Preferred has a liquidation preference of $2.00 per share ($300,000 in aggregate). Each share of Initial Preferred is convertible into 2.4 shares of Common Stock.

*Convertible Series A Preferred Stock*

In January 2024, the Company reissued 12,500 shares of Convertible Series A Preferred Stock that had been previously canceled in 2023.

As of December 31, 2024, and 2023, the Company had 576,190 shares of Convertible Series A Preferred (Series A Preferred) issued and outstanding. The Series A Preferred Stock has a liquidation preference of $4.00 per share ($2,304,760 in aggregate). Each share of Series A Preferred is convertible into two (2) shares of Common Stock.

*Convertible Series B Preferred Stock*

As of December 31, 2024 and 2023, the Company had 2,574,865 shares of Convertible Series B Preferred Stock (Series B Preferred) issued and outstanding. The Series B Preferred has a liquidation preference ranging from $2.50 to $4.00 per share ($7,360,960 in the aggregate). Each share of Series B Preferred is convertible into two (2) shares of Common Stock.

*Convertible Series C Preferred Stock*

During the year ended December 31, 2023, the Company initiated a Series C Preferred Stock Offering (the "2023 Offering") which resulted in gross proceeds of $1,695,868. The Company issued 737,334 shares of Series C Preferred Stock for $2.30 per share. The 2023 Offering generated $948,455 of proceeds, net of $120,302 for directly attributable brokerage costs and $627,111 for digital and marketing expenses directly incurred to raise such capital from the offering. Upon completion of the 2023 Offering, these direct offering costs were recorded as a reduction of additional paid-in capital.

During the period from January 16, 2024 through June 19, 2024, the Company initiated a Series C Preferred Stock Offering (the "1<sup>st</sup> 2024 Offering") which resulted in gross proceeds of $3,639,659. The Company issued 2,220,458 shares of Series C Preferred Stock for $2.30 per share, subject to bonus shares of 5% – 50%, based on predetermined schedule of the amount and timing of shares purchased. The 1<sup>st</sup> 2024 Offering generated $2,711,163 of proceeds, net of $323,511 for directly attributable brokerage costs and $604,985 for digital and marketing expenses directly incurred to raise such capital from the offering. Upon completion of the 1<sup>st</sup> 2024 Offering, these direct offering costs were recorded as a reduction of additional paid-in capital.

On May 28, 2024, the Company having received gross proceeds of $2,000,000 or more, a Qualified Financing occurred, as related to the Company's outstanding Convertible Notes. As a result, in June 2024, the Company repaid $50,000 of principal and $15,000 of interest (Full Interest on the $50,000) in cash. In addition, $295,000 of principal and $88,500 of accrued interest (Full Interest on the $295,000) was converted into an aggregate of 208,422 shares of Preferred Series C Stock.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

During the period from July 23, 2024 through October 17, 2024, the Company initiated a Series C Preferred Stock Offering (the "2<sup>nd</sup> 2024 Offering") which resulted in gross proceeds of $872,315. The Company issued 531,302 shares of Series C Preferred Stock for $2.30 per share, subject to bonus shares of 5% – 50%, based on predetermined schedule of the amount and timing of shares purchased. The 2<sup>nd</sup> 2024 Offering generated $666,631 of proceeds, net of $86,705 for directly attributable brokerage costs and $118,979 for digital and marketing expenses directly incurred to raise such capital from the offering. Upon completion of the 2<sup>nd</sup> 2024 Offering, these direct offering costs were recorded as a reduction of additional paid-in capital.

As of December 31, 2024 and 2023, the Company had 8,399,558 (7,892,442 Series C and 507,116 Series C-1) and 5,439,376 (4,932,260 Series C and 507,116 Series C-1) Series C Preferred shares, issued and outstanding, respectively.

The Series C Preferred has a liquidation preference of $2.00 per share and the Series C-1 Preferred has a liquidation preference of $1.05 per share (calculated at issuance), (each of which is the respective "Series C Purchase Price"). All other rights and privileges of the Series C Preferred and Series C-1 Preferred are identical except for their liquidation preferences. The Series C Convertible Preferred Stock has a liquidation preference of $2.00 per share ($15,784,882 and $9,864,520 in aggregate as of December 31, 2024 and 2023, respectively). The Series C-1 Convertible Preferred Stock has a liquidation preference of $1.05 per share ($532,472 in aggregate). Each share of Series C Preferred and Series C-1 is convertible into one (1) share of Common Stock.

**Stock Options**

In April 2007, the Company's shareholders adopted the 2007 Stock Incentive Plan (the "2007 Plan"), providing for the grant of stock options and restricted stock awards to employees, non-employee service providers and Board members. Stock options granted under the 2007 Plan may include non-statutory stock options as well as incentive stock options intended to qualify under Section 422 of the Internal Revenue Code. Awards under the 2007 Plan may be granted only during the ten years immediately following the effective date of the plan.

During 2018, the Company's Board adopted the 2018 Stock Incentive Plan (the "2018 Plan"), as amended on May 25, 2021, effectively replacing the 2007 Plan, to provide for the issuance of up to 10,000,000 shares of stock through the grant of stock options, restricted stock, or restricted stock units.

In January 2023, the Company granted options to three board directors to purchase an aggregate of 150,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.501 per stock option, which vested 12,500 per quarter (fully vested as of December 31, 2023) and are exercisable over five years. In June 2023, the Company granted options to its Chief Executive Officer to purchase an aggregate of 434,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.515 per stock option, which vested immediately and are exercisable over five years.

In October 2023 through December 2023, debt holders were given options to purchase an aggregate of 245,000 shares of Common Stock at an exercise price of $2.30 per share that were fully vested on issuance and are exercisable over five years (see Note 5). Stock compensation expenses for non-debt related grants during the year ended December 31, 2023 was $321,427.

In January 2024, the Company granted options to two board directors to purchase an aggregate of 100,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.150 per stock option, which vest 12,500 per quarter and are exercisable over five years. In January 2024, the Company granted options to an advisor to purchase an aggregate of 50,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.681 per stock option, which vest 4,167 per quarter and are exercisable over five years.

In June 2024, the Company canceled all outstanding and vested options (883,800 options exercisable at $2.00 per share, expiring at various dates from October 2025 through June 2028, having an aggregate fair value of $203,558 at the date of cancelation) of its Chief Executive Officer in exchange for newly granted options to purchase an aggregate of 1,760,615 shares of Common Stock at an exercise price of $1.50 per share, having a grant date fair value of $0.752 per stock option, or a total of $1,324,077, which vested immediately and are exercisable over ten years. The issuance of the new options to the Chief Executive Officer are deemed a modification of the canceled options and, accordingly, the associated expense recognized is the excess of $1,120,519 of the fair value of the newly issued options over the fair value of the options that were canceled.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

In October 2024, the Company granted options to five medical advisory board members to purchase an aggregate of 1,207,510 shares of Common Stock at an exercise price of $1.21 per share, having a grant date fair value of $0.686 per stock option, or $828,010, which vest 75,469 per quarter and are exercisable over five years.

On December 31, 2024, the Company had options outstanding to purchase 7,762,401 shares of Common Stock under the 2007 and 2018 Plans, at exercise prices ranging from $0.05 to $2.30 per share.

The Company determined the grant date fair value of the options granted using the Black Scholes Method using the following assumptions:

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended** | **For the Years Ended** |
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| Expected Volatility | 62.6% - 103.7% | 89.6% - 97.0% |
| Expected Term | 1.5 - 5 years | 2.5 years |
| Risk-Free Rate | 3.86% - 4.79% | 4.33% - 5.07% |
| Dividend Rate | 0.00% | 0.00% |

---

The following is a summary of the Company's stock option activity:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |<br>**Number of**<br>**Options** | **Weighted**<br>**Average**<br>**Exercise**<br>**Price** | **Weighted**<br>**Average**<br>**Remaining Life**<br>**In Years** |<br>**Intrinsic**<br>**Value** |
| Outstanding, December 31, 2022 | 4359876 | $1.06 |  |  |
| Granted | 829000 | $2.09 |  |  |
| Exercised |  |  |  |  |
| Forfeited/Expired | (781800) | $1.30 |  |  |
| Outstanding, December 31, 2023 | 4407076 | $1.28 |  |  |
| Granted | 4718125 | $1.35 |  |  |
| Exercised |  |  |  |  |
| Forfeited/Expired | (1362800) | $1.82 |  |  |
| Outstanding, December 31, 2024 | 7762401 | $1.23 | 5.3 | $1335044 |
| Exercisable, December 31, 2024 | 6521558 | $1.23 | 5.5 | $1335044 |

---

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

The following table summarizes stock option information at December 31, 2024:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Options Outstanding** | **Options Outstanding** | **Options Outstanding** | **Options Exercisable** | **Options Exercisable** |
| <br>**Exercise**<br>**Price** |<br>**Outstanding**<br>**Number of**<br>**Options** | **Weighted**<br>**Average**<br>**Exercise**<br>**Price** | **Weighted**<br>**Average**<br>**Remaining Life**<br>**In Years** |<br>**Exercisable**<br>**Number of**<br>**Options** | **Weighted**<br>**Average**<br>**Exercise**<br>**Price** |
| $0.05 | 800000 | $0.05 | Indefinite | 800000 | $0.05 |
| $0.38 | 629276 | $0.38 | Indefinite | 629276 | $0.38 |
| $1.00 - $1.50 | 4888125 | $1.28 | 7.7 | 3680615 | $1.30 |
| $2.00 | 1100000 | $2.00 | 2.1 | 1066667 | $2.00 |
| $2.30 | 345000 | $2.30 | 3.9 | 345000 | $2.30 |
|  | 7762401 | $1.23 | 5.3 | 6521558 | $1.23 |

---

The aggregate intrinsic value of outstanding stock options was $1,335,044, based on options with an exercise price less than the fair value of the Company's common stock price of $1.0983 per share as of December 31, 2024, which would have been received by the option holders had those option holders exercised their options as of that date.

The fair value of all options that vested during the years ended December 31, 2024 and 2023 was $1,202,051 and $321,427, respectively. As of December 31, 2024, the Company had $806,910 of total unrecognized compensation cost related to non-vested awards granted under the 2018 Plan, which the Company expects to recognize over a weighted average period of 2.00 years.

**NOTE 8 — INCOME TAXES**

The Company's provision (benefit) for income taxes consists of the following United States federal and state components:

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended** | **For the Years Ended** |
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| Current: |  |  |
| &nbsp;&nbsp;&nbsp;Federal | $- | $- |
| &nbsp;&nbsp;&nbsp;State |  |  |
| Deferred: |  |  |
| &nbsp;&nbsp;&nbsp;Federal | 932623 | 386566 |
| &nbsp;&nbsp;&nbsp;State | 193443 | 107136 |
|  | 1126066 | 493702 |
| Change in valuation allowance | (1126066) | (493702) |
| Income tax provision (benefit) | $- | $- |

---

The deferred tax expense (benefit) is the change in the deferred tax assets and liabilities representing the tax consequences of changes in the amounts of temporary differences, net operating loss carryforwards and changes in tax rates during the year. The Company's deferred tax assets and liabilities are comprised of the following:

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| Deferred tax assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net operating loss carryforwards | $4547774 | $4068416 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets | 1176820 | 834772 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock based compensation | 812469 | 507809 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax credits | 263834 | 263834 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total deferred tax assets | 6800897 | 5674831 |
| Deferred tax liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total deferred tax liabilities | - | - |
| Valuation allowance | (6800897) | (5674831) |
| Total deferred tax assets (liabilities) | $- | $- |

---

As of December 31, 2024 and 2023, the Company had U.S. federal net operating loss carryforwards of approximately $17.9 million and $16.1 million, respectively, of which $9.4 million does not expire, but is instead limited to 80% of taxable income in the year utilized. The remaining loss carryforwards expire at various dates through 2037. These net operating loss carryforwards may be used to offset future taxable income and thereby reduce the Company's U.S. federal income taxes. Section 382 of the Internal Revenue Code of 1986 (the "Code") imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by Section 382 of the Code, the Company's net operating loss carryforwards may be significantly limited as to the amount of use in a particular year. In addition, all or a portion of the Company's net operating loss carryforwards may expire unutilized.

For U.S. purposes, the Company has not completed its evaluation of NOL utilization limitations under Internal Revenue Code, as amended (the "Code") Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOL's would be limited as to the amount that could be utilized each year, based on the Code or might be eliminated.

The Company has provided a full valuation allowance against its net deferred tax assets, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits of these assets will not be realized.

The Company complies with the provisions of FASB ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10.

The Company is subject to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or any states in connection with income taxes. The Company's tax years generally remain open to examination for all federal and state tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

The Company recognizes interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense.

**CYTONICS CORPORATION AND SUBSIDIARY<br> NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 AND 2023**

The significant elements contributing to the difference between income taxes at the effective United States federal statutory tax rate of 21% and the Company's effective tax rate are as follows:

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended** | **For the Years Ended** |
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| Income taxes at the US federal statutory rate | 21.00% | 21.00% |
| State tax rate, net of federal benefit | 4.26% | 4.34% |
| Other | -0.39% | 0.01% |
| Change in valuation allowance | -24.87% | -25.35% |
| Income tax provision (benefit) | 0.00% | 0.00% |

---

**NOTE 9 — CONCENTRATIONS**

**Concentrations of Credit Risk**

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits in the United States in excess of the FDIC insured limit of $250,000. The Company also has cash deposits in Australia, which are insured up to 250,000AUD. On December 31, 2024, and 2023, the Company's cash balances were in excess of federally insured amounts by $2,070,928 and $349,538, respectively.

**Concentration of Revenues**

For the year ended December 31, 2024 and 2023, the following customers accounted for more than 10% of the Company's net revenues:

---

| | | |
|:---|:---|:---|
|  | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|  | **2024** | **2023** |
| Customer 1 | 73.9% | 57.5% |
| Customer 2 | 26.1% | 42.5% |
| Totals | 100.0% | 100.0% |

---

**Concentration of Accounts Receivable**

As of December 31, 2024 and 2023, the following customers accounted for more than 10% of the Company's consolidated accounts receivable.

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| Customer 1 | 60.0% | 100.0% |
| Customer 1 | 40.0% | - |
| Totals | 60.0% | 100.0% |

---

**NOTE 10 — SUBSEQUENT EVENTS**

Management has evaluated subsequent events and transactions for potential recognition or disclosure in the financial statements through April 30, 2025, the date these financial statements were available to be issued.

On April 16, 2025, the Company closed on the first tranche of a Common Stock Offering (the "2025 Offering") which resulted in gross proceeds of $2,336,782. The Company issued 891,024 shares of Common Stock for $3.00 per share, subject to bonus shares of 5% – 35%, based on predetermined schedule of the amount and timing of shares purchased. The 2025 Offering generated $1,940,518 of proceeds (net of subscriptions receivable of $130,045), net of $169,360 for directly attributable brokerage costs and $96,859 for digital and marketing expenses directly incurred to raise such capital from the offering. Upon completion of the 2025 Offering, these direct offering costs were recorded as a reduction of additional paid-in capital.

---

| | |
|:---|:---|
|  | **Page** |
| [Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024](#sp2_001) | [F-2](#sp2_001) |
| [Condensed Consolidated Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2025 and 2024 (unaudited)](#toc_018) | [F-3](#toc_018) |
| [Condensed Consolidated Statements of Changes in Stockholders' Equity for the Six Months Ended June 30, 2025 and 2024 (unaudited)](#toc_019) | [F-4](#toc_019) |
| [Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (unaudited)](#toc_020) | [F-5](#toc_020) |
| [Notes to Condensed Consolidated Financial Statements (unaudited)](#toc_021) | [F-6](#toc_021) |

---

---

| |
|:---|
| &nbsp;&nbsp;**CYTONICS CORPORATION AND SUBSIDIARY** |
| &nbsp;&nbsp;**CONDENSED CONSOLIDATED BALANCE SHEETS** |

---

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2025** | **December 31,**<br>**2024** |
|  | ***(Unaudited)*** |  |
| **Assets** |  |  |
| Current assets: |  |  |
| Cash | $2562193 | $2432955 |
| Accounts receivable, net of allowance for credit losses of $0 | 50000 | 50000 |
| Prepaid expenses and other current assets | 61528 | 61222 |
| Total current assets | 2673721 | 2544177 |
| Accounts receivable, non-current, net |  |  |
| Deferred offering costs |  | 29002 |
| Deposit | 197520 | 204754 |
| Total assets | $2871241 | $2777933 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| Accounts payable and accrued expenses | $1016799 | $198825 |
| Accounts payable and accrued expenses - related parties | 3000 | 62312 |
| Total current liabilities | 1019799 | 261137 |
| Notes payable, net of debt discount of $0 and $68,681, respectively | - | - |
| Total liabilities | 1019799 | 261137 |
| Commitments and contingencies - See Note 6 |  |  |
| Stockholders' equity: |  |  |
| Preferred Stock, $0.001 par value; 20,000,000 shares authorized |  |  |
| Convertible Initial Preferred Stock, $0.001 par value; |  |  |
| 150,000 shares designated, issued and outstanding | 150 | 150 |
| Convertible Series A Preferred Stock, $0.001 par value; 1,500,000 shares designated; |  |  |
| 576,190 shares issued and outstanding | 576 | 576 |
| Convertible Series B Preferred Stock, $0.001 par value; |  |  |
| 6,000,000 shares designated; 2,574,865 shares issued and outstanding | 2575 | 2575 |
| Convertible Series C and C-1 Preferred Stock, $0.001 par value; 10,000,000 shares designated; |  |  |
| 8,399,558 shares issued and outstanding | 8400 | 8400 |
| Common stock, par value $0.001 per share; 50,000,000 shares authorized; |  |  |
| 12,732,720 and 11,589,652 shares issued and outstanding, respectively | 12732 | 11589 |
| Additional paid-in capital | 35658801 | 31726570 |
| Subscriptions receivable | (168394) |  |
| Accumulated other comprehensive income | (17193) | (7102) |
| Accumulated deficit | (33646205) | (29225962) |
| Total stockholders' equity | 1851442 | 2516796 |
| Total liabilities and stockholders' equity | $2871241 | $2777933 |

---

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

---

| |
|:---|
| **CYTONICS CORPORATION AND SUBSIDIARY** |
| **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS** |
| ***(Unaudited)*** |

---

---

| | | |
|:---|:---|:---|
|  | **For the Six Months <br> Ended** | **For the Six Months <br> Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Revenues: |  |  |
| Royalty revenues | $130000 | $170002 |
| Total revenues | 130000 | 170002 |
| Operating expenses: |  |  |
| Research and development expense | 1755584 | 819724 |
| Payroll expense | 154893 | 111283 |
| Selling, general and administrative expenses | 2234201 | 1265107 |
| Professional fees | 421705 | 343732 |
| Total operating expenses | 4566383 | 2539846 |
| Loss from operations | (4436383) | (2369844) |
| Other income (expense): |  |  |
| Interest income | 16140 | 11684 |
| Interest (expense) | - | (205840) |
| Total other (expense), net | 16140 | (194156) |
| Net loss before income taxes | (4420243) | (2564000) |
| Provision for income taxes |  |  |
| Net loss | $(4420243) | $(2564000) |
| Other comprehensive income: |  |  |
| Foreign currency translation adjustment | (10091) | (3620) |
| Comprehensive loss | $(4430334) | $(2567620) |
| Net loss per share: |  |  |
| Basic and diluted | $(0.37) | $(0.25) |
| Weighted average number of common shares outstanding: |  |  |
| Basic and diluted | 11991752 | 10268781 |

---

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

**CYTONICS CORPORATION AND SUBSIDIARY**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**

**FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023**

**(Unaudited)**

---

| | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Initial<br> Convertible** | **Initial<br> Convertible** | **Series-A<br> Convertible** | **Series-A<br> Convertible** | **Series-B<br> Convertible** | **Series-B<br> Convertible** | **Series-C and C-1<br> Convertible** | **Series-C and C-1<br> Convertible** | | | | | | | |
|  | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Preferred Stock** | **Common Stock** | **Common Stock** | **Additional**<br>**Paid-In** |<br>**Subscription** | **Accumulated<br> Other**<br>**Comprehensive** |<br>**Accumulated** | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Capital** | **Receivable** | **Income** | **Deficit** |<br>**Total** |
| **Balance - December 31, 2024** | 150000 | $150 | 576190 | $576 | 2574865 | $2575 | 8399558 | $8400 | 11589652 | $11589 | $31726570 | $- | $(7102) | $(29225962) | 2516796 |
| &nbsp;&nbsp;&nbsp;Issuance of common shares and options for cash, net of issuance costs |  |  |  |  |  |  |  |  | 1143068 | 1143 | 1929289 | (168394) |  |  | 1762038 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  |  |  |  |  |  |  |  |  | 2002942 |  |  |  | 2002942 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation gain (loss) |  |  |  |  |  |  |  |  |  |  |  |  | (10091) |  | (10091) |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | (4420243) | (4420243) |
| **Balance - June 30, 2025 (unaudited)** | 150000 | $150 | 576190 | $576 | 2574865 | $2575 | 8399558 | $8400 | 12732720 | $12732 | $35658801 | $(168394) | $(17193) | $(33646205) | $1851442 |
| **Balance - December 31, 2023** | 150000 | $150 | 576190 | $576 | 2574865 | $2575 | 5439376 | $5440 | 10266391 | $10266 | $25219168 | $- | $19231 | $(24699041) | 558365 |
| &nbsp;&nbsp;&nbsp;Common shares issued for services rendered |  |  |  |  |  |  |  |  | 18913 | 19 | 19445 |  |  |  | 19464 |
| &nbsp;&nbsp;&nbsp;Issuance of preferred shares for cash, net of issuance costs |  |  |  |  |  |  | 2220458 | 2220 |  |  | 2708943 |  |  |  | 2711163 |
| &nbsp;&nbsp;&nbsp;Stock options issued with debt |  |  |  |  |  |  |  |  |  |  | 37894 |  |  |  | 37894 |
| &nbsp;&nbsp;&nbsp;Issuance of common shares and options for cash |  |  |  |  |  |  |  |  | 1304348 | 1304 | 1498696 |  |  |  | 1500000 |
| &nbsp;&nbsp;&nbsp;Issuance of preferred shares upon conversion of convertible notes and accrued interest |  |  |  |  |  |  | 208422 | 208 |  |  | 383292 |  |  |  | 383500 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  |  |  |  |  |  |  |  |  | 1145090 |  |  |  | 1145090 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation gain (loss) |  |  |  |  |  |  |  |  |  |  |  |  | (3621) |  | (3621) |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | - | - | - | - | - | - | - | (2564000) | (2564000) |
| **Balance - June 30, 2024 (unaudited)** | 150000 | $150 | 576190 | $576 | 2574865 | $2575 | 7868256 | $7868 | 11589652 | $11589 | $31012528 | $- | $15610 | $(27263041) | $3787855 |

---

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

---

| |
|:---|
| **CYTONICS CORPORATION AND SUBSIDIARY** |
| **CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** |
| ***(Unaudited)*** |

---

---

| | | |
|:---|:---|:---|
|  | **For the Six Months <br> Ended** | **For the Six Months <br> Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| **Cash Flows From Operating Activities:** |  |  |
| Net loss | $(4420243) | $(2564000) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Provision for credit losses |  | 78049 |
| Amortization of debt discount |  | 106575 |
| Stock-based compensation | 2002942 | 1164554 |
| Changes in operating assets and liabilities: |  |  |
| Accounts receivable |  | (25192) |
| Prepaid expenses and other current assets | (306) | (36825) |
| Deposit | 7234 | 4101 |
| Accounts payable and accrued expenses | 758662 | 171333 |
| **Net cash used in operating activities** | (1651711) | (1101405) |
| **Cash Flows From Financing Activities:** |  |  |
| Proceeds from issuance of common shares and warrants | 1762038 |  |
| Deferred offering costs | 29002 |  |
| Proceeds from issuance of convertible notes |  | 100000 |
| Repayments of convertible notes |  | (50000) |
| Proceeds from issuance of preferred shares, net of offering costs | - | 2661181 |
| **Net cash provided by financing activities** | 1791040 | 2711181 |
| **Effect of exchange rate changes on cash** | (10091) | (3621) |
| **Net increase (decrease) in cash** | 129238 | 1606155 |
| **Cash at beginning of period** | 2432955 | 602933 |
| **Cash at end of period** | $2562193 | $2209088 |
| **Supplemental Disclosure of Cash Flow Information:** |  |  |
| Cash paid for interest | $- | $15000 |
| Cash paid for taxes | $- | $- |
| **Supplemental Disclosure of Non-Cash Investing and Financing Activities:** |  |  |
| Portion of equity instruments issued for subscriptions receivable | $- | $1549982 |
| Issuance of preferred shares upon conversion of convertible notes and accrued interest | $- | $383500 |
| Issuance of stock options with debt | $- | $37894 |

---

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

**NOTE 1 NATURE OF BUSINESS**

**Overview**

Cytonics Corporation (the "Company") is a research and development company that develops therapies and diagnostics for back and joint pain, which it then licenses to unrelated third parties. The Company was incorporated in the State of Florida under the name Gamma Spine, Inc. on July 19, 2006 and was renamed Cytonics Corporation on April 17, 2007.

**NOTE 2 GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS**

During the six months ended June 30, 2025, the Company sustained a net loss of $4,420,243 and had net cash used in operating activities of $1,651,711. As of June 30, 2025, the Company had an accumulated deficit of $33,646,205. These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the consolidated financial statements.

To date, the Company has funded its research and development and operating activities through sales of debt and equity securities, grant funding, and revenues generated from royalties for the licensing of its products. During the six months ended June 30, 2025, the Company received proceeds of $1,762,038, net of direct offering costs, from the sale of common shares and warrants.

Management's plans regarding these matters include the raising of additional funding through investments by strategic partners and from private and public sales of securities to fund its operations and its research and development activities. The Company expects to incur net losses until such time it develops biopharmaceuticals and medical devices with the intent of licensing or selling the related intellectual property, or alternatively, until it successfully merges with another operating entity. The Company's ability to continue its operations is dependent upon its ability to obtain additional capital through public or private equity offerings, debt financings or other sources; however, financing may not be available to the Company on acceptable terms, or at all. The Company's failure to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategy, and the Company may be forced to curtail or cease operations.

The outcome of management's plans cannot be determined with any degree of certainty. Accordingly, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business for one year from the date the consolidated financial statements are issued. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

**NOTE 3 — ACCOUNTING POLICIES**

**Basis of Presentation**

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") for financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). In the opinion of the Company's management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly the consolidated results of operations and cash flows for the six months ended June 30, 2025 and 2024 and the consolidated balance sheet at June 30, 2025 have been made. The Company's results of operations for the six months ended June 30, 2025 are not necessarily indicative of the operating results to be expected for the full fiscal year ending December 31, 2025. Certain information and disclosures normally included in the notes to the Company's annual audited consolidated financial statements have been condensed or omitted from the Company's interim unaudited condensed consolidated financial statements. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2024. The December 31, 2024 balance sheet is derived from those statements.

**Foreign Currency**

Foreign currency transaction gains and losses are a result of the effect of exchange rate changes on transactions denominated in currencies other than the AUD, the functional currency of our subsidiary. Transaction gains and losses are recognized in Other income (expense), net, in the consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recorded a net foreign currency transaction gain(loss) of $(1,141) and $12, respectively, which are included in selling, general and administrative expenses in the accompanying consolidated statements of operations.

**Use of Estimates**

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying Notes. Actual results could differ materially from those estimates. The Company's most significant estimates include the allowance for credit losses, fair value of stock-based compensation, the fair value of stock options issued with convertible notes and notes payable, and the valuation allowance on deferred tax assets.

**Principles of Consolidation**

The accompanying consolidated financial statements include the accounts of Cytonics Corporation and its wholly-owned subsidiary Cytonics Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.

**Fair Value of Financial Instruments**

The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Subtopic 825-10, "Financial Instruments" ("ASC 825-10") requires disclosure of the fair value of certain financial instruments. The estimated fair value of certain financial instruments, including accounts receivable and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the consolidated financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk.

**Reclassifications**

Certain amounts in the accompanying 2024 financial statements have been reclassified to conform to the 2025 presentation.

**Cash and Cash Equivalents**

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents at June 30, 2025 and December 31, 2024.

**Fair Value Measurements**

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:

&nbsp;&nbsp;&nbsp;&nbsp;● Level 1 – Quoted prices in active markets for identical assets or liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;● Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;● Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

**Accounts Receivable and Allowance for Credit Losses**

The Company adopted ASC 326 "Financial Instruments – Credit Losses" on January 1, 2023. The Company recognizes an allowance for credit losses on accounts receivable and other receivables in an amount equal to the estimated probable losses net of recoveries under the current expected credit loss method. Accounts receivables are stated at the amount management expects to collect from outstanding balances. The Company estimates the collectability of its receivables and establishes allowances for the amount of accounts receivable that the Company estimates to be uncollectible. The Company bases these allowances on its historical collection experience, the length of time accounts receivables are outstanding, the financial condition of individual customers, and current economic conditions that may affect a customer's ability to pay. An individual balance is charged to the allowance when all collection efforts have been exhausted and it is deemed likely to be uncollectible, taking into consideration the financial condition of the customer and other factors. At June 30, 2025 and December 31, 2024, no allowance for credit losses relating to the Company's accounts receivable was deemed necessary. Accounts receivables that are expected to be received within the period of one year are classified as current. Non-current account receivables are receivables outstanding and expected to be received after the period of one year and are reflected at their present value using a discount rate of 5%.

**Australian Goods and Services Tax ("GST")**

Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office.

Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

As of June 30, 2025 and December 31, 2024, the Company was owed $9,425 and 53,127, respectively, from the Australian Taxation Office, which is included in Prepaid expenses and other current assets.

**Intangible Assets**

The Company's intangible assets include seven U.S. patents (US 10,265,388, US 11,040,092, US 10,940,189, US 9,352,021, US 9,498,514, US 10,400,028, US 10,889,631), three U.K. patents (GB2501611, GB2503131, and GB2522561), two European patents (EP 2827882 and EP 3221341; each of which is validated in FR, DE, and GB), one Canadian patent (CA 2865170), two Australian patents (AU 2013222414, AU 2015349782), and one Japanese patent (JP 6861152). The Company also has five additional related pending patent applications. The cost of issued patents is capitalized and amortized over the life of the patents, which is 20 years from the earliest filing date of the non-provisional or PCT application to which priority is claimed. The costs of patent in development are expensed as they are incurred. The unamortized costs associated with previously capitalized patents that have expired or been abandoned are written off.

The Company assesses potential impairments of its intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Any required impairment loss is measured as the amount by which the asset's carrying value exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to operating results. The Company had no impairment of intangible assets for the six months ended June 30, 2025 and 2024.

**Revenue Recognition**

The Company follows Accounting Standards Codification 606 ("ASC 606"). ASC 606 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASC also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer purchase orders, including significant judgments.

The Company recognizes revenue when obligations under the terms of a contract with a customer are satisfied. This occurs with the transfer of control or access to the Company's licenses or the performance of services. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.

Contracts with customers consist of licensing arrangements and, optionally, research and development-related services. Revenues from licensing and royalty fees are received from the granting of exclusive sales, marketing, manufacturing, and distribution rights associated with the Company's functional intellectual property (IP). The Company's performance obligation is satisfied at a point in time (upon delivery to the customer) where the Company has no remaining obligation to support or maintain the intellectual property licensed to the customer. The Company typically requires a non-refundable license fee, paid over several years, and quarterly royalty payments based on a percentage of sales, subject to minimum guaranteed quarterly royalty amounts. For contracts whereby customer payments shall be received over time, at the time of contract execution, the Company applies an implied discount to the license fees in order to calculate the net present value of the contractual payments.

Revenue from license fees is recognized at a point in time when the Company transfers the functional IP to the customer, as long as management believes the total consideration owed by the customer for the license fee is probable to be received. Due to the financing component embedded in the license fee, the Company records the revenue and accounts receivable at their net present value using an estimated discount rate at the point in time when the performance obligation associated with the license fee has been completed. Management applies a discount rate that reflects the customers' creditworthiness and the amount that would have been received from the customer if the license fee was paid upon execution of the contract. The effect of the financing component is subsequently recognized as interest income over the payment term.

Minimum guaranteed royalty (MGR) payments are not binding and are considered to be contingent on the customers' ability to generate sales. The Company's contracts include termination clauses for nonpayment by customers or mutual agreement. The termination clauses are likely to be triggered if the customer is unable to make the MGRs. The Company has historically made price concessions when needed by customers. Given the contractual nature of the MGRs and customary business practices, the Company recognizes revenue from MGRs pursuant to ASC 606-10-55-65 guidance for a sales-based or usage-based royalty, which requires recognition for a sales-based royalty promised in exchange for a license of intellectual property only when (or as) the later of the following events occurs:

a. The subsequent sale or usage occurs.

b. The performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied (or partially satisfied).

The Company recognizes revenue from MGRs when they become due under the terms of the contract and the consideration has been received or is expected to be received.

Licenses and royalties due under the contract not yet received have been reflected as accounts receivable on the balance sheets, net of any implied discounts to net present value.

Except for the estimate of the discount rate applied to license fees to be received over a period of years, the Company's contracts do not include multiple performance obligations or variable consideration. Since the Company's revenue is generated from a small number of customer contracts, it does not have material contract assets or liabilities.

During 2020, the Company received consideration from a customer in connection with the granting of exclusive sales, marketing, manufacturing, and distribution rights associated with the Company's functional intellectual property. The executed contract required a $450,000 nonrefundable license fee from the customer, payable to the Company as follows: (i) $50,000 upon execution of the contract in May 2020; and (ii) $80,000 on January 1 of each of the next five years through 2025. In the event the contract is terminated prior to its ten-year term, the customer is required to pay a portion of the license fee based on a sliding scale and the year of termination. On January 1, 2024, the customer failed to make the $80,000 installment payment due. Subsequently, on July 19, 2024, the contract was amended whereby the customer agreed to immediately make the past due $80,000 installment payment, which it did pay to the Company, and the Company waived the final $80,000 installment due January 1, 2025, which was recorded as a provision for credit losses and included in selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. In addition, the monthly royalty was decreased from $21,667 per month to $15,000 per month for the remainder of the contract through 2029.

As of June 30, 2025 and December 31, 2024, the remaining nonrefundable fee due from the customer was $0.

During the six months ended June 30, 2025 and 2024, the Company recognized revenue from MGRs of $130,000 and $170,002, respectively, which is presented on the statement of operations as royalty revenues.

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| APIC<sup>1</sup> and VET<sup>2</sup> Royalties | $130000 | $170002 |
| Total Revenues | $130000 | $170002 |

---

1 APIC stands for Autologous Protease Inhibitor Concentrate

<sup>2</sup> Royalty income from Veterinary Market

**Stock-Based Compensation Expense**

Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For stock-based awards to employees, non-employees and directors, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model, which includes variables such as the expected volatility of the Company's share price, the exercise behavior of its grantees, interest rates, and dividend yields. These variables are projected based on the Company's historical data, experience, and other factors. In the case of awards with multiple vesting periods, the Company has elected to use the graded vesting attribution method, which recognizes compensation cost on a straight-line basis over each separately vesting portion of the award as if the award was, in substance, multiple awards.

**Research and Development**

The Company enters into consulting, research, and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services. The Company's research and development expenses involves costs associated with (i) entering R&D collaboration agreements with third party contractors to manufacture and develop Cyt-108 through upcoming clinical trials; and (ii) other costs incurred in the development of intellectual property. The third party contractors include, but are not limited to, contract research organizations, contract drug manufacturing organizations, investigational sites and consultants. Costs incurred in connection with research and development activities are expensed as incurred.

In accordance with ASC 730-10, *"Research and Development-Overall,"* research and development costs are expensed when incurred. Total research and development costs for the six months ended June 30, 2025 and 2024 were $1,755,584 and $819,724, of which $380,656 and $819,724, respectively, was incurred by the Australian subsidiary.

The Company may apply for research and development tax concessions with the Australian Taxation Office, under the Research and Development Tax Incentive ("RDTI") Program, on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company's net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt. Under the RDTI Program, up to 43.5% of R&D expenditures may be reimbursed in the form of cash.

During the six months ended June 30, 2025 (the fiscal year end for the subsidiary), the Australian subsidiary incurred an aggregate of $380,656 of research and development expenditures.

**Earnings (Loss) Per Share**

Basic earnings (loss) per common share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Shares issued during the year are weighted for the portion of the year that they were outstanding. Except when the effect would be anti-dilutive, diluted earnings per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive common shares that were outstanding during the period.

The computation of basic and diluted income (loss) per share excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Options | 10510494 | 6854891 |
| Convertible preferred shares | 15061668 | 14530366 |
| Total potentially dilutive shares | 25572162 | 21385257 |

---

**Income Taxes**

The Company accounts for its income taxes in accordance with accounting principles generally accepted in the United States of America, which requires, among other things, recognition of future tax benefits and liabilities measured at enacted rates attributable to temporary differences between financial statement and income tax bases of assets and liabilities and to net tax operating loss carryforwards to the extent that realization of these benefits is more likely than not. The Company periodically evaluates the realizability of its net deferred tax assets. The Company's policy is to account for interest and penalties relating to income taxes, if any, in "income tax expense" in its consolidated statements of operations and include accrued interest and penalties within "accrued liabilities" in its consolidated balance sheets, if applicable. For the six months ended June 30, 2025 and 2024, no income tax related interest or penalties were assessed or recorded.

**Comprehensive Income (Loss)**

Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) consists of foreign currency translation adjustments that have been excluded from the determination of net income (loss).

**Segment reporting**

The Company operates as a single operating segment as a research and development company that is developing therapies and diagnostics for back and joint pain. In accordance with ASC 280 – "Segment Reporting", the Company's chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report annually selected segment information and entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under "Segment Reporting" due to their similarities in economic characteristics such as nature of services; and procurement processes. All revenues and expenses as reflected in the accompanying consolidated statements of operations and comprehensive loss, and all assets and liabilities as reflected in the accompanying consolidated balance sheets are allocated to the one segment.

**Recent Accounting Pronouncements**

In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on accounting for convertible debt instruments by removing the separation models for: (1) convertible debt with a cash conversion feature; and (2) convertible instruments with a beneficial conversion feature. As a result, the Company will not separately present in equity an embedded conversion feature in such debt. Instead, we will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. We expect the elimination of these models will reduce reported interest expense and increase reported net income for the Company's convertible instruments falling under the scope of those models before the adoption of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. ASU 2020-06 became effective for the Company on January 1, 2024. The adoption of this update did not have a material impact on the Company's consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which significantly changes how entities will measure credit losses for most financial assets, including accounts receivable. ASU No. 2016-13 will replace today's "incurred loss" approach with an "expected loss" model, under which companies will recognize allowances based on expected rather than incurred losses. On November 15, 2019, the FASB delayed the effective date of Topic 326 for certain small public companies and other private companies until fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC's definition, as well as private companies and not-for-profit entities. ASU 2016-13 became effective for the Company on January 1, 2023. The adoption of this update did not have a material impact on the Company's consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires entities to provide more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function. The new disclosures will require entities to separately present expenses for significant line items, including but not limited to, depreciation, amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and, in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company does not expect the adoption of this new guidance to have a material impact on the consolidated financial statements.

There are other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company's financial position, results of operations or cash flows.

**NOTE 4 — DEPOSIT**

In December 2023, the Company contracted with Southern Star Research ("Southern Star"), an Australian Contract Research Organization ("CRO"), for research and development services related to the Phase 1 clinical trial. Southern Star required a deposit equal to 20% of the statement of work (totaling approximately 1, 5000,000 AUD). The research and development services are expected to be completed in 2025, at which time the deposit shall be utilized to pay any remaining amounts due under the statement of work, with and any remaining deposit returned to the Company. Accordingly, the Company provided Southern Star with a deposit of $197,520 and $204,754, which is reflected as a non-current asset on the accompanying consolidated balance sheet as of June 30, 2025 and December 31, 2024, respectively.

**NOTE 5 — NOTES PAYABLE**

**2023 Notes**

During October 31, 2023 through December 21, 2023, the Company issued convertible promissory notes having an aggregate face value of $245,000 along with 5-year stock options to purchase an aggregate of 245,000 common shares at $2.30 per share in exchange for proceeds of $245,000. As a result of the issuance of the common stock options, an aggregate amount of $72,217 of debt discount was recorded with a corresponding increase in additional paid-in capital based on the relative fair value method.

**2024 Note**

On January 11, 2024, the Company issued a convertible promissory note having a face value of $100,000 (the "2024 Note") along with 5-year stock options to purchase an aggregate of 100,000 common shares at $2.30 per share in exchange for proceeds of $100,000. As a result of the issuance of the common stock options, $28,876 of debt discount was recorded with a corresponding increase in additional paid-in capital based on the relative fair value method.

The 2023 and 2024 convertible notes bear interest at 15% per annum. All unpaid outstanding principal and interest are due in two years from the respective date of each note.

If the Company issues and sells Equity Securities in which the Company receives gross proceeds of $2,000,000 or more (a "Qualified Financing"), then the 2023 Notes and Full Interest (i.e., 24 months of interest as if the loan was repaid on the maturity date) will automatically convert into Equity Securities upon consummation of the Qualified Financing at a 20% discount to the Equity Securities share price.

If the Company issues and sells Equity Securities in which the Company receives gross proceeds of $2,000,000 or more (a "Qualified Financing"), then 50% of the 2024 Note and 50% of the Full Interest (i.e., 24 months of interest as if the loan was repaid on the maturity date) will automatically convert into Equity Securities upon consummation of the Qualified Financing at a 20% discount to the Equity Securities share price.

At any time after 12 months from the issue date, the Company has the right to prepay the note whereby the Holder will be entitled to receive their principal plus Full Interest. Prior to repayment, the investors shall be given a 10-day notice and the option to convert the outstanding principal amount of the 2023 Notes plus the Full Interest at a 20% discount to the current share price of $2.30 per share of Preferred Series C Stock.

A Qualified Financing occurred on May 28, 2024. As a result, in June 2024, the Company repaid $50,000 of principal and $15,000 of interest (Full Interest on the $50,000 of principal) in cash. In addition, $295,000 of principal and $88,500 of accrued interest (Full Interest on the $295,000 of principal) was converted into an aggregate of 208,422 shares of Preferred Series C Stock.

During the six months ended June 30, 2025 and 2024, the Company amortized $0 and $106,575 of debt discount to interest expense, and recognized $0 and $99,265 of interest expense, respectively, in the statements of operations. As of June 30, 2025 and December 31, 2024, the carrying value of the convertible notes was $0.

**NOTE 6 — COMMITMENTS AND CONTINGENCIES**

**Legal Matters**

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. At June 30, 2025, there were no other pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's consolidated operations and there are no proceedings in which any of the Company's directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company's interest.

**NOTE 7 — STOCKHOLDERS' EQUITY**

**Common Stock**

The Company is authorized to issue 50,000,000 shares of Common Stock with a par value of $0.001 per share.

In January 2024, the Company reissued 25,000 shares of Common Stock that had been previously canceled in 2023.

On May 28, 2024, the Company entered into a letter of intent to sell 1,304,348 shares of Common Stock and 1,500,000 five-year stock options to purchase shares of Common Stock at $1.15 per share in exchange for a subscription receivable of $1,500,000, which was received on July 19, 2024.

In June 2024, 18,913 shares of Common Stock, having a fair value of $19,464, were issued to a consultant for services rendered.

On March 27, 2025, the Company initiated a Common Stock Offering (the "2025 Offering") expiring August 27, 2025 which resulted in gross proceeds of $3,025,866. The Company issued 1,143,068 shares of Common Stock for $3.00 per share, subject to bonus shares of 5% – 25%, based on predetermined schedule of the amount and timing of shares purchased, and options to purchase an aggregate of 515,000 shares of Common Stock at an exercise price of $3.00 per share that are fully vested on issuance and are exercisable over ten years. The 2025 Offering generated $1,762,038 of proceeds (net of subscriptions receivable of $168,394), net of $219,295 for directly attributable brokerage costs and $876,139 for digital and marketing expenses directly incurred to raise such capital from the offering. These direct offering costs were recorded as a reduction of additional paid-in capital. See also Note 9.

On June 30, 2025 and December 31, 2024, the Company had 12,732,720 and 11,589,652 shares of Common Stock issued and outstanding, respectively. The holders of Common Stock are entitled to one vote for each share held of record on such matters and in such manner as may be provided by law. Subject to preferences applicable to any shares of the Company's outstanding Preferred Stock, the holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of funds legally available. In the event of a liquidation, dissolution, or winding up of the Company, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of liabilities and liquidation preferences of any shares of the Company's outstanding Preferred Stock. Holders of Common Stock have no pre-emptive rights or rights to convert their Common Stock into any other securities. There are no redemption or sinking fund provisions applicable to the Common Stock. All outstanding shares of Common Stock are fully paid and non-assessable.

**Preferred Stock**

*Authorized Shares, Liquidation Preferences, Voting Rights, and Automatic Conversion Feature*

The Company is authorized to issue 20,000,000 shares of Preferred Stock with a par value of $0.001 per share. The Board of Directors has designated: (a) 150,000 shares as Initial Preferred Stock; (b) 1,500,000 shares as Series A Preferred Stock; (c) 6,000,000 shares as Series B Preferred Stock; and (d) 10,000,000 shares as Series C Preferred Stock of which 510,000 shares are designated as Series C-1 Preferred Stock.

In the event of any liquidation event, all shares of Initial, Series A and Series C Preferred Stock are pari passu with each other, and Series B is last in preference, but all have a liquidation preference over shares of Common Stock.

All holders of shares of Preferred Stock will vote with holders of Common Stock as a single class and will participate in all dividends that are declared and paid on Common Stock on the same basis as if each share of Preferred Stock were converted into Common Stock.

All shares of Preferred Stock will automatically convert upon a Public Offering into shares of Common Stock.

*Convertible Initial Preferred Stock*

As of June 30, 2025 and December 31, 2024, the Company had 150,000 shares of Initial Preferred Stock (Initial Preferred) issued and outstanding. The Initial Preferred has a liquidation preference of $2.00 per share ($300,000 in aggregate). Each share of Initial Preferred is convertible into 2.4 shares of Common Stock.

*Convertible Series A Preferred Stock*

In January 2024, the Company reissued 12,500 shares of Convertible Series A Preferred Stock that had been previously canceled in 2023.

As of June 30, 2025 and December 31, 2024, the Company had 576,190 shares of Convertible Series A Preferred (Series A Preferred) issued and outstanding. The Series A Preferred Stock has a liquidation preference of $4.00 per share ($2,304,760 in aggregate). Each share of Series A Preferred is convertible into two (2) shares of Common Stock.

*Convertible Series B Preferred Stock*

As of June 30, 2025 and December 31, 2024, the Company had 2,574,865 shares of Convertible Series B Preferred Stock (Series B Preferred) issued and outstanding. The Series B Preferred has a liquidation preference ranging from $2.50 to $4.00 per share ($7,360,960 in the aggregate). Each share of Series B Preferred is convertible into two (2) shares of Common Stock.

*Convertible Series C Preferred Stock*

During the period from January 16, 2024 through June 19, 2024, the Company initiated a Series C Preferred Stock Offering (the "1<sup>st</sup> 2024 Offering") which resulted in gross proceeds of $3,639,659. The Company issued 2,220,458 shares of Series C Preferred Stock for $2.30 per share, subject to bonus shares of 5% – 50%, based on predetermined schedule of the amount and timing of shares purchased. The 1<sup>st</sup> 2024 Offering generated $2,711,163 of proceeds, net of $323,511 for directly attributable brokerage costs and $604,985 for digital and marketing expenses directly incurred to raise such capital from the offering. Upon completion of the 1<sup>st</sup> 2024 Offering, these direct offering costs were recorded as a reduction of additional paid-in capital.

On May 28, 2024, the Company having received gross proceeds of $2,000,000 or more, a Qualified Financing occurred, as related to the Company's outstanding Convertible Notes. As a result, in June 2024, the Company repaid $50,000 of principal and $15,000 of interest (Full Interest on the $50,000 of principal) in cash. In addition, $295,000 of principal and $88,500 of accrued interest (Full Interest on the $295,000 of principal) was converted into an aggregate of 208,422 shares of Preferred Series C Stock.

As of June 30, 2025 and December 31, 2024, the Company had 8,399,558 (7,892,442 Series C and 507,116 Series C-1) Series C Preferred shares, issued and outstanding.

The Series C Preferred has a liquidation preference of $2.00 per share and the Series C-1 Preferred has a liquidation preference of $1.05 per share (calculated at issuance), (each of which is the respective "Series C Purchase Price"). All other rights and privileges of the Series C Preferred and Series C-1 Preferred are identical except for their liquidation preferences. The Series C Convertible Preferred Stock has a liquidation preference of $2.00 per share ($15,784,882 in aggregate). The Series C-1 Convertible Preferred Stock has a liquidation preference of $1.05 per share ($532,472 in aggregate). Each share of Series C Preferred and Series C-1 is convertible into one (1) share of Common Stock.

**Stock Options**

In April 2007, the Company's shareholders adopted the 2007 Stock Incentive Plan (the "2007 Plan"), providing for the grant of stock options and restricted stock awards to employees, non-employee service providers and Board members. Stock options granted under the 2007 Plan may include non-statutory stock options as well as incentive stock options intended to qualify under Section 422 of the Internal Revenue Code. Awards under the 2007 Plan may be granted only during the ten years immediately following the effective date of the plan.

During 2018, the Company's Board adopted the 2018 Stock Incentive Plan (the "2018 Plan"), as amended on May 25, 2021, effectively replacing the 2007 Plan, to provide for the issuance of up to 10,000,000 shares of stock through the grant of stock options, restricted stock, or restricted stock units.

In October 2023 through December 2023, debt holders were given options to purchase an aggregate of 245,000 shares of Common Stock at an exercise price of $2.30 per share that were fully vested on issuance and are exercisable over five years (see Note 5). Stock compensation expenses for non-debt related grants during the year ended December 31, 2023 was $321,427.

In January 2024, the Company granted options to two board directors to purchase an aggregate of 100,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.150 per stock option, which vest 12,500 per quarter and are exercisable over five years. In January 2024, the Company granted options to an advisor to purchase an aggregate of 50,000 shares of Common Stock at an exercise price of $2.00 per share, having a grant date fair value of $0.681 per stock option, which vest 4,167 per quarter and are exercisable over five years.

In June 2024, the Company canceled all outstanding and vested options (883,800 options exercisable at $2.00 per share, expiring at various dates from October 2025 through June 2028, having an aggregate fair value of $203,558 at the date of cancelation) of its Chief Executive Officer in exchange for newly granted options to purchase an aggregate of 1,760,615 shares of Common Stock at an exercise price of $1.50 per share, having a grant date fair value of $0.752 per stock option, or a total of $1,324,077, which vested immediately and are exercisable over ten years. The issuance of the new options to the Chief Executive Officer are deemed a modification of the canceled options and, accordingly, the associated expense recognized is the excess of $1,120,519 of the fair value of the newly issued options over the fair value of the options that were canceled.

In October 2024, the Company granted options to five medical advisory board members to purchase an aggregate of 1,207,510 shares of Common Stock at an exercise price of $1.21 per share, having a grant date fair value of $0.686 per stock option, or $828,010, which vest 75,469 per quarter and are exercisable over five years.

As part of the 2025 Offering, investors were given options to purchase an aggregate of 515,000 shares of Common Stock at an exercise price of $3.00 per share that were fully vested on issuance and are exercisable over ten years (see Note 7 – "Common Stock").

In June 2025, the Company granted options to directors and officers to purchase an aggregate of: (i) 1,450,000 shares of Common Stock at an exercise price of $3.00 per share, having a grant date fair value of $1.18 per stock option that vested immediately; and (ii) 100,000 shares of Common Stock at an exercise of $3.00 per share, having a grant date fair value of $1.23 that vest quarterly over one year, all of which are exercisable over ten years.

In June 2025, the Company granted options to consultants to purchase an aggregate of: (i) 36,923 shares of Common Stock at an exercise price of $3.00 per share, having a grant date fair value of $1.18 per stock option that vested immediately; and (ii) 25,000 shares of Common Stock at an exercise of $3.00 per share, having a grant date fair value of $1.26 that vest quarterly over two years, all of which are exercisable over ten years.

In June 2025, the Company granted options to an advisor to purchase an aggregate of 621,170 shares of Common Stock at an exercise price of $1.21 per share, having a grant date fair value of $1.08 per stock option, of which 124,234 vested immediately and 496,936 vest upon various milestones being achieved, all of which are exercisable over ten years.

On June 30, 2025, the Company had options outstanding to purchase 10,510,494 shares of Common Stock under the 2007 and 2018 Plans, at exercise prices ranging from $0.05 to $3.00 per share.

The Company determined the grant date fair value of the options granted using the Black Scholes Method using the following assumptions:

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **June 30,** | **June 30,** |
|  | **2025** | **2024** |
| Expected Volatility | 99.9% - 107.2% | 62.6% - 103.7% |
| Expected Term | 5 - 10 years | 1.5 - 5 years |
| Risk-Free Rate | 3.79% | 4.01% - 4.79% |
| Dividend Rate | 0.00% | 0.00% |

---

The following is a summary of the Company's stock option activity:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |<br>**Number of**<br>**Options** | **Weighted**<br>**Average**<br>**Exercise**<br>**Price** | **Weighted**<br>**Average**<br>**Remaining Life**<br>**In Years** |<br>**Intrinsic**<br>**Value** |
| Outstanding, December 31, 2024 | 7762401 | $1.23 |  |  |
| Granted | 2748093 | $2.60 |  |  |
| Exercised |  | $- |  |  |
| Forfeited/Expired | - | $- |  |  |
| Outstanding, June 30, 2025 | 10510494 | $1.58 | 6.3 | $4680554 |
| Exercisable, June 30, 2025 | 8806987 | $1.63 | 6.2 | $3883605 |

---

The following table summarizes stock option information at June 30, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Options Outstanding** | **Options Outstanding** | **Options Outstanding** | **Options Outstanding** | **Options Exercisable** | **Options Exercisable** |
|<br>**Exercise**<br>**Price** |<br>**Outstanding**<br>**Number of**<br>**Options** | **Weighted**<br>**Average**<br>**Exercise**<br>**Price** | **Weighted**<br>**Average**<br>**Remaining Life**<br>**In Years** |<br>**Exercisable**<br>**Number of**<br>**Options** | **Weighted**<br>**Average**<br>**Exercise**<br>**Price** |
| $0.05 | 800000 | $0.05 | Indefinite | 800000 | $0.05 |
| $0.38 | 629276 | $0.38 | Indefinite | 629276 | $0.38 |
| $1.00 - $1.50 | 5509295 | $1.27 | 7.5 | 3955788 | $1.29 |
| $2.00 | 1100000 | $2.00 | 1.7 | 1075000 | $2.00 |
| $2.30 | 345000 | $2.30 | 3.4 | 345000 | $2.30 |
| $3.00 | 2126923 | $3.00 | 10 | 2001923 | $3.00 |
|  | 10510494 | $1.58 | 6.3 | 8806987 | $1.63 |

---

The aggregate intrinsic value of outstanding stock options was $4,680,554, based on options with an exercise price less than the fair value of the Company's common stock price of $1.723 per share as of June 30, 2025, which would have been received by the option holders had those option holders exercised their options as of that date.

The fair value of all options that vested during the six months ended June 30, 2025 and 2024 was $2,002,942 and $1,145,090, respectively. As of June 30, 2025, the Company had $852,377 of total unrecognized compensation cost related to non-vested awards granted under the 2018 Plan, which the Company expects to recognize over a weighted average period of 1.56 years.

**NOTE 8 — CONCENTRATIONS**

**Concentrations of Credit Risk**

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits in the United States in excess of the FDIC insured limit of $250,000. The Company also has cash deposits in Australia, which are insured up to 250,000AUD. On June 30, 2025 and December 31, 2024, the Company's cash balances were in excess of federally insured amounts by $2,160,763 and $2,070,928, respectively.

**Concentration of Revenues**

For the six months ended June 30, 2025 and 2024, the following customers accounted for more than 10% of the Company's net revenues:

---

| | | |
|:---|:---|:---|
|  | **For the Six Months Ended June 30,** | **For the Six Months Ended June 30,** |
|  | **2025** | **2024** |
| Customer 1 | 69.2% | 76.5% |
| Customer 2 | 30.8% | 23.5% |
| Totals | 100.0% | 100.0% |

---

**Concentration of Accounts Receivable**

As of June 30, 2025 and December 31, 2024, the following customers accounted for more than 10% of the Company's consolidated accounts receivable.

---

| | | |
|:---|:---|:---|
|  | **June 30,**<br>**2025** | **December 31,**<br>**2024** |
| Customer 1 | 60.0% | 60.0% |
| Customer 2 | 40.0% | 40.0% |
| Totals | 100.0% | 100.0% |

---

**NOTE 9 — SUBSEQUENT EVENTS**

Management has evaluated subsequent events and transactions for potential recognition or disclosure in the financial statements through September 24, 2025, the date these financial statements were available to be issued.

During July 24 through August 7, 2025, as part of the 2025 Offering that commenced March 27, 2025, two closings occurred which resulted in gross proceeds of $1,122,457. The Company issued 414,717 shares of Common Stock for $3.00 per share, subject to bonus shares of 5% – 25%, based on predetermined schedule of the amount and timing of shares purchased. The closings generated $885,391 of proceeds (net of subscriptions receivable of $62,840), net of $174,225 for directly attributable brokerage costs. These direct offering costs were recorded as a reduction of additional paid-in capital.

**EXHIBITS**

The following exhibits are filed with this Offering Circular:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Exhibit No. |  | &nbsp;&nbsp;Form | &nbsp;&nbsp;File No. | &nbsp;&nbsp;Exhibit | &nbsp;&nbsp;Filing Date |
| &nbsp;&nbsp;[2.1](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-1.htm) | &nbsp;&nbsp;[Third Amended and Restated Articles of Incorporation of Cytonics Corporation filed with Florida Secretary of State on February 14, 2011.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-1.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-1.htm) | &nbsp;&nbsp;[024-11196](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-1.htm) | &nbsp;&nbsp;[2.1](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-1.htm) | &nbsp;&nbsp;[April 17, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-1.htm) |
| &nbsp;&nbsp;[2.2](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-2.htm) | &nbsp;&nbsp;[Articles of Amendment to the Third Amended and Restated Articles of Incorporation of Cytonics Corporation filed with Florida Secretary of State on February 19, 2013.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-2.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-2.htm) | &nbsp;&nbsp;[024-11196](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-2.htm) | &nbsp;&nbsp;[2.2](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-2.htm) | &nbsp;&nbsp;[April 17, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-2.htm) |
| &nbsp;&nbsp;[2.3](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-3.htm) | &nbsp;&nbsp;[Articles of Amendment to the Articles of Incorporation of Cytonics Corporation filed with Florida Secretary of State on February 16, 2018.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-3.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-3.htm) | &nbsp;&nbsp;[024-11196](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-3.htm) | &nbsp;&nbsp;[2.3](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-3.htm) | &nbsp;&nbsp;[April 17, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-3.htm) |
| &nbsp;&nbsp;[2.4](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-4.htm) | &nbsp;&nbsp;[Articles of Amendment to the Articles of Incorporation of Cytonics Corporation filed with Florida Secretary of State on March 9, 2020.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-4.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-4.htm) | &nbsp;&nbsp;[024-11196](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-4.htm) | &nbsp;&nbsp;[2.4](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-4.htm) | &nbsp;&nbsp;[April 17, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-4.htm) |
| &nbsp;&nbsp;[2.5](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-5.htm) | &nbsp;&nbsp;[Articles of Amendment to the Articles of Incorporation of Cytonics Corporation filed with Florida Secretary of State on March 17, 2020.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-5.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-5.htm) | &nbsp;&nbsp;[024-11196](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-5.htm) | &nbsp;&nbsp;[2.5](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-5.htm) | &nbsp;&nbsp;[April 17, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-5.htm) |
| &nbsp;&nbsp;[2.6](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-6.htm) | &nbsp;&nbsp;[Amended and Restated Bylaws of Cytonics Corporation.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-6.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-6.htm) | &nbsp;&nbsp;[024-11196](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-6.htm) | &nbsp;&nbsp;[2.6](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-6.htm) | &nbsp;&nbsp;[April 17, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex2-6.htm) |
| &nbsp;&nbsp;[3.1](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-1.htm) | &nbsp;&nbsp;[Term Sheet for Convertible Promissory Notes issued From June 30, 2018 to October 15, 2018.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-1.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-1.htm) | &nbsp;&nbsp;[024-11196](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-1.htm) | &nbsp;&nbsp;[3.1](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-1.htm) | &nbsp;&nbsp;[April 17, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-1.htm) |
| &nbsp;&nbsp;[3.2](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-2.htm) | &nbsp;&nbsp;[Form of Convertible Promissory Notes issued on May 17, 2019 pursuant to Regulation CF Offering.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-2.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-2.htm) | &nbsp;&nbsp;[024-11196](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-2.htm) | &nbsp;&nbsp;[3.2](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-2.htm) | &nbsp;&nbsp;[April 17, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-2.htm) |
| &nbsp;&nbsp;[3.3](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-3.htm) | &nbsp;&nbsp;[Convertible Promissory Note issued to JK Garvey Investment Co., L.P. on October 31, 2019.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-3.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-3.htm) | &nbsp;&nbsp;[024-11196](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-3.htm) | &nbsp;&nbsp;[3.3](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-3.htm) | &nbsp;&nbsp;[April 17, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex3-3.htm) |
| &nbsp;&nbsp;[4.1](tm2533753d1_ex4-1.htm) | &nbsp;&nbsp;[Form of Subscription Agreement](tm2533753d1_ex4-1.htm) |  |  |  |  |
| &nbsp;&nbsp;[6.1](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-1.htm) | &nbsp;&nbsp;[Cytonics 2018 Stock Option and Stock Issuance Plan.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-1.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-1.htm) | &nbsp;&nbsp;[024-12533](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-1.htm) | &nbsp;&nbsp;[6.1](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-1.htm) | &nbsp;&nbsp;[November 19, 2024](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-1.htm) |
| &nbsp;&nbsp;[6.2](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-2.htm) | &nbsp;&nbsp;[Form of Nonqualified Stock Option Agreement.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-2.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-2.htm) | &nbsp;&nbsp;[024-12533](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-2.htm) | &nbsp;&nbsp;[6.2](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-2.htm) | &nbsp;&nbsp;[November 19, 2024](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-2.htm) |
| &nbsp;&nbsp;[6.3](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-3.htm) | &nbsp;&nbsp;[Employment Agreement with Anjun (Joey) Bose dated July 22, 2024.](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-3.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-3.htm) | &nbsp;&nbsp;[024-12533](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-3.htm) | &nbsp;&nbsp;[6.3](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-3.htm) | &nbsp;&nbsp;[November 19, 2024](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-3.htm) |
| &nbsp;&nbsp;[6.4](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-4.htm) | &nbsp;&nbsp;[Separation Agreement between the Company and Lewis Hanna](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-4.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-4.htm) | &nbsp;&nbsp;[024-12533](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-4.htm) | &nbsp;&nbsp;[6.4](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-4.htm) | &nbsp;&nbsp;[November 19, 2024](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-4.htm) |
| &nbsp;&nbsp;[6.5](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-5.htm) | &nbsp;&nbsp;[Exclusive License Agreement for Manufacturing, Sales, Marketing and Distribution in the Veterinary Market between Cytonics Corporation and Astaria Global, LLC dated June 30, 2019.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-5.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-5.htm) | &nbsp;&nbsp;[024-12533](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-5.htm) | &nbsp;&nbsp;[6.6](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-5.htm) | &nbsp;&nbsp;[November 19, 2024](https://www.sec.gov/Archives/edgar/data/1421744/000110465920048004/tm2014693d1_ex6-5.htm) |
| &nbsp;&nbsp;[6.6](https://www.sec.gov/Archives/edgar/data/1421744/000110465920067632/tm2014693d2_ex6-6.htm) | &nbsp;&nbsp;[Exclusive Sales, Marketing, Manufacturing and Distribution Agreement for Human Market between Cytonics Corporation and Christie Medical Holdings, LLC dated April 27, 2020.](https://www.sec.gov/Archives/edgar/data/1421744/000110465920067632/tm2014693d2_ex6-6.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465920067632/tm2014693d2_ex6-6.htm) | &nbsp;&nbsp;[024-12533](https://www.sec.gov/Archives/edgar/data/1421744/000110465920067632/tm2014693d2_ex6-6.htm) | &nbsp;&nbsp;[6.71](https://www.sec.gov/Archives/edgar/data/1421744/000110465920067632/tm2014693d2_ex6-6.htm) | &nbsp;&nbsp;[November 19, 2024](https://www.sec.gov/Archives/edgar/data/1421744/000110465920067632/tm2014693d2_ex6-6.htm) |
| &nbsp;&nbsp;[6.7](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-72.htm) | &nbsp;&nbsp;[Exhibit G – revised July 2024 to that certain Exclusive Sales, Marketing, Manufacturing and Distribution Agreement for Human Market between Cytonics Corporation and Christie Medical Holdings dated April 27, 2020](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-72.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-72.htm) | &nbsp;&nbsp;[024-12533](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-72.htm) | &nbsp;&nbsp;[6.72](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-72.htm) | &nbsp;&nbsp;[November 19, 2024](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-72.htm) |
| &nbsp;&nbsp;[6.8](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-8.htm) | &nbsp;&nbsp;[Statement of Work dated September 9, 2024, between Goodwin Biotechnology, Inc. and Cytonics.](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-8.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-8.htm) | &nbsp;&nbsp;[024-12533](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-8.htm) | &nbsp;&nbsp;[6.8](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-8.htm) | &nbsp;&nbsp;[November 19, 2024](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-8.htm) |
| &nbsp;&nbsp;[6.9](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-9.htm) | &nbsp;&nbsp;[Master Services Agreement between Cytonics and Southern Star Research Pty Ltd. dated September 13, 2023](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-9.htm) | &nbsp;&nbsp;[1-A](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-9.htm) | &nbsp;&nbsp;[024-12533](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-9.htm) | &nbsp;&nbsp;[6.9](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-9.htm) | &nbsp;&nbsp;[November 19, 2024](https://www.sec.gov/Archives/edgar/data/1421744/000110465924120283/tm2427963d1_ex6-9.htm) |
| &nbsp;&nbsp;[6.10](tm2533753d1_ex6-10.htm) | &nbsp;&nbsp;[Agreement with DealMaker](tm2533753d1_ex6-10.htm) |  |  |  |  |
| &nbsp;&nbsp;[11.1](tm2533753d1_ex11-1.htm) | &nbsp;&nbsp;[Consent of Independent Registered Public Accounting Firm](tm2533753d1_ex11-1.htm) |  |  |  |  |
| &nbsp;&nbsp;[12.1](tm2533753d1_ex12-1.htm) | &nbsp;&nbsp;[Opinion of Solon Law, PC](tm2533753d1_ex12-1.htm) |  |  |  |  |

---

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, on January 13, 2026.

---

| | |
|:---|:---|
| **Cytonics Corporation** | **Cytonics Corporation** |
| By: | /s/ Joey Bose |
| Name: | Anjun (Joey) Bose |
| Title: | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this Offering Circular has been signed by the following persons in the capacities listed on January 13, 2026.

---

| | |
|:---|:---|
| **Signature** | **Title** |
| *s/ Anjun Bose* | |
| Anjun Bose, Chief Executive Officer, President, Principal Financial Officer, Principal Accounting Officer, Director |  |
| /s/ *Gaetano Scuderi* | |
| Gaetano Scuderi, MD, Director |  |
| */s/ Gordon Ramseier* | |
| Gordon Ramseier, Director |  |
| */s/ Tracy Goeken* | |
| Tracy Goeken, MD, Director |  |

---

## Ex1A-4

**Exhibit 4.1**

THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "**SECURITIES ACT**"), OR ANY STATE SECURITIES OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION ("**SEC**"), ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO INVESTOR IN CONNECTION WITH THIS OFFERING OVER THE WEB-BASED PLATFORM MAINTAINED BY THE COMPANY. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.

THE COMPANY MAY NOT BE OFFERING THE SECURITIES IN EVERY STATE. THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE OR JURISDICTION IN WHICH THE SECURITIES ARE NOT BEING OFFERED.

THE INFORMATION PRESENTED IN THE OFFERING MATERIALS WAS PREPARED BY THE COMPANY SOLELY FOR THE USE BY PROSPECTIVE INVESTORS IN CONNECTION WITH THIS OFFERING. NO REPRESENTATIONS OR WARRANTIES ARE MADE AS TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION CONTAINED IN ANY OFFERING MATERIALS, AND NOTHING CONTAINED IN THE OFFERING MATERIALS IS OR SHOULD BE RELIED UPON AS A PROMISE OR REPRESENTATION AS TO THE FUTURE PERFORMANCE OF THE COMPANY. NEITHER THE DELIVERY NOR THE PURCHASE OF THE SECURITIES SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE OF THE OFFERING MATERIALS.

**SUBSCRIPTION AGREEMENT**

To: Cytonics Corporation

658 West Indiantown Road

Suite 214

Jupiter, FL 33458

Ladies and Gentlemen:

The investor executing this Subscription Agreement ("**Investor**") hereby subscribes for the dollar amount ("**Subscription Amount**") of shares of Common Stock (the "**Shares**") of Cytonics Corporation, a Florida corporation (the "**Company**"), as indicated in the Investor Information (below defined).

WHEREAS, the Company is offering Shares at a price of $5.00 per Share, plus an additional fee of 3.5% of the dollar number of Shares purchased ("**Investor Processing Fee**"), pursuant to the Company's Form 1-A, as amended and/or supplemented from time to time ("**Offering Statement**"), filed with the Securities and Exchange Commission ("**SEC**") under Tier II of Regulation A promulgated under the Securities Act of 1933, as amended (the "**Securities Act**").

NOW, THEREFORE, it is agreed as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Investor understands and agrees that this Subscription Agreement ("**Agreement**" or "**Subscription Agreement**") is comprised of the below terms and schedules, as well as the information Investor provides via the Company's investment portal at <u>www.invest.cytonics.com</u> ("**Company Site**") relating to its purchase of Shares pursuant to this Agreement, which may include, but not be limited to, Investor's identity and personal information, contact information, signature and the amount of Shares being purchased by Investor (collectively, "**Investor Information**"), which Investor Information is incorporated herein by reference and made a part hereof. By executing this Agreement, Investor agrees to the terms of service and privacy policy contained on the Company Site.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. To induce the Company to accept this subscription, the Investor hereby agrees and represents that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Shares will be held by the Investor as indicated on the Investor Information (e.g., individual, corporation, custodial account, community property, etc.).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Concurrent with the execution hereof, the Investor authorizes the Company to request the Subscription Amount from the Investor's bank or other financial institution. The Investor has transferred funds equal to the Subscription Amount to the Company concurrently with submitting this Subscription Agreement, unless otherwise agreed by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Investor agrees to pay the Investor Processing Fee, which fee will not be applied towards the purchase of Shares, but will partially reimburse the Company for fees payable by it as a result of Investor's purchase of Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Within five (5) days after receipt of a written request from the Company, the Investor shall provide such information and execute and deliver such documents as the Company may reasonably request to comply with any and all laws and ordinances to which the Company may be subject, including the securities laws of the United States or any other applicable jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company has entered into, and from time to time may enter into, separate subscription agreements with other investors for the sale of Shares to such other investors. The sale of Shares to such other investors and this sale of the Shares shall be separate sales and this Subscription Agreement and the other subscription agreements shall be separate agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Company may elect at any time to close all or any portion of this offering, once it has raised the minimum offering amount, on various dates (each a "**Closing Date**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Investor understands and agrees that the Company will issue Shares without additional consideration for investors purchasing at least $1,000 in Shares plus the Investor Processing Fee of 3.5% ($1,035), as detailed in the Offering Statement, and that such issuances could have the effect of diluting the value of Investor's Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) The Investor understands the meaning and legal consequences of, and that the Company intends to rely upon, the representations and warranties contained in Sections 2, 3, 4 and 5 hereof, and the Investor hereby agrees to indemnify and hold harmless the Company and each and any manager, member, officer, employee, agent or affiliate thereof from and against any and all loss, damage or liability due to or arising out of a breach of any representation or warranty of the Investor. The representations, warranties and covenants made by Investor herein shall survive the closing or termination of this Subscription Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Investor hereby represents and warrants that the Investor is a "qualified purchaser," as defined in Regulation A under the Securities Act, meaning Investor is an "accredited investor" as defined in Rule 501 of Regulation D under the Securities Act and indicated on the U.S. Accredited Investor Certificate attached hereto, or the Subscription Amount does not represent more than 10% of the greater of Investor's annual income or net worth (for natural persons), or 10% of the greater of annual revenue or net worth at fiscal year-end (for non-natural persons), with net worth calculated in the same manner as for accredited investors under Rule 501 of Regulation D under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The Investor hereby further represents, warrants, acknowledges and agrees:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Investor has all requisite power and authority to (i) execute and deliver this Agreement, and (ii) to carry out and perform its obligations under the terms of this Agreement. This Agreement has been duly authorized, executed and delivered and constitutes the legal, valid and binding obligation of Investor, enforceable in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, or other laws relating to or affecting the enforcement of creditors' rights generally in effect from time to time and by general principles of equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Neither the execution and delivery of this Agreement nor the fulfillment of or compliance with the terms and provisions hereof, will conflict with, or result in a breach or violation of any of the terms, conditions or provisions of, or constitute a default under, any contract, agreement, mortgage, indenture, lease, instrument, order, judgment, statute, law, rule or regulation to which Investor is subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The information provided by the Investor to the Company via this Subscription Agreement, including the Investor Information, or otherwise is true and correct in all respects as of the date hereof and the Investor hereby agrees to promptly notify the Company and supply corrective information to the Company if, prior to the consummation of its investment in the Company, any of such information becomes inaccurate or incomplete.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Investor, if an individual, is over 21 years of age, and the address set forth above is the true residence and domicile of the Investor, and the Investor has no present intention of becoming a resident or domiciliary of any other state or jurisdiction. If a corporation, trust, partnership or other entity, the Investor has its principal place of business at the address set forth on the signature page.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) If Investor is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code of 1986, as amended), Investor hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this Subscription Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. Investor's subscription and payment for and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of Investor's jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Investor has had an opportunity to ask questions of and receive answers from the Company, or a person or persons acting on its behalf, concerning the Company and the terms and conditions of this investment, and all such questions have been answered to the full satisfaction of the Investor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Except as set forth in this Subscription Agreement, no representations or warranties have been made to the Investor by the Company or any partner, agent, employee or affiliate thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) The Investor has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of an investment in the Company and making an informed investment decision with respect thereto. The Investor has consulted its own advisers with respect to its proposed investment in the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Investor is not making this subscription in any manner as a representative of a charitable remainder unitrust or a charitable remainder trust.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) The Investor has the financial ability to bear the economic risk of the Investor's investment, including a complete loss thereof, has adequate means for providing for its current needs and possible contingencies and has no need for liquidity in its investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) The Investor acknowledges and understands that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Shares are a speculative investment and involve a substantial degree of risk;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Company does not have a significant financial or operating history;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Shares are being offered pursuant to Regulation A under the Securities Act and have not been registered
or qualified under any state blue sky or securities law; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Any federal income tax treatment which may be currently available to the Investor may be lost through
adoption of new laws or regulations, amendments to existing laws or regulations or changes in the interpretations of existing laws and
regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) The Investor represents and warrants that (i) the Shares are to be purchased with funds that are from legitimate sources in connection with its regular business activities and which do not constitute the proceeds of criminal conduct; (ii) the Shares are not being acquired, and will not be held, in violation of any applicable laws; (iii) the Investor is not listed on the list of Specially Designated Nationals and Blocked Persons maintained by the United States Office of Foreign Assets Control ("**OFAC**"); and (iv) the Investor is not a senior foreign political figure, or any immediate family member or close associate of a senior foreign political figure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) If the Investor is an individual retirement account, qualified pension, profit sharing or other retirement plan, or governmental plans or units (all such entities are herein referred to as a "Retirement Trust"), the Investor represents that the investment in the Company by the Retirement Trust has been authorized by the appropriate person or persons and that the Retirement Trust has consulted its counsel with respect to such investment and the Investor represents that it has not relied on any advice of the Company or its affiliates in making its decision to invest in the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) Investor has received and had the opportunity to review the offering Statement, as amended and supplemented. Investor has carefully reviewed all of the Company's SEC filings filed by the Company since the Company's Offering Statement was qualified by the SEC and understands the information contained therein. Investor acknowledges that the Company's SEC filings, including but not limited to the Offering Statement, are available free of charge at the SEC's web site at <u>www.sec.gov</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) Investor acknowledges and agrees that there is no ready public market for the Shares and that there is no guarantee that a market for their resale will ever exist. The Company has no obligation to list any of the Shares on any market or take any steps (including registration under the Securities Act or the Securities Exchange Act of 1934, as amended (the "**Exchange Act**") with respect to facilitating trading or resale of the Shares. Investor must bear the economic risk of this investment indefinitely and Investor acknowledges that Investor is able to bear the economic risk of losing Investor's entire investment in the Shares. Investor also understands that an investment in the Company involves significant risks and has taken full cognizance of and understands all of the risk factors relating to the purchase of Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) By submitting this payment, Investor hereby authorizes DealMaker to charge the designated payment method for the investment amount indicated. Investor understands this investment is subject to the terms of the offering and its associated rules and investor protections. Investor understands it is not a purchase of goods or services. Investor acknowledges that this transaction is final, non-refundable unless otherwise stated or required, and represents an investment subject to risk, including loss. Investor confirms that he/she/it has reviewed all offering documents and agrees not to dispute the charge with the bank or card issuer, so long as the transaction corresponds to the agreed terms and disclosures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) Investor represents and warrants that the Investor is either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Purchasing the Shares with funds that constitute the assets of one or more of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) an "employee benefit plan" as defined in Section 3(3) of the U.S. Employee Retirement Income Security Act of 1974, as amended ("**ERISA**"), that is subject to Title I of ERISA;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) an "employee benefit plan" as defined in Section 3(3) of ERISA that is not subject to either Title I of ERISA or Section 4975 of the Internal Revenue Code of 1986, as amended (the "Code") (including a governmental plan, non-electing church plan or foreign plan). The Investor hereby represents and warrants that (a) its investment in the Company: (i) does not violate and is not otherwise inconsistent with the terms of any legal document constituting or governing the employee benefit plan; (ii) has been duly authorized and approved by all necessary parties; and (iii) is in compliance with all applicable laws, and (b) neither the Company nor any person who manages the assets of the Company will be subject to any laws, rules or regulations applicable to such Investor solely as a result of the investment in the Company by such Investor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a plan that is subject to Section 4975 of the Code;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) an entity (including, if applicable, an insurance company general account) whose underlying assets include "plan assets" of one or more "employee benefit plans" that are subject to Title I of ERISA or "plans" that are subject to Section 4975 of the Code by reason of the investment in such entity, directly or indirectly, by such employee benefit plans or plans; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) an entity that (a) is a group trust within the meaning of Revenue Ruling 81-100, a common or collective trust fund of a bank or an insurance company separate account and (b) is subject to Title I of ERISA, Section 4975 of the Code or both; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Not purchasing the Shares with funds that constitute the assets of any of the entities or plans described in this Section 4(m)(1).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. All representations and warranties of Investor made above shall be true and correct as of Investor's Closing Date, unless Investor has otherwise notified the Company in writing prior to Investor's Closing Date that there has been a change that would cause any such representation or warranty to be incorrect or no longer apply.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. It is understood that this subscription is irrevocable by Investor but is not binding on the Company until accepted by the Company by signature of its authorized representative on the acceptance page hereto. The Company may accept or reject this subscription in whole or in part. In the event of rejection of this subscription in its entirety, or in the event the sale of the Shares (or any portion thereof) to Investor is not consummated for any reason, this Subscription Agreement shall have no force or effect with respect to the rejected subscription (or portion thereof), except for Section 2(h) hereof, which shall remain in force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. The Company reserves the right to request such information as is necessary to verify the identity of the Investor. The Investor shall promptly on demand provide such information and execute and deliver such documents as the Company may request to verify the accuracy of the Investor's representations and warranties herein or to comply with the USA PATRIOT Act of 2001, as amended (the "**Patriot Act**"), certain anti-money laundering laws or any other law or regulation to which the Company may be subject (the "**Relevant Legislation**"). In addition, by executing this Subscription Agreement the Investor authorizes the Company to provide the Company's legal counsel and any other appropriate third party with information regarding the Investor's account, until the authorization is revoked by the Investor in writing to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. No fractional Shares or Bonus Shares will be issued. The Investor Processing Fee will be rounded to the next whole cent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9. The Company represents and warrants to the Investor that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company is duly formed and validly existing in good standing as corporation under the laws of Florida, Canada and has all requisite power and authority to carry on its business as now conducted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The execution, delivery and performance by the Company of this Subscription Agreement have been authorized by all necessary action on behalf of the Company, and this Subscription Agreement is a legal, valid and binding agreement of the Company, enforceable against the Company in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Shares, when so issued, sold and delivered against payment therefor in accordance with the provisions of this Subscription Agreement, will be duly and validly issued, fully paid and non-assessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10. Miscellaneous.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All pronouns and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular or plural, as the identity of the person or persons or entity or entities may require.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) This Subscription Agreement is not transferable or assignable by Investor without the prior written consent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The representations, warranties and agreements contained herein shall be deemed to be made by and be binding upon Investor and its heirs, executors, administrators and successors and shall inure to the benefit of the Company and its successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) None of the provisions of this Subscription Agreement may be waived, changed or terminated orally or otherwise, except as specifically set forth herein or except by a writing signed by the Company and Investor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The invalidity, illegality or unenforceability of one or more of the provisions of this Subscription Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Subscription Agreement in such jurisdiction or the validity, legality or enforceability of this Subscription Agreement, including any such provision, in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) This Subscription Agreement, including its schedules and Investor Information, constitutes the entire agreement between the Investor and the Company with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings, if any, relating to the subject matter hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) The terms and provisions of this Subscription Agreement are intended solely for the benefit of each party hereto and their respective successors and assigns, and it is not the intention of the parties to confer, and no provision hereof shall confer, third-party beneficiary rights upon any other person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) This Subscription Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Each of the parties hereto agrees that the transaction consisting of this Agreement (and, to the extent permitted under applicable law, each related agreement) may be conducted by electronic means. Each party agrees, and acknowledges that it is such party's intent, that if such party signs this Agreement (or, if applicable, related agreement) using an electronic signature, it is signing, adopting, and accepting this Agreement or such closing document and that signing this Agreement or such related agreement using an electronic signature is the legal equivalent of having placed its handwritten signature on this Agreement or such related agreement on paper. The use of electronic signatures and electronic records (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act and any other applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) No failure or delay by any party in exercising any right, power or privilege under this Subscription Agreement shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) Notice, requests, demands and other communications relating to this Subscription Agreement and the transactions contemplated herein shall be in writing and shall be deemed to have been duly given if and when (a) delivered personally, on the date of such delivery; or (b) mailed by registered or certified mail, postage prepaid, return receipt requested, on the third day after the posting thereof; or (c) emailed, telecopied or cabled, on the date of such delivery to the respective parties at the addresses set forth in the Investor Information with respect to the Investor and above with respect to the Company. The Company will not accept notice by email or other electronic communication. Investor agrees that the Company may deliver all notices, tax reports and other documents and information to Investor by email or another electronic delivery method chosen by the Company. Investor agrees to tell the Company right away if Investor changes its email address or home mailing address so the Company can send information to the new address.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) THE COMPANY WILL NOT BE LIABLE TO INVESTOR FOR ANY LOST PROFITS OR SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES, EVEN IF INVESTOR TELLS THE COMPANY IT MIGHT INCUR THOSE DAMAGES.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) **NOTICE OF DISPUTE RESOLUTION BY BINDING ARBITRATION AND CLASS ACTION/CLASS ARBITRATION WAIVER.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) IMPORTANT: PLEASE READ CAREFULLY. THE FOLLOWING PROVISION ("ARBITRATION PROVISION") CONSTITUTES
A BINDING AGREEMENT THAT LIMITS CERTAIN RIGHTS, INCLUDING YOUR RIGHT TO OBTAIN RELIEF OR DAMAGES THROUGH COURT ACTION OR AS A MEMBER
OF A CLASS. THAT MEANS THAT, IN THE EVENT THAT YOU HAVE A COMPLAINT AGAINST THE COMPAY RELATING TO THE TRANSACTIONS CONTEMPLATED
BY THIS AGREEMENT THAT THE COMPANY IS UNABLE TO RESOLVE TO YOUR SATISFACTION AND THAT CANNOT BE RESOLVED THROUGH MEDIATION, YOU AND THE
COMPANY AGREE TO RESOLVE YOUR DISPUTE THROUGH BINDING ARBITRATION, INSTEAD OF THROUGH COURTS OF GENERAL JURISDICTION OR THROUGH A
CLASS ACTION. BY ENTERING INTO THIS AGREEMENT, YOU AND THE COMPANY ARE EACH WAIVING THE RIGHT TO A TRIAL BY JURY AND TO PARTICIPATE
IN ANY CLASS ACTION. THE ARBITRATION PROVISION AND THE WAIVER OF THE RIGHT TO A JURY TRIAL AND CLASS ACTION IS NOT INTENDED
TO BE DEEMED A WAIVER BY YOU OF OUR COMPLIANCE WITH THE EXCHANGE ACT AND SECURITIES ACT AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) "Claim" shall mean any dispute or controversy arising out of or relating to this Agreement
and/or the transactions, activities, or relationships that involve, lead to, or result from the foregoing. Claims include, but are not
limited to, breach of contract, fraud, misrepresentation, express or implied warranty, and equitable, injunctive, or declaratory relief.
Claims include matters arising as initial claims, counter-claims, cross-claims, third-party claims, or otherwise and include those brought
by or against your assigns, heirs, or beneficiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) If a Claim arises and such Claim cannot be settled through direct discussions, the parties hereto agree
to endeavor first to settle the dispute by mediation administered by the American Arbitration Association (the "AAA") under
its Commercial Mediation Procedures before resorting to arbitration pursuant to this Section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Any unresolved Claim shall be settled by binding arbitration as the sole and exclusive forum and remedy
for resolution of a Claim between you and the Company. The Party initiating arbitration shall do so with the AAA. The procedure shall
be governed by the AAA Commercial Arbitration Rules, and the parties stipulate that the laws of the State of Florida shall apply, without
regard to conflict-of-law principles. In the case of a conflict between the rules and policies of the administrator and this Arbitration
Provision, this Arbitration Provision shall control, subject to controlling law, unless all parties to the arbitration consent to have
the rules and policies of the administrator apply. Arbitration shall take place in the county and state where the principal office
for the Company is located or in such location as agreed upon by the parties. Each party will, upon written request of the other party,
promptly provide the other with copies of all relevant documents. There shall be no other discovery allowed. Except as may be required
by law, neither a party nor an arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior
written consent of both parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Absent agreement among the parties, the presiding arbitrator shall determine how to allocate the fees
and costs of arbitration among the parties according to the administrator's rules or in accordance with controlling law if
contrary to those rules. Each party shall bear the expense of that party's attorneys, experts, and witnesses, regardless of which
party prevails in the arbitration, unless controlling law provides a right for the prevailing party to recover fees and costs from the
other party. Notwithstanding the foregoing, if the arbitrator determines that a Claim is frivolous or brought for an improper purpose
(as measured by the standards set forth in Federal Rule of Civil Procedure 11(b)), the other party shall not be required to pay any
fees or costs of the arbitration proceeding, and any previously paid fees or costs shall be reimbursed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) If the amount in controversy exceeds $5,000, any party may appeal the arbitrator's award to a three-arbitrator
panel within thirty (30) days of the final award. Additionally, in the event of such an appeal, any opposing party may cross-appeal within
thirty (30) days after notice of the appeal. The three-arbitrator panel may consider all of the evidence and issue a new award, and the
panel does not have to adopt or give any weight to the first arbitrator's findings of fact or conclusion. This is called "de
novo" review. Costs and conduct of any appeal shall be governed by this Arbitration Provision and the administrator's rules,
in the same way as the initial arbitration proceeding. Any award by the individual arbitrator that is not subject to appeal, and any panel
award on appeal, shall be final and binding, except for any appeal right under the Federal Arbitration Act (the "FAA"), and
may be entered as a judgment in any court of competent jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) The parties agree that this Arbitration Provision is made pursuant to a transaction between the parties
that involves and affects interstate commerce and therefore shall be governed by and enforceable under the FAA. The arbitrator will apply
substantive law consistent with the FAA and applicable statutes of limitations. The arbitrator may award damages or other types of relief
permitted by the law of the State of Florida, subject to the limitations set forth in this Agreement. The arbitrator will not be bound
by judicial rules of procedure and evidence that would apply in a court. The parties also agree that the proceedings shall be confidential
to protect intellectual property rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) IF YOU DO NOT AGREE TO THE TERMS OF THIS ARBITRATION AGREEMENT, YOU MAY OPT OUT OF THIS ARBITRATION
PROVISION BY SENDING AN ARBITRATION OPT-OUT NOTICE TO THE COMPANY THAT IS RECEIVED AT THE ABOVE ADDRESS WITHIN THIRTY (30) DAYS OF YOUR
FIRST ELECTRONIC ACCEPTANCE OF THIS FORM. YOUR OPT-OUT NOTICE MUST CLEARLY STATE THAT YOU ARE REJECTING ARBITRATION; IDENTIFY THE AGREEMENT
TO WHICH IT APPLIES BY DATE; PROVIDE YOUR NAME, ADDRESS, AND SOCIAL SECURITY NUMBER; AND BE SIGNED BY YOU. YOU MAY CONVEY THE OPT-OUT
NOTICE BY U.S. MAIL OR ANY PRIVATE MAIL CARRIER (E.G. FEDERAL EXPRESS, UNITED PARCEL SERVICE, DHL EXPRESS, ETC.), SO LONG AS IT IS
RECEIVED AT THE ABOVE MAILING ADDRESS WITHIN THIRTY (30) DAYS OF YOUR FIRST ELECTRONIC ACCEPTANCE OF THE TERMS OF THIS AGREEMENT. IF THE
NOTICE IS SENT BY A THIRD PARTY, SUCH THIRD PARTY MUST INCLUDE EVIDENCE OF HIS OR HER LEGAL AUTHORITY TO SUBMIT THE OPT-OUT NOTICE ON
YOUR BEHALF. IF YOUR OPT-OUT NOTICE IS NOT RECEIVED WITHIN THIRTY (30) DAYS FROM THE DATE YOU SIGN THIS AGREEMENT, YOU WILL BE DEEMED
TO HAVE ACCEPTED ALL TERMS OF THIS ARBITRATION AGREEMENT.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) NO ARBITRATION SHALL PROCEED ON A CLASS, REPRESENTATIVE, OR COLLECTIVE BASIS (INCLUDING AS PRIVATE ATTORNEY
GENERAL ON BEHALF OF OTHERS), EVEN IF THE CLAIM OR CLAIMS THAT ARE THE SUBJECT OF THE ARBITRATION HAD PREVIOUSLY BEEN ASSERTED (OR COULD
HAVE BEEN ASSERTED) IN A COURT AS CLASS REPRESENTATIVE, OR COLLECTIVE ACTIONS IN A COURT. UNLESS CONSENTED TO IN WRITING BY ALL PARTIES
TO THE ARBITRATION, NO PARTY TO THE ARBITRATION MAY JOIN, CONSOLIDATE, OR OTHERWISE BRING CLAIMS FOR OR ON BEHALF OF TWO OR MORE
INDIVIDUALS OR UNRELATED CORPORATE ENTITIES IN THE SAME ARBITRATION.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) This Arbitration Provision shall survive (i) suspension, termination, revocation, closure, termination,
or amendments to this Agreement and the relationship of the parties; (ii) the bankruptcy or insolvency of any party or other person;
and (iii) any transfer of any Shares. If any portion of this Arbitration Provision other than the prohibitions on class arbitration
in this Section is deemed invalid or unenforceable under any law or statute consistent with the FAA, it shall not invalidate the
other provisions of this Arbitration Provision or this Agreement; if the prohibition on class arbitration is deemed invalid, however,
then this entire Arbitration Provision shall be null and void.

[**EXECUTION PAGE FOLLOWS**]

## Ex1A-6

**Exhibit 6.10**

![](tm2533753d1_ex6-10x001.jpg)

1/57 Orde r Form Re g A Prepare d for : Cytonic s Corporation Quot e Date: Jan 13 , 2026 Contact : Joey Bose Vali d Until : Fe b 12 , 2026 Email : joey.bose@cytonics.com Propose d By: Jonatha n Self Billin g Information Effectiv e Date: Ja n 13 , 202 6 12:02:3 7 P M UTC - 0500 Paymen t Terms: 100% Due on Signing Billin g Contact: Joey Bose Billin g Phone: 4438278135 Billin g Email: joey.bose@cytonics.com Billin g Address : 658 W . Indiantow n Road , Suit e 214, Jupite r Florid a Unite d State s 33458 Se t U p Fees Se t U p Fees Ne t Price DealMake r Marketin g Service s - Ful l Packag e Setup 0 DealMake r Shareholde r Service s - Setup 0 DealMake r Securitie s – Re g A Onboardin g Setup 0 DealMaker.tec h Plu s Setup 0 Tota l Ne t Setup $0 Monthl y Fees Monthl y Fees Ne t Price DealMake r Marketin g Service s - Marketin g Consultin g Monthl y Fee $2,000 DealMake r Marketin g Service s - Marketin g Advisor y Monthl y Fee $8,000 DealMaker.tec h - Plu s Platfor m Monthl y Fee $2,000 Discount 20% Tota l Ne t Monthly $12,000

![](tm2533753d1_ex6-10x002.jpg)

2/57 Thi s Orde r Form set s fort h th e terms of service by which a number o f separat e DealMake r affiliate s are engage d t o provide services t o Custome r (collectively , th e " Service s "). B y it s signatur e below in each applicabl e section , Custome r hereby agrees t o th e terms of service of each company reference d in such section. Unless otherwis e specifie d above , th e Service s shall commence on th e dat e hereof. B y proceedin g wit h it s order , Custome r agrees t o be bound contractuall y wit h each respectiv e company . Th e Applicabl e Terms o f Servic e include and contain , among othe r things , warrant y disclaimers , liabilit y limitation s and use limitations. I n particular , Custome r understand s and agrees tha t it is carrying ou t a self - hoste d capita l raise and bears primary responsibilit y for th e success of its own raise. No DealMake r entit y is ever responsibl e fo r th e success o f Customer' s campaign and no guarantee s or representation s are ever in place wit h respec t t o (i) capita l raised (ii) investo r solicitatio n or (iii) completio n of investo r transaction s wit h Customers. Custome r agrees and acknowledge s tha t online capita l formatio n is uncertain , and tha t nothin g in thi s agreemen t prevent s Custome r fro m pursuing concurren t or sequentia l alternativ e forms o f capita l formation. Custome r should use it s discretio n in choosing t o engage th e vendors described in thi s Agreemen t and agrees tha t such entitie s bear no responsibilit y to Custome r wit h respec t t o raising capital. Ther e shall be no forc e or effec t to any differen t terms othe r tha n as described or reference d herein (includin g all term s include d or incorporate d by reference) excep t as entere d int o by one o f th e companies reference d herein and Custome r in writing. A summary of Service s purchased is described in th e Schedul e "Summar y o f Compensation " attached. Th e applicabl e Terms o f Servic e are described on th e Schedule s thereafter , and are incorporate d herein. Service s NEVE R include providin g any investmen t advice nor any investmen t recommendation s t o any investor.

![](tm2533753d1_ex6-10x003.jpg)

3/57 Cytonic s Corporation Name Joey Bose Title Presiden t & CEO Signature %BSIG1% Date Jan 13, 2026 12:02:3 7 PM UTC - 0500

![](tm2533753d1_ex6-10x004.jpg)

4/57 Schedul e "Summar y o f Compensation " A . Regulatio n A Offerin g Advance  $0 Advanc e (an advance agains t accountabl e expenses anticipate d t o be incurred , and refunde d t o exten t no t actuall y incurred) Thi s advance includes: i. $0 prepaid t o DealMake r Securitie s LLC fo r Pre - Offerin g Analysis ii . $0 prepaid t o Novatio n Solution s Inc . O/ A DealMaker fo r infrastructure for self - directe d electroni c roadshow iii . $0 prepaid to DealMake r Marketin g Service s LLC (O/ A "DealMake r Reach") for consultin g and developin g material s fo r self - directe d electroni c roadshow  $10,00 0 monthl y accoun t managemen t compensation. o Monthl y accoun t managemen t and softwar e access fee s commence in th e mont h o f th e Commencemen t date . I f no Commencemen t dat e is state d on th e Orde r Form , monthly fee s commence in th e firs t mont h followin g th e Effectiv e Date. o T o th e exten t services are commenced in advance of a FINR A no objectio n lette r being received , such amount s shall be considere d an advance agains t accountabl e expenses anticipate d to be incurred , and full y refunde d to exten t no t actuall y incurred). A maximum o f $30,00 0 or thre e month s o f accoun t managemen t fee s are payable prior t o a no objectio n lette r being received. o Monthl y compensatio n includes:  $2,00 0 accoun t maintenanc e fee s payable t o DealMake r (up t o a maximum o f $24,00 0 during th e Offering)  $8,00 0 marketin g advisory fee s payable to Marketin g Service s (up t o a maximum o f $96,00 0 during th e Offering)  4. 5 % Cas h Compensatio n Fro m Al l Proceeds: o Cash compensatio n does no t include processing investo r refund s fo r Customers , which are chargeabl e a t $50.0 0 per refund. o Custome r shall be responsibl e for third - part y fee s wit h respec t t o paymen t processing.\* o Custome r may elec t t o offse t all or a portio n of thes e fee s by levying an administrativ e fe e t o investors.  Medi a Fee s to b e determine d o n a case - by - cas e basis , as may b e authorize d b y th e Customer , u p to a maximu m of a n additiona l $741,00 0 of compensatio n durin g th e Offering.  $7,91 0 i n Corporat e Filin g Fee s (payabl e to FINRA) \*Fee s are estimate d to b e approximatel y 2% of offerin g proceeds.

![](tm2533753d1_ex6-10x005.jpg)

5/57 Fai r Compensation T o ensure adherenc e t o fai r compensatio n guidelines , DealMake r Securitie s will ensure that , in any scenario , th e aggregat e fee s payable t o DealMaker Securitie s and its affiliate s in respec t o f Service s relate d t o th e Offerin g shall never exceed th e amount s set fort h in th e tabl e below (th e column entitle d "Maximum Compensation"). I f th e Offerin g is full y subscribed , th e maximum amoun t of underwritin g compensatio n will be $2,617,000 \*I n the even t tha t th e Financia l Industr y Regulator y Authorit y ("FINRA") Departmen t of Corporat e Financ e does no t issue a no objectio n lette r for the Offering , all DM S Fees are full y refundabl e othe r tha n services actuall y rendered. B . Non - Regulatio n A Offerin g Fees  $0 DealMake r Shareholde r Service s accoun t setu p , includin g upload o f existin g shareholde r lis t and general review and complianc e (Directors ' resolutions , etc.) in respec t o f up t o 2,50 0 shareholder s wit h no additiona l charge. Additiona l services beyond th e firs t 2,50 0 shareholder s will be charged ou t a t DM Shareholde r Service s standar d hourly rates.  DealMake r Shareholde r Services: o $250 monthl y subscriptio n fe e for DealMake r Shareholde r Service s Managemen t portal. o DealMake r Shareholde r Service s include th e issuance o f securitie s by DealMake r Shareholde r Service s to investor s in any Offerin g conducte d on DealMaker , as well as th e maintenanc e o f Customer' s registe r o f securities o Compensatio n for additiona l DealMaker Shareholde r Service s is liste d on th e DM Shareholde r Service s Rat e card and is subjec t to regular updat e in th e ordinary course.  $2,00 0 monthl y consultin g fees to DealMake r Marketin g Service s LL C (O/ A "DealMake r Reach") fo r brandin g an d marketin g service s unrelate d to th e Offering. Note : Price s are standar d base compensatio n and subjec t t o additiona l customizatio n compensation . A conditio n o f th e use of DealMaker Transfe r Agen t LLC (O/ A "DealMake r Shareholde r Services") is tha t Custome r continu e t o pay any and all outstandin g compensatio n owing to DealMaker , includin g softwar e compensatio n fo r use o f th e DealMake r Shareholde r Service s Managemen t porta l on a monthl y basis , on th e fee s and term s establishe d in th e Orde r For m entere d int o betwee n Custome r and DealMaker. .

![](tm2533753d1_ex6-10x006.jpg)

6/57 S chedul e "Scop e o f Marketin g Services " (provide d by DealMake r Marketin g Services) Ful l Marketin g Compensatio n Includes: 1. Websit e Desig n and Development:  Copywritin g and desig n of th e websit e wit h up t o 3 round s of revision s at th e copywritin g stag e and desig n stag e each.  Developmen t of th e websit e usin g Webflow.  Integratio n of tracking , analytics , and pixels.  Ongoin g maintenanc e and managemen t of websit e content. 2. Audience - Buildin g Infrastructure:  Audienc e buildin g throug h emai l captur e on landin g pages.  Creatio n of th e followin g emai l series: i. Investo r educationa l emai l serie s (4 t o 6 emails) ii. Pos t investmen t serie s (1 - 2 emails)  Ongoin g emai l lis t nurturin g wit h update s fro m th e Customer' s campaig n announcements , relevan t news , and webinars.  Desig n and implementatio n of emai l captur e in Klaviyo.  Integratio n of DealMake r webhook s t o buil d and trac k th e investo r funne l and status. 3. Conversio n Rat e Optimizatio n (CRO):  Continuou s testin g of websit e conten t t o improv e conversio n rates. 4. Emai l Marketing:  Ongoin g nurturin g of th e emai l lis t wit h update s repurpose d fro m th e Customer' s campaig n announcements , relevan t news , and webinars. 5. A d Creative  4 - 6 imag e asset s resize d fo r all channels  2 - 3 vide o asset s resize d fo r al l channels  3 - 4 cop y variation s applicabl e t o respectiv e channels 6. Pai d Media  Managemen t of Googl e AD s includin g Search , Display , Googl e Discovery , and YouTub e ads.  Managemen t of Met a Ad s (Faceboo k & Instagram) as wel l as Twitter/ X ads upo n request.  Ongoin g testin g of ad cop y and creative. 7. Media Network:  Sourcin g and negotiatin g privat e media placement s wit h relevan t publisher s and email newsletters.  Purchase s o f media placement s will include a fe e equal t o 15% o f th e tota l spend . Aggregat e fee s shall no t exceed th e maximum liste d in "Schedule : Summar y o f Compensation" 8. Reporting:  Regula r calls : bi - weekl y  Strategi c planning , implementation , and executio n of th e marketin g budget.  Coordinatio n wit h third - part y agent s in connectio n wit h th e performanc e of services.  Monthl y forecasting.

![](tm2533753d1_ex6-10x007.jpg)

7/57  Monthl y and bimonthl y repor t generation. Custome r is responsibl e fo r reviewin g item s 1 throug h 8 wit h Customer' s professiona l advisors , as require d Marketin g Service s monthl y fe e will commence in th e firs t mont h followin g th e Effectiv e Date . COMPENSATIO N NOT INCLUDED  Expenses Marketin g Service s are provide d by DealMake r Marketin g Service s (O/ A "DealMake r Reach , LLC") . Custome r hereb y agree s to th e terms set fort h i n th e DealMake r Marketin g Service s Term s of Service , wit h compensatio n describe d o n Schedule s "Summar y of Compensation " an d "Scop e of Marketin g Services " hereto. Custome r Signature %BSIG1%

![](tm2533753d1_ex6-10x008.jpg)

![](tm2533753d1_ex6-10x009.jpg)

![](tm2533753d1_ex6-10x010.jpg)

1 0 /57 Schedul e "Transfe r Agen t Service s " (DealMake r Shareholde r Services) Accoun t Setup : Genera l onboardin g an d custome r accoun t setup , includes: ● Upload of existin g shareholde r lis t (2,50 0 shareholder s or fewer) ● Issue r review and complianc e package (director s resolutions , etc) Shareholde r Service s Managemen t Porta l Monthl y Compensation . Numbe r of Shareholders Monthl y Compensation 0 - 250 $250 minimum fla t fee 251 - 500 $0.7 5 / shareholder 501 - 1500 $0.5 0 / shareholder 1,501 - 5,000 $0.2 0 / shareholder 5,001 - 10,000 $0.1 0 / shareholder 10,001+ $0.0 8 / shareholder Issuanc e Compensatio n (Pe r Action) Electroni c Record (Boo k Entry) securit y issuance compensatio n included Compensatio n for additiona l services is liste d on th e DealMake r Shareholde r Service s Rat e card and is subjec t t o regular updat e in th e ordinary course. Uploa d of histori c shareholde r lis t include s u p to 2,50 0 shareholder s provide d tha t that shareholde r dat a meets DealMaker' s standar d dat a format. Service s relate d to onboardin g historica l shareholder s wher e dat a i s no t provide d i n DealMaker' s standar d forma t o r abov e an d beyon d the firs t 2,50 0 shareholder s wil l b e billabl e at DealMake r Shareholde r Service s standar d hourl y rates of $50 pe r hour. A conditio n of th e use o f DealMake r Shareholde r Service s is tha t Custome r continu e t o pay any and all outstandin g compensatio n owing to DealMaker , includin g softwar e compensatio n fo r use o f th e DealMaker Shareholde r Service s Managemen t porta l on a monthl y basis , on th e compensatio n and term s establishe d in th e Orde r Form entere d int o betwee n Custome r and DealMaker. Custome r hereb y engage s an d retain s DealMake r Transfe r Agen t LLC , a registere d Transfe r Agent , (O/ A "DealMake r Shareholde r Services") to provid e the applicabl e services , wit h compensatio n describe d o n Schedul e "Summar y of Compensation " hereto.

![](tm2533753d1_ex6-10x011.jpg)

1 1 /57 Custome r Signature %BSIG1% Shareholde r Service s Rate Card Accoun t Setu p & Onboarding DealMake r Shareholde r Service s Onboardin g includes:  Configuratio n o f a Custome r Shareholde r Service s porta l fo r shareholde r management  Issue r review and complianc e package  Upload of historica l shareholde r lis t (must be provided in appropriat e CS V Format) up to 2,50 0 holders $2,500 Dat a cleanin g and reconciliation $125/hour Note: DealMaker standar d hourly rate s o f $125 per hour will apply to: (a) uploadin g all histori c shareholde r dat a tha t is no t in standar d CS V format ; and (b) Issuer s importing greate r tha n 2,50 0 histori c shareholders . Request s to upload more tha n 2500 histori c shareholder s may also incur additiona l fee s fo r dat a integration , availabl e upon request. Shareholde r Service s Managemen t Porta l Monthl y Fee 0 - 250 shareholder s (minimum fla t fe e) $250 251 - 500 shareholders $0.7 5 / shareholder 501 - 1,50 0 shareholders $0.5 0 / shareholder 1,50 1 - 5,00 0 shareholders $0.2 0 / shareholder 5,00 1 - 10,00 0 shareholders $0.1 0 / shareholder 10,001 + shareholders $0.0 8 / shareholder Monthl y Fe e includes: - Porta l access and use o f DM Shareholde r Managemen t Technolog y - shareholde r ledger management , shareholde r inquiry and I R functionality , Communit y buildin g tools , and more. - Functionalit y supportin g corporat e updates , announcements , trackin g engagement. - Document - sharin g functionalit y t o disseminat e book entr y statements , ta x documentation , and othe r file s t o shareholders. Note : Pricin g is graduate d - tier s apply progressivel y as shareholde r quantit y increases .

![](tm2533753d1_ex6-10x012.jpg)

1 2 /57 Issuanc e Fees Electroni c Record (Boo k Entry) securit y issuance fee included Bas e Usage Fee s - Corporat e Actions Stoc k Split $2,500 Name Change $2,500 Stoc k Dividend $2,500 Shareholde r Actions Non - restricte d share transfe r (issue/cancel) . Include s electroni c record - keepin g o f documentatio n received for transfer $50/transfer Removal of Restrictiv e Legend $100 Transactio n Rejection $25 Note : all shares are maintaine d in book - entr y form , we do no t issue paper certificate s so significan t savings on paper certificat e costs (lost/stolen/mailing) Digita l Dividend Dividen d Setup $1,500 Administrativ e Fee $500 per disbursement Pe r distributio n (plus associate d paymen t processing costs) $3.00 1099s Issue/Send\* $3.99 Note : Custome r is responsibl e for issuing K - 1 s in place of 1099s. Customer' s accountan t can prepare K - 1s . DealMake r Shareholde r Service s can be used to share K - 1 statement s wit h Customer' s investor s and FAQ s prepared to easily manage investor' s inquiries. Bas e Shareholde r Digita l Votin g & Annua l Meetings Voting , Websit e setup , Digita l Meetin g Hosting , Digita l Q&A , Shareholde r Technolog y Support $15,000\*\* Emai l notic e and Electroni c I D Generation $1.5 0 per shareholder Vot e Tabulation $0.5 0 per vot e tabulated \*\*Pe r Quarter . Votin g extende d beyond th e quarte r is subjec t t o additiona l fees. Note : By - Law s mus t be drafte d by counsel t o permi t digita l meetings . Othe r Services Audi t Verification $125 Additiona l OFA C investo r checks $2.5 0 /shareholder

![](tm2533753d1_ex6-10x013.jpg)

1 3 /57 Othe r Services Earl y Termination Pe r contrac t term Warrant s and Convertibl e Notes: Genera l onboardin g and custome r accoun t setup , includes:  services rendered in connectio n wit h th e creatio n of th e issue .  including , among othe r things , reviewin g and providin g our comment s t o counsel on th e draf t Warran t Indentur e and othe r relate d documents .  executio n o f th e Warran t Indentur e in its fina l approved for m in acceptanc e of the responsibilities and duties of the agency .  settin g up records , and all telephon e communication s and correspondenc e incidenta l thereto. Monthl y Record Maintenanc e Fee $300 per month Exercis e Fee  Include s review o f exercise forms , confirmatio n of payment  Cancellatio n o f warrant s and updat e of warran t register  Issuanc e o f new securities , updat e of new securit y register  AM L verificatio n include d in .tec h portal $60.0 0 per exercise and issuance Cancellation , De - Registration , Re - Registratio n o f Warrants $20.0 0 per cancellation Removal of Restrictiv e Legend $100 per transaction Othe r Services Rush Fees Fractiona l Shar e Payments Audi t Verification Earl y Termination Consultin g Fee \*Quote d based on Custome r tim e limitation s and projec t scope \* Quote d upon request $125 $2,500 $50/hour \* Consultin g fe e for issuer & investo r question s outsid e our mandat e fo r example , question s no t directl y relate d t o th e series raise for

![](tm2533753d1_ex6-10x014.jpg)

1 4 /57 which we have been engaged. NOTE : Price s are standar d base fee s and subjec t to additiona l customizatio n fees. A conditio n o f th e use o f DealMake r Transfe r Agen t LLC services is tha t Issue r continu e t o pay any and all outstandin g fee s owing t o DealMaker , includin g softwar e fee s for use of th e DealMake r Shareholde r Service s Managemen t porta l on a monthl y basis , on th e fee s and terms establishe d in th e Orde r For m entere d int o betwee n Issue r and DealMaker.

![](tm2533753d1_ex6-10x015.jpg)

1 5 /57 DEALMAKE R TERM S O F SERVICE Thes e Term s o f Service s ("Terms") govern access to th e softwar e and services provided by any o f th e DealMake r entitie s such as Novatio n Solution s Inc. , O/ A DealMake r ("DealMaker.tech "), DealMake r Reach , LLC ("DM Reach "), DealMaker Securitie s LLC ("DMS ") and DealMake r Transfe r Agen t LLC, O/ A DealMake r Shareholde r Service s ("DMTA ") (individually , each a "DealMake r Entity " and collectively , th e "DealMake r Entities "). Eac h o f th e entitie s may be referre d t o as "DealMaker " or th e "Company " in thes e Terms. Thes e Term s have legal implications. I t is importan t tha t you read thes e term s carefully , and consul t legal counsel if you determin e tha t is appropriate , in order to understan d thes e Terms. Th e Terms , togethe r wit h th e DealMake r order form from which thi s page was linked ("Orde r Form "), for m an agreemen t betwee n th e Custome r (as define d in th e order form) and th e applicabl e DealMake r entit(ies) being engage d for technolog y or services (each an "Agreement "). Eac h o f thes e Agreement s may be referre d to as "an Agreement " or "th e Agreement " in thes e Terms . Eac h Agreemen t contains , among othe r things , warrant y disclaimers , liabilit y limitation s and use limitations . Eac h Agreemen t also contain s an arbitratio n provision which is enforceabl e agains t th e partie s and may impac t your right s and obligations. By signing th e Orde r For m and using th e DealMake r Entit y services described in such Orde r Form , Custome r accept s and agrees t o be bound by thes e Terms . Thes e Term s apply t o all DealMaker Entitie s unless a DealMake r Entit y is explicitl y excluded or alternativ e term s are supplemented , as indicate d below. 1 . Definitions "Account " means Investmen t fund s deposite d in Customer' s accoun t wit h a financia l institutio n by (i) Customer' s investor s directly , funde d via wire or check or (ii) a thir d part y paymen t processor , prior t o th e Closing of any transactio n involvin g such investments. "Closing " means th e resolutio n of all applicabl e AML - relate d exception s or discrepancie s identifie d throug h any searches provided by thir d partie s throug h Company or otherwis e identifie d by or t o Company fo r all transaction s associate d wit h an investmen t and th e acceptanc e by th e Custome r o f th e investmen t associate d wit h such transactions. "Closin g Date" means th e dat e o f each Closing.

![](tm2533753d1_ex6-10x016.jpg)

1 6 /57 "Commencemen t Date" occurs in th e mont h th e Custome r begins paying monthl y subscriptio n fees . I f no Commencemen t Dat e is state d on th e Orde r Form , monthl y subscriptio n fee s are payable in th e mont h followin g th e Effectiv e Date. "Custome r Paymen t Processin g Account " means a Customer' s accoun t wit h a thir d part y paymen t processor int o which Custome r deposit s investmen t funds . "DM Shareholde r Managemen t Technology " means DealMaker' s investo r communicatio n functionalit y technolog y and/o r services provided by DealMaker.tech . "Effectiv e Date" is th e dat e th e Agreemen t is signed . "Escro w Account " means Customer' s thir d part y escrow accoun t int o which Custome r direct s investmen t fund s from Investors. "Improvements " means any improvements , updates , variations , modifications , alterations , additions , error corrections , enhancements , functiona l changes or othe r changes t o th e Software , including , withou t limitation : (i) improvement s or upgrades to improve softwar e efficienc y and maintainability ; (ii) improvement s or upgrades t o improve operationa l integrit y and efficiency ; (iii) changes or modification s t o correc t errors ; and (iv) additiona l licensed compute r programs to otherwis e updat e th e Software. "Intende d Purpose " means Customer' s use of th e Softwar e t o raise capita l online via technolog y or services provided by DealMaker.tech. "Offerings " refer s t o online capita l formatio n transaction s complete d by Company' s Customer s or Customer' s clients , using th e Software . "Software " means th e DealMaker cloud - base d softwar e program develope d by Company , includin g it s features , functionality , performance , applicatio n and use , any relate d printed , electroni c and online documentation , manuals , trainin g aids , user guides , syste m administratio n documentatio n and any othe r file s tha t may accompany th e Softwar e used by th e Customer. "TOS " means th e DealMaker.tec h websit e terms of service locate d a t https://www.dealmaker.tech/terms . 2 . Ter m an d Termination 2.1 . Term Unles s otherwis e state d i n the Orde r Form , th e Agreemen t wil l remai n i n effect fro m th e Effectiv e Date unti l th e firs t da y of the mont h followin g th e completio n of a n Offerin g ("Term"). Th e Ter m fo r DMT A is set fort h i n th e DMT A terms. 2.2 . Renewal 2.2.1 . Activatio n Fee s : Unless otherwis e specifie d in th e Orde r Form , activatio n fee s do no t renew . Activatio n fee s are one - tim e fees . Thes e may also be referre d t o as "Launch Expenses " or "Setup, "

![](tm2533753d1_ex6-10x017.jpg)

1 7 /57 i f the y precede th e Offerin g launch or commencemen t of Services 2.2.2 . Monthl y Subscriptio n Fee s : Unless otherwis e specifie d in th e Orde r Form , Monthl y Subscriptio n Fee s ("Subscriptio n Fee") automaticall y renew each month. 2.2. 3 . DM Shareholde r Managemen t Technolog y Fee s : DM Shareholde r Managemen t Technolog y is a service offere d by DealMaker.tech. Unless otherwis e specifie d in th e DealMaker.tec h or DMT A fe e schedules t o your Orde r Form , fee s for use of th e DM Shareholde r Managemen t Technology , when applicable , will automaticall y renew each mont h and th e services can be canceled withi n any mont h upon writte n notice , effectiv e th e mont h followin g cancellatio n o f DealMaker.tec h services , excep t for DMT A Customers. Cancellatio n o f fee s fo r use o f DM Shareholde r Managemen t Technolog y for DMT A customer s is governed by th e DMT A terms. 2.2.4 . DealMake r Transactiona l Fee s are incurred at th e tim e o f each transactio n and charged on a per use basis , as specifie d in th e Orde r Form. 2.3 . Terminatio n 2.3.1 . Terminatio n for Cause. Custome r or any DealMake r Entit y may terminat e thi s Agreemen t immediatel y for Cause , as t o any or all Subscriptio n services. "Cause" includes a determinatio n tha t a part y is acting , or have acted , in a way tha t has negativel y reflecte d on or impacted , or may negativel y reflec t on or impac t th e othe r party , its prospects , or it s customers , includin g withou t limitatio n in a way tha t violate s or causes a violatio n of applicabl e law or regulation. Upon terminatio n fo r cause , ther e are no additiona l fee s incurred. Al l prepaid unused fee s would be returned. 2.3.2 . Otherwise , an Agreemen t may only be terminate d as follows: a . Materia l Breac h : A part y may terminat e thi s Agreemen t upon sixt y (60) days writte n notic e i f th e breachin g part y fail s t o perfor m or observe any materia l term , covenant , or conditio n to be performe d or observed by it under thi s Agreemen t and such failur e continue s t o be unremedie d afte r sixt y (60) days' writte n notic e o f such failur e fro m Company t o Customer . I f th e breach has no t been cured withi n th e sixty day period , th e non - breachin g part y may terminat e thi s Agreemen t forthwit h and may immediatel y exercise any one or more o f th e remedies availabl e t o i t under th e Terms of thi s Agreement , in additio n t o any remedy availabl e at law. b . Custome r Defaul t . I f Custome r default s in performin g its obligation s under an Agreement , Company may terminat e thi s Agreemen t (i) upon writte n notic e i f any materia l representatio n or warrant y made by Custome r proves t o be incorrec t a t any tim e in any materia l respec t or (ii) upon writte n notice , in order to comply wit h a legal requirement , i f such complianc e canno t be timel y achieved using commercially reasonabl e efforts , afte r Company has provided Custome r wit h as much notic e as practicable. c. Righ t of Terminatio n – Insolvency/Bankruptc y : A part y may terminat e an Agreemen t immediately , if th e othe r part y becomes th e subjec t o f a petitio n in bankruptc y or any othe r

![](tm2533753d1_ex6-10x018.jpg)

1 8 /57 proceedin g relatin g t o insolvency , cessatio n of business , liquidatio n or assignmen t fo r th e benefi t of creditors , reorganizatio n or othe r relief , or is adjudge d bankrup t or insolven t or has entere d agains t i t a fina l and unappealabl e order for relief , under any bankruptcy , insolvency , or othe r similar law. In th e even t of Company insolvency , all o f th e Customer' s asset s are immediatel y released . (collectively , "Terminatio n Reasons ") Othe r tha n th e Terminatio n Reasons , unless explicitl y state d otherwise , an Agreemen t may no t otherwis e be terminate d prior t o th e end of th e Term. 2.3.3 . Th e terminatio n o f an Agreemen t as described herein shall no t exclude th e availabilit y o f any othe r remedies . An y delay or failur e by eithe r part y to exercise , in whole or in part , any right , power , remedy or privileg e shall no t be construe d as a waiver or limitatio n t o exercise , in whole or in part , such right , power , remedy or privilege. 2.3.4 . Al l term s o f an Agreement , which should reasonabl y survive termination , shall survive , including , withou t limitation , confidentiality, limitation s of liabilit y and indemnities , arbitratio n and th e obligatio n t o pay fee s relatin g to services provided by th e DealMake r Entit y prior t o termination . 3 . Paymen t & Billing DealMake r shall be compensate d as set ou t in th e Orde r Form. Unless otherwis e specifie d in th e schedules t o th e Orde r Form , Custome r will be invoiced on a monthl y basis. Paymen t will be automaticall y debite d fro m th e Customer' s bank accoun t or credi t card on file , wit h a receip t t o be automaticall y delivered. Invoice s will be availabl e for th e Custome r t o review upon request. In th e even t tha t any Custome r paymen t fails , in respec t of any invoice due and payable to a DealMake r Entit y ("Arrears "), Custome r must re – connec t it s bank accoun t or updat e credi t card withi n fourtee n (14) days and submi t paymen t fo r any Arrears . Unless Arrear s are cleared and account s are brough t back int o good standin g withi n 14 days , automate d payout s and reconciliatio n reportin g will be disabled. In th e even t th e Arrear s are no t cleared or account s are no t brough t back int o good standin g withi n 30 days , all services will be paused unti l paymen t is received and th e Customer' s bank accoun t or credi t card authorizatio n is restored. DealMake r reserves th e righ t t o debi t fro m Customer' s paymen t accoun t in respec t of any Arrear s aged beyond thirt y days unless th e Custome r dispute s th e charges in writing. 4 . Intellectua l Property 4.1 . Titl e . Company retain s titl e to and sole ownershi p o f th e Softwar e and all Improvements. 4.2 . Cloud - Base d Softwar e . Th e Softwar e is cloud based . As such , th e source and objec t code are locate d on servers outsid e o f th e Customer' s premises . Custome r shall have no access t o th e facilitie s a t which th e Softwar e is hosted. 4.3 . Intellectua l Propert y . Al l Intellectua l Property , Intellectua l Propert y Right s and distributio n right s associate d wit h or arising from Company' s Confidentia l Informatio n includin g bu t no t limite d t o th e Software , remain exclusively wit h Company . "Intellectua l Property " includes , withou t limitation , wit h respec t to all DealMake r Products : all technica l data , designs , specifications , software , data , drawings , plans , reports , patterns , models , prototypes , demonstratio n units , practices , inventions , method s and relate d technology , processes or othe r information , and all right s therein , including , withou t limitation , patents , copyrights , industria l designs , trade - mark s and any registration s or application s fo r th e same and

![](tm2533753d1_ex6-10x019.jpg)

1 9 /57 all othe r right s o f intellectua l propert y therein , includin g any right s tha t arise fro m th e above item s being treate d by th e partie s as trad e secret s (th e right s being "Intellectua l Propert y Rights. ") 4.4 . Restrictions. 4.4.1 . Custome r may not : (i) modify , enhance , reverse - engineer , decompile , disassembl e or creat e derivativ e forms o f th e Software ; (ii) copy th e Software ; (iii) sell , sub - license , lease , transmit , distribut e or otherwis e transfe r right s in/t o th e Software ; (iv) allow third - part y use o f th e Softwar e installe d at th e Site ; or (v) pledge , hypothecate , alienat e or otherwis e encumber th e Softwar e t o any thir d party. 4.4.2 . Use of th e Softwar e is restricte d to th e Intende d Purpos e only. Custome r agrees no t t o engage in any activit y restricte d by th e TO S or transfe r any informatio n restricte d by th e TOS . 4.4.3 . Custome r acknowledge s tha t unauthorize d reproductio n or distributio n o f th e Softwar e is expressly prohibite d by law , and may resul t in civil and criminal penalties . Violator s may be prosecuted . Custome r may no t reverse engineer , decompile , disassembl e or otherwis e attemp t t o discover th e source code o f th e Software , DealMake r websit e or any par t thereof , excep t and only t o th e exten t tha t such activit y is expressly permitte d by applicabl e law notwithstandin g thi s limitation. 4.5 . Custome r represent s and warrant s tha t any Custome r asset s or material s provided and th e intende d use thereo f in accordance wit h th e terms of each Agreement , will no t infringe , violate , or misappropriat e any thir d part y rights , includin g withou t limitation , any copyrights , trademarks , trad e secrets , privacy , publicity , or othe r proprietar y or intellectua l propert y rights. 4.6 . Custome r represent s and warrant s tha t Custome r will no t t o bid on or use any DealMaker Entit y trademarks , brand names , or any variation s thereo f in Customer' s paid search advertisin g campaigns . Thi s includes , bu t is no t limite d to , Googl e AdWords , Bin g Ads , and othe r search engine marketin g platforms . Unless otherwis e provided fo r in th e Agreement , Custome r shall not: 4.6.1.bi d on or use our trademark s as keywords in Customer' s paid search campaigns; 4.6.2 . include DealMake r Entit y trademark s in Customer' s ad copy , display URL , or landin g page URL ; or 4.6.3 . use any misspellings , variations , or confusingl y similar term s t o DealMake r Entit y trademark s in Customer' s paid search activities; DealMake r reserves th e righ t t o monito r and enforc e complianc e wit h thes e trademar k biddin g restrictions. 5 . Confidentia l Information 5.1 . "Confidentia l Information " means any and all confidentia l or proprietar y informatio n o f DealMake r or Customer , includin g affiliate s thereof , which has been or may be disclosed by one part y t o thi s Agreemen t ("Disclosin g Party") to th e othe r part y ("Receivin g Party") , a t any tim e prior t o and during th e Agreemen t Term , including , withou t limitation , th e names o f employees and owners , th e names or othe r

![](tm2533753d1_ex6-10x020.jpg)

2 0 /57 personall y identifiabl e informatio n of customers , business and marketin g information , technology , know - how , ideas , reports , techniques , methods , processes , uses , composites , skills , and configurations , intellectua l propert y o f any kind and all documentatio n provided by investor s in th e Offering . Withou t limitin g th e generalit y o f th e foregoing , DealMaker' s Confidentia l Informatio n includes : (i) th e Software ; (ii) th e compute r code underlyin g th e Software , includin g source and compile d code and all associate d documentatio n and files ; (iii) informatio n relatin g t o th e performanc e or qualit y o f th e Softwar e and services provided by th e DealMaker Entity ; (iv) th e detail s o f any technica l assistanc e provided t o Custome r during th e Term ; (v) any othe r product s or service made availabl e t o Custome r by DealMake r during th e Agreemen t Term ; and (vi) informatio n regardin g DealMaker' s business operation s includin g it s research and developmen t activities. Al l work product , pricing , Agreemen t term s and process informatio n o f eithe r part y exchange d wit h th e othe r part y to perfor m th e term s o f th e Agreemen t is agreed t o be Confidentia l Information , excep t tha t any logos or marketin g reference s are no t Confidentia l Information. 5.2 . "Confidentia l Information " does no t include informatio n that : (i) is or has become generall y known t o th e public withou t any actio n by th e non - disclosin g party ; (ii) was known by eithe r part y prior t o enterin g int o th e Agreement ; (iii) was independentl y determine d by eithe r party ; or (iv) was disclosed t o th e relevan t part y withou t restrictio n by a thir d part y who , to th e bes t o f such party' s knowledg e and belief , had no obligatio n no t t o disclose such information . 5.3 . Neithe r part y may disclose Confidentia l Informatio n withou t th e express writte n consen t o f th e othe r party , excep t as specificall y contemplate d in thi s Agreement. 5.4 . Trad e Secret s . Notwithstandin g anythin g to th e contrar y herein , wit h respec t t o Confidentia l Informatio n tha t constitute s a trad e secre t under th e laws o f any jurisdiction , such right s and obligation s shall survive such expiratio n or terminatio n until , if ever , such Confidentia l Informatio n loses it s trad e secre t protectio n othe r tha n due to an ac t or omission of th e receivin g Part y or it s Representatives. 5.5 . B y executin g thi s Agreement , th e Custome r is providin g writte n consen t fo r DealMaker t o disclose Confidentia l Informatio n bu t only to th e exten t required to carry ou t th e term s o f thi s Agreement . Customer' s investor s will be required to sign - in to th e DealMaker.tec h porta l and agree t o th e DealMaker.tec h TOS . Th e partie s agree tha t thi s process shall no t constitut e a disclosur e o f "Confidentia l Information " as described in thi s section . 5.6 . Notwithstandin g anythin g in thi s section , Custome r and DealMake r hereby agree tha t each part y may use th e othe r party' s logo for promotiona l purposes ("Log o Use"). Th e partie s acknowledg e tha t Logo Use does no t include th e use of any descriptiv e copy , all o f which mus t be approved by Custome r and DealMake r in writing. Excep t as provided fo r in thi s paragraph , nothin g containe d in thi s Agreemen t will be construe d as grantin g Custome r or DealMake r any right , titl e or interes t in or t o any or t o use any o f th e othe r party' s Confidentia l Information. Custome r or DealMake r may terminat e Logo Use a t any time , wit h or withou t cause , upon writte n notic e t o th e othe r party . Fo r any Custome r conductin g a public offerin g on th e DealMake r platfor m (i.e . Regulatio n A or Regulatio n C F offerings) , in which th e offerin g is already in th e public domain , Custome r agrees tha t DealMake r may disclose Custome r name and offerin g proceeds t o thir d part y dat a aggregator s for th e purpose of generatin g industr y reports. Industr y report s shall no t include publicatio n o f Custome r name or th e amoun t raised. 5.7 . Authorize d Disclosur e . Eac h part y may, withou t th e consen t o f th e othe r party , disclose Confidentia l Informatio n to th e exten t reasonabl y necessary to comply wit h applicabl e regulator y demands or orders in connectio n wit h th e purpose fo r which th e Custome r enter s int o thi s Agreement . Eac h part y may disclose th e existenc e o f thi s Agreement and any relationshi p betwee n th e parties.

![](tm2533753d1_ex6-10x021.jpg)

2 1 /57 6 . Exclusio n of Warranties 6.1 . Excep t as expressly state d in thi s Agreement , DealMake r makes no representation s or warrantie s or covenant s to Customer , eithe r express or implied , wit h respec t t o th e Software , services provided by th e DealMake r Entit y or wit h respec t to any Confidentia l Informatio n disclosed t o Customer . DealMake r specificall y disclaims any implied warrant y or conditio n of non - infringement , merchantabl e qualit y or fitnes s for a particula r purpose . Custome r acknowledge s tha t th e Softwar e is in continuou s developmen t and tha t it has been advised by DealMaker to undertak e its own due diligenc e wit h respec t t o all matter s arising fro m thi s Agreement. Al l services are provided on an "a s is " and "a s available " basis withou t any warranties , express or implied , including , withou t limitation , implied warrantie s o f merchantabilit y or fitnes s fo r a particula r purpose , and DealMake r expressly disclaims all warranties . Custome r agrees and understand s tha t no DealMaker entit y has any fiduciar y dut y t o Customer. 6.2 . No Improvement s . Company is under no obligatio n to provide Improvement s t o th e Softwar e during th e Term . 6.3 . An y Improvement s Gratuitou s . An y Improvement s provided by DealMake r t o Custome r fro m tim e t o tim e during th e Term shall be , unless otherwis e stated , construe d as being provided on a purely gratuitou s basis and shall no t give rise to any righ t or entitlemen t on th e par t o f Customer , excep t as otherwis e specificall y provided in thi s Agreement . An y Improvement s so provided shall be governed by th e same term s and condition s applicabl e to th e Software , as described herein , unless otherwis e outline d in a fe e schedule or addendu m t o thi s Agreement. 6.4 . No Futur e Entitlement . Nothin g in thi s Agreemen t shall be construe d as creatin g any obligatio n on DealMake r to continu e t o develop , commercialize , offer , make availabl e or suppor t (i) th e Software ; or (ii) any feature , functionalit y or Improvemen t as may be encompasse d in th e Softwar e fro m tim e t o tim e during th e Term , beyond th e duratio n of th e Term. 6.5 . Company Template s and Sample s are Provide d wit h No Warrantie s . Custome r may reques t access t o DealMaker' s template s and resources to help organize and se t up an offerin g or any communication s relate d thereto . Thes e resources may include templat e communications , educationa l packages , resources fo r th e managemen t o f administrativ e and collaborativ e tasks , and bes t practice s observed fro m othe r offering s and industries . Custome r acknowledge s and agrees that , by providin g access t o any documents , training , or resources , DealMake r is no t renderin g and shall no t be deemed t o have rendered any legal , tax , investment , or financia l plannin g advice. Custome r shall , as i t deems necessary or advisable , consul t it s own legal , tax , investment , or financia l plannin g advisers. Al l template s and samples are provided wit h no warrantie s whatsoeve r and by making use o f such materials , Custome r is agreein g t o voluntaril y assume any liabilit y wit h respec t thereto. 7 . Limitatio n an d Exclusio n of Liability Unless otherwis e specifie d herein , in no even t is DealMaker' s liabilit y fo r any damages on any basis , in contract , tor t or otherwise , o f any kind and natur e whatsoever , arising in respec t o f thi s Agreement , howsoever caused , includin g damages of any kind and natur e caused by DealMaker' s negligenc e or by a breach of contrac t or any othe r breach of dut y whatsoever , t o exceed th e fee s actuall y paid t o DealMake r by Custome r during th e Term . Custome r acknowledge s tha t DealMake r has se t it s fee s under thi s Agreemen t in reliance on th e limitation s and exclusions o f liabilit y se t fort h in thi s Agreemen t and such relianc e form s an essentia l basis of thi s Agreement.

![](tm2533753d1_ex6-10x022.jpg)

2 2 /57 8 . Indemnification Applicabilit y of Indemnificatio n Clause: Customer s of DMT A are bound by th e separat e indemnificatio n clauses applyin g only t o DMTA. 8.1 . Indemnificatio n b y Custome r . Custome r shall indemnif y and hold each DealMake r Entity , it s affiliate s and thei r respectiv e members , officers , director s and agent s ("Indemnifie d Parties ") harmless fro m any and all actua l or direc t losses , liabilities , claims , demands , judgements , arbitration s awards , settlements , damages , direc t fees , costs and expenses (includin g attorne y fee s and costs) (collectivel y "Losses "), resultin g from or arising ou t o f any thir d part y suits , actions , claims , demands , investigation s or similar proceeding s (collectivel y "Claim ") to th e exten t the y are based upon (i) a breach o f thi s Agreemen t by Customer , (ii) th e wrongfu l acts or omissions o f Customer , (iii) Customer , or Customer' s clients ' engagemen t wit h DealMake r and any action s take n in conjunctio n therewith , includin g bu t no limite d to usage o f th e Software , whethe r or no t such activitie s are in accordance wit h Intende d Usage or (iv) th e Offering . "Losses " includes , losses arising from paymen t processing which are losses arising fro m chargebacks , clawbacks , paymen t reversals , fraudulen t charges , insufficien t credit , unauthorize d charges , claims o f Custome r or thir d partie s regardin g paymen t disputes , and any othe r problems relatin g t o card or AC H payment s made for th e benefi t of Custome r ("Paymen t Processin g Losses "). 8.2 . Indemnificatio n b y Company . Th e applicabl e DealMake r Entit y shall indemnif y and hold Customer , Customer' s affiliate s and Customer' s representative s and agent s harmless fro m any Losses resultin g fro m or arising ou t o f Claims t o th e exten t the y are based upon (i) such DealMake r Entity' s breach o f thi s Agreemen t (ii) th e negligence , fraud , bad fait h or willfu l misconduc t o f th e DealMake r Entit y or (iii) DealMake r Entity' s failur e t o comply wit h any applicabl e laws in th e performanc e o f it s obligation s under thi s Agreement. 8.3 . Indemnificatio n Procedur e . I f any proceedin g is commenced agains t a part y entitle d t o indemnificatio n under thi s section , promp t notic e of th e proceedin g shall be given t o th e part y obligate d t o provide such indemnification . Th e indemnifyin g part y shall be entitle d t o tak e contro l o f th e defense , investigatio n or settlemen t o f th e Proceeding s and th e indemnifie d part y agrees t o reasonabl y cooperate , a t th e indemnifyin g party' s cost in ensuing investigations , defens e or settlement. Th e indemnifyin g part y shall reimburse th e indemnifie d part y for all expenses (includin g reasonabl e fees , disbursement s and othe r charges o f counsel) as the y are incurred in connectio n wit h investigating , preparing , pursuing , defending , or settlin g a Claim (includin g withou t limitatio n any shareholde r or derivativ e action) ; provided , however , tha t indemnifyin g part y will no t be liabl e to indemnif y and hold harmless or reimburse an indemnifie d part y pursuan t t o thi s paragrap h to th e exten t tha t an arbitrato r (or panel o f arbitrators) or cour t of competen t jurisdictio n will have determine d by a fina l non - appealabl e judgmen t tha t such Claim resulte d from th e gross negligenc e or willfu l misconduc t o f such indemnifie d party. Th e Indemnifyin g Part y will no t settle , compromise or consen t to th e entr y of a judgmen t in any pendin g or threatene d Claim unless such settlement , compromise or consen t includes a release o f th e indemnifie d partie s satisfactor y t o th e indemnifie d parties. 8.4 . Indemnifie d Part y Limitatio n Of Liabilit y . In no even t shall th e Indemnifie d Partie s be liabl e or obligate d in any manner for any consequential , exemplary or punitiv e damages or los t profit s incurred by Custome r arising fro m or relatin g t o th e Agreement , an Offering , or any action s or inaction s take n by an Indemnifie d Partie s in connectio n wit h th e Agreement , and th e Custome r agrees no t t o seek or claim any such damages under any circumstances.

![](tm2533753d1_ex6-10x023.jpg)

2 3 /57 8.5 . Recover y of Paymen t Processin g Losses . Notwithstandin g anythin g t o th e contrar y in thi s Agreement , upon Company giving Custome r prior writte n notic e o f no less tha n fiv e business days , DealMaker.tec h shall have th e right , in its sole discretion , t o reques t Custome r reimburse Company fo r Paymen t Processin g Losses from Custome r Accoun t or fro m Customer' s Paymen t Processin g Account , unless prohibite d by law. Custome r acknowledge s and agrees tha t recovery o f Losses fro m Customer' s Paymen t Processin g Accoun t will no t serve as any limitatio n on th e indemnificatio n obligation s o f Custome r under thi s Agreemen t or any remedy or claim tha t Company may be entitle d t o pursue agains t Custome r in respec t o f such Losses . 9 . Thir d Part y Services Custome r may reques t introduction s t o DealMaker' s networ k o f partner s and vendors fo r th e purpose o f sourcing additiona l services (includin g bu t no t limite d to , a call center , marketin g support , investmen t relations) . Unless otherwis e specifie d in writing , all engagement s wit h thir d partie s in thi s respec t are t o be made directl y betwee n th e Custome r and th e vendor a t th e Customer' s discretion . Custome r acknowledge s and agrees that , by making such introductions , DealMake r is no t recommendin g and shall no t be deemed t o have recommende d any partne r or vendor's product s or services or t o have assumed any responsibilit y for Customer' s selectio n of any partne r or vendor or procuremen t o f such product s or services. Withou t limitin g any othe r protectio n of DealMake r under thi s Agreemen t and notwithstandin g anythin g t o th e contrary , DealMake r shall bear no responsibilit y or liabilit y whatsoeve r in connectio n wit h any thir d part y services provided by a vendor engage d by Customer , th e decision t o engage such vendors rest s solely wit h th e managemen t of th e Custome r on th e terms contracte d betwee n th e Custome r and such parties. 10 . Escrow Custome r acknowledge s tha t if Custome r opens a third - part y escrow accoun t (eithe r by Customer' s choice or as necessary t o comply wit h applicabl e laws or regulations) in connectio n wit h th e Company services , Custome r will apply for escrow accoun t wit h a DealMaker - approve d escrow provider. 11 . Custome r Obligations 11.1 . General 11.1.1 . Custome r shall be responsibl e for providin g Offerin g term s t o it s subscribers . Suc h disclosure shall include , bu t is no t limite d to th e followin g materia l information : a metho d o f Custome r valuation , a descriptio n of th e securit y availabl e in th e Offering , th e risks relate d t o th e investment , whethe r ther e are existin g investor s and any additiona l capita l expectations. 11.1.2 . Custome r is solely responsibl e fo r ensuring tha t th e fund s raised in th e Offerin g are used , allocate d or investe d in accordance wit h th e use o f fund s described in th e Offerin g disclosure. 11.1.3 . Custome r acknowledge s tha t followin g th e fina l closing fo r th e Offering , Custome r will have sufficien t liquidit y (from th e proceeds raised in th e Offerin g or alternat e Custome r funds) t o sustai n Custome r operation s for tha t period of tim e which is clearly identifie d in th e Offerin g disclosure or

![](tm2533753d1_ex6-10x024.jpg)

2 4 /57 alternatively , unti l th e nex t Custome r fundin g round. 11.1.4 . Nothin g in thi s Agreemen t shall be construe d to relieve th e managers or officer s o f Custome r fro m th e performanc e of thei r respectiv e dutie s or limi t th e exercise o f thei r powers in accordance wit h th e Customer' s bylaws , operatin g and constituen t documents , writte n supervisory procedures , applicabl e law or otherwise. Th e Custome r bears ultimatel y responsibilit y fo r all decisions wit h regard t o any matte r upon which Company has rendered it s services. Th e Company shall not , and shall have no authorit y to contro l Custome r or Customer' s day - to - da y operations , whethe r throug h th e performanc e of th e Company' s dutie s hereunde r or otherwise . Th e Customer' s directors , managers , officer s and employees shall retai n all responsibilit y fo r Customer , and it s operation s as and t o th e exten t required by Customer' s bylaws , operatin g and constituen t documents , and applicabl e law. In furtheranc e and no t in limitatio n o f th e above , and notwithstandin g any othe r provision o f thi s Agreemen t or o f any othe r agreement , understandin g or documen t tha t purport s t o have any contrar y effec t or meaning , th e DealMake r shall no t control , or have th e righ t t o control , directl y or indirectly , th e wages , hours , or term s and condition s o f employmen t o f th e Customer. 11.2 . Privacy . 11.2.1 . Notwithstandin g any othe r provisio n of thi s Agreement , Custome r shall no t tak e or direc t any actio n tha t would contravene , or cause th e othe r part y t o contravene , applicabl e legislatio n tha t addresses th e protectio n o f individuals ' personal informatio n (collectively , "Privac y Laws "). Custome r shall , prior t o transferrin g or causing to be transferre d personal informatio n t o Company , obtai n and retai n required consent s o f the relevan t individual s t o th e collection , use and disclosure o f thei r personal information , or shall have determine d tha t such consent s eithe r have previousl y been given upon which th e partie s can rely or are no t required under th e Privac y Laws , includin g any consent s required from thir d partie s pursuan t to applicabl e Privac y Laws. 11.2.2 . Custome r acknowledge s that , when used for an Offering , th e Customer' s personalize d Softwar e dashboar d ("Softwar e Dashboard ") will contai n personal identifyin g informatio n ("PII ") o f Customer' s investors . Custome r is solely responsibl e fo r ensuring complianc e wit h all applicabl e Privac y Laws when Custome r (a) download s and store s any PI I obtaine d fro m th e Softwar e Dashboar d and (b) provides Customer' s representative s wit h access t o th e Softwar e Dashboard . 11.2.3 . Custome r is solely responsibl e fo r notifyin g Company when any Custome r representativ e is no longer working fo r th e Custome r and/o r authorize d to access th e Softwar e Dashboar d fo r th e Offering. 11.2. 4 Custome r shall cause all thir d partie s wit h access to PI I obtaine d fro m th e Softwar e Dashboar d to execut e agreement s acknowledgin g th e thir d parties ' obligatio n t o comply wit h applicabl e Privac y Laws. 11.2.5 . Custome r has implemente d and continuall y monitor s and enforce s an agreemen t or policy wit h it s Custome r representatives , employees and agent s tha t addresses (i) confidentialit y and securit y provision s for all data , includin g dat a obtaine d throug h th e Softwar e Dashboar d and (ii) permitte d and impermissibl e use of thi s data. 11.3 . Ba d Acto r Checks

![](tm2533753d1_ex6-10x025.jpg)

2 5 /57 Custome r agrees t o provide DealMaker Entit y wit h documentatio n verifyin g completio n o f bad acto r checks in complianc e wit h all applicabl e regulation s ("Ba d Acto r Checks "). Custome r shall provide DealMake r Entit y wit h a copy of Customer' s Ba d Acto r Checks withi n thirt y (30) days o f th e Effectiv e Dat e o f thi s Agreement , failin g which , DealMake r Entit y shall notif y Custome r in writin g tha t i t shall tak e step s to complet e Customer' s Ba d Acto r Checks a t Customer' s sole expense. 12 . Genera l Terms 12.1 . Publications . Eac h part y acknowledge s tha t its name , logo(s) and a descriptio n o f th e general natur e o f thi s Agreemen t may be used in any press release , public announcemen t or public communicatio n during and followin g th e Term . Withou t limitin g th e generalit y o f th e foregoing , Company may publish such informatio n on it s website s and in its promotiona l materials. 12.2 . Genera l Cooperatio n . Th e partie s shall wit h reasonabl e diligenc e do all such thing s and provide all such reasonabl e assurances and execut e all such documents , agreement s and othe r instrument s as may reasonabl y be necessary for th e purpose o f carrying ou t th e provision s and inten t o f any Agreement . Th e partie s furthe r acknowledg e tha t th e implementatio n of each Agreemen t will require th e co - operatio n and assistanc e of each o f them. 12.3 . No Book s An d Records Obligation s . An y and all obligation s o f Custome r relate d t o th e storag e o f books and records remains th e sole obligatio n of Customer. Company expressly disclaims any and all responsibilit y wit h respec t t o any regulator y or industr y requirement s wit h respec t t o th e Customer' s obligation s relate d t o record keeping and maintenance. 12.4 . Survival . Thes e term s shall continu e in effec t unti l th e expiratio n or terminatio n o f th e Agreement , whichever is earlier. Th e provisions of thes e Terms of Servic e which should by thei r natur e survive expiratio n or terminatio n o f thi s Agreemen t shall so survive. 12.5 . Currency. Al l currencies referre d to herein are in U S dollars. 12.6 . Amendmen t and Waive r . Amendment s to any Agreement , includin g any schedule or attachmen t hereto , shall be enforceabl e only if in writin g and signed by authorize d representative s o f each o f th e applicabl e parties. A part y does no t waive any righ t under thi s Agreemen t by failin g t o insis t on complianc e wit h any o f th e terms of thi s Agreemen t or by failin g t o exercise any righ t hereunder. No waiver of any breach o f any terms or provisions of thi s Agreemen t is effectiv e or bindin g unless made in writin g and signed by th e authorize d representativ e of each o f th e parties. 12.7 . Assignmen t : No part y may assign an Agreemen t or any o f it s right s or obligation s hereunde r withou t th e prior writte n consen t o f th e othe r party , such consen t no t t o be unreasonabl y withheld. 12.8 . Inuremen t . Eac h Agreemen t inures to th e benefi t of and is bindin g on each o f th e partie s and thei r respectiv e successors and permitte d assignees , heirs and legal representatives . 12.9 . Forc e Majeure. Excludin g any obligation s of a part y t o pay monies due hereunder , neithe r part y will be responsibl e for any delay or failur e in its performanc e or obligation s under thi s Agreemen t due t o causes beyond it s reasonabl e control , including , withou t limitation , labor disputes , strikes , civil disturbances , governmen t actions , fire , floods , acts of God , war , terrorism , or othe r similar occurrences

![](tm2533753d1_ex6-10x026.jpg)

2 6 /57 (each , a "Forc e Majeur e Event "); provided tha t th e part y affecte d by such Forc e Majeure Even t (a) is withou t faul t in causing such delay or failure , (b) notifie s th e othe r part y o f th e circumstance s causing th e Forc e Majeure Event , and (c) take s commerciall y reasonabl e step s t o eliminat e th e delay or failur e and resume performanc e as soon as practicable. 12.10 . Governin g Law . Eac h Agreemen t is made in New Yor k governed by and construe d in accordance wit h th e laws o f th e stat e o f New Yor k and th e federa l laws applicabl e therein . I n connectio n wit h each Agreement , th e Partie s attor n to th e jurisdictio n o f th e court s o f th e Stat e o f New York . 12.11 . Arbitratio n . An y and all controversies , claims , or dispute s arising ou t o f or relatin g t o each Agreement , or th e interpretation , performance , or breach thereof , includin g th e scope or applicabilit y o f thi s provision to arbitrat e ("Dispute ") shall be referre d to senior managemen t o f th e partie s fo r good fait h discussion and resolution . I n th e even t th e partie s canno t resolve any Disput e informally , the n such Disput e shall be submitte d t o confidential , final , and bindin g arbitratio n wit h venue in New York , NY , pursuan t to th e rules o f th e America n Arbitratio n Association . 12.11.1 . Arbitratio n Procedur e . Th e arbitratio n shall tak e place in New York. Th e arbitratio n shall be befor e a single , neutra l arbitrato r who is a forme r or retire d New Yor k stat e or federa l cour t judge . Th e arbitratio n may be initiate d by any part y by giving t o th e othe r part y writte n notic e requestin g arbitration , which notic e shall also include a statemen t o f th e claims asserte d and th e fact s upon which th e claims are based . Custome r and Company each consen t t o thi s metho d o f disput e resolution , as well as jurisdiction , and consen t to thi s being a convenien t foru m fo r any such claim or disput e and waive any righ t it may have to objec t t o eithe r th e metho d or jurisdictio n fo r such claim or dispute. I n th e even t of any disput e among th e parties , th e prevailin g part y shall be entitle d to recover damages plus reasonabl e costs and attorney' s fee s and th e decision o f th e arbitrato r shall be final , bindin g and enforceabl e in any court . 12.11.2 . Compellin g Arbitratio n . An y part y may bring an actio n in any cour t o f competen t jurisdictio n to compel arbitratio n under thi s Agreemen t and t o enforc e an arbitratio n award . Notwithstandin g thi s arbitratio n provision , eithe r part y shall be entitle d t o seek injunctiv e relie f (unless otherwis e preclude d by any othe r provisio n of thi s Agreement) fro m any cour t o f competen t jurisdiction . I f fo r any reason an actio n proceeds in cour t rathe r tha n in arbitration , i t shall be brough t exclusivel y in a stat e or federa l cour t of competen t jurisdictio n locate d in New Yor k and th e partie s expressly consen t t o personal jurisdictio n and venue therei n and expressly waive any righ t t o tria l by jury. 12.11.3 . EAC H PART Y HERET O HEREB Y IRREVOCABL Y WAIVE S AL L RIGH T T O TRIA L B Y JUR Y IN AN Y LITIGATION , ACTION , PROCEEDING , CROSS - CLAIM , O R COUNTERCLAI M I N AN Y COUR T (WHETHE R BASE D ON CONTRACT , TORT , O R OTHERWISE) ARISIN G OU T OF , RELATIN G T O O R I N CONNECTIO N WIT H (I) THI S AGREEMEN T O R TH E VALIDITY , PERFORMANCE , INTERPRETATION , COLLECTIO N O R ENFORCEMEN T HEREO F O R (II) TH E ACTION S O F TH E PARTIE S IN TH E NEGOTIATION , AUTHORIZATION , EXECUTION , DELIVERY , ADMINISTRATION , PERFORMANC E OR ENFORCEMEN T HEREOF. 12.12 . Entir e Agreemen t : Eac h Agreemen t includin g all schedules thereto , constitute s th e entir e agreemen t betwee n th e partie s concernin g th e applicabl e subjec t matte r and supersedes all prior or collatera l agreements , communications , presentations , representations , understandings , negotiation s and discussions , oral or written.

![](tm2533753d1_ex6-10x027.jpg)

2 7 /57 12.13 . Heading s : Heading s are inserte d for th e convenienc e o f th e partie s only and are no t t o be considere d when interpretin g thi s Agreement. 12.14 . Number and Gende r . Word s importin g th e singular mean th e plural and vice versa . Word s in th e masculine gender include th e feminin e gender and vice versa. 12.15 . Severability . I f any term , covenant , conditio n or provision o f an Agreemen t is held by a cour t or arbitrator(s) of competen t jurisdictio n to be invalid , void or unenforceable , i t is th e parties ' inten t tha t such provision be reduced in scope by th e cour t or arbitrator(s) only t o th e exten t deemed necessary by tha t cour t or arbitrator(s) t o render th e provision reasonabl e and enforceabl e and th e remainde r o f th e provision s of thi s Agreemen t will in no way be affected , impaire d or invalidate d as a result. 12.16 . Notices . An y notic e required to be given pursuan t to an Agreemen t shall be in writin g and delivere d by electroni c mail , addressed to th e appropriat e party . An y notic e given is deemed t o have been received on th e dat e on which i t was delivere d if a business day , or, failin g that , on th e nex t business day. 12.17 . Testimonials . Custome r acknowledge s tha t DealMaker' s material s may fro m tim e t o tim e include testimonials , real world experience s and insight s or opinion s abou t othe r people' s experience s wit h DealMake r ("Examples ") and tha t thi s informatio n is for illustratio n purposes only. Custome r furthe r acknowledge s tha t campaigns are affecte d by a variet y of factor s includin g bu t no t limite d t o time , externa l global events , varying business plans , differen t industries , and tha t thes e Example s are in no way a representatio n or guarante e tha t curren t or futur e customer s will achieve th e same or similar results. DealMake r Additiona l Term s Applicabl e to Certai n DealMaker.tec h Services : Thir d Part y Paymen t Processing , AML/KY C Backgroun d Checks , Accreditatio n Verificatio n an d Analytics , Marketin g Revie w Tool . Th e followin g section s of th e Term s onl y appl y to thos e DealMaker.tec h Customer s wh o purchas e th e specifi c service s noted. 13 . Backgroun d Checks : AML complianc e an d "clearing" DealMaker' s integrate d AM L searches are tool s provided t o Custome r t o assis t Custome r (or it s agents) in complying wit h applicabl e obligation s relate d t o KYC/AM L regulations. Company is no t engage d t o perfor m and will no t perform , and shall no t be deemed responsibl e fo r performing , any services relate d t o reviewin g or analyzin g search results , sources of fund s or wealth , or making any determinatio n as t o whethe r Custome r has complied wit h its obligation s under applicabl e anti - mone y launderin g legislatio n and regulation s or as t o whethe r any prospectiv e investo r poses any risk o f money laundering , terroris t financing , or othe r criminal or suspicious activity. Custome r and/o r it s agent s (includin g counsel or broker dealer as applicable) shall bear primary responsibilit y t o determin e complianc e wit h applicabl e AM L legislatio n and regulatio n and shall assis t in th e clearin g o f any AM L exceptions. Customer' s KYC/AM L clearin g obligations may require Custome r to undertak e effort s t o ensure tha t individua l and corporat e investor s provide applicabl e identit y verification , explanation s o f adverse regulatory/disciplinary/bankruptc y histor y or media reports , confirmatio n o f fals e positiv e results , or othe r document s or informatio n required for AM L purposes. DealMaker.tech' s AM L searches are limite d by capabilitie s and design o f product s and services of th e thir d partie s DealMaker.tec h engages t o perfor m such searches , includin g limitation s on th e search methodology , matchin g logic , dat a sources , and informatio n accuracy.

![](tm2533753d1_ex6-10x028.jpg)

2 8 /57 14 . Regulatio n D , 506(c) Accredite d Investo r Verification 14.1 . Custome r may engage eithe r Company or a thir d part y (each a "Reviewer ") t o assis t Custome r in complying wit h applicabl e obligation s relate d to accredite d investo r verificatio n pursuan t t o Rule 506(c) o f Regulatio n D promulgate d under th e Securitie s Ac t ("Regulatio n D"). I f Reviewe r is Company , Company shall review investo r submissions and uploade d documentatio n on th e DealMake r porta l and make a determinatio n as t o whethe r Custome r has complie d wit h it s obligation s t o verif y accredite d investor s (as define d by Rule 501 o f Regulatio n D promulgate d under th e Securitie s Act) ("DM Verification "). Custome r acknowledge s tha t Company may contac t investo r fo r th e purpose o f accredite d investo r verificatio n and tha t Custome r has obtaine d investor' s consen t t o receive communication s fro m Company and/o r DealMake r regardin g investor' s accreditatio n verification. I f Reviewe r is a thir d party , Company will no t perform , and shall no t be deemed responsibl e for performing , any services relate d t o reviewin g or analyzin g search results , sources o f fund s or wealth , or making any determinatio n as t o whethe r Custome r has complie d wit h its obligation s to verif y accredite d investor s (as define d by Rule 501 o f Regulatio n D promulgate d under th e Securitie s Act). 14.2 . Company does no t make and hereby disclaims any warranty , expressed or implied wit h respec t t o th e informatio n provided throug h DM Verification. Company does no t guarante e or warran t th e correctness , merchantability , or fitnes s for a particula r purpose o f th e informatio n provided throug h DM Verification. Custome r acknowledge s that: 14.2.1 . DM Verificatio n shall no t include accreditatio n verificatio n o f non - U.S . investor s ("foreig n accredite d investors ") who may be subjec t to foreig n accreditatio n verificatio n requirements. 14.2.2 . DM Verificatio n is conducte d using a variet y of thir d part y databas e searches , public record services and user submissions . Company canno t represen t or warran t tha t th e dat a provided will be 100% accurate , complet e or up to date. Th e dat a is tim e sensitiv e and Company provides th e informatio n as is . Publi c records may be incomplete , ou t of dat e or have errors. 14.2.3 . Th e result s o f a DM Verificatio n search for any typ e o f personal verificatio n should be interprete d cautiously. Crimina l and civil record search result s may no t provide a complet e or accurat e representatio n o f a person' s criminal backgroun d or civil judgmen t history . Records are availabl e for th e majority , bu t no t all , of state s and counties . Records can be incomplete , contai n inaccuracie s or fals e matches. 14.2.4 . Company is no t a consumer reportin g agency as define d in th e Fai r Credi t Reportin g Ac t ("FCRA "), and th e informatio n in DealMaker.tech' s database s has no t been collecte d in whole or in par t fo r th e purpose o f furnishin g consumer reports , as define d in th e FCRA. CUSTOME R SHAL L NO T US E DM VERIFICATIO N SERVICE S A S A FACTO R I N (1) ESTABLISHIN G A N INDIVIDUAL' S ELIGIBILIT Y FO R PERSONA L CREDI T O R INSURANC E O R ASSESSIN G RISK S ASSOCIATE D WIT H EXISTIN G CONSUME R CREDI T OBLIGATIONS , (2) EVALUATIN G A N INDIVIDUA L FO R EMPLOYMENT , PROMOTION , REASSIGNMEN T O R RETENTION , O R (3) AN Y OTHE R PERSONA L BUSINES S TRANSACTIO N WIT H ANOTHE R INDIVIDUAL. 14.2.5 . Custome r assumes all risks arising from its use or disclosure o f DM Verificatio n informatio n Company provides t o Customer. 14.2.6 . DM Verificatio n Service s are provided in Englis h only . Custome r acknowledge s tha t dat a provided in any othe r languag e will require a certifie d translatio n which Custome r shall pay for , or

![](tm2533753d1_ex6-10x029.jpg)

2 9 /57 alternatively , rejec t th e investment. 14.2.7 . Notwithstandin g anythin g in th e DealMaker Term s o f Service , Custome r agrees tha t i t shall indemnify , defen d and hold harmless Company , its officers , directors , employees and agents , and th e entitie s tha t have contribute d informatio n to or provided services fo r DM Verificatio n agains t any and all direc t or indirec t losses , claims , demands , expenses (includin g attorneys ' fee s and cost) or liabilitie s of whateve r natur e or kind arising ou t o f Customer' s use o f th e informatio n provided by DM Verificatio n and Customer' s use or distributio n of any informatio n obtaine d therefrom , excep t fo r losses caused exclusivel y and directl y by Company's gross negligence , fraud , bad fait h or wilfu l misconduct. 14.2.8 . TH E DM VERIFICATIO N SERVICE S AN D INFORMATIO N AR E PROVIDE D "AS - IS " AN D "A S AVAILABLE " AN D NEITHE R COMPAN Y NO R AN Y O F IT S DAT A SUPPLIER S REPRESENT S O R WARRANT S THA T TH E INFORMATIO N I S CURRENT , COMPLET E O R ACCURATE . COMPAN Y HEREB Y DISCLAIM S AL L REPRESENTATION S AN D WARRANTIE S REGARDIN G TH E PERFORMANC E O F TH E WEBSIT E O R OU R SERVICES , AN D TH E ACCURACY , CURRENCY , OR COMPLETENES S O F TH E INFORMATION , INCLUDIN G (WITHOU T LIMITATION) AL L WARRANTIE S O F MERCHANTABILIT Y O R FITNES S FO R A PARTICULA R PURPOSE. Custome r acknowledge s tha t thes e disclaimers are an integra l par t o f thi s Agreement , and tha t Company would no t provide DM Verificatio n services i f Custome r did no t agree to thes e disclaimers. 15 . Third - Part y Paymen t Processin g 15.1 . Fo r the processin g of electroni c payment s (includin g bank - to - ban k payments , credi t card , etc.) , the Compan y may submi t material(s) an d or application(s) to partne r third - part y paymen t processor s o n behal f of the Customer . Upo n approval , th e Compan y wil l enabl e th e partne r processors ' intak e form/syste m withi n th e Customer' s onlin e DealMaker.tec h portal. 15.2 . Custome r acknowledge s tha t Company makes no guarante e tha t Custome r will be approved by any thir d party , and approval is subjec t to each thir d party' s sole discretion , including , t o th e exten t applicable , it s due diligenc e and complianc e policie s and procedures . Use o f paymen t processing service(s) is furthe r contingen t on th e mutua l acceptanc e by Company and Custome r o f each thir d party' s respectiv e terms , service agreements , and fee s (includin g fee s fo r merchan t processing accoun t and ongoin g maintenance , which may be applie d on a per - issuer basis) t o be include d as an addendu m t o thi s Agreemen t and/o r presente d to Custome r for acceptanc e a t th e tim e Custome r engages thir d party , and as update d fro m tim e t o time . Not e holdback periods may apply fo r electroni c paymen t transfe r methods , as enforce d by processors. Company shall no t be deemed responsibl e fo r delivery or any interruptio n or cessatio n o f any services provided by any thir d party. 15.3 . Al l transaction s mus t clear prior t o being made availabl e t o Customer. U S Federa l regulation s provide investor s wit h 60 days t o recall funds. Custome r remains liabl e t o immediatel y and withou t protestatio n or delay retur n any fund s recalle d by investor s fo r whateve r reason. 15.4 . Custome r agrees tha t fund s deposite d int o Customer' s Accoun t shall remain in Customer' s Accoun t and shall no t be withdraw n by Custome r or a person authorize d by Customer , fro m th e Customer' s Accoun t prior t o Closing .

![](tm2533753d1_ex6-10x030.jpg)

3 0 /57 15.5 . Company reserves th e righ t to deny , suspend or terminat e participatio n o f any investo r in th e offerin g to th e exten t Company , in its sole discretion , deems i t advisabl e or necessary t o comply wit h applicabl e laws or t o eliminat e practice s tha t are no t consisten t wit h laws , rules , regulations , bes t practices , or th e protectio n of its reputation. 15.6 . Holdbacks. Th e Custome r hereby acknowledge s tha t certai n term s apply in respec t o f electroni c or credi t card paymen t t o cover agains t charge - backs and/o r rescission ("Chargeback "). Chargebac k windows can vary in duratio n and amount. For thi s reason , a holdback is applie d t o all fund s processed online and deposite d in Custome r Paymen t Processin g Account. Company shall have th e right , in it s sole discretion , to revise th e amoun t and duratio n of any holdback. Unless otherwis e advised in writin g prior t o th e Effectiv e Date , th e holdback is 5.00 % of payment s processed , fo r a ninet y (90) day period. 15.7 . I n th e even t tha t a Customer' s investo r disputes , throug h thei r financia l institution , a subscriptio n paymen t made using electroni c or credi t card payment s ("Chargebac k Dispute") , Custome r acknowledge s that: 15.7.1 . I f th e Chargebac k Disput e is initiate d by a subscriber befor e th e Custome r has accepte d th e subscriber' s investment , th e Company shall refun d th e subscriber , and no furthe r actio n will be taken. 15.7.2 . I f th e Chargebac k Disput e is initiate d by a subscriber afte r th e Custome r has accepte d th e subscriber's investment , th e Company shall: 15.7.2.1 . notif y th e Custome r withi n twenty - fou r (24) hours o f th e Chargebac k Dispute ; and 15.7.2.2 . Provid e Custome r wit h fiv e (5) business days to resolve th e Chargebac k Disput e directl y wit h th e subscriber. 15.7.3 . If , afte r (5) business days , th e subscriber and Custome r fai l t o resolve th e Chargebac k Disput e , Company will submi t evidence contestin g th e Chargebac k Dispute , on behal f o f th e Customer . 15.7.4 . Custome r agrees t o promptl y notif y Company upon receip t o f any Chargebac k Disput e notifications , provide all necessary informatio n and documentatio n requeste d by th e Company t o suppor t th e Chargebac k Disput e and refrai n from directl y engagin g wit h th e paymen t processor or any othe r thir d part y regardin g th e Chargebac k Dispute. 15.7.5 . Custome r acknowledge s tha t contestin g a Chargebac k Disput e may require th e Company t o share certai n transactio n detail s wit h thir d part y paymen t processors. Th e Custome r agrees t o (a) only share informatio n necessary to contes t th e Chargeback Disput e and (b) comply wit h all applicabl e dat a protectio n and privacy laws when handlin g Custome r dat a and providin g Custome r dat a t o Company relate d t o th e Chargebac k Dispute. 15.7.6 . Fo r th e avoidanc e o f doubt , althoug h th e Company will make bes t effort s t o represen t th e Custome r in contestin g a Chargebac k Dispute , Company shall no t be liabl e fo r and bares no responsibilit y whatsoeve r for : 15.7.6.1 . Th e outcom e o f th e Chargebac k Dispute ;

![](tm2533753d1_ex6-10x031.jpg)

3 1 /57 15.7.6.2 . An y fee s or penaltie s imposed by paymen t processors or financia l institution s as a resul t of th e Chargebac k or Chargebac k Dispute ; or 15.7.6.3 . An y loss o f revenue or business opportunit y resultin g fro m th e Chargebac k or Chargebac k Dispute. 16 . Analytics 16.1 . Dat a and Analytic s . Company reserves th e righ t to collec t dat a relatin g t o Customer' s usage o f th e Softwar e during th e Term . Withou t limitin g th e generalit y o f th e foregoing , Company may collec t informatio n relatin g to : (i) Softwar e use (includin g th e number o f users , duratio n o f usage sessions , and number of transaction s initiate d or complete d using th e Software) ; (ii) error informatio n (includin g error messages and any feedbac k tex t submitte d via any in - applicatio n feedbac k form) ; (iii) performanc e dat a (includin g softwar e run time) ; (iv) user experienc e informatio n (includin g tim e spen t on each page o f th e user interface) ; and (v) license statu s informatio n (includin g confirmatio n o f license activatio n status) . Custome r shall have th e righ t to access and use dat a relatin g t o it s usage o f th e Softwar e fo r it s own purposes , as availabl e throug h th e online dashboar d or othe r report s provided by Company. 17 . Marketin g Revie w Tool 17.1 . DealMaker' s integrate d thir d part y marketin g review too l is made availabl e t o Custome r (or it s agents) to review Customer' s marketin g material s and assis t Custome r in complyin g wit h applicabl e marketin g regulation s ("Marketin g Revie w Tool "). I f reviewer is Company , Custome r may reques t tha t a DealMake r Entit y assistan t Custome r wit h uploadin g documentatio n int o th e Marketin g Review Too l bu t Company will no t perform , and shall no t be deemed responsibl e fo r performing , any services relate d t o reviewin g or analyzin g search results. Company is no t engage d t o perfor m and will no t perform , and shall no t be deemed responsibl e fo r making any determinatio n as t o whethe r Custome r has complie d wit h it s obligation s under applicabl e marketin g regulation s based on informatio n provided by th e Marketin g Review Tool. Custome r and/o r its agent s (if so designated) shall be responsibl e fo r reviewin g th e results , and determinin g complianc e wit h applicabl e marketin g legislatio n and regulations. 17.2 . Use of th e Marketin g Review Too l is contingen t upon Customer' s acceptanc e o f thir d part y provider's term s and fee s (i f applicable) to be presente d to th e Custome r a t th e tim e Custome r initiate s engagemen t wit h th e Marketin g Review Tool. 17.3 . Company does no t make and hereby disclaims any warranty , express or implied wit h respec t t o th e informatio n provided throug h th e Marketin g Review Tool. Custome r acknowledge s that (i) Company does no t guarante e or warran t th e correctness , merchantabilit y or fitnes s fo r a particula r purpose o f th e informatio n provided throug h Marketin g Review Tool ; (ii) Marketin g Review Too l is PROVIDE D "AS - IS " AN D "A S AVAILABLE " AN D NEITHE R COMPAN Y NO R AN Y O F IT S THIR D PART Y SUPPLIE R REPRESENT S O R WARRANT S THA T TH E INFORMATIO N I S CURRENT , COMPLET E O R ACCURATE ; and (iii) Custome r assumes all risks arising fro m Company or it s agents ' use o f th e Marketin g Review Tool. 17.4 . Notwithstandin g anythin g in th e DealMake r Term s o f Service , Custome r agrees tha t i t shall indemnify , defen d and hold harmless Company , its officers , directors , employees and agents , and affiliate s tha t have contribute d informatio n to or provided services relate d t o th e Marketin g Review Too l agains t any and all direc t or indirec t losses , claims , demands , expenses (includin g attorneys ' fee s and

![](tm2533753d1_ex6-10x032.jpg)

3 2 /57 cost) or liabilitie s o f whateve r natur e or kind arising ou t of Customer' s or it s agent' s use o f the Marketin g Review Tool and Customer' s use or distributio n of any informatio n obtaine d therefrom. Enterpris e Custome r Terms Fo r DealMake r Customer s wh o hav e signe d an Enterpris e Orde r Form , th e Term s apply , as wel l as th e followin g additiona l terms. If yo u are no t an Enterpris e Customer , thes e additiona l terms d o no t appl y to you: 18 . Definitions "Enterpris e Customer " means a Custome r tha t has entere d int o an Enterpris e Orde r Form. "License " means th e Company' s gran t to Enterpris e Custome r o f a non - exclusive , non - transferabl e license fo r use of th e Softwar e by an unlimite d number of individua l users. Company will designat e a DealMake r Enterpris e Accoun t t o Enterpris e Customer s wit h a License. "Intende d Purpose " For th e purposes of thi s section , Intende d Purpos e also includes usage by issuers invite d by Enterpris e Custome r to use Enterpris e Customer' s Enterpris e Accoun t fo r th e above - describe d purpose . "Software " as i t pertain s t o thi s section , shall also include any relate d printed , electroni c and online documentation , manuals , trainin g aids , user guides , syste m administratio n documentatio n and any othe r file s tha t may accompany th e Softwar e licensed by Enterpris e Customer. 19 . SLA 19.1 . I t is expressly understoo d and agreed tha t th e Company shall determin e it s capacit y t o offe r consultin g services , only t o such exten t and at such time s and places as may be mutuall y convenien t t o th e parties. Company shall be fre e t o provide similar services t o such othe r business enterprise s or activitie s as th e Company may deem fi t withou t any limitatio n or restrictio n whatsoever. 20 . License d Intermediar y Terms. If Enterpris e Custome r i s a license d Intermediar y (as define d below) , th e followin g additiona l terms apply: A . Book s and Records Book s and Records. An y and all obligation s of Custome r relate d t o th e storag e o f books and records includin g bu t no t limite d to , obligation s in accordance wit h Section s 17(a)(1) , 17(a)(3) and 17(a)(4) o f th e Securitie s Exchang e Ac t o f 1934 ("Exchang e Act" or "SEA") remain th e sole obligatio n o f Custome r and it s clients. Company expressly disclaims any and all responsibilit y wit h respec t t o any regulator y or industr y requirement s wit h respec t t o th e Custome r and its clients ' obligation s relate d t o record keeping and maintenance.

![](tm2533753d1_ex6-10x033.jpg)

3 3 /57 B . Regulatio n C F Offerings i . Obligation s o f th e Custome r (actin g as an Licensed Intermediary): Wher e Custome r using th e Softwar e has been engage d by it s clien t t o (i) ac t as a Broker - Deale r and a licensed Intermediar y pursuan t to Regulatio n CF , 17 C.F.R . Par t 227 (th e "Regulatio n CF"), or (ii) ac t as a registere d Fundin g Porta l and licensed Intermediar y pursuan t t o Regulatio n CF, in a transactio n involvin g th e offe r or sale of securitie s in relianc e on sectio n 4(a)(6) o f th e Securitie s Ac t (15 U.S.C . 77d(a)(6)) , Custome r shall comply wit h th e requirement s o f Regulatio n CF ("License d Intermediary "). Fo r greate r certainty , thi s includes th e requirement s tha t Custome r shall: 1 . Registe r wit h th e Securitie s and Exchang e Commissio n ("Commission ") as eithe r (i) a broker or (ii) a Fundin g Porta l under sectio n 15(b) of th e Exchang e Ac t (15 U.S.C . 78o(b)) , pursuan t t o Regulatio n CF , § 227.400; 2 . I f registerin g wit h th e Commission as a Fundin g Portal , refrai n from: a . Offerin g investmen t advice or recommendations; b . Solicitin g purchases , sales or offer s t o buy th e securitie s displaye d on it s platform; c. Compensat e employees , agents , or othe r persons for such solicitatio n or based on th e sale o f securitie s displaye d or reference d on th e DealMake r platform ; or d . Hold , manage , possess , or otherwis e handle investo r fund s or securities. (Regulatio n CF , § 227.300(2)(c)) 3 . Verif y tha t no director , office r or partne r of Customer , or any person occupying a similar statu s or performin g a similar functio n has a prohibite d "financia l interes t in an issuer" as th e ter m is define d in Regulatio n CF , § 227.300(b); 4 . Have a reasonabl e basis fo r believin g tha t Customer' s clien t seeking t o initiat e an offerin g o f securitie s under th e Regulatio n has a reasonabl e basis fo r keeping accurat e records o f securit y holders and is no t disqualifie d to offe r securitie s pursuan t t o Regulatio n CF , § 227.301(c); 5 . Make availabl e t o SE C and to th e public , th e disclosur e required by Regulatio n CF , § 227.20 1 and § 227.303; 6 . Provid e educationa l material s to all investors , pursuan t t o Regulatio n CF , § 227.302(b) ; 7 . Verif y tha t Customer' s client s are no t disqualifie d from offerin g securitie s pursuan t t o Regulatio n CF , § 227.100(b); 8 . Onl y accep t an Investo r int o an offerin g afte r (1) th e Investo r opens an accoun t wit h Customer , (2) th e Investo r consent s t o electroni c delivery and th e review of th e educationa l material s regardin g th e offerin g

![](tm2533753d1_ex6-10x034.jpg)

3 4 /57 and (3) Custome r has a reasonabl e basis to believe tha t th e Investo r meet s th e investmen t limitation s in Regulatio n CF pursuan t t o Regulatio n CF , § 227.30 2 and § 227.303.; 9 . Provid e communicatio n channels by which Investor s who have opened account s can communicat e wit h one anothe r and wit h representative s of th e Custome r abou t offering s made availabl e throug h th e Custome r or it s clients , pursuan t to Regulatio n CF , § 227.303(c) ; and 10 . Provid e Investor s th e opportunit y to reconsider thei r investmen t decision and t o cancel thei r investmen t commitmen t unti l 48 hours prior to th e new offerin g deadline , pursuan t t o Regulatio n CF § 227.304 11 . Provid e Investor s wit h notic e o f materia l changes as described in Regulatio n CF , § 227.30 4 ("Notice "), includin g bu t no t limite d to notic e tha t th e investor' s investmen t commitmen t will be canceled unless th e investo r reconfirm s his or her investmen t commitmen t withi n fiv e business days o f receip t o f th e Notice. 12 . I f registerin g wit h th e Commissio n as a Fundin g Portal , comply wit h th e Conditiona l Saf e Harbor provision s in Regulatio n CF , § 227.402 ; and 13 . I f registerin g wit h th e Commissio n as a Fundin g Portal , implemen t writte n policie s and procedures reasonabl y designe d t o achieve complianc e wit h federa l securitie s laws and th e rules and regulation s thereunder , relatin g t o it s business as a Fundin g Portal , as required by Regulatio n CF , § 227.402(a). 14 . I f registerin g wit h th e Commissio n as a Fundin g Portal , manage any reconciliatio n or reportin g question s wit h th e Issue r directly. ("Regulatio n C F Requirements ") Fo r greate r certainty , th e partie s acknowledg e tha t Company shall bear no responsibilit y fo r or liabilit y whatsoeve r in connectio n wit h th e Regulatio n CF Requirement s and Custome r shall be solely responsibl e fo r ensuring tha t Custome r and its client s comply wit h Regulatio n CF . Furthe r Assurances. Whe n Custome r or its client s use th e Softwar e fo r an offerin g in reliance on Regulatio n CF , Custome r shall verif y that: 1 . Th e issuer has file d a For m C Offerin g Statemen t wit h th e SEC , as described in Regulatio n CF , § 227.203(a) , prior t o making an offerin g to th e public pursuan t t o Regulatio n CF; 2 . Issue r complies wit h marketin g and advertisin g requirement s o f Regulatio n CF , § 227.204; 3 . Provide r is notifie d o f any investo r who , having received Customer' s Notic e pursuan t t o Regulatio n C F § 227.304 , opts - ou t o f thei r investmen t and whose investmen t mus t therefor e be refunded; 4 . Signe d and funde d subscriptio n agreements , execute d by investor s who have cleared AML/KYC , are reviewed by th e Custome r prior to countersignature; 5 . Th e aggregat e amoun t o f all securitie s sold to all Investor s by th e Issue r in a single offerin g during a 12 mont h period shall no t exceed $5,000,000 ; and

![](tm2533753d1_ex6-10x035.jpg)

3 5 /57 6 . Non - accredite d Investor s (as define d by Rule 501 , CFR § 230.301) investin g in th e offerin g pursuan t t o Regulatio n CF do no t exceed th e maximum investmen t permitte d in a 12 mont h period per Regulatio n CF , § 227.100. Payment s To Escrow. Custome r acknowledge s tha t it shall direc t all payment s fro m Investor s in respec t o f a Regulatio n CF offerin g t o Issuer' s Escro w Account. Customer is responsibl e fo r (1) applyin g fo r escrow accoun t wit h a DealMaker - selecte d Escro w Provider ; (2) configurin g instruction s on th e DealMaker platfor m t o ensure tha t all payment s are directe d t o th e appropriat e Escro w Account ; (3) using th e DealMaker.tec h applicatio n to manage closings pursuan t to th e DealMake r user guide and (4) coordinatin g wit h th e escrow company managin g th e Escro w Accoun t t o disburse fund s upon reques t fro m th e issuer. C . Regulatio n A/A + Offerings Obligation s of th e Customer. Wher e Custome r has been engage d by it s clien t as a broker - deale r in connectio n wit h an offerin g pursuan t to Regulatio n A , 17 C.F.R . Part s 230.251 - 230.26 3 ("Regulatio n A"), th e Custome r shall verif y that: 1 . Custome r shall complet e a reasonabl e due diligenc e ensuring no anti - frau d or civil liabilitie s provision s o f federa l securitie s laws have been violated. As such , Custome r shall maintai n a Due Diligenc e fil e includin g th e Issue r Agreemen t (or Sellin g Agreement) ; organizational , constating , financial , and administrativ e suppor t t o accep t such Issue r engagement ; and Issuer' s Offerin g Memoranda , Subscriptio n Document . Further , th e Due Diligenc e folde r shall evidence th e collectio n o f such document s in a for m as described in Customer' s Writte n Supervisor y Procedure s ("WSPs"). Custome r shall creat e and maintai n custome r files , includin g new account , accredite d investor , or qualifie d purchaser questionnaires , includin g Investo r attestations. 2 . Issue r has file d a For m 1 - A Offerin g Statemen t wit h th e SEC , as described in Regulatio n A , § 230.25 2 and § 239.90 , prior t o making an offerin g to th e public pursuan t t o Regulatio n A; 3 . Issue r complies wit h marketin g and advertisin g requirement s o f 17 C.F.R . Par t II , Securitie s and Exchang e Commissio n and th e SRO , FINRA , includin g bu t no t limite d to , settin g up th e issuer landin g page fo r th e Offerin g website . 4 . Signe d and funde d subscriptio n agreements , execute d by investor s who have cleared AML/KYC , are reviewed by th e Custome r and a recommendatio n is made by Custome r t o Issue r regardin g countersignature. 5 . Prio r to enablin g countersignature: a . Issue r has provided writte n confirmatio n to Custome r tha t i t has BlueSk y notic e file d in each state , as applicabl e dependin g on th e state s in which th e securitie s are offere d and whethe r th e offerin g is conducte d pursuan t to Tie r 1 or Tie r 2 o f Regulatio n A § 230.252 ; and b . Fo r th e firs t 25 days o f an offering , Custome r will monito r investor s unti l th e issuer has provided writte n confirmatio n tha t all stat e BlueSk y requirement s have been me t fo r th e 53 U S jurisdictions.

![](tm2533753d1_ex6-10x036.jpg)

3 6 /57 6 . Issue r and Issue r counsel have take n th e step s required t o review non - U S investors , as required by th e applicabl e internationa l regulations . DEALMAKE R SECURITIE S LL C ("DMS") CUSTOME R TERMS Fo r an y DealMake r Securitie s Customer , th e followin g additiona l terms als o apply: Broker - Deale r Agreement. Thes e terms and condition s fo r DealMaker Securitie s LLC ("DM S Terms "), along wit h th e Orde r Form and schedules attache d t o th e Orde r Form creat e a bindin g agreemen t by and betwee n th e Custome r who has signed th e Orde r For m ("DM S Customer "), and DealMake r Securitie s LLC , a FINRA - registere d Broker - Deale r ("DMS ")(th e "DM S Agreement "), as o f th e Effectiv e Date. DM S Custome r may also be considere d a Custome r o f th e othe r DealMaker Entities , dependin g on th e services th e Custome r purchases. DM S is a registere d broker - deale r providin g services in th e equit y and deb t securitie s market , includin g offering s conducte d via SE C approved exemption s such as Rules 506(b) and 506(c) o f Regulatio n D under th e Securitie s Ac t o f 1933 (th e "Securitie s Act"); Regulatio n A under th e Securitie s Ac t ("Regulatio n A"); Regulatio n CF under th e Securitie s Ac t ("Regulatio n CF") and others. DM S Custome r is offerin g securitie s directl y to th e public in an offerin g exemp t fro m registratio n under eithe r Regulatio n A or Regulatio n C F (th e "Offering "). DM S Custome r recognizes th e benefi t o f having DM S provide advisory and othe r services as described herein , on th e term s hereof. Capitalize d term s used bu t no t define d in thes e DM S Terms have th e meanings se t fort h in th e Orde r For m or the Terms. I n th e even t o f a conflic t betwee n th e Term s and th e DM S Terms , th e DM S Term s shall control . 1 . Appointmen t & Termination DM S Custome r hereby engages and retain s DM S to provide operation s and complianc e services a t Customer' s discretion / subjec t t o DMS' s approval as a FINRA - registere d broker - dealer. DM S Custome r acknowledge s tha t DM S obligation s hereunde r are subjec t t o (a) DMS' s acceptanc e o f DM S Custome r as a custome r followin g DMS' s due diligenc e review and (b) i f applicable , issuance by th e Financia l Industr y Regulator y Authorit y ("FINRA") Departmen t of Corporat e Finance o f a no objectio n lette r fo r th e Offering. I n additio n to th e Terminatio n Reasons , DM S may terminat e thi s DM S Agreemen t if , a t any tim e afte r th e commencemen t o f DMS' s due diligenc e o f th e potentia l DM S Customer , DM S reasonabl y believes tha t is no t advisabl e t o proceed wit h th e contemplate d Offering. 2 . Service s DM S will perfor m th e services liste d on th e Orde r Form in connectio n wit h th e Offerin g (th e "Services ").

![](tm2533753d1_ex6-10x037.jpg)

3 7 /57 3 . Fees A s paymen t for th e Services , DM S Custome r shall pay to DM S such fee s as described in th e Orde r Form . Transaction - base d Fee s includin g equit y are earned once th e DM S Customer' s investor s are reviewed by DMS . DM S Customer' s acceptanc e of an investo r complete s DMS' s service obligatio n a t which tim e fee s are due and payable to DMS. DM S Custome r authorize s DM S t o deduc t any fee s owing directl y fro m th e DM S Customer' s bank accoun t or third - part y escrow accoun t (i f Custome r has engage d an escrow provider). In th e even t thi s DM S Agreemen t is terminate d in accordance wit h paragrap h 1 o f th e DM S Terms , any advance agains t accountabl e expenses anticipate d t o be incurred , shall be refunde d t o th e exten t said expenses are no t actuall y incurred as o f th e terminatio n date. 4 . Regulator y Compliance a . DM S Custome r and all it s third - part y providers shall at all time s (i) comply wit h direc t reasonabl e request s of DMS : (ii) maintai n all required registration s and licenses , includin g foreig n qualification , i f necessary ; and (iii) pay all relate d fee s and expenses (includin g th e FINR A corporat e filin g fee) in each case tha t are necessary or appropriat e to perfor m thei r respectiv e obligation s under thi s Agreement . Custome r shall comply wit h and adhere to all DM S policies and procedures. b . DM S Custome r shall a t all time s disclose all compensatio n received by any thir d part y promoter s (includin g bu t no t limite d t o social media influencers) in connectio n wit h th e Offering , in accordance wit h applicabl e rules and regulations. c. DM S Custome r and DM S will have shared responsibilit y fo r th e review o f all documentatio n relate d t o th e Offerin g bu t th e ultimat e discretio n abou t acceptin g an Investor will be th e sole decision o f th e DM S Customer . Eac h Investo r will be considere d to be tha t of th e DM S Custome r and NO T tha t o f DMS . DM S Custome r shall advise DM S of each Investo r who shall no t be accepte d int o th e Offering. d . DM S Custome r and DM S shall each supervise and trai n thei r respectiv e employees , agents , representative s and independen t contractor s in th e performanc e o f function s allocate d t o the m pursuan t t o th e terms of thi s DM S Agreement. e . DM S Custome r may reques t DM S assistanc e wit h preparatio n o f th e For m C fo r th e Offerin g and guidanc e on filin g th e For m C for th e Offerin g in th e SEC - Edga r syste m bu t DM S Custome r is ultimatel y responsibl e fo r th e review and filin g th e Form C relate d to th e Offering. I n th e even t tha t DM S Custome r file s a Form C - W or For m 1 - A - W withdrawin g its filin g in relatio n t o it s Offering , DM S Custome r agrees t o th e promp t retur n t o investor s of all fund s received from investors. f. DM S Custome r agrees t o  Provid e accurate , complete , and timel y informatio n throug h th e online for m provided . Th e filin g creatio n timelin e will commence only upon receip t of all required information  Review all filing s wit h thei r securitie s counsel t o ensure accuracy befor e each EDGA R filing . DealMake r Securities , LLC is no t liable for errors , omissions , or inaccuracie s in filing s due t o incomplet e or inaccurat e informatio n provided by th e Customer.  Submi t requeste d revisions withi n th e specifie d review windows , as additiona l rounds or delays may incur furthe r fee s and impac t timelines.

![](tm2533753d1_ex6-10x038.jpg)

3 8 /57 g . I f eithe r DM S Custome r or DM S receives materia l communication s (orally or in writing) fro m any Governmenta l Authorit y or Self - Regulator y Organizatio n wit h respec t t o thi s Agreemen t or th e performanc e o f eithe r party' s obligation s thereunder , th e receivin g part y shall promptl y provide said communication s t o th e othe r party , unless such notificatio n is expressly prohibite d by th e applicabl e Governmenta l Authority . h . DM S Custome r is responsibl e for th e preparatio n of financia l statement s using th e going concern basis o f accountin g and required disclosure s alertin g investor s abou t any underlyin g financia l condition s and management' s plans t o address them. DM S Custome r acknowledge s tha t i t mus t maintai n a t leas t six month s of operatin g capita l and updat e investo r disclosures t o reflec t any change in operatin g capita l below thi s threshold. DM S Custome r acknowledge s tha t thes e update s t o investor s disclosure s will be made in accordance wit h th e advice of th e DM S Customer' s professiona l advisors. i. DM S Custome r is solely responsibl e for confirmin g tha t DM S Custome r is authorize d t o use or wholly owns all DM S Custome r intellectua l propert y used in connectio n wit h th e Offering. 5 . Rol e of DMS DM S Custome r acknowledge s and agrees tha t it relies on it s own judgmen t in engagin g DM S Services . DM S Custome r understand s and agrees tha t (i) DM S is no t assuming any responsibilit y fo r th e DM S Customer' s underlyin g business decision to pursue any business strateg y or effec t any Offering ; (ii) DM S makes no representation s wit h respec t to th e qualit y o f any investmen t opportunit y in connectio n wit h th e Offerin g (iii) DM S does no t guarante e th e performanc e to or o f any Investo r in th e Offering , (iv) DM S does no t guarante e th e performanc e of any thir d part y which provides services t o DM S or DM S Custome r wit h respec t t o th e Offering) , (v) DM S will make commercially reasonabl e effort s t o perfor m th e Service s pursuan t t o thi s DM S Agreement , (vi) DM S is no t an investmen t adviser , does no t provide investmen t advice and does no t recommend securitie s transaction s and any display o f dat a or othe r informatio n abou t th e Offering , does no t constitut e a recommendatio n as t o th e appropriateness , suitability , legality , validity , or profitabilit y of any Offering , (vii) DM S Service s in connectio n wit h thi s DM S Agreemen t should no t be construe d as creating a partnership , join t venture , or employer - employe e relationshi p of any kind , (ix) Service s in connectio n wit h thi s DM S Agreemen t tha t require registratio n as a FINRA/SE C registere d broker - deale r shall be performe d exclusivel y by DM S or an associate d person o f DMS , (x) DM S is no t providin g any accounting , legal or ta x advice , and (xi) will use "commercially reasonabl e efforts " t o perfor m Service s pursuan t to thi s DM S Agreemen t bu t tha t thi s shall no t give rise t o any express or implie d commitmen t by DM S to purchase or place any o f th e DM S Customer' s securities . DM S Custome r explicitl y acknowledge s tha t DM S shall no t and is under no dut y t o recommend DM S Customer' s securit y and DM S is no t sellin g DM S Customer' s securit y t o retai l investors . 6 . Indemnification Insufficien t Fundin g Fo r A Claim. I f th e foregoin g indemnificatio n or reimbursemen t is judiciall y determine d to be unavailabl e or insufficien t to fully indemnif y and hold harmless DM S as an indemnifie d part y agains t a Claim , th e DM S Custome r will contribut e to th e amoun t paid or payable by an indemnifie d part y as a resul t of such Claim in such proportio n as is appropriat e t o reflec t th e relativ e financia l benefit s o f th e Offerin g t o th e Company , on th e one hand , and th e indemnifie d party , on th e othe r hand ; or i f such allocatio n is no t permitte d by applicabl e law , in such proportio n as is appropriat e t o reflec t no t only th e relativ e benefit s bu t also th e relativ e faul t o f th e DM S Custome r on th e one hand and

![](tm2533753d1_ex6-10x039.jpg)

3 9 /57 th e indemnifie d part y on th e othe r hand wit h respec t to such Claim as well as any othe r relevan t equitabl e considerations . Notwithstandin g th e precedin g paragraphs , in no even t will th e aggregat e amoun t to be contribute d by all indemnifie d partie s toward s all Claims and DM S Custome r losses , exceed th e actua l fee s received by DM S pursuan t to th e DM S Agreement. 7 . Witnes s Reimbursement I n th e even t tha t DM S or any of its employees , officers , directors , affiliate s or agent s are requeste d or required to appear as a witnes s or subpoenae d to produce document s in any actio n in which th e DM S Custome r or any o f it s affiliate s is a part y t o and DM S is not , th e DM S Custome r will reimburse DM S fo r all expenses incurred by it s employees , officers , directors , affiliate s or agent s in preparin g fo r and appearin g as a witnes s or producin g documents , includin g th e reasonabl e fee s and disbursement s o f legal counsel. 8 . Notices An y notice s required by th e agreemen t shall be in writin g and shall be addressed , and delivere d via email at th e email address include d in th e Orde r Form. 9 . Confidentialit y an d Mutua l Non - Disclosure: Nothin g containe d herein shall be construe d to prohibi t th e SEC , FINRA , or othe r governmen t entitie s fro m obtaining , reviewing , and auditin g any information , records , or dat a o f eithe r part y containin g Confidentia l Information , as define d in thi s Agreement . Disclosure and Retentio n O f Confidentia l Information. DMS is hereby expressly permitte d by DM S Custome r to disclose Confidentia l Informatio n to thir d partie s involved in th e Offerin g contemplate d herein , provided tha t DM S Custome r has been informe d o f such disclosure in advance and has approved such disclosur e (eithe r orally or in writing) . DM S may retai n one copy o f th e DM S Customer' s Confidentia l Informatio n t o th e exten t necessary to comply wit h industry - specifi c documen t retentio n rules and othe r regulations , and in an archived compute r backup syste m store d as a resul t o f automate d backup procedures for complianc e purposes. DM S Custome r acknowledge s tha t regulator y record - keeping requirements , as well as securitie s industr y bes t practices , require DM S t o maintai n copies o f practicall y all dat a and communications , even afte r thi s Agreemen t is terminated . 10 . Miscellaneous 10.1 . FINR A Arbitratio n Rule s Appl y T o DM S Customer s . Notwithstandin g anythin g t o th e contrar y in thi s Agreement , AN Y DISPUTE, CONTROVERSY , CLAI M O R CAUS E O F ACTIO N BETWEE N TH E DM S Custome r AN D DM S DIRECTL Y OR INDIRECTL Y RELATIN G T O O R ARISIN G OU T O F THI S AGREEMENT , O R BREAC H THEREOF required or allowe d t o be conducte d by th e Financia l Industr y Regulator y Authority' s ("FINRA") rules (includin g th e FINR A Code o f Arbitratio n Procedur e fo r Industr y Disputes) shall be arbitrate d in accordance wit h such rules . An y arbitratio n shall be befor e a neutra l arbitrato r or panel o f arbitrator s selecte d under th e FINR A Neutra l Lis t Selectio n Syste m (or any successor system) and in a foru m designate d by th e Directo r o f FINR A Disput e Resolutio n or any member of FINR A Staf f t o whom such Directo r has delegate d authority. I n general accordance wit h

![](tm2533753d1_ex6-10x040.jpg)

4 0 /57 FINR A Rule 2268 , by signing an arbitratio n agreemen t th e partie s agree as follows: 10.1.1 . Thi s Agreemen t contain s a pre - disput e arbitratio n clause . 10.1.2 . Excep t as otherwis e provided in thi s Agreement , all partie s t o thi s Agreemen t are giving up th e righ t to sue each othe r in court , includin g th e righ t to a tria l by jury , excep t as provided by th e rules o f th e arbitratio n foru m in which a claim is filed. 10.1.3 . Arbitratio n awards are generall y fina l and binding ; a party' s abilit y t o have a cour t reverse or modif y an arbitratio n award is very limited. 10.1.4 . Th e abilit y o f th e partie s to obtai n documents , witnes s statement s and othe r discovery is generall y more limite d in arbitratio n tha n in cour t proceedings. 10.1.5 . Th e arbitrator s do no t have t o explain th e reason(s) fo r thei r award unless , in an eligibl e case , a join t reques t for an explaine d decision has been submitte d by all partie s t o th e panel a t leas t 20 days prior t o th e firs t schedule d hearing date. 10.1.6 . An y panel o f arbitrator s may include a minorit y of arbitrator s who were or are affiliate d wit h th e securitie s industry. 10.1.7 . Th e rules o f some arbitratio n forum s may impose tim e limit s fo r bringin g a claim in arbitration . In some cases , a claim tha t is ineligibl e for arbitratio n may be brough t in court. 10.1.8 . Th e rules o f th e arbitratio n foru m in which th e claim is filed , and any amendment s thereto , shall be incorporate d int o thi s Agreement. 10.1.9 . As provided in FINR A Rule 2268 , no person shall bring a putativ e or certifie d class actio n t o arbitration , nor seek t o enforc e any pre - disput e arbitratio n agreemen t agains t any person who has initiate d in cour t a putativ e class action ; or who is a member o f a putativ e class who has no t opte d ou t of th e class wit h respec t t o any claims encompasse d by th e putativ e class actio n until : (i) th e class certificatio n is denied ; or (ii) th e class is decertified ; or (iii) th e DM S Custome r is excluded fro m th e class by th e court . Suc h forbearanc e to enforc e an agreemen t t o arbitrat e shall no t constitut e a waiver o f any right s under thi s Agreemen t excep t t o th e exten t state d herein. 10.2 . DM S Custome r Identifyin g Informatio n . Pursuan t t o th e requirement s o f Titl e II I o f Pub . L . 107 - 56 (th e US A Patrio t Act) , as amended (th e "Patrio t Act") and othe r applicabl e laws , rules and regulations , DM S is required t o obtain , verif y and record informatio n tha t identifie s th e DM S Custome r which informatio n includes th e name and address of th e DM Custome r and othe r informatio n tha t tha t allows DM S to identif y th e DM S Custome r in accordance wit h th e Patrio t Ac t and othe r such laws , rules and regulations. 10.3 . Affiliate s of DM S : DM S Custome r acknowledge s tha t agreement s wit h DM S affiliate s (also referre d to as DealMaker Entitie s in thi s Agreement) , if any , shall be governed by th e DM S affiliates ' applicabl e terms o f service and exclusive remedy for DM Reach t o recover any Losses agains t Custome r in respec t of th e Agreement."

![](tm2533753d1_ex6-10x041.jpg)

4 1 /57 DEALMAKE R REACH , LL C CUSTOME R TERMS Fo r usag e of DealMake r Reac h Services , the followin g additiona l terms appl y to yo u ("Reac h Terms"): 1. TH E SERVICES 1.1. Overview . DM Reach shall provide certai n digita l marketin g services as described on th e Orde r For m (collectively , th e "DM Reac h Services ") subjec t to th e followin g additiona l term s and condition s o f thi s Agreement. 1.2. Custome r shall provide DM Reach wit h all reasonabl y necessary materials , company history , financia l statements , business and marke t description , bios o f principal s and key employees , customers , products , services , ta x returns , financia l models , systems , pricing , intellectua l property , technica l specifications , access t o social media channels , and all othe r pre - condition s necessary fo r providin g th e DM Reach Service s (th e "Information "). 1.3. Th e partie s acknowledg e and agree tha t all such Informatio n comes fro m Custome r and tha t DM Reach does no t creat e such Informatio n and relies on its accuracy , ownershi p and property. Custome r represent s and warrant s t o th e DM Reach tha t all such Informatio n is accurate , tru e and correc t and that , in th e even t Informatio n changes during th e Reach Term (as define d below) , Custome r shall provide update d Informatio n t o DM Reach. Custome r furthe r acknowledge s tha t DM Reach bases it s DM Reach Service s on such Information. 2. RELATIONSHIP 2.1. DM Reach and Custome r are independen t contractor s in all matter s relatin g t o DM Reach Services . DM Reach is no t a broker - dealer , investmen t advisor , investmen t bank or financia l advisor . Nothin g in thi s Agreemen t shall be construe d t o creat e any partnership , join t venture , agency , employment , or any othe r relationshi p betwee n th e parties . Excep t for DM Reach's provisio n o f DM Reach Service s t o Custome r in connectio n wit h th e Marketin g Spend , neithe r part y has th e authorit y t o ac t on behal f o f or t o ente r int o any contract , incur any liability , or make any representatio n on behal f o f th e othe r party , unless otherwis e expressly agreed t o in writin g signed by bot h parties . DM Reach has exclusive contro l over it s employees , representatives , agents , contractor s and subcontractors , and none o f th e foregoin g shall be deemed t o be employees of Custome r or eligibl e to participat e in any employmen t benefi t plans or othe r benefit s availabl e to Custome r employees . Custome r shall exercise no immediat e contro l over th e actua l means and manner o f DM Reach's performanc e under thi s Agreement , excep t t o th e exten t tha t Custome r

![](tm2533753d1_ex6-10x042.jpg)

4 2 /57 expect s th e satisfactor y completio n of th e DM Reach Service s under thi s Agreement . Eac h part y is responsibl e fo r it s respectiv e employees , representatives , agents , contractor s and subcontractors , and th e foregoing' s complianc e wit h th e terms of thi s Agreement . DM Reach is no t and shall no t be deemed t o be a dealer , broker , finder , intermediar y or otherwis e entitle d t o any brokerage , finder's , or othe r fe e or commission in connectio n wit h any purchase or sale of securitie s resultin g fro m DM Reach's general marketin g services . DM Reach shall be solely responsibl e fo r all local , stat e and federa l ta x liabilitie s arising fro m any income received under thi s Agreement , whethe r cash or stock. 3 . FEE S AND EXPENSES 3.1. Custome r is responsibl e for all cost s and expenses incurred on Customer' s behal f in connectio n wit h th e provision o f th e DM Reach Service s ("Expenses "). An y Expense s outsid e o f th e agreed budge t are subjec t to Customer' s prior writte n approval . Custome r is also responsibl e fo r it s own cost s and expenses incurred in connectio n wit h th e Offerin g on th e platform , and Custome r acknowledge s and agrees tha t th e platfor m charges fee s relate d t o th e Offerin g as set fort h in th e platform' s term s and conditions . Thes e platfor m fee s are completel y unrelate d to DM Reach's compensatio n as se t fort h in thi s Agreement. 3.2 . Budge t an d Marketin g Spend . 3.2.1 . As par t o f engagin g DM Reach , Custome r is authorizin g and directin g DM Reach t o allocat e th e marketin g and advertisin g budge t expende d during th e Customer' s marketin g campaign ("Marketin g Spend "). 3.2.2 . Partnershi p Program. Th e Partnershi p Progra m is an invitatio n based program in which Customer s may have th e opportunit y t o purchase advertisin g slot s in a variet y o f publication s subjec t to Customer' s agreemen t to th e program terms and condition s ("Partnershi p Program") as par t o f th e Marketin g Spend. Custome r acknowledge s tha t i t may be eligibl e fo r th e DealMake r Partnershi p Program , however DM Reach has sole contro l o f whethe r Custome r is admitte d t o th e Partnershi p Program . Custome r acknowledge s tha t DM Reach manages th e program and charges fee s for th e Partnershi p Program. Custome r explicitl y acknowledge s tha t DM Reach shall have sole discretio n t o terminat e Customer' s participatio n in th e Partnershi p Progra m fo r non - complianc e wit h Partnershi p Progra m terms and conditions . 3.2.3 . For Customer s eligibl e for th e Partnershi p Program , DM Reach shall have discretio n t o allocat e Marketin g Spen d during th e marketin g campaign , excep t fo r fee s in connectio n wit h th e placemen t of partnershi p advertisement s ("Partnershi p Fees. ") Onc e invoiced , Partnershi p Fee s are non - refundable . 3.2.4 . Custome r shall approve Partnershi p Fee s in accordance wit h required timelines by eithe r (a) executin g an authorizatio n for each placemen t ("Partnershi p Insertio n Order ") or (b) pre - approval of a bi - weekl y budge t for all Partnershi p Fee s ("Approve d Partnershi p Budget ") as follows: (a) Partnershi p Insertio n Orde r : Custome r shall authoriz e DM Reach in writin g via executio n of electroni c confirmatio n to incur Partnershi p Fees. DM Reach shall no t incur Partnershi p Fee s withou t th e writte n approved Partnershi p Insertio n Orde r fro m Customer . Custome r acknowledge s tha t Custome r must execut e Partnershi p Insertio n Orde r and

![](tm2533753d1_ex6-10x043.jpg)

4 3 /57 prepay DM Reach fo r all Partnershi p Fee s befor e DM Reach places an advertisemen t on Customer' s behalf . (b) Approve d Partnershi p Budge t : On a bi - weekly basis , Custome r shall provide writte n approval of a Partnershi p Budget. DM Reach shall have ful l discretio n t o allocat e Partnershi p Fee s for th e placemen t of partnershi p advertisement s up t o th e bi - weekl y Approve d Partnershi p Budget . Al l Marketin g Spen d up to th e agreed budge t amoun t will be charged directl y t o Customer' s provided paymen t method . 3.2.5 . Custome r acknowledge s tha t DM Reach or its affiliate s (a) may have an ownershi p interes t in some providers o f placemen t advertisements , detail s of which are availabl e upon Customer' s request ; and (b) as a resul t of DM Reach relationship s and negotiate d term s wit h various vendors , certai n benefit s may accrue to DM Reach or its affiliate s includin g bu t no t limite d t o additiona l revenue fro m certai n partnershi p placements . Unless Custome r expressly instruct s otherwise , DM Reach may use it s discretio n in deployin g Marketin g Spend , includin g bu t no t limite d t o approved Partnershi p Fees . 3.3 . Custome r Representation s . Custome r further acknowledge s that: 3.3.1 . Retur n on Marketin g Spend , Partnershi p spend and/o r advertisin g spend ("Return ") can vary greatl y wit h each Offerin g or campaign and may diffe r fro m historica l averages , bot h wit h respec t to DM Reach fee s and fee s for any thir d part y partner s introduce d by DM Reach or it s affiliates. Historica l data , averages and informatio n are no t a representatio n o f wha t can be achieved in any particula r Offerin g or campaign as each Offerin g and campaign is unique and influence d by numerous externa l factor s includin g bu t no t limite d t o th e Customer' s industry , th e Customer' s managemen t team , th e economic environmen t a t th e tim e o f an Offerin g and th e fund s availabl e for Marketin g Spen d and Partnershi p Fees . 3.3.2. Ther e are many marketin g strategie s and tools availabl e t o raise capital. Custome r is responsibl e for selectin g th e capita l raising approach tha t is bes t suite d t o Customer' s business . DM Reach and it s affiliate s canno t predic t and do no t guarante e tha t a marke t participan t will attai n a particula r result . Th e success o f an Offerin g depends on th e Customer' s own effort , motivation , commitmen t and follow - through. 3.3.3. Custome r may use th e marketin g asset s create d pursuan t t o thi s Agreemen t fo r purposes othe r tha n raising capital. For example Marketin g Spen d and Partnershi p Fee s may be used t o creat e valuabl e Custome r brand collateral , brand positioning , investo r mailin g list s and investo r analytics , regardless o f th e amoun t o f capita l raised. Customer shall be solely responsibl e fo r using th e marketin g asset s create d pursuan t to thi s Agreemen t fo r purposes othe r tha n raising capital . 3.3.4. DM Reach Service s may involve , among othe r things , communicatin g wit h thir d part y publisher s to secure advertisin g space for DM Reach Custome r ("Publishers "). Custome r agrees and warrant s tha t i t shall not , directl y or indirectly , or throug h a thir d party , contac t said Publisher s by any means and shall no t interfer e with , circumvent , attemp t t o circumvent , avoid or bypass DM Reach' s communicatio n wit h Publishers , interfer e wit h th e relationshi p betwee n DM Reach and Publisher s fo r th e purpose o f gainin g any benefit , whethe r such benefi t is monetar y or otherwis e or re - sell paid media or advertisin g placement s t o DealMake r Customer s withou t th e express writte n consen t of DM Reach .

![](tm2533753d1_ex6-10x044.jpg)

4 4 /57 3.4 Payment . Th e Custome r will be billed as set ou t in th e Terms. A t th e end o f th e mont h in which th e DM Reach Service s are delivered , paymen t will be automaticall y debite d fro m th e Customer' s bank accoun t or credi t card on file , wit h a receip t to be automaticall y delivered. Invoice s will be availabl e fo r th e Custome r to review upon request. In respec t o f Partnershi p Fee s only , such fee s shall be due and payable on or befor e th e due dat e on th e invoice ("Du e Date") using AC H or th e Client' s pre - authorize d paymen t metho d on file, unless state d otherwis e on th e Custome r Partnershi p Insertio n Order . DealMake r reserves th e righ t to charge th e Client' s pre - authorize d paymen t metho d on fil e fo r th e amoun t o f th e Partnershi p Fe e invoice in Arrear s (as define d below) . 3.5 . Pause d DM Reac h Services. Custome r may reques t tha t DM Reach Service s (and correspondin g Fees) be paused ("Paus e Date"). Custome r shall pay (a) any Partnershi p Fee s incurred prior t o th e Paus e Date ; and (b) DM Reach's monthl y service fee s for sixt y (60) days fro m th e Paus e Date. Whe n a campaign is paused , DM Reach may place th e campaign in a queue behind othe r marketin g Campaign s tha t are ready t o launch ("Launc h Queue "). Custome r acknowledge s tha t DM Reach may no t have staf f availabl e to relaunch a paused campaign on th e Customer' s dat e o f choice. Custome r campaign may be relaunche d once Customer' s campaign reaches th e beginnin g o f th e Launch Queue . 3.6 . Unpai d Invoice s . Notwithstandin g anythin g to th e contrar y in th e Agreement , in th e even t tha t Custome r fail s t o pay all outstandin g invoices pursuant to thi s Agreement, Custome r agrees tha t i t shall pay th e ful l amoun t o f th e outstandin g invoices from th e proceeds o f th e Offering , withi n seven (7) days o f th e disbursemen t o f such proceeds to th e Customer , plus applicabl e interest. I n th e even t tha t a Custome r paymen t fo r any DM Reach fe e fails , Custome r has fourtee n (14) days t o re – connec t thei r bank accoun t or credi t card and submi t paymen t for any outstandin g invoices. I n th e even t tha t paymen t fo r all outstandin g invoices is no t cleared withi n 14 days , all partnershi p advertisement s and DM Reach Service s will be paused unti l paymen t is received and th e Customer' s bank accoun t or credi t card authorizatio n is restored , excep t for non - paymen t of Partnershi p Fee s by Due Date , which shall resul t in immediat e cancellatio n o f th e advertisin g placements. In th e even t tha t Custome r fail s t o pay any invoice due and payable ("Arrears ") to DM Reach and such Arrear s are no t cleared or Custome r accoun t is no t brough t back int o good standin g withi n 30 days , all DM Reach Service s pursuan t t o thi s Agreemen t will be paused and Customer' s campaign will be placed a t th e end o f th e Launch Queu e unti l paymen t is received in full. Onc e paymen t is received in full , Customer' s campaign will move forwar d throug h th e Launch Queue. Custome r acknowledge s that marketin g assets create d usin g DM Reac h Service s shal l no t b e release d to Custome r unti l al l outstandin g invoice s an d Arrear s are pai d i n full. DM Reach shall have th e righ t t o registe r a lien on any asset s or propert y o f th e Custome r in respec t o f fee s owed and outstandin g to DM Reach for more tha n sixty (60) days. 4. WOR K PRODUC T OWNERSHIP An y copyrightabl e works , ideas , discoveries , inventions , patents , products , or othe r informatio n develope d in whole or in par t by DM Reach in connectio n wit h th e DM Reach Service s provided t o Custome r (collectivel y th e "Wor k Produc t ") will be work made for hire and th e exclusive propert y o f th e Customer . To th e exten t deemed no t to be work made for hire , DM Reach hereby assigns all Wor k Produc t and any and all intellectua l propert y right s relate d theret o t o Customer . Upon request , DM Reach will execut e all document s necessary t o confir m or perfec t Customer' s exclusive ownershi p o f th e Work Product . Withou t limitin g th e generalit y o f th e foregoing , all asset s and othe r creativ e works create d by DM Reach in th e provisio n o f th e DM Reach Service s and all dat a and analytic s in connectio n wit h th e DM Reach Service s shall be th e exclusive propert y o f th e Customer . Notwithstandin g any provision in thi s Agreemen t to th e contrary , (a) Work Produc t shall no t include , and DM

![](tm2533753d1_ex6-10x045.jpg)

4 5 /57 Reach shall be allowe d t o use , any and all audienc e dat a whatsoeve r including , withou t limitation , lookalik e data , investo r dat a and digita l footprints , targete d investor s and thei r dat a and digita l footprints , and th e like and (b) Custome r shall no t be permitte d t o use Work Produc t on competin g "Technolog y Platforms " withou t th e writte n consen t of DM Reach. A s used in thi s paragraph , "Technolog y Platforms " means capita l raising platform s tha t would complet e or replace any par t of th e DealMake r technolog y offering , includin g alternativ e order - takin g paymen t technology , and does no t include technolog y offering s tha t DealMake r does no t provide . 5. ADDITIONA L INDEMNIFICATION Notwithstandin g and withou t limitatio n o f any othe r provision o f thi s Agreement , and notwithstandin g whethe r such losses or damages are foreseeabl e or unforeseeable , DM Reach shall no t be liabl e under any circumstance s whatsoeve r fo r any breach by any othe r Custome r Partner , which ter m includes thir d part y consultants , agents , corporations , partnerships , trust s or any othe r entitie s involved in th e placemen t o f partnershi p advertisements , of securitie s laws or othe r rule o f any securitie s regulator y authority , fo r los t profit s or fo r special , indirect , incidental , consequential, exemplary , aggravate d or punitiv e losses or damages . Custome r agrees tha t it s liabilit y hereunde r shall be absolut e and unconditional, regardless o f th e correctnes s o f any representation s o f any thir d partie s and regardless of any liabilit y o f thir d partie s t o DM Reach or any o f th e Indemnifie d Partie s and shall accrue and become enforceabl e withou t prior demand or any othe r preceden t actio n or proceeding. Custome r shall ensure tha t all agreement s wit h th e Customer' s Partner s include th e followin g indemnity: "Partne r agrees t o indemnify , defen d and hold Custome r and any curren t or forme r officers , directors , employees , subsidiaries , affiliates , partners , agent s or contractor s ("Representatives ") harmless fro m any and all costs , demands , damages , losses , fees , expenses and liabilitie s (includin g attorneys ' fee s and costs) ("Losses ") as a resul t of any thir d partie s demands , regulator y investigations , causes o f action , losses , damages , liabilities , costs , fines , claims , class action s and expenses (includin g reasonabl e attorney' s fees) ("Claims ") in connectio n wit h th e services provided and th e conten t prepared by th e Partne r for th e Offering , unless Custome r is proven t o have been grossly negligent. " Th e Partie s hereby agree tha t DM Reach shall be a thir d part y beneficiar y o f such indemnit y provisions in th e Customer' s agreemen t wit h Partne r in respec t of any "Losses" suffere d by DM Reach relate d t o th e Partner' s services in respec t of th e Offering . Th e Partie s furthe r agree tha t thi s remedy shall no t be th e sole and exclusive remedy for DM Reach to recover any Losses agains t Custome r in respec t o f th e Agreement." Custome r furthe r agree s tha t wit h respec t to Publisher s wh o are retaine d by DM Reac h o n Customer' s behal f to plac e Customer' s advertisement s i n thir d part y publications , Custome r shal l indemnif y an d hol d harmles s Publisher s an d thei r Representative s wit h respec t to an y Claim s arisin g fro m Custome r conten t provide d directl y or indirectl y to Publisher . 6. GENERAL 6.1. Custome r No Unauthorize d Usage . Custome r acknowledge s tha t DM Reach Customer s mus t use DealMake r as th e platfor m fo r thei r Offering , and Custome r mus t execut e a separat e Orde r for m wit h Novatio n Solution s Inc. , o/ a DealMaker. 6.2 . Custome r acknowledge s tha t it is engagin g in a self - hoste d raise. Custome r is responsibl e fo r carrying ou t th e self - hoste d capita l raise and bears primary responsibilit y fo r th e success o f it s own Offering. Custome r understand s tha t DM Reach does no t and canno t make any guarantee s abou t

![](tm2533753d1_ex6-10x046.jpg)

4 6 /57 Customer' s campaign o f Offering . No languag e or provision in thi s Agreemen t or any relate d proposal shall be construe d as a guarante e or warrant y of any typ e by DM Reach , including , withou t limitation , th e success of th e Customer' s campaign or th e Offering , th e amoun t o f fund s raised in th e Offering , th e cost s associate d wit h th e capita l raised in an Offerin g or anythin g relatin g t o th e scope o f work or qualit y o f work by DM Reach on th e Customer' s campaign . 6.3 . Custome r understand s and acknowledge s tha t all changes t o marketin g asset s and marketin g collateral , includin g bu t no t limite d to , th e Customer' s websit e fo r th e Offerin g and all press releases , mus t be reviewed according t o th e terms o f Customer' s broker - deale r engagemen t agreement , where Custome r has retaine d a broker - dealer .

![](tm2533753d1_ex6-10x047.jpg)

4 7 /57 DEALMAKE R TRANSFE R AGENT LL C O/ A "DEALMAKE R SHAREHOLDE R SERVICES " CUSTOME R TERMS I f you are DealMake r Shareholde r Service s Customer , th e followin g additiona l term s also apply t o you . Thes e term s and condition s for DealMake r Transfe r Agen t LLC , O/ A "DealMake r Shareholde r Service s ("DMT A Terms") , along wit h th e Orde r Form and schedules attache d t o th e Orde r Form creat e a bindin g agreemen t by and betwee n th e Custome r who has signed th e Orde r For m ("DMT A Customer") , and DMTA , as o f th e Effectiv e Dat e ("DMT A Agreement"). DMT A Custome r may also be considere d a Custome r o f th e othe r DealMake r Entities , dependin g on th e services th e DMT A Custome r purchases. Wher e thes e DMT A Term s replace a provision in th e Terms , i t is so stated. I n th e even t o f a conflic t betwee n these DMT A Term s and th e Terms , th e DMT A Term s shall control: 1 . Mandat e DMT A is hereby appointe d as th e service provider for th e registe r o f securitie s issued by th e DMT A Custome r via th e online platfor m hoste d at dealmaker.tec h or as requeste d by th e DMT A Customer , othe r classes of Securitie s tha t may have been issued , from tim e t o tim e by th e DMT A Custome r (th e "Securities") . DMTA' s appointmen t shall tak e effec t upon receip t of a DMT A Custome r Boar d resolutio n in a for m acceptabl e to DMT A and upon DMTA' s acceptanc e of its mandat e as articulate d in th e DMT A Custome r Boar d resolution. Th e Securitie s may be issued by th e DMT A Custome r subjec t t o Regulatio n A , Regulatio n C F or Regulatio n D o f th e Securitie s Ac t of 1933. In some cases , in th e even t th e partie s agree , DMT A may ac t as sub - registe r fo r th e Securities , whereas th e registe r fo r certai n othe r o f th e DMT A Customer' s securitie s may be held by a differen t transfe r agent. DMT A may also ac t as DMT A Customer' s Dividen d Distributin g Agent , in th e even t th e DMT A Custome r confirm s in writin g such additiona l reques t (th e "DMT A Services"). 2 . DMT A Ter m & Terminatio n Term Notwithstandin g anythin g t o th e contrar y in any Agreement , th e DMT A Service s provided pursuan t t o thi s DMT A Agreemen t shall have a term of thirty - si x (36) month s ("DMT A Term") , commencing on th e Effectiv e Date , which DMT A Ter m shall automaticall y renew fo r successive three - yea r term s unless DMT A Custome r provides writte n notic e t o DMT A at leas t sixty days (60) prior t o th e completio n o f th e DMTA Term. Termination Notwithstandin g anythin g t o th e contrar y in thi s Agreement , th e followin g terminatio n provision s shall apply t o DMT A Services: Earl y Termination.

![](tm2533753d1_ex6-10x048.jpg)

4 8 /57 I n th e even t tha t DMT A Custome r terminate s thi s DMT A Agreemen t prior t o th e end o f th e DMT A Ter m ("Earl y Termination") , DMT A Custome r shall pay th e DMT A a break fe e ("Brea k Fee.") Th e Brea k Fe e shall be equivalen t t o th e remainin g fee s due for th e balance of th e DMT A Term , pursuan t t o thi s DMT A Agreement , calculate d as follows : (a) Month s remainin g in th e DMT A Term shall be equivalen t t o th e DMT A Ter m minus the number o f month s of th e DMT A Ter m expired up to th e Earl y Terminatio n dat e requeste d by DMT A Custome r ("Month s Remaining"); (b) Month s Remainin g multiplie d by record maintenanc e fee s (pro - rate d monthly) plus Month s Remaining multiplie d by th e Shareholde r Service s Managemen t Porta l Monthl y Fee . Thi s DMT A Agreemen t may be terminate d by DMT A (i) if th e DMT A Custome r is in breach o f thi s Agreemen t and does no t remedy such breach within sixty (60) days notice , in writing , or (ii) upon ninet y (90) days ' notice , in writing , being given to DMT A Customer. Thi s DMT A Agreemen t may be terminate d by eithe r th e DMT A Custome r or DMT A immediatel y upon notificatio n or writte n confirmatio n of any bankruptcy , receivership , or dissolutio n o f eithe r party. Withi n thirt y (30) days of th e terminatio n of thi s DMT A Agreemen t and provided tha t th e DMT A Custome r is in compliance wit h all o f th e terms of thi s Agreement , DMT A shall deliver over t o th e DMT A Custome r (or t o such thir d party as th e DMT A Custome r otherwis e requests) th e Registers , share certificate s and any othe r document s connecte d wit h th e business o f th e DMT A Custome r as reasonabl y requested . 3 . Statu s of DMTA DMT A is a stoc k transfe r agen t registere d wit h th e Securitie s and Exchang e Commission. DMT A will no t custody , hold , manage , possess or otherwis e handle securities. DMT A is no t providin g escrow services t o DMT A Customer. 3.1 . DMT A Customer' s Securitie s and Appointmen t o f DMTA "Securities" , as used in thi s Agreemen t shall mean th e equity , deb t and revenue share securities , includin g any warrant s and options , o f DMT A Custome r issued. DMT A Custome r affirms , represent s and warrant s tha t i t has provided to DMT A all applicabl e dat a concernin g it s Securitie s t o be covered by thi s Agreemen t and associate d holder positions. DMT A Custome r hereby certifie s tha t it has take n such actio n required t o appoin t DMT A t o provide th e services set ou t in thi s Agreement , which actio n shall remain valid so long as thi s Agreemen t is in forc e and effect . 3.2 . Managemen t o f Holders Registers , Records and Transfe r o f Securitie s DMT A shall keep and maintai n an electroni c registe r of holders and registe r o f transfer s o f Securities . Subjec t to any laws and governmen t regulation s in forc e fro m tim e t o tim e and t o any general or

![](tm2533753d1_ex6-10x049.jpg)

4 9 /57 particula r instruction s as may from tim e to tim e be given to i t by th e DMTA Customer , and subjec t t o any othe r writte n agreemen t applicabl e to DMT A from tim e t o time , DMT A shall: 1.1 . make such entrie s fro m tim e t o tim e in th e Registe r as are necessary in order tha t th e account s of each holder o f Securitie s be properly and accuratel y kep t and transfer s o f Securitie s properly recorded; 1.2 . record on th e Registe r th e particular s o f all transfer s o f Securities; 1.3 . furnis h to th e DMT A Customer , upon th e reasonabl e reques t and a t th e expense o f the DMT A Customer , such statements , lists , entries , informatio n and material , concernin g transfers and othe r matters , as are maintaine d or prepared by it pursuan t hereto ; and shall be th e sole person authorize d to add , modif y or remove Securitie s fro m th e Register. 3.3 . Shar e Certificates 1 . Securitie s issued followin g th e dat e hereo f shall be held in "book entry " for m only . "Boo k entry " means tha t ownershi p interest s shall be recorded and kep t only on th e books and records o f DMT A Custome r (including , i f applicable , in Direc t Registratio n Statemen t form). No physical certificate s shall be issued or received by DMTA. Th e Securitie s covered by thi s Agreemen t are no t DT C eligibl e unless explicitl y state d otherwis e in th e Orde r Form. 2 . Th e DMT A Customer hereby confirm s tha t it has reviewe d it s articles/certificat e o f incorporation , by - laws and other governin g document s and such document s allow fo r th e issuance o f book - based securities . Th e DMT A Custome r acknowledge s and agrees tha t upon receip t o f writte n instruction s from th e DMTA Custome r to th e DMTA , DMT A may issue such book - base d positions , as represente d by DR S advice or otherwise , on all new share issuances and/o r transfers. I f a shareholde r or it s representativ e request s a change to a physical share certificate , DMT A shall convert said share certificat e to book entr y form and make th e requeste d change. 3 . Th e DMT A Custome r shall no t issue any share certificat e withou t such certificat e being countersigne d by DMT A in its capacit y as Transfe r Agent . 4 . I n th e case o f th e loss , thef t or destructio n o f any share certificate , befor e a replacemen t certificat e will be issued , DMT A mus t receive : a . evidence satisfactor y t o DMT A of th e loss , thef t or destructio n o f such certificate ; and

![](tm2533753d1_ex6-10x050.jpg)

5 0 /57 b . a lette r of indemnit y fro m th e shareholde r and th e DMT A Custome r in a for m acceptabl e t o DMTA . 5 . Th e DMT A Customer represent s and warrant s tha t all Securitie s t o be covered by thi s Agreemen t tha t are issued and outstandin g on th e Effectiv e Date are issued and outstandin g as full y paid and non - assessabl e and tha t wit h respec t t o futur e allotment s and issuances o f Securities , DMT A shall be entitle d to regard such Securitie s as full y paid and non - assessable. 6 . DMT A shall be entitle d t o trea t as valid any shareholde r data , share certificat e or DR S positio n fo r Securitie s purportin g t o have been issued or prepared by or on behal f o f th e DMT A Custome r prior to th e Effectiv e Dat e o f thi s Agreemen t and th e DMT A Custome r shall indemnif y and save harmless DMTA , it s officers , directors , employees , successors , assigns and agent s from any liabilit y or claims tha t may be made agains t the m by reason o f DMT A treatin g any such shareholde r data , certificat e or DR S positio n as valid . DMT A is hereby expressly relieve d from any dut y or obligatio n t o (a) correc t incomplet e shareholde r dat a prepared on behal f o f th e DMT A Custome r prior t o th e Effectiv e Dat e o f thi s Agreement ; and (b) verif y th e signatur e or th e authorit y t o sign of th e person or persons purportin g to sign any such certificat e on behal f o f th e DMT A Custome r or on behal f o f any other institutio n tha t was appointe d th e Transfe r Agen t o f th e Securitie s prior t o the Effectiv e Date . 4 . Dividen d Distributio n Agen t (if requeste d b y DMT A Customer) 4.1 . I n th e even t tha t DMT A Custome r appoint s DMT A as agen t t o distribut e t o holders o f Securitie s dividend s as may from tim e to tim e be declared by th e board o f director s o f the DMT A Customer , DMT A agrees to accep t such appointmen t subjec t to terms t o be agreed upon by th e parties . 4.2 . DMT A Custome r shall provide securit y holder informatio n t o DMT A in order fo r DMT A Custome r t o contac t such holders and obtai n th e informatio n necessary t o make dividen d payment s or pay amount s owing under deb t securities . 4.3 . I f directe d by DMT A Customer , DMT A may provide administrativ e reconciliatio n services fo r investo r ta x form completio n bu t DMT A Custome r is solely responsibl e fo r submittin g required ta x form s t o th e IRS . 4.4 . I f DMT A Custome r chooses to appoin t DMT A as th e Dividen d Distributio n Agen t in accordance wit h thi s section , DMT A Custome r acknowledge s tha t DMT A is no t th e dividen d distributio n paying agent. DMT A shall disburse dividend s in accordance herewit h upon receiving writte n direction fro m th e DMT A Custome r and a certifie d copy o f a resolutio n of th e board o f director s o f th e DMT A Custome r declarin g such dividend s bu t all payment s shall be made by DMT A Custome r fro m DMT A Custome r funds .

![](tm2533753d1_ex6-10x051.jpg)

5 1 /57 4.5 . A t leas t one business day befor e th e dat e on which such dividend s are payable , the DMT A Custome r shall deliver to DMT A by electroni c transfe r or certifie d cheque , funds sufficien t t o pay such dividends , or make such othe r arrangement s fo r th e provision of fund s as may be agreeabl e betwee n th e parties . 4.6 . I f any fund s are received by DMT A in th e form o f uncertifie d cheques , DMT A shall be entitle d t o delay th e tim e fo r release o f such fund s unti l such uncertifie d cheques shall be determine d t o have cleared th e financia l institutio n upon which th e same are drawn . 5 . Othe r Services 5.1 . DMT A shall perfor m such othe r services normally inciden t wit h th e role o f Transfe r Agent and Registra r or Dividen d Disbursin g Agent , if applicable , as th e DMT A Custome r may reques t in writin g fro m tim e t o tim e for such fee s as may be agreed t o from tim e to tim e betwee n th e parties , in accordance wit h the term s hereof . 5.2 . DMT A may , in connectio n wit h th e services described in thi s Agreement , engage , a t DMTA' s sole expense (unless agreed in writin g by DMT A Customer) , withou t notice , subcontractors , agent s and service providers in it s sole and absolut e discretion. DMT A Custome r agrees tha t DMT A is authorize d t o appoin t such individual s and entitie s and do all othe r acts required t o carry ou t th e Agreement. 5.3 . DMT A may be required t o perfor m othe r work on behal f o f th e DMT A Custome r wit h respect t o new or existin g industr y regulation s (for example , relate d to provincia l Securitie s Acts , th e U.S. Securitie s Exchang e Ac t o f 1934 ("1934 Act") , th e Interna l Revenue Code , stat e escheatmen t or unclaime d propert y legislatio n or other) . DMT A is hereby authorized , a t its discretio n and a t th e expense of th e DMT A Customer , where applicable , to perfor m such work. 5.4 . Th e DMT A Custome r hereby acknowledge s and authorize s DMT A t o use th e DMT A Customer' s online DealMake r Shareholde r online porta l to communicat e wit h shareholder s fo r th e purpose o f deliverin g th e DMT A shareholde r Service s described herein , includin g bu t no t limited t o (i) uploadin g book entr y statements and (2) respondin g t o shareholde r actio n requests . 5.5 . Th e DMT A Custome r acknowledges and agrees tha t DMT A is no t responsibl e fo r th e escheatmen t o f unclaime d property, includin g securitie s or fund s issued and/o r held by DMT A as a resul t o f DMT A performin g its services as Transfe r Agen t and Disbursin g Agen t ("Unclaime d Property"), which may be required under any stat e laws or th e 1934 Act . DMTA' s role is limite d t o completin g tw o los t holder searches pursuan t t o SE C rule 17 Ad - 1 7 ("Los t Holder Searches") . Th e DMT A Custome r acknowledge s tha t i t is solely responsibl e for all obligation s wit h respec t t o Unclaime d Propert y tha t is in th e possession o f DMT A at any tim e and agrees tha t DMT A does no t offe r escheatmen t services. DMT A shall have no responsibilit y to provide additional services regardin g los t holder account s fo r DMT A Customer' s Securities .

![](tm2533753d1_ex6-10x052.jpg)

5 2 /57 5.6 . Notwithstandin g th e foregoing , in th e even t one or more shareholder s is no t responsive t o th e Los t Holder Searches , DMT A Custome r may retai n DMT A to conduc t additional databas e searches t o locat e th e shareholder , a t th e DMT A Customer' s sole expense , in accordance wit h DMTA' s the n applicabl e fee s ("Additiona l Searches") . DMT A Custome r acknowledge s tha t i t remains solely responsibl e fo r all obligation s wit h respec t t o Unclaime d Propert y even if DMT A is directe d t o conduc t Additiona l Searches. 6 . Fee s an d Expenses Thi s sectio n applies only t o th e provision o f DMT A Service s and in th e even t o f a conflict , supersedes any prior paragraph s concernin g Fee s containe d in thi s Agreement: 6.1.Th e DMT A Custome r shall pay th e fee s outline d on th e Orde r For m fo r th e services described therein . Fee s are subjec t t o revision by DMT A from tim e to time DMT A Custome r shall reimburse DMT A fo r all cost s and expenses incurred in connectio n herewith. Withou t limitin g th e generalit y o f th e foregoin g and notwithstandin g any othe r provision of thi s Agreemen t or of any fees , th e DMT A Custome r agrees t o pay DMT A such additiona l compensation , costs and expenses as are agreed betwee n th e partie s t o be warrante d by any additiona l time , effor t and/o r responsibilit y incurred or expende d by DMT A in order t o comply wit h any laws or regulation s it may be subjec t to as Registrar, Transfe r Agen t or as dividen d distributio n disbursin g agent , including , withou t limitation, unclaime d propert y legislatio n or futur e imposed regulations. 6.2 . Al l DMT A Fee s are incurred immediatel y at tim e of service and non - refundable. Th e DMT A Custome r will be bille d as set ou t in th e Terms . 6.3 . Al l ou t of pocke t costs and expense recoveries are payable in advance , unless otherwise agreed t o in writing . 6.4 . I n th e even t tha t a corporat e actio n or reorganizatio n occurs , th e DMT A Custome r agrees t o compensat e DMT A a t a rat e based on th e terms of th e transactio n and th e duties required o f DMTA . 6.5 . I n th e even t th e DMT A Custome r default s in its paymen t obligation s t o DMT A ("Paymen t Default") , DMT A shall have th e right , commencing thirt y (30) days followin g writte n notificatio n to th e DMT A Custome r of Paymen t Defaul t and unless such Paymen t Defaul t has been remedied , t o immediatel y suspend service or terminat e thi s Agreement , subjec t to DMTA' s right s and recourses under thi s Agreemen t or applicabl e law . 7 . DMT A Customer' s Responsibilit y Fo r Documents 7.1 . Th e DMT A Custome r agrees tha t it will promptl y furnis h t o DMT A fro m tim e t o time : 7.1.1 . certifie d copies o f all articles , any amendment s theret o and all relevan t By - laws; 7.1.2 . certifie d copies o f all resolution s or othe r authorizin g document s allottin g or providin g for th e issuance of Securities;

![](tm2533753d1_ex6-10x053.jpg)

5 3 /57 7.1.3 . a curren t lis t o f th e director s of th e DMT A Custome r upon any change t o thi s information ; and 7.1.4 . tha t number o f unissued Shar e certificate s as is necessary fo r DMT A t o perfor m it s obligation s hereunde r from tim e to time 7.2 . DMT A Custome r agrees to direc t its broker - dealer , as applicable , t o share required onboardin g document s wit h DMT A upon request . 8 . DMT A Customer' s Responsibilit y Fo r Signatories 8.1 . Th e DMT A Custome r shall deliver evidence of th e appointmen t o f it s signatorie s as such evidence may be requeste d fro m tim e t o tim e by DMTA . Th e DMT A Custome r shall promptly advise DMTA , in writing , as to any changes in th e authorize d signatorie s and the director s o f th e DMT A Custome r and DMT A shall no t be charged wit h notic e of any such change in authorize d signatorie s unless and unti l such notic e is provided in writin g in accordance wit h th e provisions herein wit h respec t t o Notice . 8.2 . DMT A may ac t upon any email or certificat e or othe r documen t believe d by i t t o be genuin e and t o have been signed by th e proper person or persons . DMT A may refuse t o process any requeste d transfe r or perfor m any othe r ac t requeste d o f it if it is no t satisfied as t o th e propriet y o f th e reques t or th e sufficienc y of th e evidence provided in suppor t of such request . 9 . Authorizatio n T o Act O n Electroni c Instructions 9.1 . Th e DMT A Custome r hereby direct s DMT A to accep t and ac t upon direction s including treasur y direction s sen t t o DMT A via e - mail or via communication s initiate d by DMT A Custome r throug h th e DMT A Customer' s online porta l licensed from DealMaker.tech. 9.2 . Th e DMT A Custome r acknowledge s that: E - mai l is no t a secure means o f communication . Som e o f th e risks of e - mail communication s are that :  someone could intercept , read , retransmi t or alte r a communication ;  e - mails can be lost , delivere d late , or not received ; and  someone can send unauthorize d e - mails that appear to emanat e fro m a secure source . 9.3 . I n reviewin g direction s received via email , DMT A shall rely upon the customar y signatur e block o f th e individua l authorize d t o sign for th e DMT A Customer , as provided by th e DMT A Customer , fro m tim e t o time. I n reviewin g directio n received via DMT A Customer' s deal portal , DMT A shall rely upon th e user credential s customaril y associate d wit h th e DMT A Customer' s account.

![](tm2533753d1_ex6-10x054.jpg)

5 4 /57 9.4 . DMT A shall be entitle d t o act upon any directio n received via e - mail or DealMaker.tec h tha t DMT A believes to be genuine . 9.5 . DMT A retain s th e right , at all times , to refus e to process any directio n where DMTA question s th e legitimac y of th e direction . Wher e DMT A question s th e legitimac y o f a direction , DMT A shall make a good fait h effor t to promptl y confir m th e legitimac y of the direction , which may include requestin g an originall y signed direction . DMT A shall not be liabl e to th e DMT A Custome r or any part y fo r any losses caused by DMTA' s refusa l t o act on a directio n tha t DMT A is no t able t o confir m t o be legitimate. 10 . DMTA' s Reservatio n Of Rights 10.1 . DMT A shall no t incur any liabilit y in refusin g in good fait h t o affec t any transfe r which in it s judgmen t is improper or unauthorized. 10.2 . DMT A shall retai n all right s and be entitle d to: 10.2.1 . refus e t o act , and shall no t be liabl e for refusin g to act , unless i t has received clear instruction s and/o r documentatio n and sufficien t tim e to give effec t to such instruction s and/o r documentation; 10.2.2 . refus e th e transfe r o f any Securitie s unti l such tim e as DMTA is satisfied , actin g reasonably , that : 10.2.2.1 . th e share certificate , if applicable , presente d to DMT A is valid; 10.2.2.2 . th e endorsemen t on th e Shar e Certificat e or DR S statemen t or appended stoc k power of attorney , as applicable , is genuine ; and 10.2.2.3 . th e transfe r requeste d is properly and legally authorized. 10.2.3 . trea t as valid any shareholde r dat a or share certificat e purportin g t o have been issued by or on behal f of th e DMT A Custome r prior to th e dat e o f thi s Agreement , as se t ou t in sectio n above; 10.2.4 . no t transfe r any Securit y if such Securit y is subjec t t o any restrictio n or prohibitio n on transfer , and DMT A shall no t be liable t o DMT A Custome r or any othe r part y fo r refusin g toaffec t any such transfer;

![](tm2533753d1_ex6-10x055.jpg)

5 5 /57 10.2.5 . refus e t o act , and shall no t be liabl e for refusin g to ac t if , due t o a lack of informatio n or fo r any othe r reason whatsoever , DMTA , in its sole judgment , determines tha t such ac t migh t cause i t t o be in non - complianc e wit h any applicabl e anti - money launderin g or anti - terroris t legislation , regulatio n or guideline . 10.2.5.1 . Further , should DMTA , in its sole judgment , determin e a t any tim e tha t it s actin g under thi s Agreemen t has resulted in its being in non - complianc e wit h any applicabl e anti - money launderin g or anti - terrorist legislation , regulatio n or guideline , the n DMT A shall have th e righ t to resign on 10 days' writte n notic e to th e DMT A Customer , provided tha t (i) DMTA' s writte n notic e shall describe th e circumstance s o f such non - compliance ; and (ii) i f such circumstance s are rectifie d to DMTA' s satisfactio n withi n such 10 day period , the n such resignatio n shall no t be effective ; and 10.3 . DMT A shall be under no obligatio n t o prosecut e or defen d any actio n or sui t in respec t o f it s agency relationshi p under thi s Agreemen t bu t will do so at th e reques t o f th e DMT A Customer , provided tha t th e DMT A Custome r furnishe s indemnit y and fundin g satisfactor y t o DMTA , acting reasonably , agains t any liability , cost or expense which migh t be incurred . 11 . Lega l Advic e 11.1 . DMT A is hereby authorized , at its discretio n and at th e expense o f th e DMT A Custome r t o refe r all document s or request s relatin g to any transfer s or any othe r matters contemplate d by thi s Agreemen t or requeste d to be performe d pursuan t to thi s Agreement to th e DMT A Customer' s or DMTA' s legal counsel fo r advice , and DMT A shall be entitled bu t no t required t o rely on such advice. DMT A will , in all cases , endeavor to consul t wit h th e DMT A Custome r prior to engagin g outsid e counsel , unless as otherwis e required by a regulator y body . 12 . Data Access By Thir d Parties 12.1 . DMT A Custome r agrees tha t inspectio n of Securitie s records and Register s on th e systems o f DMT A may be subjec t t o th e inspectio n right s of securitie s regulator y authoritie s includin g th e Securitie s and Exchang e Commission . 12.2 . For thi s purpose , DMT A is hereby authorize d to make Securitie s and holder Registe r dat a availabl e t o industr y third - part y systems , bot h directl y and via an integrate d API , includin g bu t no t limite d t o DMTA s and securitie s exchanges , t o enable the m to obtai n informatio n abou t th e DMT A Customer' s Securities , paymen t histor y o f Securities , confirmation s of holders ' ownershi p positions , among others. 13 . Warrantie s an d Disclaimer

![](tm2533753d1_ex6-10x056.jpg)

5 6 /57 13.1 . Mutua l Warranties: Eac h part y to thi s Agreemen t represent s t o th e othe r tha t (i) i t has th e righ t and authorit y to ente r int o thi s Agreemen t and t o perfor m all of it s respectiv e obligations ; (ii) th e Agreemen t has been duly execute d and delivere d and constitute d a valid , bindin g agreemen t enforceabl e in accordance wit h it s terms ; (iii) no othe r person is required t o authoriz e th e party' s execution , delivery or performanc e o f th e Agreement ; and (iv) execution , delivery and performanc e o f thi s Agreemen t does no t violat e th e term s or condition s of any othe r agreemen t to which i t is a part y or by which i t is otherwis e bound. 14 . Warrantie s By DMT A Customer 14.1 . DMT A Custome r warrant s and represent s to DMT A tha t i t will provide complet e and accurat e informatio n and records wit h respec t to th e Securities , th e holders thereo f and th e restriction s applicabl e t o transfe r of th e Securitie s (includin g th e date s tha t any such restriction s are no longer applicable. 14. 2 I n th e even t o f a breach of any of th e DMT A Customer' s warrantie s or responsibilitie s herein , DMT A will have th e righ t a t it s sole discretio n t o suspend DMT A Service s i f deemed necessary by DMT A t o preven t or eliminat e difficultie s in th e provisio n of DMT A Service s pursuan t t o thi s Agreemen t or t o preven t potentia l litigation. 14.3 . Disclaime r B y DMTA: Excep t as expressly set fort h in thi s Agreement , DMT A makes no representatio n or warrant y or any kind whethe r express , implied , or statutory. 15 . Limitatio n of Liabilit y Thi s sectio n applies only t o th e provision o f DMT A Service s and in th e even t o f a conflict , supersedes any prior paragraph s concernin g LImitatio n o f Liability containe d in thi s Agreement: 15.1 . Limit s O n Damages. DMT A shall no t be liabl e for any actio n take n or omitte d t o be take n by DMT A under or in connectio n wit h thi s Agreement , excep t for losses caused principall y and directl y by DMTA' s gross negligence , fraud, bad fait h or willfu l misconduct. Notwithstandin g any othe r provision in thi s Agreement , DMT A shall not , under any circumstances , be liabl e t o DMT A Custome r fo r special , indirect , incidental , consequential, exemplary , aggravate d or punitiv e damages arising ou t o f or relate d t o th e transaction s contemplate d under thi s Agreement , includin g bu t no t limite d t o los t profits , loss o f business or holder claims. 15.2 . Cap on LIability. Notwithstandin g any othe r provisio n o f thi s Agreement , DMT A Custome r agrees tha t DMTA' s tota l liabilit y arising ou t of or relate d to thi s Agreement , regardless o f whethe r th e actio n or claim is based on contract , tort , warrant y or otherwise , shall be limited t o the amoun t o f fee s paid by th e DMT A Custome r t o DMT A in th e twelv e (12) month s immediately precedin g th e firs t receip t by DMT A o f notic e o f th e claim. 15.3 . Notwithstandin g and withou t limitatio n o f any othe r provisio n o f thi s Agreement , and notwithstandin g

![](tm2533753d1_ex6-10x057.jpg)

5 7 /57 whethe r such losses or damages are foreseeabl e or unforeseeable, DMT A and each Indemnifie d Part y shall no t be liabl e under any circumstances whatsoeve r fo r any breach by any othe r person , which ter m includes corporations, partnerships , trust s or othe r entities , o f securitie s laws or othe r rule o f any securities regulator y authority , for los t profit s or for special , indirect , incidental , consequential, exemplary , aggravate d or punitiv e losses or damages . DMT A Custome r agrees tha t it s liabilit y hereunde r shall be absolut e and unconditional, regardless of th e correctnes s o f any representation s o f any thir d partie s and regardless of any liabilit y o f thir d partie s to any of th e Indemnifie d Partie s and shall accrue and become enforceabl e withou t prior demand or any othe r preceden t actio n or proceeding . 15.4 . For so long as th e DMT A Custome r is a clien t of DMTA , th e DMTA Custome r undertake s t o advise DMT A in writin g as soon as reasonabl y practicabl e in th e even t tha t th e DMT A Customer becomes , or ceases to be , a reportin g DMT A Custome r wit h th e Unite d State s Securitie s and Exchang e Commission . 15.5 . Th e provision s o f thi s sectio n shall survive th e resignatio n or removal o f DMT A and th e terminatio n o f thi s Agreement. 16 . Miscellaneous 16.1 . No Implie d License. DMT A Custome r has no right , titl e or interes t in th e technolog y used and th e DMT A Service s or by thir d partie s engage d by th e DMTA. Thi s Agreemen t is no t intende d and will no t be construe d to confe r upon eithe r part y any license right s t o any patent , trademark , copyright , or othe r intellectua l propert y right s o f eithe r part y heret o or any othe r right s o f any kind no t specificall y conferre d in thi s Agreement . 16.2 . No Underwriting . DMT A Custome r agrees tha t DMT A is no t actin g as an underwrite r o f any Securitie s offering , nor as a broker or dealer on any Securitie s transaction. 16.3 . No Investmen t Advice. DMT A Custome r agrees tha t DMT A is no t providin g investmen t advice , does no t make any Securitie s recommendation , and does no t solici t th e offe r or sale o f Securitie s t o any investo r or DMT A Customer . 16.4 . No Legal or Accountin g Advice. DMT A Custome r agrees tha t DMT A does no t provide any legal or accountin g advice , includin g bu t no t limite d to legal advice or recommendation s wit h respec t t o th e vesting , conversion or expiry of any securitie s (collectivel y "Conversio n Events"). DMT A Custome r shall rely solely on it s own professional advisors as it deems appropriat e t o do so , includin g bu t no t limite d t o matter s in relatio n t o Conversio n Events. DMT A reserves th e righ t t o seek legal advice as needed and in it s sole discretion , as se t ou t in thi s Agreement.

## Ex1A-11

**Exhibit 11.1**

**Consent of Independent Registered Public Accounting Firm**

We hereby consent to the use of our report dated April 30, 2025 on the consolidated financial statements of Cytonics Corporation and Subsidiary as of December 31, 2024 and 2023 and for each of the two years in the period ended December 31, 2024 included in this Regulation A Offering Statement of Cytonics Corporation on Form 1-A.

---

| |
|:---|
| /s/ Salberg & Company, P.A. |
| SALBERG & COMPANY, P.A. |
| Boca Raton, Florida |
| January 12, 2026 |

---

## Ex1A-12

**Exhibit 12.1**

![](logo-1.jpg)

info@solonlaw.com<br> 619-254-4459<br> www.solonlaw.com

Cytonics Corporation

658 West Indiantown Road, Suite 214

Jupiter, FL 33458

January 12, 2026

<u>Re: Form 1-A Offering Statement</u>

Ladies and Gentlemen:

Solon Law, PC has acted as counsel to Cytonics Corporation, a Florida corporation (the "Company"), in connection with the preparation and filing with the Securities and Exchange Commission of a Regulation A Offering Statement on Form 1-A (the "Offering Statement") relating to the sale by the Company of up to 8,000,000 shares of common stock for total potential gross proceeds of $40,000,000, and up to 1,600,000 additional shares of common stock being offered as investment bonuses. This opinion is being delivered in accordance with the requirements of Part III of Form 1-A. The shares of common stock described above may collectively be referred to herein as the "shares" and each, individually, as a "share."

In rendering this opinion, we have examined (i) the Offering Statement and the exhibits thereto, (ii) certain resolutions of the Company, relating to the issuance and sale of the shares, and (iii) such other records, instruments and documents as we have deemed advisable in order to render this opinion. In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies and the authenticity of the originals of such latter documents. As to certain factual matters, we have relied upon resolutions and representations of the management of the Company and have not sought independently to verify such matters.

Based on the foregoing, we are of the opinion that when sold and issued against payment therefor, as described in the Offering Statement, the shares will be validly authorized, legally issued, fully paid and non-assessable.

Our opinion herein is expressed solely with respect to the Florida Business Corporation Act, as currently in effect, and we express no opinion as to whether the laws of any jurisdiction are applicable to the subject matter hereof. No opinion is being rendered hereby with respect to the truth, accuracy or completeness of the Offering Statement or any portion thereof.

The information set forth herein is as of the date hereof. We assume no obligation to supplement this opinion letter if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed herein after the date hereof. Our opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the shares, the Offering Statement, or the circular included therein.

We hereby consent to the filing of this opinion as an exhibit to the Offering Statement. In giving such consent, we do not believe that we are "experts" within the meaning of such term as used in the Securities Act of 1933 or the rules and regulations of the Commission issued thereunder with respect to any part of the Offering Statement, including this opinion as an exhibit or otherwise.

---

| |
|:---|
| &nbsp;&nbsp;Sincerely, |
| &nbsp;&nbsp;/s/ Solon Law |
| &nbsp;&nbsp;SOLON LAW, PC |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 1-A

### REGULATION A OFFERING STATEMENT
### UNDER THE SECURITIES ACT OF 1933

### Item 1. Issuer Information

**Exact name of issuer:** Cytonics Corp

**Jurisdiction of Incorporation/Organization:** FL

**Year of Incorporation:** 2006

**CIK:** 0001421744

**I.R.S. Employer Identification Number:** 20-8883869

**Primary Standard Industrial Classification Code:** 2836

**Total number of full-time employees:** 1

**Total number of part-time employees:** 0

**Address of Principal Executive Offices:** 658 W. INDIANTOWN ROAD SUITE 214, —, JUPTER, FL 33458

**Company Phone:** 443-827-8135

**Person to contact:** Arden Anderson, Esq.

### Financial Statements

**Balance Sheet Information**

| Metric                                   | Amount      |
|:---|:---|
| Cash and Cash Equivalents                | $2562193.00 |
| Investment Securities                    | $0.00       |
| Accounts and Notes Receivable            | $50000.00   |
| Property, Plant and Equipment (PP&E)     | $0.00       |
| Total Assets                             | $2871241.00 |
| Accounts Payable and Accrued Liabilities | $1019799.00 |
| Long-Term Debt                           | $0.00       |
| Total Liabilities                        | $1019799.00 |
| Total Stockholders' Equity               | $1851241.00 |
| Total Liabilities and Equity             | $2871241.00 |

**Statement of Comprehensive Income Information**

| Metric                                    | Amount       |
|:---|:---|
| Total Revenues                            | $130000.00   |
| Costs and Expenses Applicable to Revenues | $4566383.00  |
| Depreciation and Amortization             | $0.00        |
| Net Income                                | $-4430334.00 |
| Earnings Per Share - Basic                | -0.37        |
| Earnings Per Share - Diluted              | -0.37        |

**Auditor Information**

| Metric          | Amount               |
|:---|:---|
| Name of Auditor | Salberg & Company PA |

### Outstanding Securities

| Class                   |   Outstanding |     CUSIP | Publicly Traded   |
|:---|---:|---:|:---|
| Common Stock            |      13858460 | 000000000 | CYTONCOM9         |
| Initial Preferred Stock |        150000 | 000000000 | CYTONPFDI         |

### Item 2. Issuer Eligibility
- [x] The issuer certifies that all of the statements in this part are true.

### Item 3. Application of Rule 262
- [x] The issuer certifies that it is not disqualified and has not been involved in any disqualifying event.

### Item 4. Summary Information Regarding the Offering

**Tier:** Tier2

**Financial Statement Status:** Audited

**Type of Securities Offered:** Equity (common or preferred stock)

**Is this a delayed or continuous offering?** Yes

**Was or is the offering to take place within one year after qualification?** Yes

**Was or is the offering to commence within two days after qualification?** No

**Is this a best efforts offering?** Yes

**Was there any solicitation of interest?** No

**Are there any resale securities by affiliates of the issuer?** No

**Offering Amounts**

| Description                                                     | Amount       |
|:---|:---|
| Number of securities offered                                    | 9600000      |
| Number of securities outstanding                                | 13858460     |
| Price per security                                              | $5.00        |
| Issuer's aggregate offering price                               | $49400000.00 |
| Aggregate offering price of securities held by security holders | $0.00        |
| Aggregate price of securities offered concurrently              | $6220427.00  |
| Total aggregate offering price                                  | $55620427.00 |

**Anticipated Fees**

| Service Provider   | Name                 | Fees      |
|:---|:---|:---|
| Auditor            | Salberg & Company PA | $50000.00 |
| Legal              | Solon Law            | $40000.00 |
| Promoters          | None                 | $0.00     |

**Estimated Net Proceeds to the Issuer:** $39059000.00

### Item 5. Jurisdictions in Which Securities are to be Offered

AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY

### Item 6. Unregistered Securities Issued or Sold Within One Year

**Name of Such Issuer:** Cytonics Corporation

**Title of Securities Issued:** Common Stock

**Total Amount of Securities Issued:** 2305444

**Amount of such securities sold by principal security holders:** 0

**Aggregate consideration:** 6,220,426.98

**Basis for aggregate consideration:** —

**Securities Act Exemption:** Regulation A, Regulation D, Regulation CF, 4(a)(2) of Securities Act